US8258289B2	NNP	O
-	:	O
Modulation	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
CROSS-REFERENCE	NNP	O
TO	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
is	VBZ	O
a	DT	O
divisional	JJ	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/066,725	CD	O
,	,	O
filed	VBN	O
Aug.	NNP	O
24	CD	O
,	,	O
2005	CD	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation	NN	O
of	IN	O
International	NNP	O
Application	NNP	O
No	NNP	O
.	.	O
PCT/US2004/024384	NNP	O
,	,	O
filed	VBN	O
Aug.	NNP	O
18	CD	O
,	,	O
2004	CD	O
,	,	O
which	WDT	O
claims	VBZ	O
the	DT	O
benefit	NN	O
of	IN	O
U.S.	NNP	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
10/643,801	CD	O
,	,	O
filed	VBN	O
Aug.	NNP	O
18	CD	O
,	,	O
2003	CD	O
,	,	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
each	DT	O
are	VBP	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
SEQUENCE	NNP	O
LISTING	NNP	O
The	DT	O
present	JJ	O
application	NN	O
is	VBZ	O
being	VBG	O
filed	VBN	O
along	IN	O
with	IN	O
a	DT	O
Sequence	NNP	O
Listing	NNP	O
in	IN	O
electronic	JJ	O
format	NN	O
.	.	O
The	DT	O
Sequence	NNP	O
Listing	NNP	O
is	VBZ	O
provided	VBN	O
as	IN	O
a	DT	O
file	NN	O
entitled	VBN	O
RTS0678USD1SEQ.txt	NNP	O
,	,	O
created	VBD	O
on	IN	O
Mar	NNP	O
.	.	O
26	CD	O
,	,	O
2010	CD	O
which	WDT	O
is	VBZ	O
164	CD	O
Kb	NNP	O
in	IN	O
size	NN	O
.	.	O
The	DT	O
information	NN	O
in	IN	O
the	DT	O
electronic	JJ	O
format	NN	O
of	IN	O
the	DT	O
sequence	NN	O
listing	NN	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
FIELD	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
compositions	NNS	O
and	CC	O
methods	NNS	O
for	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
this	DT	O
invention	NN	O
relates	VBZ	O
to	TO	O
antisense	VB	O
compounds	NNS	O
,	,	O
particularly	RB	O
oligonucleotide	JJ	O
compounds	NNS	O
,	,	O
which	WDT	O
,	,	O
in	IN	O
preferred	JJ	O
embodiments	NNS	O
,	,	O
hybridize	NN	O
with	IN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
Such	JJ	O
compounds	NNS	O
are	VBP	O
shown	VBN	O
herein	NNS	O
to	TO	O
modulate	VB	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Triglycerides	NNP	O
are	VBP	O
one	CD	O
of	IN	O
the	DT	O
major	JJ	O
energy	NN	O
storage	NN	O
molecules	NNS	O
in	IN	O
eukaryotes	NNS	O
.	.	O
The	DT	O
absorption	NN	O
of	IN	O
triglycerides	NNS	O
(	(	O
also	RB	O
called	VBN	O
triacylglycerols	NNS	O
)	)	O
from	IN	O
food	NN	O
is	VBZ	O
a	DT	O
very	RB	O
efficient	JJ	O
process	NN	O
which	WDT	O
occurs	VBZ	O
by	IN	O
a	DT	O
series	NN	O
of	IN	O
steps	NNS	O
wherein	VBP	O
the	DT	O
dietary	JJ	O
triacylglycerols	NNS	O
are	VBP	O
hydrolyzed	VBN	O
in	IN	O
the	DT	O
intestinal	JJ	O
lumen	NNS	O
and	CC	O
then	RB	O
resynthesized	VBD	O
within	IN	O
enterocytes	NNS	O
.	.	O
The	DT	O
resynthesis	NN	O
of	IN	O
triacylglycerols	NNS	O
can	MD	O
occur	VB	O
via	IN	O
the	DT	O
monoacylglycerol	NN	O
pathway	NN	O
which	WDT	O
commences	VBZ	O
with	IN	O
monoacylglycerol	NN	O
acyltransferase	NN	O
(	(	O
MGAT	NNP	O
)	)	O
catalyzing	VBG	O
the	DT	O
synthesis	NN	O
of	IN	O
diacylglycerol	NN	O
from	IN	O
monoacylglycerol	NN	O
and	CC	O
fatty	JJ	O
acyl-CoA	NN	O
.	.	O
An	DT	O
alternative	JJ	O
synthesis	NN	O
of	IN	O
diacylglycerols	NNS	O
is	VBZ	O
provided	VBN	O
by	IN	O
the	DT	O
glycerol-phosphate	JJ	O
pathway	NN	O
which	WDT	O
describes	VBZ	O
the	DT	O
coupling	NN	O
of	IN	O
two	CD	O
molecules	NNS	O
of	IN	O
fatty	JJ	O
acyl-CoA	JJ	O
to	TO	O
glycerol-3-phosphate	NN	O
.	.	O
In	IN	O
either	DT	O
case	NN	O
,	,	O
diacylglycerol	NN	O
is	VBZ	O
then	RB	O
acylated	VBN	O
with	IN	O
another	DT	O
molecule	NN	O
of	IN	O
fatty	JJ	O
acyl-CoA	JJ	O
in	IN	O
a	DT	O
reaction	NN	O
catalyzed	VBN	O
by	IN	O
one	CD	O
of	IN	O
two	CD	O
diacylglycerol	NN	O
acyltransferase	NN	O
enzymes	VBZ	O
to	TO	O
form	VB	O
the	DT	O
triglyceride	NN	O
(	(	O
Farese	JJ	B
et	NN	I
al.	NN	I
,	,	I
Curr	NNP	I
.	.	I
Opin	NNP	I
.	.	I
Lipidol.	NNP	I
,	,	I
2000	CD	I
,	,	I
11	CD	I
,	,	I
229-234	JJ	I
)	)	O
.	.	O
The	DT	O
reaction	NN	O
catalyzed	VBN	O
by	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
is	VBZ	O
the	DT	O
final	JJ	O
and	CC	O
only	RB	O
committed	JJ	O
step	NN	O
in	IN	O
triglyceride	JJ	O
synthesis	NN	O
.	.	O
As	IN	O
such	JJ	O
,	,	O
diacylglycerol	JJ	O
acyltransferase	NN	O
is	VBZ	O
involved	VBN	O
in	IN	O
intestinal	JJ	O
fat	JJ	O
absorption	NN	O
,	,	O
lipoprotein	NN	O
assembly	RB	O
,	,	O
regulating	VBG	O
plasma	JJ	O
triglyceride	JJ	O
concentrations	NNS	O
,	,	O
and	CC	O
fat	JJ	O
storage	NN	O
in	IN	O
adipocytes	NNS	O
.	.	O
The	DT	O
first	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
,	,	O
diacylglycerol	NN	O
transferase	NN	O
1	CD	O
,	,	O
was	VBD	O
identified	VBN	O
in	IN	O
1960	CD	O
and	CC	O
the	DT	O
human	JJ	O
and	CC	O
mouse	NN	O
genes	NNS	O
encoding	VBG	O
this	DT	O
protein	NN	O
were	VBD	O
isolated	VBN	O
in	IN	O
1998	CD	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
1998	CD	I
,	,	I
95	CD	I
,	,	I
13018-13023	CD	I
;	:	O
Oelkers	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
1998	CD	I
,	,	I
273	CD	I
,	,	I
26765-26771	JJ	I
)	)	O
.	.	O
Mice	NNP	O
lacking	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
1	CD	O
are	VBP	O
viable	JJ	O
and	CC	O
can	MD	O
still	RB	O
synthesize	VB	O
triglycerides	NNS	O
through	IN	O
other	JJ	O
biological	JJ	O
routes	NNS	O
,	,	O
suggesting	VBG	O
the	DT	O
existence	NN	O
of	IN	O
multiple	JJ	O
mechanisms	NNS	O
for	IN	O
triglyceride	JJ	O
synthesis	NN	O
(	(	O
Smith	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Genet.	NNP	I
,	,	I
2000	CD	I
,	,	I
25	CD	I
,	,	I
87-90	JJ	I
)	)	O
.	.	O
A	DT	O
second	JJ	O
diacylglycerol	NN	O
transferase	NN	O
,	,	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
DGAT2	NNP	O
,	,	O
diacylglycerol	VBD	O
O-transferase	NNP	O
2	CD	O
,	,	O
acyl-CoA	NN	O
:	:	O
diacylglycerol	NN	O
acyltransferase	IN	O
2	CD	O
)	)	O
,	,	O
was	VBD	O
subsequently	RB	O
identified	VBN	O
in	IN	O
the	DT	O
fungus	NN	O
Mortierella	NNP	O
,	,	O
humans	NNS	O
and	CC	O
mice	NN	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38870-38876	CD	I
;	:	O
Lardizabal	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38862-38869	JJ	I
)	)	O
.	.	O
Enzymatic	JJ	O
assays	NNS	O
indicate	VBP	O
that	IN	O
this	DT	O
recently	RB	O
identified	VBN	O
protein	NN	O
does	VBZ	O
possess	VB	O
diacylglycerol	VB	O
transferase	JJ	O
activity	NN	O
that	WDT	O
utilizes	VBZ	O
a	DT	O
broad	JJ	O
range	NN	O
of	IN	O
long	JJ	O
chain	NN	O
fatty	JJ	O
acyl-CoA	JJ	O
substrates	NNS	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38870-38876	JJ	I
)	)	O
.	.	O
Diacylglycerol	NNP	O
transferase	NN	O
2	CD	O
is	VBZ	O
a	DT	O
member	NN	O
of	IN	O
a	DT	O
family	NN	O
of	IN	O
genes	NNS	O
whose	WP$	O
sequences	NNS	O
are	VBP	O
unrelated	JJ	O
to	TO	O
diacylglycerol	VB	O
transferase	NN	O
1	CD	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
differing	VBG	O
in	IN	O
sequence	NN	O
compared	VBN	O
to	TO	O
diacylglycerol	VB	O
transferase	NN	O
1	CD	O
,	,	O
in	IN	O
vitro	JJ	O
assays	NNS	O
illustrate	VBP	O
that	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
has	VBZ	O
higher	JJR	O
activity	NN	O
at	IN	O
lower	JJR	O
concentrations	NNS	O
of	IN	O
magnesium	NN	O
chloride	NN	O
and	CC	O
oleoyl-CoA	NN	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38870-38876	JJ	I
)	)	O
.	.	O
The	DT	O
predicted	JJ	O
protein	NN	O
sequence	NN	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
contains	NNS	O
at	IN	O
least	JJS	O
one	CD	O
putative	JJ	O
transmembrane	NN	O
domain	NN	O
,	,	O
three	CD	O
potential	JJ	O
N-linked	JJ	O
glycosylation	NN	O
sites	NNS	O
,	,	O
six	CD	O
potential	JJ	O
protein	NN	O
kinase	NN	O
C	NNP	O
phosphorylation	NN	O
consensus	NN	O
sites	VBZ	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
sequences	NNS	O
in	IN	O
common	JJ	O
with	IN	O
a	DT	O
putative	JJ	O
glycerol	NN	O
phosphorylation	NN	O
site	NN	O
found	VBN	O
in	IN	O
acyltransferase	NN	O
enzymes	NNS	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38870-38876	JJ	I
)	)	O
.	.	O
The	DT	O
International	NNP	O
Radiation	NNP	O
Hybrid	NNP	O
Mapping	NNP	O
Consortium	NNP	O
has	VBZ	O
mapped	VBN	O
human	JJ	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
to	TO	O
chromosome	VB	O
11q13.3	CD	O
.	.	O
In	IN	O
human	JJ	O
tissues	NNS	O
,	,	O
the	DT	O
highest	JJS	O
levels	NNS	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
are	VBP	O
detected	VBN	O
in	IN	O
liver	NN	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissues	NNS	O
,	,	O
with	IN	O
lower	JJR	O
levels	NNS	O
found	VBN	O
in	IN	O
mammary	JJ	O
gland	NN	O
,	,	O
testis	NN	O
and	CC	O
peripheral	JJ	O
blood	NN	O
leukocytes	NNS	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38870-38876	JJ	I
)	)	O
.	.	O
Two	CD	O
mRNA	JJ	O
species	NNS	O
of	IN	O
2.4	CD	O
and	CC	O
1.8	CD	O
kilobases	NNS	O
are	VBP	O
detected	VBN	O
in	IN	O
human	JJ	O
tissues	NNS	O
,	,	O
whereas	IN	O
the	DT	O
major	JJ	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
mRNA	NN	O
species	NNS	O
in	IN	O
mouse	NN	O
tissues	NNS	O
is	VBZ	O
2.4	CD	O
kilobases	NNS	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
liver	VB	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissues	NNS	O
,	,	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
is	VBZ	O
expressed	VBN	O
in	IN	O
all	DT	O
segments	NNS	O
of	IN	O
the	DT	O
small	JJ	O
intestine	NN	O
in	IN	O
mice	NN	O
,	,	O
with	IN	O
higher	JJR	O
expression	NN	O
in	IN	O
the	DT	O
proximal	JJ	O
intestine	NN	O
and	CC	O
lower	JJR	O
expression	NN	O
in	IN	O
the	DT	O
distal	JJ	O
intestine	NN	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38870-38876	JJ	I
)	)	O
.	.	O
Diacylglycerol	NNP	O
transferase	NN	O
activity	NN	O
exhibits	VBZ	O
distinct	JJ	O
patterns	NNS	O
during	IN	O
postnatal	JJ	O
development	NN	O
of	IN	O
the	DT	O
rat	NN	O
liver	NN	O
.	.	O
As	IN	O
there	EX	O
is	VBZ	O
no	DT	O
correlation	NN	O
between	IN	O
the	DT	O
mRNA	NN	O
expression	NN	O
and	CC	O
activity	NN	O
patterns	NNS	O
,	,	O
post-translational	JJ	O
modifications	NNS	O
may	MD	O
participate	VB	O
in	IN	O
the	DT	O
regulation	NN	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
activity	NN	O
during	IN	O
rat	NN	O
development	NN	O
(	(	O
Waterman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Lipid	NNP	I
.	.	I
Res.	NNP	I
,	,	I
2002	CD	I
,	,	I
43	CD	I
,	,	I
1555-1562	JJ	I
)	)	O
.	.	O
Diacylglycerol	NNP	O
transferase	VBD	O
2	CD	O
mRNA	NN	O
is	VBZ	O
preferentially	RB	O
upregulated	VBN	O
by	IN	O
insulin	NN	O
treatment	NN	O
,	,	O
as	IN	O
shown	VBN	O
by	IN	O
in	IN	O
vitro	NN	O
assays	NNS	O
measuring	VBG	O
the	DT	O
diacylglycerol	NN	O
activity	NN	O
from	IN	O
the	DT	O
membrane	NN	O
fraction	NN	O
of	IN	O
cultured	JJ	O
mouse	NN	O
adipocytes	NNS	O
(	(	O
Meegalla	NNP	B
et	RB	I
al.	RB	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun.	NNP	I
,	,	I
2002	CD	I
,	,	I
298	CD	I
,	,	I
317-323	JJ	I
)	)	O
.	.	O
In	IN	O
fasting	VBG	O
mice	NN	O
,	,	O
diacylglycerol	VB	O
transferase	NN	O
2	CD	O
expression	NN	O
is	VBZ	O
greatly	RB	O
reduced	VBN	O
,	,	O
and	CC	O
dramatically	RB	O
increases	VBZ	O
upon	IN	O
refeeding	VBG	O
.	.	O
The	DT	O
expression	NN	O
patterns	NNS	O
of	IN	O
two	CD	O
enzymes	NNS	O
that	WDT	O
participate	VBP	O
in	IN	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
and	CC	O
fatty	JJ	O
acid	NN	O
synthase	NN	O
,	,	O
respond	NN	O
to	TO	O
fasting	NN	O
and	CC	O
refeeding	NN	O
in	IN	O
a	DT	O
similar	JJ	O
fashion	NN	O
.	.	O
These	DT	O
results	NNS	O
,	,	O
combined	VBN	O
with	IN	O
the	DT	O
observation	NN	O
that	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
is	VBZ	O
abundantly	RB	O
expressed	VBN	O
in	IN	O
liver	NN	O
,	,	O
suggest	VBP	O
that	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
is	VBZ	O
tightly	RB	O
linked	VBN	O
to	TO	O
the	DT	O
endogenous	JJ	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
pathway	NN	O
(	(	O
Meegalla	NNP	B
et	RB	I
al.	RB	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun.	NNP	I
,	,	I
2002	CD	I
,	,	I
298	CD	I
,	,	I
317-323	JJ	I
)	)	O
.	.	O
Studies	NNS	O
of	IN	O
mice	NNS	O
harboring	VBG	O
a	DT	O
disruption	NN	O
in	IN	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
1	CD	O
gene	NN	O
provide	VBP	O
evidence	NN	O
that	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
contributes	NNS	O
to	TO	O
triglyceride	VB	O
synthesis	NN	O
.	.	O
Levels	NNS	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
mRNA	NN	O
expression	NN	O
are	VBP	O
similar	JJ	O
in	IN	O
intestinal	JJ	O
segments	NNS	O
from	IN	O
both	DT	O
wild	JJ	O
type	NN	O
and	CC	O
diacylglycerol	VB	O
transferase	JJ	O
1-deficient	JJ	O
mice	NN	O
(	(	O
Buhman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2002	CD	I
,	,	I
277	CD	I
,	,	I
25474-25479	JJ	I
)	)	O
.	.	O
Using	VBG	O
magnesium	NN	O
chloride	NN	O
to	TO	O
distinguish	VB	O
between	IN	O
diacylglycerol	NN	O
transferase	NN	O
1	CD	O
and	CC	O
2	CD	O
activity	NN	O
,	,	O
Buhman	NNP	O
,	,	O
et	RB	O
al	NN	O
.	.	O
observed	VBN	O
that	DT	O
,	,	O
in	IN	O
diacylglycerol	JJ	O
transferase	NN	O
1-deficient	JJ	O
mice	NN	O
,	,	O
diacylglycerol	JJ	O
transferase	NN	O
activity	NN	O
is	VBZ	O
reduced	VBN	O
to	TO	O
50	CD	O
%	NN	O
in	IN	O
the	DT	O
proximal	JJ	O
intestine	NN	O
and	CC	O
to	TO	O
10-15	CD	O
%	NN	O
in	IN	O
the	DT	O
distal	JJ	O
intestine	NN	O
(	(	O
Buhman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2002	CD	I
,	,	I
277	CD	I
,	,	I
25474-25479	JJ	I
)	)	O
.	.	O
Additionally	RB	O
,	,	O
diacylglycerol	VB	O
transferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
are	VBP	O
not	RB	O
up-regulated	JJ	O
the	DT	O
liver	NN	O
or	CC	O
adipose	JJ	O
tissues	NNS	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
1-deficient	JJ	O
mice	NN	O
,	,	O
even	RB	O
after	IN	O
weeks	NNS	O
of	IN	O
high-fat	JJ	O
diet	NN	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
2001	CD	I
,	,	I
276	CD	I
,	,	I
38870-38876	CD	I
;	:	O
Chen	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
2002	CD	I
,	,	I
109	CD	I
,	,	I
1049-1055	JJ	I
)	)	O
.	.	O
However	RB	O
,	,	O
in	IN	O
ob/ob	JJ	O
mice	NN	O
,	,	O
which	WDT	O
have	VBP	O
a	DT	O
mutation	NN	O
in	IN	O
the	DT	O
leptin	NN	O
gene	NN	O
that	WDT	O
results	NNS	O
in	IN	O
obesity	NN	O
,	,	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
is	VBZ	O
more	RBR	O
highly	RB	O
expressed	VBN	O
than	IN	O
in	IN	O
wild	JJ	O
type	NN	O
mice	NN	O
,	,	O
suggesting	VBG	O
that	IN	O
diacylglycerol	NN	O
transferase	VBD	O
2	CD	O
may	MD	O
be	VB	O
partly	RB	O
responsible	JJ	O
for	IN	O
the	DT	O
highly	RB	O
accumulated	JJ	O
fat	JJ	O
mass	NN	O
seen	VBN	O
in	IN	O
these	DT	O
mice	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
combined	JJ	O
mutations	NNS	O
of	IN	O
leptin	NN	O
and	CC	O
diacylglycerol	NN	O
transferase	NN	O
1	CD	O
leads	VBZ	O
to	TO	O
a	DT	O
three-fold	JJ	O
elevation	NN	O
in	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
expression	NN	O
in	IN	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
levels	NNS	O
in	IN	O
the	DT	O
same	JJ	O
tissue	NN	O
from	IN	O
diacylglycerol	NN	O
transferase	NN	O
1-deficient	JJ	O
mice	NN	O
(	(	O
Chen	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
2002	CD	I
,	,	I
109	CD	I
,	,	I
1049-1055	JJ	I
)	)	O
.	.	O
Diacylglycerol	NNP	O
transferase	VBD	O
2	CD	O
mRNA	NN	O
is	VBZ	O
also	RB	O
upregulated	VBN	O
in	IN	O
the	DT	O
skin	NN	O
of	IN	O
these	DT	O
mice	NNS	O
(	(	O
Chen	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
2002	CD	I
,	,	I
109	CD	I
,	,	I
175-181	JJ	I
)	)	O
.	.	O
These	DT	O
data	NNS	O
suggest	VBP	O
leptin	NN	O
normally	RB	O
downregulates	VBZ	O
diacylglycerol	JJ	O
transferase	NN	O
2	CD	O
expression	NN	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
upregulation	NN	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
in	IN	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
in	IN	O
these	DT	O
mice	NNS	O
may	MD	O
provide	VB	O
an	DT	O
alternate	JJ	O
pathway	NN	O
for	IN	O
the	DT	O
triglyceride	JJ	O
synthesis	NN	O
that	WDT	O
still	RB	O
occurs	VBZ	O
in	IN	O
leptin	NN	O
deficient/diacylglycerol	NN	O
transferase	NN	O
1-deficient	JJ	O
mice	NN	O
(	(	O
Chen	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
2002	CD	I
,	,	I
109	CD	I
,	,	I
1049-1055	JJ	I
)	)	O
.	.	O
Diacylglycerol	NNP	O
acyltransferase	VBD	O
1	CD	O
knockout	NN	O
mice	NN	O
exhibit	NN	O
interesting	JJ	O
phenotypes	NNS	O
in	IN	O
that	DT	O
they	PRP	O
are	VBP	O
lean	JJ	O
,	,	O
resistant	JJ	O
to	TO	O
diet-induce	JJ	O
obesity	NN	O
,	,	O
have	VBP	O
decreased	VBN	O
levels	NNS	O
of	IN	O
tissue	NN	O
triglycerides	NNS	O
and	CC	O
increased	JJ	O
sensitivity	NN	O
to	TO	O
insulin	VB	O
and	CC	O
leptin	VB	O
(	(	O
Chen	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Clin	NNP	I
.	.	I
Invest.	NNP	I
,	,	I
2002	CD	I
,	,	I
109	CD	I
,	,	I
1049-1055	JJ	I
;	:	O
Smith	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nat	NNP	I
.	.	I
Genet.	NNP	I
,	,	I
2000	CD	I
,	,	I
25	CD	I
,	,	I
87-90	JJ	I
)	)	O
.	.	O
As	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
also	RB	O
participates	VBZ	O
in	IN	O
triglyceride	JJ	O
synthesis	NN	O
,	,	O
interfering	VBG	O
with	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
may	MD	O
similarly	RB	O
lead	VB	O
to	TO	O
reduced	VB	O
body	NN	O
fat	JJ	O
content	NN	O
.	.	O
The	DT	O
US	NNP	O
pre-grant	JJ	O
publications	NNS	O
20030124126	CD	O
and	CC	O
20020119138	CD	O
claim	NN	O
and	CC	O
disclose	VB	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
human	JJ	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
alpha	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
compositions	NNS	O
,	,	O
including	VBG	O
antisense	NN	O
oligonucleotides	NNS	O
,	,	O
for	IN	O
modulating	VBG	O
the	DT	O
activity	NN	O
of	IN	O
said	VBD	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
alpha	NN	O
(	(	O
Cases	NNP	B
et	RB	I
al.	RB	I
,	,	I
2003	CD	I
)	)	O
.	.	O
The	DT	O
US	NNP	O
pre-grant	JJ	O
publication	NN	O
20030104414	CD	O
refers	NNS	O
to	TO	O
nucleic	VB	O
acid	NN	O
sequences	NNS	O
which	WDT	O
are	VBP	O
members	NNS	O
of	IN	O
a	DT	O
group	NN	O
of	IN	O
genes	NNS	O
referred	VBN	O
to	TO	O
as	IN	O
“	NNP	O
protein	VBP	O
cluster	NN	O
V	NNP	O
”	NNP	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
method	NN	O
for	IN	O
identification	NN	O
of	IN	O
an	DT	O
agent	NN	O
capable	JJ	O
of	IN	O
modulating	VBG	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
in	IN	O
the	DT	O
protein	NN	O
cluster	NN	O
V	NNP	O
group	NN	O
.	.	O
This	DT	O
application	NN	O
also	RB	O
refers	VBZ	O
to	TO	O
the	DT	O
use	NN	O
of	IN	O
RNA	NNP	O
interference	NN	O
or	CC	O
double-stranded	JJ	O
RNA	NNP	O
to	TO	O
disrupt	VB	O
the	DT	O
function	NN	O
of	IN	O
protein	NN	O
cluster	NN	O
V	NNP	O
gene	NN	O
family	NN	O
members	NNS	O
(	(	O
Attersand	NNP	O
,	,	O
2003	CD	O
)	)	O
.	.	O
The	DT	O
US	NNP	O
pre-grant	JJ	O
publication	NN	O
20030100480	CD	O
refers	NNS	O
to	TO	O
modifying	VBG	O
diacylglycerol	JJ	O
transferase	NN	O
activity	NN	O
,	,	O
including	VBG	O
that	IN	O
of	IN	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
,	,	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
methods	NNS	O
,	,	O
including	VBG	O
antisense	NN	O
,	,	O
RNA	NNP	O
interference	NN	O
and	CC	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
antisense	NN	O
plasmid	NN	O
constructs	NNS	O
(	(	O
Smith	NNP	B
et	FW	I
al.	NN	I
,	,	I
2003	CD	I
)	)	O
.	.	O
The	DT	O
US	NNP	O
pre-grant	JJ	O
publication	NN	O
20030028923	CD	O
refers	NNS	O
to	TO	O
a	DT	O
method	NN	O
for	IN	O
modifying	VBG	O
the	DT	O
triacylglycerol	NN	O
composition	NN	O
in	IN	O
a	DT	O
plant	NN	O
cell	NN	O
,	,	O
comprising	VBG	O
transforming	VBG	O
a	DT	O
plant	NN	O
cell	NN	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
construct	NN	O
encoding	VBG	O
an	DT	O
enzyme	JJ	O
active	JJ	O
in	IN	O
the	DT	O
formation	NN	O
of	IN	O
triacylglycerol	NN	O
from	IN	O
diacylglycerol	NN	O
and	CC	O
fatty	JJ	O
acyl	NN	O
substrates	NNS	O
,	,	O
including	VBG	O
nucleic	JJ	O
acid	JJ	O
constructs	NNS	O
in	IN	O
the	DT	O
antisense	JJ	O
orientation	NN	O
.	.	O
Also	RB	O
referred	VBN	O
to	TO	O
is	VBZ	O
a	DT	O
method	NN	O
for	IN	O
ameliorating	VBG	O
a	DT	O
disease	NN	O
or	CC	O
condition	NN	O
associated	VBN	O
with	IN	O
altered	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
activity	NN	O
by	IN	O
administering	VBG	O
to	TO	O
a	DT	O
subject	NN	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
agonist	NN	O
.	.	O
This	DT	O
application	NN	O
indicates	VBZ	O
that	IN	O
such	JJ	O
antagonists	NNS	O
can	MD	O
include	VB	O
antisense	JJ	O
molecules	NNS	O
(	(	O
Lardizabal	NNP	B
et	RB	I
al.	RB	I
,	,	I
2003	CD	I
)	)	O
.	.	O
The	DT	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
00/78961	CD	O
refers	NNS	O
to	TO	O
isolated	VB	O
nucleic	JJ	O
acid	JJ	O
molecules	NNS	O
selected	VBN	O
from	IN	O
a	DT	O
group	NN	O
including	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
.	.	O
This	DT	O
publication	NN	O
also	RB	O
comments	NNS	O
that	IN	O
sense	NN	O
or	CC	O
antisense	NN	O
oligonucleotides	NNS	O
binding	VBG	O
to	TO	O
target	VB	O
nucleic	JJ	O
acid	JJ	O
sequences	NNS	O
can	MD	O
interfere	VB	O
with	IN	O
transcription	NN	O
or	CC	O
translation	NN	O
of	IN	O
the	DT	O
disclosed	VBN	O
and	CC	O
claimed	VBN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
(	(	O
Baker	NNP	B
et	VBZ	I
al.	RB	I
,	,	I
2000	CD	I
)	)	O
.	.	O
The	DT	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
01/77389	CD	O
refers	NNS	O
to	TO	O
polynucleotides	NNS	O
selected	VBN	O
from	IN	O
a	DT	O
group	NN	O
of	IN	O
sequences	NNS	O
including	VBG	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
encoding	VBG	O
a	DT	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
.	.	O
A	DT	O
method	NN	O
for	IN	O
screening	VBG	O
for	IN	O
the	DT	O
altered	JJ	O
expression	NN	O
of	IN	O
said	VBD	O
polynucleotides	NNS	O
and	CC	O
a	DT	O
method	NN	O
for	IN	O
screening	VBG	O
a	DT	O
library	NN	O
of	IN	O
molecules	NNS	O
that	WDT	O
specifically	RB	O
bind	VBP	O
to	TO	O
said	VBD	O
polynucleotide	JJ	O
sequences	NNS	O
are	VBP	O
discussed	VBN	O
(	(	O
Shiffman	NNP	B
et	VBZ	I
al.	RB	I
,	,	I
2001	CD	I
)	)	O
.	.	O
The	DT	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
01/68848	CD	O
refers	NNS	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
secreted	VBN	O
and	CC	O
transmembrane	JJ	O
polypeptides	NNS	O
,	,	O
including	VBG	O
a	DT	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
,	,	O
and	CC	O
oligonucleotide	RB	O
probes	NNS	O
derived	VBN	O
from	IN	O
any	DT	O
of	IN	O
these	DT	O
sequences	NNS	O
(	(	O
Baker	NNP	B
et	VBZ	I
al.	RB	I
,	,	I
2001	CD	I
)	)	O
.	.	O
European	JJ	O
Patent	NNP	O
Application	NNP	O
No	NNP	O
.	.	O
EP	NNP	O
1	CD	O
308	CD	O
459	CD	O
refers	NNS	O
to	TO	O
a	DT	O
group	NN	O
of	IN	O
polynucleotide	NN	O
sequences	NNS	O
,	,	O
including	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
and	CC	O
antisense	JJ	O
polynucleotides	NNS	O
against	IN	O
this	DT	O
group	NN	O
of	IN	O
polynucleotide	NN	O
sequences	NNS	O
(	(	O
Isogai	NNP	B
et	RB	I
al.	RB	I
,	,	I
2003	CD	I
)	)	O
.	.	O
The	DT	O
PCT	NNP	O
publication	NN	O
WO	NNP	O
02/08260	CD	O
refers	NNS	O
to	TO	O
an	DT	O
isolated	JJ	O
,	,	O
purified	JJ	O
polynucleotide	NN	O
sequence	NN	O
with	IN	O
identity	NN	O
to	TO	O
a	DT	O
human	JJ	O
diacylglycerol	NN	O
transferase	NN	O
2	CD	O
nucleotide	JJ	O
sequence	NN	O
.	.	O
This	DT	O
application	NN	O
also	RB	O
refers	VBZ	O
to	TO	O
a	DT	O
substantially	RB	O
purified	VBN	O
oligonucleotide	IN	O
that	DT	O
includes	VBZ	O
a	DT	O
region	NN	O
of	IN	O
nucleotide	JJ	O
sequence	NN	O
that	WDT	O
hybridizes	VBZ	O
to	TO	O
at	IN	O
least	JJS	O
8	CD	O
consecutive	JJ	O
nucleotides	NNS	O
of	IN	O
sense	NN	O
or	CC	O
antisense	JJ	O
sequence	NN	O
of	IN	O
a	DT	O
nucleotide	JJ	O
sequence	NN	O
selected	VBN	O
from	IN	O
a	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
sequences	NNS	O
with	IN	O
identity	NN	O
to	TO	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
(	(	O
Botstein	NNP	B
et	VBZ	I
al.	RB	I
,	,	I
2002	CD	I
)	)	O
.	.	O
Currently	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
known	JJ	O
therapeutic	JJ	O
agents	NNS	O
that	WDT	O
effectively	RB	O
inhibit	VBP	O
the	DT	O
synthesis	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
Consequently	RB	O
,	,	O
there	EX	O
remains	VBZ	O
a	DT	O
long	JJ	O
felt	NN	O
need	NN	O
for	IN	O
additional	JJ	O
agents	NNS	O
capable	JJ	O
of	IN	O
effectively	RB	O
inhibiting	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
function	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
compositions	NNS	O
and	CC	O
methods	NNS	O
for	IN	O
modulating	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
.	.	O
SUMMARY	NN	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
directed	VBN	O
to	TO	O
compounds	NNS	O
,	,	O
especially	RB	O
nucleic	JJ	O
acid	NN	O
and	CC	O
nucleic	JJ	O
acid-like	JJ	O
oligomers	NNS	O
,	,	O
which	WDT	O
are	VBP	O
targeted	VBN	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
and	CC	O
which	WDT	O
modulate	VBP	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
Pharmaceutical	NNP	O
and	CC	O
other	JJ	O
compositions	NNS	O
comprising	VBG	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
also	RB	O
provided	VBN	O
.	.	O
Further	RB	O
provided	VBN	O
are	VBP	O
methods	NNS	O
of	IN	O
screening	VBG	O
for	IN	O
modulators	NNS	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and	CC	O
methods	NNS	O
of	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
cells	NNS	O
,	,	O
tissues	NNS	O
or	CC	O
animals	NNS	O
comprising	VBG	O
contacting	NN	O
said	VBD	O
cells	NNS	O
,	,	O
tissues	NNS	O
or	CC	O
animals	NNS	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Antisense	NNP	O
technology	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
means	NNS	O
for	IN	O
reducing	VBG	O
the	DT	O
expression	NN	O
of	IN	O
specific	JJ	O
gene	NN	O
products	NNS	O
and	CC	O
may	MD	O
therefore	VB	O
prove	VB	O
to	TO	O
be	VB	O
uniquely	RB	O
useful	JJ	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
therapeutic	JJ	O
,	,	O
diagnostic	JJ	O
,	,	O
and	CC	O
research	NN	O
applications	NNS	O
for	IN	O
the	DT	O
modulation	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
.	.	O
Methods	NNS	O
of	IN	O
treating	VBG	O
an	DT	O
animal	NN	O
,	,	O
particularly	RB	O
a	DT	O
human	JJ	O
,	,	O
suspected	VBN	O
of	IN	O
having	VBG	O
or	CC	O
being	VBG	O
prone	NN	O
to	TO	O
a	DT	O
disease	NN	O
or	CC	O
condition	NN	O
associated	VBN	O
with	IN	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
are	VBP	O
also	RB	O
set	VBN	O
forth	NN	O
herein	NN	O
.	.	O
Such	JJ	O
methods	NNS	O
comprise	VBP	O
administering	VBG	O
a	DT	O
therapeutically	RB	O
or	CC	O
prophylactically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
compounds	NNS	O
or	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
to	TO	O
the	DT	O
person	NN	O
in	IN	O
need	NN	O
of	IN	O
treatment	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
compound	NN	O
or	CC	O
composition	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
the	DT	O
manufacture	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
any	DT	O
and	CC	O
all	DT	O
conditions	NNS	O
disclosed	VBD	O
herein	NN	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
A.	NNP	O
Overview	NNP	O
of	IN	O
the	DT	O
Invention	NNP	O
The	DT	O
present	JJ	O
invention	NN	O
employs	VBZ	O
antisense	JJ	O
compounds	NNS	O
,	,	O
preferably	RB	O
oligonucleotides	NNS	O
and	CC	O
similar	JJ	O
species	NNS	O
for	IN	O
use	NN	O
in	IN	O
modulating	VBG	O
the	DT	O
function	NN	O
or	CC	O
effect	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
This	DT	O
is	VBZ	O
accomplished	VBN	O
by	IN	O
providing	VBG	O
oligonucleotides	NNS	O
that	WDT	O
specifically	RB	O
hybridize	VBP	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
the	DT	O
terms	NNS	O
“	VBP	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
”	NN	O
and	CC	O
“	NNP	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
”	NN	O
have	VBP	O
been	VBN	O
used	VBN	O
for	IN	O
convenience	NN	O
to	TO	O
encompass	VB	O
DNA	NNP	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
RNA	NNP	O
(	(	O
including	VBG	O
pre-mRNA	NN	O
and	CC	O
mRNA	NN	O
or	CC	O
portions	NNS	O
thereof	VBP	O
)	)	O
transcribed	VBN	O
from	IN	O
such	JJ	O
DNA	NNP	O
,	,	O
and	CC	O
also	RB	O
cDNA	VBP	O
derived	VBN	O
from	IN	O
such	JJ	O
RNA	NNP	O
.	.	O
The	DT	O
hybridization	NN	O
of	IN	O
a	DT	O
compound	NN	O
of	IN	O
this	DT	O
invention	NN	O
with	IN	O
its	PRP$	O
target	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
generally	RB	O
referred	VBN	O
to	TO	O
as	IN	O
“	JJ	O
antisense	NN	O
”	NN	O
.	.	O
Consequently	RB	O
,	,	O
the	DT	O
preferred	JJ	O
mechanism	NN	O
believed	VBN	O
to	TO	O
be	VB	O
included	VBN	O
in	IN	O
the	DT	O
practice	NN	O
of	IN	O
some	DT	O
preferred	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
referred	VBN	O
to	TO	O
herein	VB	O
as	IN	O
“	JJ	O
antisense	NN	O
inhibition.	NN	O
”	NNP	O
Such	JJ	O
antisense	JJ	O
inhibition	NN	O
is	VBZ	O
typically	RB	O
based	VBN	O
upon	IN	O
hydrogen	JJ	O
bonding-based	JJ	O
hybridization	NN	O
of	IN	O
oligonucleotide	JJ	O
strands	NNS	O
or	CC	O
segments	NNS	O
such	JJ	O
that	IN	O
at	IN	O
least	JJS	O
one	CD	O
strand	NN	O
or	CC	O
segment	NN	O
is	VBZ	O
cleaved	VBN	O
,	,	O
degraded	VBN	O
,	,	O
or	CC	O
otherwise	RB	O
rendered	VBN	O
inoperable	JJ	O
.	.	O
In	IN	O
this	DT	O
regard	NN	O
,	,	O
it	PRP	O
is	VBZ	O
presently	RB	O
preferred	VBN	O
to	TO	O
target	VB	O
specific	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
and	CC	O
their	PRP$	O
functions	NNS	O
for	IN	O
such	JJ	O
antisense	JJ	O
inhibition	NN	O
.	.	O
The	DT	O
functions	NNS	O
of	IN	O
DNA	NN	O
to	TO	O
be	VB	O
interfered	VBN	O
with	IN	O
can	MD	O
include	VB	O
replication	NN	O
and	CC	O
transcription	NN	O
.	.	O
Replication	NN	O
and	CC	O
transcription	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
can	MD	O
be	VB	O
from	IN	O
an	DT	O
endogenous	JJ	O
cellular	JJ	O
template	NN	O
,	,	O
a	DT	O
vector	NN	O
,	,	O
a	DT	O
plasmid	JJ	O
construct	NN	O
or	CC	O
otherwise	RB	O
.	.	O
The	DT	O
functions	NNS	O
of	IN	O
RNA	NNP	O
to	TO	O
be	VB	O
interfered	VBN	O
with	IN	O
can	MD	O
include	VB	O
functions	NNS	O
such	JJ	O
as	IN	O
translocation	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
a	DT	O
site	NN	O
of	IN	O
protein	JJ	O
translation	NN	O
,	,	O
translocation	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
sites	NNS	O
within	IN	O
the	DT	O
cell	NN	O
which	WDT	O
are	VBP	O
distant	JJ	O
from	IN	O
the	DT	O
site	NN	O
of	IN	O
RNA	NNP	O
synthesis	NN	O
,	,	O
translation	NN	O
of	IN	O
protein	NN	O
from	IN	O
the	DT	O
RNA	NNP	O
,	,	O
splicing	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
to	TO	O
yield	VB	O
one	CD	O
or	CC	O
more	JJR	O
RNA	JJ	O
species	NNS	O
,	,	O
and	CC	O
catalytic	JJ	O
activity	NN	O
or	CC	O
complex	JJ	O
formation	NN	O
involving	VBG	O
the	DT	O
RNA	NNP	O
which	WDT	O
may	MD	O
be	VB	O
engaged	VBN	O
in	IN	O
or	CC	O
facilitated	VBN	O
by	IN	O
the	DT	O
RNA	NNP	O
.	.	O
One	CD	O
preferred	JJ	O
result	NN	O
of	IN	O
such	JJ	O
interference	NN	O
with	IN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
function	NN	O
is	VBZ	O
modulation	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
“	JJ	O
modulation	NN	O
”	NN	O
and	CC	O
“	JJ	O
modulation	NN	O
of	IN	O
expression	NN	O
”	NNP	O
mean	NN	O
either	CC	O
an	DT	O
increase	NN	O
(	(	O
stimulation	NN	O
)	)	O
or	CC	O
a	DT	O
decrease	NN	O
(	(	O
inhibition	NN	O
)	)	O
in	IN	O
the	DT	O
amount	NN	O
or	CC	O
levels	NNS	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
the	DT	O
gene	NN	O
,	,	O
e.g.	NN	O
,	,	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
.	.	O
Inhibition	NN	O
is	VBZ	O
often	RB	O
the	DT	O
preferred	JJ	O
form	NN	O
of	IN	O
modulation	NN	O
of	IN	O
expression	NN	O
and	CC	O
mRNA	NN	O
is	VBZ	O
often	RB	O
a	DT	O
preferred	JJ	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
“	JJ	O
hybridization	NN	O
”	NN	O
means	VBZ	O
the	DT	O
pairing	NN	O
of	IN	O
complementary	JJ	O
strands	NNS	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
.	.	O
In	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
preferred	JJ	O
mechanism	NN	O
of	IN	O
pairing	VBG	O
involves	NNS	O
hydrogen	NN	O
bonding	NN	O
,	,	O
which	WDT	O
may	MD	O
be	VB	O
Watson-Crick	NNP	O
,	,	O
Hoogsteen	NNP	O
or	CC	O
reversed	VBN	O
Hoogsteen	NNP	O
hydrogen	NN	O
bonding	NN	O
,	,	O
between	IN	O
complementary	JJ	O
nucleoside	NN	O
or	CC	O
nucleotide	JJ	O
bases	NNS	O
(	(	O
nucleobases	NNS	O
)	)	O
of	IN	O
the	DT	O
strands	NNS	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
adenine	NN	O
and	CC	O
thymine	NN	O
are	VBP	O
complementary	JJ	O
nucleobases	NNS	O
which	WDT	O
pair	VBP	O
through	IN	O
the	DT	O
formation	NN	O
of	IN	O
hydrogen	NN	O
bonds	NNS	O
.	.	O
Hybridization	NN	O
can	MD	O
occur	VB	O
under	IN	O
varying	VBG	O
circumstances	NNS	O
.	.	O
An	DT	O
antisense	NN	O
compound	NN	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
when	WRB	O
binding	NN	O
of	IN	O
the	DT	O
compound	NN	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
interferes	NNS	O
with	IN	O
the	DT	O
normal	JJ	O
function	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
cause	VB	O
a	DT	O
loss	NN	O
of	IN	O
activity	NN	O
,	,	O
and	CC	O
there	EX	O
is	VBZ	O
a	DT	O
sufficient	JJ	O
degree	NN	O
of	IN	O
complementarity	NN	O
to	TO	O
avoid	VB	O
non-specific	JJ	O
binding	NN	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
to	TO	O
non-target	JJ	O
nucleic	JJ	O
acid	NN	O
sequences	NNS	O
under	IN	O
conditions	NNS	O
in	IN	O
which	WDT	O
specific	JJ	O
binding	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
e.g.	FW	O
,	,	O
under	IN	O
physiological	JJ	O
conditions	NNS	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
in	IN	O
vivo	NN	O
assays	NNS	O
or	CC	O
therapeutic	JJ	O
treatment	NN	O
,	,	O
and	CC	O
under	IN	O
conditions	NNS	O
in	IN	O
which	WDT	O
assays	NNS	O
are	VBP	O
performed	VBN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
in	IN	O
vitro	NN	O
assays	NNS	O
.	.	O
In	IN	O
the	DT	O
present	JJ	O
invention	NN	O
the	DT	O
phrase	NN	O
“	NNP	O
stringent	JJ	O
hybridization	NN	O
conditions	NNS	O
”	VBP	O
or	CC	O
“	VBP	O
stringent	JJ	O
conditions	NNS	O
”	VBP	O
refers	NNS	O
to	TO	O
conditions	NNS	O
under	IN	O
which	WDT	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
will	MD	O
hybridize	VB	O
to	TO	O
its	PRP$	O
target	NN	O
sequence	NN	O
,	,	O
but	CC	O
to	TO	O
a	DT	O
minimal	JJ	O
number	NN	O
of	IN	O
other	JJ	O
sequences	NNS	O
.	.	O
Stringent	JJ	O
conditions	NNS	O
are	VBP	O
sequence-dependent	JJ	O
and	CC	O
will	MD	O
be	VB	O
different	JJ	O
in	IN	O
different	JJ	O
circumstances	NNS	O
and	CC	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
“	JJ	O
stringent	JJ	O
conditions	NNS	O
”	VBP	O
under	IN	O
which	WDT	O
oligomeric	JJ	O
compounds	NNS	O
hybridize	VBP	O
to	TO	O
a	DT	O
target	NN	O
sequence	NN	O
are	VBP	O
determined	VBN	O
by	IN	O
the	DT	O
nature	NN	O
and	CC	O
composition	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
and	CC	O
the	DT	O
assays	NNS	O
in	IN	O
which	WDT	O
they	PRP	O
are	VBP	O
being	VBG	O
investigated	VBN	O
.	.	O
“	JJ	O
Complementary	NNP	O
,	,	O
”	NNP	O
as	IN	O
used	VBN	O
herein	NN	O
,	,	O
refers	NNS	O
to	TO	O
the	DT	O
capacity	NN	O
hydrogen	NN	O
bonding	VBG	O
between	IN	O
the	DT	O
oligonucleotide	NN	O
and	CC	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
a	DT	O
complementary	JJ	O
position	NN	O
.	.	O
The	DT	O
oligonucleotide	NN	O
and	CC	O
the	DT	O
further	JJ	O
DNA	NNP	O
,	,	O
RNA	NNP	O
,	,	O
or	CC	O
oligonucleotide	IN	O
molecule	NN	O
are	VBP	O
complementary	JJ	O
to	TO	O
each	DT	O
other	JJ	O
when	WRB	O
a	DT	O
sufficient	JJ	O
number	NN	O
of	IN	O
complementary	JJ	O
positions	NNS	O
in	IN	O
each	DT	O
molecule	NN	O
are	VBP	O
occupied	VBN	O
by	IN	O
nucleobases	NNS	O
which	WDT	O
can	MD	O
hydrogen	VB	O
bond	NN	O
with	IN	O
each	DT	O
other	JJ	O
.	.	O
Thus	RB	O
,	,	O
“	NNP	O
specifically	RB	O
hybridizable	JJ	O
”	NN	O
and	CC	O
“	NNP	O
complementary	JJ	O
”	NNS	O
are	VBP	O
terms	NNS	O
which	WDT	O
are	VBP	O
used	VBN	O
to	TO	O
indicate	VB	O
a	DT	O
sufficient	JJ	O
degree	NN	O
of	IN	O
precise	NN	O
pairing	NN	O
or	CC	O
complementarity	NN	O
over	IN	O
a	DT	O
sufficient	JJ	O
number	NN	O
of	IN	O
nucleobases	NNS	O
such	JJ	O
that	IN	O
stable	JJ	O
and	CC	O
specific	JJ	O
binding	VBG	O
occurs	NN	O
between	IN	O
the	DT	O
oligonucleotide	NN	O
and	CC	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
It	PRP	O
is	VBZ	O
understood	JJ	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
the	DT	O
sequence	NN	O
of	IN	O
an	DT	O
antisense	JJ	O
compound	NN	O
may	MD	O
be	VB	O
,	,	O
but	CC	O
need	MD	O
not	RB	O
be	VB	O
,	,	O
100	CD	O
%	NN	O
complementary	JJ	O
to	TO	O
that	DT	O
of	IN	O
its	PRP$	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
be	VB	O
specifically	RB	O
hybridizable	JJ	O
.	.	O
Moreover	RB	O
,	,	O
an	DT	O
oligonucleotide	NN	O
may	MD	O
hybridize	VB	O
over	RP	O
one	CD	O
or	CC	O
more	JJR	O
segments	NNS	O
such	JJ	O
that	IN	O
intervening	VBG	O
or	CC	O
adjacent	JJ	O
segments	NNS	O
are	VBP	O
not	RB	O
involved	VBN	O
in	IN	O
the	DT	O
hybridization	NN	O
event	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
loop	JJ	O
structure	NN	O
or	CC	O
hairpin	NN	O
structure	NN	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
preferred	VBN	O
that	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
comprise	NN	O
at	IN	O
least	JJS	O
70	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
75	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
80	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
85	CD	O
%	NN	O
sequence	NN	O
complementarity	NN	O
to	TO	O
a	DT	O
target	NN	O
region	NN	O
within	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
Moreover	RB	O
,	,	O
they	PRP	O
may	MD	O
comprise	VB	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
complementarity	NN	O
,	,	O
at	IN	O
least	JJS	O
95	CD	O
%	NN	O
or	CC	O
at	IN	O
least	JJS	O
99	CD	O
%	NN	O
sequence	NN	O
complementarity	NN	O
to	TO	O
the	DT	O
target	NN	O
region	NN	O
within	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
to	TO	O
which	WDT	O
they	PRP	O
are	VBP	O
targeted	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
an	DT	O
antisense	NN	O
compound	NN	O
in	IN	O
which	WDT	O
18	CD	O
of	IN	O
20	CD	O
nucleobases	NNS	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
are	VBP	O
complementary	JJ	O
to	TO	O
a	DT	O
target	NN	O
region	NN	O
,	,	O
and	CC	O
would	MD	O
therefore	VB	O
specifically	RB	O
hybridize	JJ	O
,	,	O
would	MD	O
represent	VB	O
90	CD	O
percent	NN	O
complementarity	NN	O
.	.	O
In	IN	O
this	DT	O
example	NN	O
,	,	O
the	DT	O
remaining	VBG	O
noncomplementary	JJ	O
nucleobases	NNS	O
may	MD	O
be	VB	O
clustered	VBN	O
or	CC	O
interspersed	VBN	O
with	IN	O
complementary	JJ	O
nucleobases	NNS	O
,	,	O
and	CC	O
need	MD	O
not	RB	O
be	VB	O
contiguous	JJ	O
to	TO	O
each	DT	O
other	JJ	O
or	CC	O
to	TO	O
complementary	JJ	O
nucleobases	NNS	O
.	.	O
As	IN	O
such	JJ	O
,	,	O
an	DT	O
antisense	NN	O
compound	NN	O
which	WDT	O
is	VBZ	O
18	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
having	VBG	O
4	CD	O
(	(	O
four	CD	O
)	)	O
noncomplementary	NN	O
nucleobases	NNS	O
which	WDT	O
are	VBP	O
flanked	VBN	O
by	IN	O
two	CD	O
regions	NNS	O
of	IN	O
complete	JJ	O
complementarity	NN	O
with	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
would	MD	O
have	VB	O
77.8	CD	O
%	NN	O
overall	JJ	O
complementarity	NN	O
with	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
would	MD	O
thus	RB	O
fall	VB	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Percent	NNP	O
complementarity	NN	O
of	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
with	IN	O
a	DT	O
region	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
can	MD	O
be	VB	O
determined	VBN	O
routinely	RB	O
using	VBG	O
BLAST	NNP	O
programs	NNS	O
(	(	O
basic	JJ	O
local	JJ	O
alignment	NN	O
search	NN	O
tools	NNS	O
)	)	O
and	CC	O
PowerBLAST	NNP	O
programs	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
Altschul	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol.	NNP	I
,	,	I
1990	CD	I
,	,	I
215	CD	I
,	,	I
403-410	JJ	I
;	:	O
Zhang	NNP	B
and	CC	I
Madden	NNP	I
,	,	I
Genome	NNP	I
Res.	NNP	I
,	,	I
1997	CD	I
,	,	I
7	CD	I
,	,	I
649-656	JJ	I
)	)	O
.	.	O
Percent	NNP	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
,	,	O
or	CC	O
complementarity	NN	O
,	,	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
Gap	NNP	O
program	NN	O
(	(	O
Wisconsin	NNP	O
Sequence	NNP	O
Analysis	NNP	O
Package	NNP	O
,	,	O
Version	NNP	O
8	CD	O
for	IN	O
Unix	NNP	O
,	,	O
Genetics	NNP	O
Computer	NNP	O
Group	NNP	O
,	,	O
University	NNP	O
Research	NNP	O
Park	NNP	O
,	,	O
Madison	NNP	O
Wis.	NNP	O
)	)	O
,	,	O
using	VBG	O
default	NN	O
settings	NNS	O
,	,	O
which	WDT	O
uses	VBZ	O
the	DT	O
algorithm	NN	O
of	IN	O
Smith	NNP	B
and	CC	I
Waterman	NNP	I
(	(	I
Adv	NNP	I
.	.	I
Appl	NNP	I
.	.	I
Math.	NNP	I
,	,	I
1981	CD	I
,	,	I
2	CD	I
,	,	I
482-489	JJ	I
)	)	I
.	.	O
In	IN	O
some	DT	O
preferred	JJ	O
embodiments	NNS	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
,	,	O
or	CC	O
complementarity	NN	O
,	,	O
between	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
and	CC	O
target	NN	O
is	VBZ	O
between	IN	O
about	RB	O
50	CD	O
%	NN	O
to	TO	O
about	RB	O
60	CD	O
%	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
is	VBZ	O
between	IN	O
about	RB	O
60	CD	O
%	NN	O
to	TO	O
about	RB	O
70	CD	O
%	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
is	VBZ	O
between	IN	O
about	RB	O
70	CD	O
%	NN	O
and	CC	O
about	IN	O
80	CD	O
%	NN	O
.	.	O
In	IN	O
further	JJ	O
embodiments	NNS	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
is	VBZ	O
between	IN	O
about	RB	O
80	CD	O
%	NN	O
and	CC	O
about	IN	O
90	CD	O
%	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
homology	NN	O
,	,	O
sequence	NN	O
identity	NN	O
or	CC	O
complementarity	NN	O
,	,	O
is	VBZ	O
about	IN	O
90	CD	O
%	NN	O
,	,	O
about	RB	O
92	CD	O
%	NN	O
,	,	O
about	RB	O
94	CD	O
%	NN	O
,	,	O
about	RB	O
95	CD	O
%	NN	O
,	,	O
about	RB	O
96	CD	O
%	NN	O
,	,	O
about	RB	O
97	CD	O
%	NN	O
,	,	O
about	RB	O
98	CD	O
%	NN	O
,	,	O
about	RB	O
99	CD	O
%	NN	O
or	CC	O
about	IN	O
100	CD	O
%	NN	O
.	.	O
B	NNP	O
.	.	O
Compounds	NNS	O
of	IN	O
the	DT	O
Invention	NNP	O
According	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
antisense	JJ	O
compounds	NNS	O
include	VBP	O
antisense	JJ	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
antisense	NN	O
oligonucleotides	NNS	O
,	,	O
siRNAs	NN	O
,	,	O
external	JJ	O
guide	NN	O
sequence	NN	O
(	(	O
EGS	NNP	O
)	)	O
oligonucleotides	VBZ	O
,	,	O
alternate	JJ	O
splicers	NNS	O
,	,	O
and	CC	O
other	JJ	O
oligomeric	JJ	O
compounds	NNS	O
which	WDT	O
hybridize	VBP	O
to	TO	O
at	IN	O
least	JJS	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
As	IN	O
such	JJ	O
,	,	O
these	DT	O
compounds	NNS	O
may	MD	O
be	VB	O
introduced	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
single-stranded	JJ	O
,	,	O
double-stranded	JJ	O
,	,	O
circular	JJ	O
or	CC	O
hairpin	JJ	O
oligomeric	JJ	O
compounds	NNS	O
and	CC	O
may	MD	O
contain	VB	O
structural	JJ	O
elements	NNS	O
such	JJ	O
as	IN	O
internal	JJ	O
or	CC	O
terminal	JJ	O
bulges	NNS	O
or	CC	O
loops	NNS	O
.	.	O
Once	RB	O
introduced	VBN	O
to	TO	O
a	DT	O
system	NN	O
,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
elicit	VB	O
the	DT	O
action	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
enzymes	NNS	O
or	CC	O
structural	JJ	O
proteins	NNS	O
to	TO	O
effect	NN	O
modification	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
One	CD	O
non-limiting	JJ	O
example	NN	O
of	IN	O
such	JJ	O
an	DT	O
enzyme	NN	O
is	VBZ	O
RNase	NNP	O
H	NNP	O
,	,	O
a	DT	O
cellular	JJ	O
endonuclease	NN	O
which	WDT	O
cleaves	VBZ	O
the	DT	O
RNA	NNP	O
strand	NN	O
of	IN	O
an	DT	O
RNA	NN	O
:	:	O
DNA	NN	O
duplex	NN	O
.	.	O
It	PRP	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
single-stranded	JJ	O
antisense	NN	O
compounds	NNS	O
that	WDT	O
are	VBP	O
“	JJ	O
DNA-like	NNP	O
”	NNP	O
elicit	JJ	O
RNase	NNP	O
H.	NNP	O
Activation	NNP	O
of	IN	O
RNase	NNP	O
H	NNP	O
,	,	O
therefore	RB	O
,	,	O
results	NNS	O
in	IN	O
cleavage	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
target	NN	O
,	,	O
thereby	RB	O
greatly	RB	O
enhancing	VBG	O
the	DT	O
efficiency	NN	O
of	IN	O
oligonucleotide-mediated	JJ	O
inhibition	NN	O
of	IN	O
gene	NN	O
expression	NN	O
.	.	O
Similar	JJ	O
roles	NNS	O
have	VBP	O
been	VBN	O
postulated	VBN	O
for	IN	O
other	JJ	O
ribonucleases	NNS	O
such	JJ	O
as	IN	O
those	DT	O
in	IN	O
the	DT	O
RNase	NNP	O
III	NNP	O
and	CC	O
ribonuclease	VB	O
L	NNP	O
family	NN	O
of	IN	O
enzymes	NNS	O
.	.	O
While	IN	O
the	DT	O
one	CD	O
form	NN	O
of	IN	O
antisense	NN	O
compound	NN	O
is	VBZ	O
a	DT	O
single-stranded	JJ	O
antisense	NN	O
oligonucleotide	NN	O
,	,	O
in	IN	O
many	JJ	O
species	NNS	O
the	DT	O
introduction	NN	O
of	IN	O
double-stranded	JJ	O
structures	NNS	O
,	,	O
such	JJ	O
as	IN	O
double-stranded	JJ	O
RNA	NNP	O
(	(	O
dsRNA	NN	O
)	)	O
molecules	NNS	O
,	,	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
induce	VB	O
potent	NN	O
and	CC	O
specific	JJ	O
antisense-mediated	JJ	O
reduction	NN	O
of	IN	O
the	DT	O
function	NN	O
of	IN	O
a	DT	O
gene	NN	O
or	CC	O
its	PRP$	O
associated	VBN	O
gene	NN	O
products	NNS	O
.	.	O
This	DT	O
phenomenon	NN	O
occurs	VBZ	O
in	IN	O
both	DT	O
plants	NNS	O
and	CC	O
animals	NNS	O
and	CC	O
is	VBZ	O
believed	VBN	O
to	TO	O
have	VB	O
an	DT	O
evolutionary	JJ	O
connection	NN	O
to	TO	O
viral	JJ	O
defense	NN	O
and	CC	O
transposon	NN	O
silencing	NN	O
.	.	O
The	DT	O
first	JJ	O
evidence	NN	O
that	IN	O
dsRNA	NN	O
could	MD	O
lead	VB	O
to	TO	O
gene	NN	O
silencing	VBG	O
in	IN	O
animals	NNS	O
came	VBD	O
in	IN	O
1995	CD	O
from	IN	O
work	NN	O
in	IN	O
the	DT	O
nematode	NN	O
,	,	O
Caenorhabditis	NNP	O
elegans	VBZ	O
(	(	O
Guo	NNP	B
and	CC	I
Kempheus	NNP	I
,	,	I
Cell	NNP	I
,	,	I
1995	CD	I
,	,	I
81	CD	I
,	,	I
611-620	JJ	I
)	)	O
.	.	O
The	DT	O
primary	JJ	O
interference	NN	O
effects	NNS	O
of	IN	O
dsRNA	NN	O
are	VBP	O
posttranscriptional	JJ	O
(	(	O
Montgomery	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
1998	CD	I
,	,	I
95	CD	I
,	,	I
15502-15507	JJ	I
)	)	O
.	.	O
The	DT	O
posttranscriptional	JJ	O
antisense	NN	O
mechanism	NN	O
defined	VBN	O
in	IN	O
Caenorhabditis	NNP	O
elegans	NNS	O
resulting	VBG	O
from	IN	O
exposure	NN	O
to	TO	O
double-stranded	JJ	O
RNA	NNP	O
(	(	O
dsRNA	NN	O
)	)	O
has	VBZ	O
since	IN	O
been	VBN	O
designated	VBN	O
RNA	NNP	O
interference	NN	O
(	(	O
RNAi	NNP	O
)	)	O
.	.	O
This	DT	O
term	NN	O
has	VBZ	O
been	VBN	O
generalized	VBN	O
to	TO	O
mean	VB	O
antisense-mediated	JJ	O
gene	NN	O
silencing	VBG	O
involving	VBG	O
the	DT	O
introduction	NN	O
of	IN	O
dsRNA	NN	O
leading	VBG	O
to	TO	O
the	DT	O
sequence-specific	JJ	O
reduction	NN	O
of	IN	O
endogenous	JJ	O
targeted	VBN	O
mRNA	NN	O
levels	NNS	O
(	(	O
Fire	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
1998	CD	I
,	,	I
391	CD	I
,	,	I
806-811	JJ	I
)	)	O
.	.	O
Recently	RB	O
,	,	O
the	DT	O
single-stranded	JJ	O
RNA	NNP	O
oligomers	NNS	O
of	IN	O
antisense	JJ	O
polarity	NN	O
of	IN	O
the	DT	O
dsRNAs	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
the	DT	O
potent	JJ	O
inducers	NNS	O
of	IN	O
RNAi	NNP	O
(	(	O
Tijsterman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
2002	CD	I
,	,	I
295	CD	I
,	,	I
694-697	JJ	I
)	)	O
.	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
also	RB	O
include	VBP	O
modified	JJ	O
compounds	NNS	O
in	IN	O
which	WDT	O
a	DT	O
different	JJ	O
base	NN	O
is	VBZ	O
present	JJ	O
at	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
nucleotide	JJ	O
positions	NNS	O
in	IN	O
the	DT	O
compound	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
if	IN	O
the	DT	O
first	JJ	O
nucleotide	NN	O
is	VBZ	O
an	DT	O
adenosine	NN	O
,	,	O
modified	VBD	O
compounds	NNS	O
may	MD	O
be	VB	O
produced	VBN	O
which	WDT	O
contain	VBP	O
thymidine	NN	O
,	,	O
guanosine	NN	O
or	CC	O
cytidine	NN	O
at	IN	O
this	DT	O
position	NN	O
.	.	O
This	DT	O
may	MD	O
be	VB	O
done	VBN	O
at	IN	O
any	DT	O
of	IN	O
the	DT	O
positions	NNS	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
.	.	O
These	DT	O
compounds	NNS	O
are	VBP	O
then	RB	O
tested	VBN	O
using	VBG	O
the	DT	O
methods	NNS	O
described	VBD	O
herein	NN	O
to	TO	O
determine	VB	O
their	PRP$	O
ability	NN	O
to	TO	O
inhibit	VB	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
oligomeric	JJ	O
compound	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
polymer	NN	O
or	CC	O
oligomer	NN	O
comprising	VBG	O
a	DT	O
plurality	NN	O
of	IN	O
monomeric	JJ	O
units	NNS	O
.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
oligonucleotide	IN	O
”	NNP	O
refers	NNS	O
to	TO	O
an	DT	O
oligomer	NN	O
or	CC	O
polymer	NN	O
of	IN	O
ribonucleic	NN	O
acid	NN	O
(	(	O
RNA	NNP	O
)	)	O
or	CC	O
deoxyribonucleic	JJ	O
acid	NN	O
(	(	O
DNA	NNP	O
)	)	O
or	CC	O
mimetics	NNS	O
,	,	O
chimeras	NNS	O
,	,	O
analogs	NNS	O
and	CC	O
homologs	NNS	O
thereof	NN	O
.	.	O
This	DT	O
term	NN	O
includes	VBZ	O
oligonucleotides	NNS	O
composed	VBN	O
of	IN	O
naturally	RB	O
occurring	VBG	O
nucleobases	NNS	O
,	,	O
sugars	NNS	O
and	CC	O
covalent	JJ	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	VBZ	O
as	RB	O
well	RB	O
as	IN	O
oligonucleotides	NNS	O
having	VBG	O
non-naturally	RB	O
occurring	VBG	O
portions	NNS	O
which	WDT	O
function	VBP	O
similarly	RB	O
.	.	O
Such	JJ	O
modified	VBD	O
or	CC	O
substituted	VBN	O
oligonucleotides	NNS	O
are	VBP	O
often	RB	O
preferred	VBN	O
over	RP	O
native	JJ	O
forms	NNS	O
because	IN	O
of	IN	O
desirable	JJ	O
properties	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
enhanced	VBD	O
cellular	JJ	O
uptake	NN	O
,	,	O
enhanced	VBD	O
affinity	NN	O
for	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
increased	JJ	O
stability	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
nucleases	NNS	O
.	.	O
While	IN	O
oligonucleotides	NNS	O
are	VBP	O
a	DT	O
preferred	JJ	O
form	NN	O
of	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
comprehends	VBZ	O
other	JJ	O
families	NNS	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
as	RB	O
well	RB	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
oligonucleotide	VB	O
analogs	NNS	O
and	CC	O
mimetics	NNS	O
such	JJ	O
as	IN	O
those	DT	O
described	JJ	O
herein	NN	O
.	.	O
The	DT	O
antisense	NN	O
compounds	VBZ	O
in	IN	O
accordance	NN	O
with	IN	O
this	DT	O
invention	NN	O
preferably	RB	O
comprise	NN	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
(	(	O
i.e	NN	O
.	.	O
from	IN	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
linked	VBD	O
nucleosides	NNS	O
)	)	O
.	.	O
One	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
the	DT	O
invention	NN	O
embodies	VBZ	O
compounds	NNS	O
of	IN	O
8	CD	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
50	CD	O
,	,	O
51	CD	O
,	,	O
52	CD	O
,	,	O
53	CD	O
,	,	O
54	CD	O
,	,	O
55	CD	O
,	,	O
56	CD	O
,	,	O
57	CD	O
,	,	O
58	CD	O
,	,	O
59	CD	O
,	,	O
60	CD	O
,	,	O
61	CD	O
,	,	O
62	CD	O
,	,	O
63	CD	O
,	,	O
64	CD	O
,	,	O
65	CD	O
,	,	O
66	CD	O
,	,	O
67	CD	O
,	,	O
68	CD	O
,	,	O
69	CD	O
,	,	O
70	CD	O
,	,	O
71	CD	O
,	,	O
72	CD	O
,	,	O
73	CD	O
,	,	O
74	CD	O
,	,	O
75	CD	O
,	,	O
76	CD	O
,	,	O
77	CD	O
,	,	O
78	CD	O
,	,	O
79	CD	O
,	,	O
or	CC	O
80	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
12	CD	O
to	TO	O
50	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
compounds	NNS	O
of	IN	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
or	CC	O
50	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
13	CD	O
to	TO	O
40	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
compounds	NNS	O
of	IN	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
or	CC	O
40	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
15	CD	O
to	TO	O
30	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
One	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
this	DT	O
embodies	VBZ	O
compounds	NNS	O
of	IN	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
,	,	O
19	CD	O
,	,	O
20	CD	O
,	,	O
21	CD	O
,	,	O
22	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
or	CC	O
30	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
further	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
oligonucleotides	IN	O
from	IN	O
about	IN	O
12	CD	O
to	TO	O
about	IN	O
50	CD	O
nucleobases	NNS	O
,	,	O
or	CC	O
from	IN	O
about	RB	O
13	CD	O
to	TO	O
40	CD	O
nucleobases	NNS	O
,	,	O
or	CC	O
from	IN	O
about	RB	O
15	CD	O
to	TO	O
about	IN	O
30	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
comprise	NN	O
at	IN	O
least	JJS	O
8	CD	O
contiguous	JJ	O
nucleobases	NNS	O
of	IN	O
an	DT	O
antisense	NN	O
compound	NN	O
disclosed	VBD	O
herein	NN	O
.	.	O
Antisense	NNP	O
compounds	VBZ	O
8-80	JJ	O
nucleobases	NNS	O
in	IN	O
length	NN	O
comprising	VBG	O
a	DT	O
stretch	NN	O
of	IN	O
at	IN	O
least	JJS	O
eight	CD	O
(	(	O
8	CD	O
)	)	O
consecutive	JJ	O
nucleobases	NNS	O
selected	VBN	O
from	IN	O
within	IN	O
the	DT	O
illustrative	JJ	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
suitable	JJ	O
antisense	JJ	O
compounds	NNS	O
as	RB	O
well	RB	O
.	.	O
Further	JJ	O
antisense	NN	O
compounds	NNS	O
include	VBP	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
5′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
(	(	O
the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
oligonucleotide	IN	O
beginning	VBG	O
immediately	RB	O
upstream	NN	O
of	IN	O
the	DT	O
5′-terminus	NN	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
that	WDT	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
)	)	O
.	.	O
Similarly	RB	O
,	,	O
antisense	JJ	O
compounds	NNS	O
are	VBP	O
represented	VBN	O
by	IN	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
(	(	O
the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
oligonucleotide	IN	O
beginning	VBG	O
immediately	RB	O
downstream	NN	O
of	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
the	DT	O
antisense	NN	O
compound	NN	O
that	WDT	O
is	VBZ	O
specifically	RB	O
hybridizable	JJ	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
understood	JJ	O
that	IN	O
antisense	JJ	O
compounds	NNS	O
may	MD	O
be	VB	O
represented	VBN	O
by	IN	O
oligonucleotide	JJ	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
an	DT	O
internal	JJ	O
portion	NN	O
of	IN	O
the	DT	O
sequence	NN	O
of	IN	O
an	DT	O
illustrative	JJ	O
preferred	JJ	O
antisense	NN	O
compound	NN	O
,	,	O
and	CC	O
may	MD	O
extend	VB	O
in	IN	O
either	DT	O
or	CC	O
both	DT	O
directions	NNS	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	NN	O
compound	NN	O
includes	VBZ	O
SEQ	NNP	O
ID	NNP	O
NOS	NNP	O
:	:	O
20	CD	O
,	,	O
21	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
50	CD	O
,	,	O
51	CD	O
,	,	O
52	CD	O
,	,	O
53	CD	O
,	,	O
54	CD	O
,	,	O
56	CD	O
,	,	O
57	CD	O
,	,	O
58	CD	O
,	,	O
60	CD	O
,	,	O
61	CD	O
,	,	O
62	CD	O
,	,	O
63	CD	O
,	,	O
64	CD	O
,	,	O
65	CD	O
,	,	O
66	CD	O
,	,	O
68	CD	O
,	,	O
69	CD	O
,	,	O
70	CD	O
,	,	O
71	CD	O
,	,	O
72	CD	O
,	,	O
73	CD	O
,	,	O
75	CD	O
,	,	O
76	CD	O
,	,	O
77	CD	O
,	,	O
78	CD	O
,	,	O
80	CD	O
,	,	O
81	CD	O
,	,	O
82	CD	O
,	,	O
83	CD	O
,	,	O
84	CD	O
,	,	O
85	CD	O
,	,	O
86	CD	O
,	,	O
87	CD	O
,	,	O
88	CD	O
,	,	O
89	CD	O
,	,	O
90	CD	O
,	,	O
91	CD	O
,	,	O
92	CD	O
,	,	O
94	CD	O
,	,	O
95	CD	O
,	,	O
96	CD	O
,	,	O
97	CD	O
,	,	O
101	CD	O
,	,	O
109	CD	O
,	,	O
114	CD	O
,	,	O
115	CD	O
,	,	O
120	CD	O
,	,	O
121	CD	O
,	,	O
122	CD	O
,	,	O
123	CD	O
,	,	O
124	CD	O
,	,	O
127	CD	O
,	,	O
128	CD	O
,	,	O
130	CD	O
,	,	O
133	CD	O
,	,	O
136	CD	O
or	CC	O
142	CD	O
.	.	O
In	IN	O
still	RB	O
other	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NOS	NNP	O
:	:	O
277	CD	O
through	IN	O
411	CD	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	NN	O
compound	NN	O
includes	VBZ	O
SEQ	NNP	O
ID	NNP	O
NOS	NNP	O
:	:	O
21	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
47	CD	O
,	,	O
49	CD	O
,	,	O
57	CD	O
,	,	O
62	CD	O
,	,	O
65	CD	O
,	,	O
66	CD	O
,	,	O
71	CD	O
,	,	O
73	CD	O
,	,	O
77	CD	O
,	,	O
81	CD	O
,	,	O
82	CD	O
,	,	O
90	CD	O
,	,	O
92	CD	O
or	CC	O
94	CD	O
One	CD	O
having	VBG	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
armed	VBN	O
with	IN	O
the	DT	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
illustrated	VBN	O
herein	NN	O
will	MD	O
be	VB	O
able	JJ	O
,	,	O
without	IN	O
undue	JJ	O
experimentation	NN	O
,	,	O
to	TO	O
identify	VB	O
further	RB	O
preferred	JJ	O
antisense	JJ	O
compounds	NNS	O
.	.	O
C.	NNP	O
Targets	NNP	O
of	IN	O
the	DT	O
Invention	NNP	O
“	NNP	O
Targeting	NNP	O
”	NNP	O
an	DT	O
antisense	NN	O
compound	NN	O
to	TO	O
a	DT	O
particular	JJ	O
nucleic	NN	O
acid	NN	O
molecule	NN	O
,	,	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
can	MD	O
be	VB	O
a	DT	O
multistep	NN	O
process	NN	O
.	.	O
The	DT	O
process	NN	O
usually	RB	O
begins	VBZ	O
with	IN	O
the	DT	O
identification	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
whose	WP$	O
function	NN	O
is	VBZ	O
to	TO	O
be	VB	O
modulated	VBN	O
.	.	O
This	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
may	MD	O
be	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
cellular	JJ	O
gene	NN	O
(	(	O
or	CC	O
mRNA	VB	O
transcribed	VBN	O
from	IN	O
the	DT	O
gene	NN	O
)	)	O
whose	WP$	O
expression	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
particular	JJ	O
disorder	NN	O
or	CC	O
disease	NN	O
state	NN	O
,	,	O
or	CC	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
from	IN	O
an	DT	O
infectious	JJ	O
agent	NN	O
.	.	O
In	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
encodes	NNS	O
diacylglycerol	VBP	O
acyltransferase	JJ	O
2	CD	O
.	.	O
The	DT	O
targeting	VBG	O
process	NN	O
usually	RB	O
also	RB	O
includes	VBZ	O
determination	NN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
target	NN	O
region	NN	O
,	,	O
segment	NN	O
,	,	O
or	CC	O
site	NN	O
within	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
for	IN	O
the	DT	O
antisense	JJ	O
interaction	NN	O
to	TO	O
occur	VB	O
such	JJ	O
that	IN	O
the	DT	O
desired	JJ	O
effect	NN	O
,	,	O
e.g.	NN	O
,	,	O
modulation	NN	O
of	IN	O
expression	NN	O
,	,	O
will	MD	O
result	VB	O
.	.	O
Within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
region	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
at	IN	O
least	JJS	O
one	CD	O
identifiable	JJ	O
structure	NN	O
,	,	O
function	NN	O
,	,	O
or	CC	O
characteristic	JJ	O
.	.	O
Within	IN	O
regions	NNS	O
of	IN	O
target	NN	O
nucleic	JJ	O
acids	NNS	O
are	VBP	O
segments	NNS	O
.	.	O
“	JJ	O
Segments	NNS	O
”	WDT	O
are	VBP	O
defined	VBN	O
as	IN	O
smaller	JJR	O
or	CC	O
sub-portions	NNS	O
of	IN	O
regions	NNS	O
within	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
“	NN	O
Sites	NNS	O
,	,	O
”	NN	O
as	IN	O
used	VBN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
are	VBP	O
defined	VBN	O
as	IN	O
positions	NNS	O
within	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
Since	IN	O
,	,	O
as	IN	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
is	VBZ	O
typically	RB	O
5′-AUG	JJ	O
(	(	O
in	IN	O
transcribed	VBN	O
mRNA	NN	O
molecules	NNS	O
;	:	O
5′-ATG	JJ	O
in	IN	O
the	DT	O
corresponding	JJ	O
DNA	NNP	O
molecule	NN	O
)	)	O
,	,	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
is	VBZ	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
“	NNP	O
AUG	NNP	O
codon	NN	O
,	,	O
”	VBP	O
the	DT	O
“	NNP	O
start	NN	O
codon	NN	O
”	NN	O
or	CC	O
the	DT	O
“	JJ	O
AUG	NNP	O
start	NN	O
codon	NN	O
”	NN	O
.	.	O
A	DT	O
minority	NN	O
of	IN	O
genes	NNS	O
having	VBG	O
a	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
with	IN	O
the	DT	O
RNA	NNP	O
sequence	NN	O
5′-GUG	CD	O
,	,	O
5′-UUG	CD	O
or	CC	O
5′-CUG	JJ	O
,	,	O
and	CC	O
5′-AUA	JJ	O
,	,	O
5′-ACG	JJ	O
and	CC	O
5′-CUG	JJ	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
function	NN	O
in	IN	O
vivo	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
terms	NNS	O
“	VBP	O
translation	NN	O
initiation	NN	O
codon	NN	O
”	NN	O
and	CC	O
“	JJ	O
start	NN	O
codon	NN	O
”	NN	O
can	MD	O
encompass	VB	O
many	JJ	O
codon	NN	O
sequences	NNS	O
,	,	O
even	RB	O
though	IN	O
the	DT	O
initiator	NN	O
amino	NN	O
acid	NN	O
in	IN	O
each	DT	O
instance	NN	O
is	VBZ	O
typically	RB	O
methionine	JJ	O
(	(	O
in	IN	O
eukaryotes	NNS	O
)	)	O
or	CC	O
formylmethionine	NN	O
(	(	O
in	IN	O
prokaryotes	NNS	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
eukaryotic	JJ	O
and	CC	O
prokaryotic	JJ	O
genes	NNS	O
may	MD	O
have	VB	O
two	CD	O
or	CC	O
more	JJR	O
alternative	JJ	O
start	NN	O
codons	NNS	O
,	,	O
any	DT	O
one	CD	O
of	IN	O
which	WDT	O
may	MD	O
be	VB	O
preferentially	RB	O
utilized	JJ	O
for	IN	O
translation	NN	O
initiation	NN	O
in	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
type	NN	O
or	CC	O
tissue	NN	O
,	,	O
or	CC	O
under	IN	O
a	DT	O
particular	JJ	O
set	NN	O
of	IN	O
conditions	NNS	O
.	.	O
In	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
“	JJ	O
start	VBP	O
codon	VB	O
”	NN	O
and	CC	O
“	JJ	O
translation	NN	O
initiation	NN	O
codon	NN	O
”	NNP	O
refer	NN	O
to	TO	O
the	DT	O
codon	NN	O
or	CC	O
codons	NNS	O
that	WDT	O
are	VBP	O
used	VBN	O
in	IN	O
vivo	NN	O
to	TO	O
initiate	VB	O
translation	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
transcribed	NN	O
from	IN	O
a	DT	O
gene	NN	O
encoding	VBG	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
sequence	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
such	JJ	O
codons	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
a	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
(	(	O
or	CC	O
“	VB	O
stop	JJ	O
codon	NN	O
”	NNP	O
)	)	O
of	IN	O
a	DT	O
gene	NN	O
may	MD	O
have	VB	O
one	CD	O
of	IN	O
three	CD	O
sequences	NNS	O
,	,	O
i.e.	FW	O
,	,	O
5′-UAA	JJ	O
,	,	O
5′-UAG	JJ	O
and	CC	O
5′-UGA	JJ	O
(	(	O
the	DT	O
corresponding	NN	O
DNA	NN	O
sequences	NNS	O
are	VBP	O
5′-TAA	JJ	O
,	,	O
5′-TAG	JJ	O
and	CC	O
5′-TGA	JJ	O
,	,	O
respectively	RB	O
)	)	O
.	.	O
The	DT	O
terms	NNS	O
“	VBP	O
start	VBP	O
codon	JJ	O
region	NN	O
”	NN	O
and	CC	O
“	JJ	O
translation	NN	O
initiation	NN	O
codon	NN	O
region	NN	O
”	NNP	O
refer	NN	O
to	TO	O
a	DT	O
portion	NN	O
of	IN	O
such	JJ	O
an	DT	O
mRNA	NN	O
or	CC	O
gene	NN	O
that	WDT	O
encompasses	VBZ	O
from	IN	O
about	RB	O
25	CD	O
to	TO	O
about	IN	O
50	CD	O
contiguous	JJ	O
nucleotides	NNS	O
in	IN	O
either	DT	O
direction	NN	O
(	(	O
i.e.	JJ	O
,	,	O
5′	CD	O
or	CC	O
3′	CD	O
)	)	O
from	IN	O
a	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
.	.	O
Similarly	RB	O
,	,	O
the	DT	O
terms	NNS	O
“	VBP	O
stop	JJ	O
codon	NN	O
region	NN	O
”	NNP	O
and	CC	O
“	NNP	O
translation	NN	O
termination	NN	O
codon	NN	O
region	NN	O
”	NNP	O
refer	NN	O
to	TO	O
a	DT	O
portion	NN	O
of	IN	O
such	JJ	O
an	DT	O
mRNA	NN	O
or	CC	O
gene	NN	O
that	WDT	O
encompasses	VBZ	O
from	IN	O
about	RB	O
25	CD	O
to	TO	O
about	IN	O
50	CD	O
contiguous	JJ	O
nucleotides	NNS	O
in	IN	O
either	DT	O
direction	NN	O
(	(	O
i.e.	JJ	O
,	,	O
5′	CD	O
or	CC	O
3′	CD	O
)	)	O
from	IN	O
a	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
.	.	O
Consequently	RB	O
,	,	O
the	DT	O
“	NNP	O
start	NN	O
codon	NN	O
region	NN	O
”	NNP	O
(	(	O
or	CC	O
“	VB	O
translation	NN	O
initiation	NN	O
codon	NN	O
region	NN	O
”	NNP	O
)	)	O
and	CC	O
the	DT	O
“	NNP	O
stop	NN	O
codon	NN	O
region	NN	O
”	NNP	O
(	(	O
or	CC	O
“	VB	O
translation	NN	O
termination	NN	O
codon	NN	O
region	NN	O
”	NN	O
)	)	O
are	VBP	O
all	DT	O
regions	NNS	O
which	WDT	O
may	MD	O
be	VB	O
targeted	VBN	O
effectively	RB	O
with	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
(	(	O
ORF	NNP	O
)	)	O
or	CC	O
“	$	O
coding	VBG	O
region	NN	O
,	,	O
”	NNP	O
which	WDT	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
region	NN	O
between	IN	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
and	CC	O
the	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
,	,	O
is	VBZ	O
also	RB	O
a	DT	O
region	NN	O
which	WDT	O
may	MD	O
be	VB	O
targeted	VBN	O
effectively	RB	O
.	.	O
Within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
a	DT	O
preferred	JJ	O
region	NN	O
is	VBZ	O
the	DT	O
intragenic	JJ	O
region	NN	O
encompassing	VBG	O
the	DT	O
translation	NN	O
initiation	NN	O
or	CC	O
termination	NN	O
codon	NN	O
of	IN	O
the	DT	O
open	JJ	O
reading	NN	O
frame	NN	O
(	(	O
ORF	NNP	O
)	)	O
of	IN	O
a	DT	O
gene	NN	O
.	.	O
Other	JJ	O
target	NN	O
regions	NNS	O
include	VBP	O
the	DT	O
5′	CD	O
untranslated	JJ	O
region	NN	O
(	(	O
5′UTR	CD	O
)	)	O
,	,	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
portion	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
in	IN	O
the	DT	O
5′	CD	O
direction	NN	O
from	IN	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
,	,	O
and	CC	O
thus	RB	O
including	VBG	O
nucleotides	NNS	O
between	IN	O
the	DT	O
5′	CD	O
cap	NN	O
site	NN	O
and	CC	O
the	DT	O
translation	NN	O
initiation	NN	O
codon	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
(	(	O
or	CC	O
corresponding	VBG	O
nucleotides	NNS	O
on	IN	O
the	DT	O
gene	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
3′	CD	O
untranslated	JJ	O
region	NN	O
(	(	O
3′UTR	CD	O
)	)	O
,	,	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
refer	VB	O
to	TO	O
the	DT	O
portion	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
in	IN	O
the	DT	O
3′	CD	O
direction	NN	O
from	IN	O
the	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
,	,	O
and	CC	O
thus	RB	O
including	VBG	O
nucleotides	NNS	O
between	IN	O
the	DT	O
translation	NN	O
termination	NN	O
codon	NN	O
and	CC	O
3′	CD	O
end	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
(	(	O
or	CC	O
corresponding	VBG	O
nucleotides	NNS	O
on	IN	O
the	DT	O
gene	NN	O
)	)	O
.	.	O
The	DT	O
5′	CD	O
cap	NN	O
site	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
comprises	VBZ	O
an	DT	O
N7-methylated	JJ	O
guanosine	NN	O
residue	NN	O
joined	VBD	O
to	TO	O
the	DT	O
5′-most	JJ	O
residue	NN	O
of	IN	O
the	DT	O
mRNA	NN	O
via	IN	O
a	DT	O
5′-5′	JJ	O
triphosphate	NN	O
linkage	NN	O
.	.	O
The	DT	O
5′	CD	O
cap	NN	O
region	NN	O
of	IN	O
an	DT	O
mRNA	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
include	VB	O
the	DT	O
5′	CD	O
cap	NN	O
structure	NN	O
itself	PRP	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
first	JJ	O
50	CD	O
nucleotides	NNS	O
adjacent	JJ	O
to	TO	O
the	DT	O
cap	NN	O
site	NN	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
preferred	VBN	O
to	TO	O
target	VB	O
the	DT	O
5′	CD	O
cap	NN	O
region	NN	O
.	.	O
Accordingly	RB	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
provides	VBZ	O
antisense	JJ	O
compounds	NNS	O
that	WDT	O
target	VBP	O
a	DT	O
portion	NN	O
of	IN	O
nucleotides	NNS	O
1-2439	JJ	O
as	IN	O
set	NN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
target	NN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
nucleotides	NNS	O
1-230	JJ	O
,	,	O
comprising	VBG	O
the	DT	O
5′UTR	CD	O
as	IN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
target	NN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
nucleotides	NNS	O
1395-2439	JJ	O
,	,	O
comprising	VBG	O
the	DT	O
3′UTR	CD	O
as	IN	O
set	VBN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
target	NN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
nucleotides	NNS	O
231-1394	JJ	O
,	,	O
comprising	VBG	O
the	DT	O
coding	VBG	O
region	NN	O
as	IN	O
set	NN	O
forth	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
.	.	O
In	IN	O
still	RB	O
other	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
target	NN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
a	DT	O
“	NN	O
preferred	JJ	O
target	NN	O
segment	NN	O
”	NN	O
(	(	O
as	IN	O
defined	VBN	O
herein	NN	O
)	)	O
as	IN	O
set	VBN	O
forth	NN	O
in	IN	O
Table	JJ	O
3	CD	O
or	CC	O
additional	JJ	O
Tables	NNS	O
in	IN	O
the	DT	O
Examples	NNP	O
below	IN	O
.	.	O
Although	IN	O
some	DT	O
eukaryotic	JJ	O
mRNA	NN	O
transcripts	NNS	O
are	VBP	O
directly	RB	O
translated	VBN	O
,	,	O
many	JJ	O
contain	VBP	O
one	CD	O
or	CC	O
more	JJR	O
regions	NNS	O
,	,	O
known	VBN	O
as	IN	O
“	JJ	O
introns	NNS	O
,	,	O
”	NN	O
which	WDT	O
are	VBP	O
excised	VBN	O
from	IN	O
a	DT	O
transcript	NN	O
before	IN	O
it	PRP	O
is	VBZ	O
translated	VBN	O
.	.	O
The	DT	O
remaining	VBG	O
(	(	O
and	CC	O
therefore	RB	O
translated	VBD	O
)	)	O
regions	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
“	JJ	O
exons	NNS	O
”	NN	O
and	CC	O
are	VBP	O
spliced	VBN	O
together	RB	O
to	TO	O
form	VB	O
a	DT	O
continuous	JJ	O
mRNA	NN	O
sequence	NN	O
,	,	O
resulting	VBG	O
in	IN	O
exon-exon	JJ	O
junctions	NNS	O
at	IN	O
the	DT	O
sites	NNS	O
where	WRB	O
exons	NNS	O
are	VBP	O
joined	VBN	O
.	.	O
Targeting	VBG	O
exon-exon	JJ	O
junctions	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
in	IN	O
situations	NNS	O
where	WRB	O
the	DT	O
overproduction	NN	O
of	IN	O
a	DT	O
normal	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease	NN	O
,	,	O
or	CC	O
where	WRB	O
the	DT	O
overproduction	NN	O
of	IN	O
an	DT	O
aberrant	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease	NN	O
.	.	O
Targeting	VBG	O
splice	NN	O
sites	NNS	O
,	,	O
i.e.	FW	O
,	,	O
intron-exon	JJ	O
junctions	NNS	O
or	CC	O
exon-intron	JJ	O
junctions	NNS	O
,	,	O
may	MD	O
also	RB	O
be	VB	O
particularly	RB	O
useful	JJ	O
in	IN	O
situations	NNS	O
where	WRB	O
aberrant	JJ	O
splicing	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease	NN	O
,	,	O
or	CC	O
where	WRB	O
an	DT	O
overproduction	NN	O
of	IN	O
a	DT	O
particular	JJ	O
splice	NN	O
product	NN	O
is	VBZ	O
implicated	VBN	O
in	IN	O
disease	NN	O
.	.	O
Aberrant	JJ	O
fusion	NN	O
junctions	NNS	O
due	JJ	O
to	TO	O
rearrangements	NNS	O
or	CC	O
deletions	NNS	O
are	VBP	O
also	RB	O
preferred	JJ	O
target	NN	O
sites	NNS	O
.	.	O
mRNA	NN	O
transcripts	NNS	O
produced	VBD	O
via	IN	O
the	DT	O
process	NN	O
of	IN	O
splicing	VBG	O
of	IN	O
two	CD	O
(	(	O
or	CC	O
more	JJR	O
)	)	O
mRNAs	NN	O
from	IN	O
different	JJ	O
gene	NN	O
sources	NNS	O
,	,	O
known	VBN	O
as	IN	O
“	JJ	O
fusion	NN	O
transcripts	NNS	O
”	VBP	O
,	,	O
are	VBP	O
also	RB	O
suitable	JJ	O
target	NN	O
sites	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
that	IN	O
introns	NNS	O
can	MD	O
be	VB	O
effectively	RB	O
targeted	VBN	O
using	VBG	O
antisense	JJ	O
compounds	NNS	O
targeted	VBN	O
to	TO	O
,	,	O
for	IN	O
example	NN	O
,	,	O
DNA	NNP	O
or	CC	O
pre-mRNA	NN	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	WDT	O
alternative	JJ	O
RNA	NNP	O
transcripts	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
region	NN	O
of	IN	O
DNA	NNP	O
.	.	O
These	DT	O
alternative	JJ	O
transcripts	NNS	O
are	VBP	O
generally	RB	O
known	VBN	O
as	IN	O
“	JJ	O
variants	NNS	O
”	VBP	O
.	.	O
More	RBR	O
specifically	RB	O
,	,	O
“	JJ	O
pre-mRNA	JJ	O
variants	NNS	O
”	WDT	O
are	VBP	O
transcripts	NNS	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
DNA	NN	O
that	WDT	O
differ	VBP	O
from	IN	O
other	JJ	O
transcripts	NNS	O
produced	VBN	O
from	IN	O
the	DT	O
same	JJ	O
genomic	JJ	O
DNA	NN	O
in	IN	O
either	CC	O
their	PRP$	O
start	NN	O
or	CC	O
stop	VB	O
position	NN	O
and	CC	O
contain	VB	O
both	DT	O
intronic	JJ	O
and	CC	O
exonic	JJ	O
sequence	NN	O
.	.	O
Upon	IN	O
excision	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
exon	NNS	O
or	CC	O
intron	NN	O
regions	NNS	O
,	,	O
or	CC	O
portions	NNS	O
thereof	VBP	O
during	IN	O
splicing	NN	O
,	,	O
pre-mRNA	JJ	O
variants	NNS	O
produce	VBP	O
smaller	JJR	O
“	NN	O
mRNA	NN	O
variants	NNS	O
”	VBP	O
.	.	O
Consequently	RB	O
,	,	O
mRNA	JJ	O
variants	NNS	O
are	VBP	O
processed	VBN	O
pre-mRNA	JJ	O
variants	NNS	O
,	,	O
and	CC	O
each	DT	O
unique	JJ	O
pre-mRNA	JJ	O
variant	NN	O
must	MD	O
always	RB	O
produce	VB	O
a	DT	O
unique	JJ	O
mRNA	NN	O
variant	NN	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
splicing	NN	O
.	.	O
These	DT	O
mRNA	JJ	O
variants	NNS	O
are	VBP	O
also	RB	O
known	VBN	O
as	IN	O
“	JJ	O
alternative	JJ	O
splice	NN	O
variants	NNS	O
”	VBP	O
.	.	O
If	IN	O
no	DT	O
splicing	NN	O
of	IN	O
the	DT	O
pre-mRNA	JJ	O
variant	NN	O
occurs	VBZ	O
then	RB	O
the	DT	O
pre-mRNA	JJ	O
variant	NN	O
is	VBZ	O
identical	JJ	O
to	TO	O
the	DT	O
mRNA	NN	O
variant	NN	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
variants	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
alternative	JJ	O
signals	NNS	O
to	TO	O
start	VB	O
or	CC	O
stop	VB	O
transcription	NN	O
and	CC	O
that	IN	O
pre-mRNAs	JJ	O
and	CC	O
mRNAs	NN	O
can	MD	O
possess	VB	O
more	JJR	O
that	DT	O
one	CD	O
start	NN	O
codon	NN	O
or	CC	O
stop	VB	O
codon	NN	O
.	.	O
Variants	NNS	O
that	WDT	O
originate	VBP	O
from	IN	O
a	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA	NN	O
that	IN	O
use	NN	O
alternative	JJ	O
start	NN	O
codons	NNS	O
are	VBP	O
known	VBN	O
as	IN	O
“	JJ	O
alternative	JJ	O
start	NN	O
variants	NNS	O
”	CD	O
of	IN	O
that	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA	NN	O
.	.	O
Those	DT	O
transcripts	NNS	O
that	WDT	O
use	VBP	O
an	DT	O
alternative	JJ	O
stop	NN	O
codon	NN	O
are	VBP	O
known	VBN	O
as	IN	O
“	JJ	O
alternative	JJ	O
stop	NN	O
variants	NNS	O
”	CD	O
of	IN	O
that	DT	O
pre-mRNA	NN	O
or	CC	O
mRNA	NN	O
.	.	O
One	CD	O
specific	JJ	O
type	NN	O
of	IN	O
alternative	JJ	O
stop	NN	O
variant	NN	O
is	VBZ	O
the	DT	O
“	JJ	O
polyA	NN	O
variant	NN	O
”	NN	O
in	IN	O
which	WDT	O
the	DT	O
multiple	NN	O
transcripts	NNS	O
produced	VBD	O
result	NN	O
from	IN	O
the	DT	O
alternative	JJ	O
selection	NN	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
“	NNP	O
polyA	NN	O
stop	NN	O
signals	NNS	O
”	VBN	O
by	IN	O
the	DT	O
transcription	NN	O
machinery	NN	O
,	,	O
thereby	RB	O
producing	VBG	O
transcripts	NNS	O
that	WDT	O
terminate	VBP	O
at	IN	O
unique	JJ	O
polyA	NN	O
sites	NNS	O
.	.	O
Within	IN	O
the	DT	O
context	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
types	NNS	O
of	IN	O
variants	NNS	O
described	VBN	O
herein	NNS	O
are	VBP	O
also	RB	O
preferred	JJ	O
target	NN	O
nucleic	JJ	O
acids	NNS	O
.	.	O
The	DT	O
locations	NNS	O
on	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
which	WDT	O
the	DT	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
hybridize	VBP	O
are	VBP	O
hereinbelow	JJ	O
referred	VBN	O
to	TO	O
as	IN	O
“	JJ	O
preferred	JJ	O
target	NN	O
segments.	NN	O
”	NN	O
As	IN	O
used	VBN	O
herein	PDT	O
the	DT	O
term	NN	O
“	NNP	O
preferred	VBD	O
target	NN	O
segment	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
a	DT	O
target	NN	O
region	NN	O
to	TO	O
which	WDT	O
an	DT	O
active	JJ	O
antisense	NN	O
compound	NN	O
is	VBZ	O
targeted	VBN	O
.	.	O
While	IN	O
not	RB	O
wishing	VBG	O
to	TO	O
be	VB	O
bound	VBN	O
by	IN	O
theory	NN	O
,	,	O
it	PRP	O
is	VBZ	O
presently	RB	O
believed	VBN	O
that	IN	O
these	DT	O
target	NN	O
segments	NNS	O
represent	JJ	O
portions	NNS	O
of	IN	O
the	DT	O
target	NN	O
nucleic	NN	O
acid	NN	O
which	WDT	O
are	VBP	O
accessible	JJ	O
for	IN	O
hybridization	NN	O
.	.	O
While	IN	O
the	DT	O
specific	JJ	O
sequences	NNS	O
of	IN	O
certain	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
are	VBP	O
set	VBN	O
forth	JJ	O
herein	NN	O
,	,	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
that	IN	O
these	DT	O
serve	VBP	O
to	TO	O
illustrate	VB	O
and	CC	O
describe	VB	O
particular	JJ	O
embodiments	NNS	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Additional	JJ	O
preferred	VBD	O
target	NN	O
segments	NNS	O
may	MD	O
be	VB	O
identified	VBN	O
by	IN	O
one	CD	O
having	VBG	O
ordinary	JJ	O
skill	NN	O
.	.	O
Target	NN	O
segments	NNS	O
8-80	JJ	O
nucleobases	NNS	O
in	IN	O
length	NN	O
comprising	VBG	O
a	DT	O
stretch	NN	O
of	IN	O
at	IN	O
least	JJS	O
eight	CD	O
(	(	O
8	CD	O
)	)	O
consecutive	JJ	O
nucleobases	NNS	O
selected	VBN	O
from	IN	O
within	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
are	VBP	O
considered	VBN	O
to	TO	O
be	VB	O
suitable	JJ	O
for	IN	O
targeting	VBG	O
as	RB	O
well	RB	O
.	.	O
Target	NN	O
segments	NNS	O
can	MD	O
include	VB	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
5′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
(	(	O
the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
beginning	VBG	O
immediately	RB	O
upstream	NN	O
of	IN	O
the	DT	O
5′-terminus	NN	O
of	IN	O
the	DT	O
target	NN	O
segment	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
)	)	O
.	.	O
Similarly	RB	O
preferred	VBN	O
target	NN	O
segments	NNS	O
are	VBP	O
represented	VBN	O
by	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
the	DT	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
illustrative	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
(	(	O
the	DT	O
remaining	VBG	O
nucleobases	NNS	O
being	VBG	O
a	DT	O
consecutive	JJ	O
stretch	NN	O
of	IN	O
the	DT	O
same	JJ	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
beginning	VBG	O
immediately	RB	O
downstream	NN	O
of	IN	O
the	DT	O
3′-terminus	CD	O
of	IN	O
the	DT	O
target	NN	O
segment	NN	O
and	CC	O
continuing	VBG	O
until	IN	O
the	DT	O
DNA	NN	O
or	CC	O
RNA	NNP	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
understood	JJ	O
that	IN	O
preferred	JJ	O
antisense	NN	O
target	NN	O
segments	NNS	O
may	MD	O
be	VB	O
represented	VBN	O
by	IN	O
DNA	NNP	O
or	CC	O
RNA	NNP	O
sequences	NNS	O
that	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
8	CD	O
consecutive	JJ	O
nucleobases	NNS	O
from	IN	O
an	DT	O
internal	JJ	O
portion	NN	O
of	IN	O
the	DT	O
sequence	NN	O
of	IN	O
an	DT	O
illustrative	JJ	O
preferred	JJ	O
target	NN	O
segment	NN	O
,	,	O
and	CC	O
may	MD	O
extend	VB	O
in	IN	O
either	DT	O
or	CC	O
both	DT	O
directions	NNS	O
until	IN	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
about	IN	O
8	CD	O
to	TO	O
about	IN	O
80	CD	O
nucleobases	NNS	O
.	.	O
One	CD	O
having	VBG	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
armed	VBN	O
with	IN	O
the	DT	O
preferred	JJ	O
target	NN	O
segments	NNS	O
illustrated	VBD	O
herein	NN	O
will	MD	O
be	VB	O
able	JJ	O
,	,	O
without	IN	O
undue	JJ	O
experimentation	NN	O
,	,	O
to	TO	O
identify	VB	O
further	RB	O
preferred	JJ	O
target	NN	O
segments	NNS	O
.	.	O
Once	RB	O
one	CD	O
or	CC	O
more	JJR	O
target	NN	O
regions	NNS	O
,	,	O
segments	NNS	O
or	CC	O
sites	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
,	,	O
antisense	JJ	O
compounds	NNS	O
are	VBP	O
chosen	VBN	O
which	WDT	O
are	VBP	O
sufficiently	RB	O
complementary	JJ	O
to	TO	O
the	DT	O
target	NN	O
,	,	O
i.e.	FW	O
,	,	O
hybridize	VB	O
sufficiently	RB	O
well	RB	O
and	CC	O
with	IN	O
sufficient	JJ	O
specificity	NN	O
,	,	O
to	TO	O
give	VB	O
the	DT	O
desired	JJ	O
effect	NN	O
.	.	O
The	DT	O
oligomeric	JJ	O
antisense	NN	O
compounds	NNS	O
can	MD	O
also	RB	O
be	VB	O
targeted	VBN	O
to	TO	O
regions	NNS	O
of	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
such	JJ	O
as	IN	O
those	DT	O
disclosed	VBN	O
herein	NN	O
(	(	O
e.g.	JJ	O
,	,	O
in	IN	O
Example	NNP	O
13	CD	O
)	)	O
All	DT	O
regions	NNS	O
of	IN	O
a	DT	O
nucleobase	JJ	O
sequence	NN	O
to	TO	O
which	WDT	O
an	DT	O
oligomeric	JJ	O
antisense	NN	O
compound	NN	O
can	MD	O
be	VB	O
targeted	VBN	O
,	,	O
wherein	VBZ	O
the	DT	O
regions	NNS	O
are	VBP	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
nucleobases	NNS	O
,	,	O
are	VBP	O
described	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
Let	VB	O
R	NNP	O
(	(	O
n	JJ	O
,	,	O
n+m−1	JJ	O
)	)	O
be	VB	O
a	DT	O
region	NN	O
from	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
where	WRB	O
“	NN	O
n	JJ	O
”	NN	O
is	VBZ	O
the	DT	O
5′-most	JJ	O
nucleobase	JJ	O
position	NN	O
of	IN	O
the	DT	O
region	NN	O
,	,	O
where	WRB	O
“	NN	O
n+m−1	JJ	O
”	NN	O
is	VBZ	O
the	DT	O
3′-most	JJ	O
nucleobase	JJ	O
position	NN	O
of	IN	O
the	DT	O
region	NN	O
and	CC	O
where	WRB	O
“	NNP	O
m	NN	O
”	NN	O
is	VBZ	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
region	NN	O
.	.	O
A	DT	O
set	NN	O
“	NN	O
S	NNP	O
(	(	O
m	NN	O
)	)	O
”	NN	O
,	,	O
of	IN	O
regions	NNS	O
of	IN	O
length	NN	O
“	NNP	O
m	NN	O
”	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
the	DT	O
regions	NNS	O
where	WRB	O
n	JJ	O
ranges	NNS	O
from	IN	O
1	CD	O
to	TO	O
L−m+1	NNP	O
,	,	O
where	WRB	O
L	NNP	O
is	VBZ	O
the	DT	O
length	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
and	CC	O
L	NNP	O
>	NNP	O
m	NN	O
.	.	O
A	DT	O
set	NN	O
,	,	O
“	VB	O
A	NNP	O
”	NNP	O
,	,	O
of	IN	O
all	DT	O
regions	NNS	O
can	MD	O
be	VB	O
constructed	VBN	O
as	IN	O
a	DT	O
union	NN	O
of	IN	O
the	DT	O
sets	NNS	O
of	IN	O
regions	NNS	O
for	IN	O
each	DT	O
length	NN	O
from	IN	O
where	WRB	O
m	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
is	VBZ	O
less	RBR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
.	.	O
This	DT	O
set	NN	O
of	IN	O
regions	NNS	O
can	MD	O
be	VB	O
represented	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
mathematical	JJ	O
notation	NN	O
:	:	O
where	WRB	O
the	DT	O
mathematical	JJ	O
operator	NN	O
|	NN	O
indicates	VBZ	O
“	NNS	O
such	JJ	O
that	IN	O
”	NN	O
,	,	O
where	WRB	O
the	DT	O
mathematical	JJ	O
operator	NN	O
ε	NN	O
indicates	VBZ	O
“	VBP	O
a	DT	O
member	NN	O
of	IN	O
a	DT	O
set	NN	O
”	NN	O
(	(	O
e.g	NN	O
.	.	O
yεZ	NN	O
indicates	VBZ	O
that	IN	O
element	NN	O
y	NN	O
is	VBZ	O
a	DT	O
member	NN	O
of	IN	O
set	VBN	O
Z	NNP	O
)	)	O
,	,	O
where	WRB	O
x	NN	O
is	VBZ	O
a	DT	O
variable	JJ	O
,	,	O
where	WRB	O
N	NNP	O
indicates	VBZ	O
all	DT	O
natural	JJ	O
numbers	NNS	O
,	,	O
defined	VBD	O
as	IN	O
positive	JJ	O
integers	NNS	O
,	,	O
and	CC	O
where	WRB	O
the	DT	O
mathematical	JJ	O
operator	NN	O
∪	NN	O
indicates	VBZ	O
“	IN	O
the	DT	O
union	NN	O
of	IN	O
sets	NNS	O
”	NNP	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
for	IN	O
m	JJ	O
equal	JJ	O
to	TO	O
8	CD	O
,	,	O
20	CD	O
and	CC	O
80	CD	O
can	MD	O
be	VB	O
constructed	VBN	O
in	IN	O
the	DT	O
following	JJ	O
manner	NN	O
.	.	O
The	DT	O
set	NN	O
of	IN	O
regions	NNS	O
,	,	O
each	DT	O
8	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
S	NNP	O
(	(	O
m=8	NN	O
)	)	O
,	,	O
in	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
(	(	O
L=100	NNP	O
)	)	O
,	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
(	(	O
n=1	NN	O
)	)	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
can	MD	O
be	VB	O
created	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression	NN	O
:	:	O
S	NNP	O
(	(	O
8	CD	O
)	)	O
=	NN	O
{	(	O
R	NNP	O
1,8	CD	O
|n	NNP	O
ε	NNP	O
{	(	O
1,2,3	CD	O
,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
93	CD	O
}	)	O
}	)	O
and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-8	JJ	O
,	,	O
2-9	JJ	O
,	,	O
3-10	JJ	O
,	,	O
4-11	JJ	O
,	,	O
5-12	JJ	O
,	,	O
6-13	JJ	O
,	,	O
7-14	JJ	O
,	,	O
8-15	JJ	O
,	,	O
9-16	JJ	O
,	,	O
10-17	JJ	O
,	,	O
11-18	JJ	O
,	,	O
12-19	JJ	O
,	,	O
13-20	JJ	O
,	,	O
14-21	JJ	O
,	,	O
15-22	JJ	O
,	,	O
16-23	JJ	O
,	,	O
17-24	JJ	O
,	,	O
18-25	JJ	O
,	,	O
19-26	JJ	O
,	,	O
20-27	JJ	O
,	,	O
21-28	JJ	O
,	,	O
22-29	JJ	O
,	,	O
23-30	JJ	O
,	,	O
24-31	JJ	O
,	,	O
25-32	JJ	O
,	,	O
26-33	JJ	O
,	,	O
27-34	JJ	O
,	,	O
28-35	JJ	O
,	,	O
29-36	JJ	O
,	,	O
30-37	JJ	O
,	,	O
31-38	JJ	O
,	,	O
32-39	JJ	O
,	,	O
33-40	JJ	O
,	,	O
34-41	JJ	O
,	,	O
35-42	JJ	O
,	,	O
36-43	JJ	O
,	,	O
37-44	JJ	O
,	,	O
38-45	JJ	O
,	,	O
39-46	JJ	O
,	,	O
40-47	JJ	O
,	,	O
41-48	JJ	O
,	,	O
42-49	JJ	O
,	,	O
43-50	JJ	O
,	,	O
44-51	JJ	O
,	,	O
45-52	JJ	O
,	,	O
46-53	JJ	O
,	,	O
47-54	JJ	O
,	,	O
48-55	JJ	O
,	,	O
49-56	JJ	O
,	,	O
50-57	JJ	O
,	,	O
51-58	JJ	O
,	,	O
52-59	JJ	O
,	,	O
53-60	JJ	O
,	,	O
54-61	JJ	O
,	,	O
55-62	JJ	O
,	,	O
56-63	JJ	O
,	,	O
57-64	JJ	O
,	,	O
58-65	JJ	O
,	,	O
59-66	JJ	O
,	,	O
60-67	JJ	O
,	,	O
61-68	JJ	O
,	,	O
62-69	JJ	O
,	,	O
63-70	JJ	O
,	,	O
64-71	JJ	O
,	,	O
65-72	JJ	O
,	,	O
66-73	JJ	O
,	,	O
67-74	JJ	O
,	,	O
68-75	JJ	O
,	,	O
69-76	JJ	O
,	,	O
70-77	JJ	O
,	,	O
71-78	JJ	O
,	,	O
72-79	JJ	O
,	,	O
73-80	JJ	O
,	,	O
74-81	JJ	O
,	,	O
75-82	JJ	O
,	,	O
76-83	JJ	O
,	,	O
77-84	JJ	O
,	,	O
78-85	JJ	O
,	,	O
79-86	JJ	O
,	,	O
80-87	JJ	O
,	,	O
81-88	JJ	O
,	,	O
82-89	JJ	O
,	,	O
83-90	JJ	O
,	,	O
84-91	JJ	O
,	,	O
85-92	JJ	O
,	,	O
86-93	JJ	O
,	,	O
87-94	JJ	O
,	,	O
88-95	JJ	O
,	,	O
89-96	JJ	O
,	,	O
90-97	JJ	O
,	,	O
91-98	JJ	O
,	,	O
92-99	JJ	O
,	,	O
93-100	JJ	O
.	.	O
An	DT	O
additional	JJ	O
set	NN	O
for	IN	O
regions	NNS	O
20	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
in	IN	O
a	DT	O
target	NN	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression	NN	O
:	:	O
S	NNP	O
(	(	O
20	CD	O
)	)	O
=	NN	O
{	(	O
R	NNP	O
1,20	CD	O
|n	NNP	O
ε	NNP	O
{	(	O
1,2,3	CD	O
,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
81	CD	O
}	)	O
}	)	O
and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-20	JJ	O
,	,	O
2-21	JJ	O
,	,	O
3-22	JJ	O
,	,	O
4-23	JJ	O
,	,	O
5-24	JJ	O
,	,	O
6-25	JJ	O
,	,	O
7-26	JJ	O
,	,	O
8-27	JJ	O
,	,	O
9-28	JJ	O
,	,	O
10-29	JJ	O
,	,	O
11-30	JJ	O
,	,	O
12-31	JJ	O
,	,	O
13-32	JJ	O
,	,	O
14-33	JJ	O
,	,	O
15-34	JJ	O
,	,	O
16-35	JJ	O
,	,	O
17-36	JJ	O
,	,	O
18-37	JJ	O
,	,	O
19-38	JJ	O
,	,	O
20-39	JJ	O
,	,	O
21-40	JJ	O
,	,	O
22-41	JJ	O
,	,	O
23-42	JJ	O
,	,	O
24-43	JJ	O
,	,	O
25-44	JJ	O
,	,	O
26-45	JJ	O
,	,	O
27-46	JJ	O
,	,	O
28-47	JJ	O
,	,	O
29-48	JJ	O
,	,	O
30-49	JJ	O
,	,	O
31-50	JJ	O
,	,	O
32-51	JJ	O
,	,	O
33-52	JJ	O
,	,	O
34-53	JJ	O
,	,	O
35-54	JJ	O
,	,	O
36-55	JJ	O
,	,	O
37-56	JJ	O
,	,	O
38-57	JJ	O
,	,	O
39-58	JJ	O
,	,	O
40-59	JJ	O
,	,	O
41-60	JJ	O
,	,	O
42-61	JJ	O
,	,	O
43-62	JJ	O
,	,	O
44-63	JJ	O
,	,	O
45-64	JJ	O
,	,	O
46-65	JJ	O
,	,	O
47-66	JJ	O
,	,	O
48-67	JJ	O
,	,	O
49-68	JJ	O
,	,	O
50-69	JJ	O
,	,	O
51-70	JJ	O
,	,	O
52-71	JJ	O
,	,	O
53-72	JJ	O
,	,	O
54-73	JJ	O
,	,	O
55-74	JJ	O
,	,	O
56-75	JJ	O
,	,	O
57-76	JJ	O
,	,	O
58-77	JJ	O
,	,	O
59-78	JJ	O
,	,	O
60-79	JJ	O
,	,	O
61-80	JJ	O
,	,	O
62-81	JJ	O
,	,	O
63-82	JJ	O
,	,	O
64-83	JJ	O
,	,	O
65-84	JJ	O
,	,	O
66-85	JJ	O
,	,	O
67-86	JJ	O
,	,	O
68-87	JJ	O
,	,	O
69-88	JJ	O
,	,	O
70-89	JJ	O
,	,	O
71-90	JJ	O
,	,	O
72-91	JJ	O
,	,	O
73-92	JJ	O
,	,	O
74-93	JJ	O
,	,	O
75-94	JJ	O
,	,	O
76-95	JJ	O
,	,	O
77-96	JJ	O
,	,	O
78-97	JJ	O
,	,	O
79-98	JJ	O
,	,	O
80-99	JJ	O
,	,	O
81-100	JJ	O
.	.	O
An	DT	O
additional	JJ	O
set	NN	O
for	IN	O
regions	NNS	O
80	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
in	IN	O
a	DT	O
target	NN	O
sequence	NN	O
100	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
,	,	O
beginning	VBG	O
at	IN	O
position	NN	O
1	CD	O
of	IN	O
the	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
,	,	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
expression	NN	O
:	:	O
S	NNP	O
(	(	O
80	CD	O
)	)	O
=	NN	O
{	(	O
R	NNP	O
1,80	CD	O
|n	NNP	O
γ	NNP	O
{	(	O
1,2,3	CD	O
,	,	O
.	.	O
.	.	O
.	.	O
,	,	O
21	CD	O
}	)	O
}	)	O
and	CC	O
describes	VBZ	O
the	DT	O
set	NN	O
of	IN	O
regions	NNS	O
comprising	VBG	O
nucleobases	NNS	O
1-80	CD	O
,	,	O
2-81	CD	O
,	,	O
3-82	CD	O
,	,	O
4-83	CD	O
,	,	O
5-84	JJ	O
,	,	O
6-85	JJ	O
,	,	O
7-86	JJ	O
,	,	O
8-87	JJ	O
,	,	O
9-88	CD	O
,	,	O
10-89	CD	O
,	,	O
11-90	CD	O
,	,	O
12-91	CD	O
,	,	O
13-92	CD	O
,	,	O
14-93	CD	O
,	,	O
15-94	CD	O
,	,	O
16-95	CD	O
,	,	O
17-96	CD	O
,	,	O
18-97	CD	O
,	,	O
19-98	CD	O
,	,	O
20-99	CD	O
,	,	O
21-100	CD	O
.	.	O
Thus	RB	O
,	,	O
in	IN	O
this	DT	O
example	NN	O
,	,	O
A	NNP	O
would	MD	O
include	VB	O
regions	NNS	O
1-8	JJ	O
,	,	O
2-9	JJ	O
,	,	O
3-10	JJ	O
.	.	O
.	.	O
.	.	O
93-100	CD	O
,	,	O
1-20	CD	O
,	,	O
2-21	JJ	O
,	,	O
3-22	JJ	O
.	.	O
.	.	O
.	.	O
81-100	JJ	O
,	,	O
1-80	JJ	O
,	,	O
2-81	JJ	O
,	,	O
3-82	JJ	O
.	.	O
.	.	O
.	.	O
21-100	JJ	O
.	.	O
The	DT	O
union	NN	O
of	IN	O
these	DT	O
aforementioned	JJ	O
example	NN	O
sets	NNS	O
and	CC	O
other	JJ	O
sets	NNS	O
for	IN	O
lengths	NNS	O
from	IN	O
10	CD	O
to	TO	O
19	CD	O
and	CC	O
21	CD	O
to	TO	O
79	CD	O
can	MD	O
be	VB	O
described	VBN	O
using	VBG	O
the	DT	O
mathematical	JJ	O
expression	NN	O
:	:	O
where	WRB	O
∪	NN	O
represents	VBZ	O
the	DT	O
union	NN	O
of	IN	O
the	DT	O
sets	NNS	O
obtained	VBN	O
by	IN	O
combining	VBG	O
all	DT	O
members	NNS	O
of	IN	O
all	DT	O
sets	NNS	O
.	.	O
The	DT	O
mathematical	JJ	O
expressions	NNS	O
described	VBD	O
herein	JJ	O
define	NN	O
all	DT	O
possible	JJ	O
target	NN	O
regions	NNS	O
in	IN	O
a	DT	O
target	NN	O
nucleobase	JJ	O
sequence	NN	O
of	IN	O
any	DT	O
length	NN	O
L	NNP	O
,	,	O
where	WRB	O
the	DT	O
region	NN	O
is	VBZ	O
of	IN	O
length	NN	O
m	NN	O
,	,	O
and	CC	O
where	WRB	O
m	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
8	CD	O
and	CC	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
80	CD	O
nucleobases	NNS	O
,	,	O
and	CC	O
where	WRB	O
m	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
L	NNP	O
,	,	O
and	CC	O
where	WRB	O
n	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
L−m+1	NNP	O
.	.	O
D.	NNP	O
Screening	NNP	O
and	CC	O
Target	NNP	O
Validation	NNP	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
“	NN	O
preferred	VBD	O
target	NN	O
segments	NNS	O
”	VBP	O
identified	VBN	O
herein	NN	O
may	MD	O
be	VB	O
employed	VBN	O
in	IN	O
a	DT	O
screen	NN	O
for	IN	O
additional	JJ	O
compounds	NNS	O
that	WDT	O
modulate	VBP	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
“	JJ	O
Modulators	NNS	O
”	VBP	O
are	VBP	O
those	DT	O
compounds	NNS	O
that	WDT	O
decrease	VBP	O
or	CC	O
increase	VB	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and	CC	O
which	WDT	O
comprise	VBP	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
which	WDT	O
is	VBZ	O
complementary	JJ	O
to	TO	O
a	DT	O
preferred	JJ	O
target	NN	O
segment	NN	O
.	.	O
The	DT	O
screening	NN	O
method	NN	O
comprises	VBZ	O
the	DT	O
steps	NNS	O
of	IN	O
contacting	VBG	O
a	DT	O
preferred	JJ	O
target	NN	O
segment	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	VBD	O
2	CD	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
candidate	JJ	O
modulators	NNS	O
,	,	O
and	CC	O
selecting	VBG	O
for	IN	O
one	CD	O
or	CC	O
more	JJR	O
candidate	NN	O
modulators	NNS	O
which	WDT	O
decrease	VBP	O
or	CC	O
increase	VB	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
Once	IN	O
it	PRP	O
is	VBZ	O
shown	VBN	O
that	IN	O
the	DT	O
candidate	NN	O
modulator	NN	O
or	CC	O
modulators	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
modulating	VBG	O
(	(	O
e.g	NN	O
.	.	O
either	DT	O
decreasing	NN	O
or	CC	O
increasing	VBG	O
)	)	O
the	DT	O
expression	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
the	DT	O
modulator	NN	O
may	MD	O
then	RB	O
be	VB	O
employed	VBN	O
in	IN	O
further	JJ	O
investigative	JJ	O
studies	NNS	O
of	IN	O
the	DT	O
function	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
or	CC	O
for	IN	O
use	NN	O
as	IN	O
a	DT	O
research	NN	O
,	,	O
diagnostic	JJ	O
,	,	O
or	CC	O
therapeutic	JJ	O
agent	NN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
preferred	JJ	O
target	NN	O
segments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
also	RB	O
be	VB	O
combined	VBN	O
with	IN	O
their	PRP$	O
respective	JJ	O
complementary	JJ	O
antisense	NN	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
to	TO	O
form	VB	O
stabilized	VBN	O
double-stranded	JJ	O
(	(	O
duplexed	JJ	O
)	)	O
oligonucleotides	NNS	O
.	.	O
Such	JJ	O
double	JJ	O
stranded	VBN	O
oligonucleotide	NN	O
moieties	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
modulate	VB	O
target	NN	O
expression	NN	O
and	CC	O
regulate	VB	O
translation	NN	O
as	RB	O
well	RB	O
as	IN	O
RNA	NNP	O
processing	VBG	O
via	IN	O
an	DT	O
antisense	NN	O
mechanism	NN	O
.	.	O
Moreover	RB	O
,	,	O
the	DT	O
double-stranded	JJ	O
moieties	NNS	O
may	MD	O
be	VB	O
subject	JJ	O
to	TO	O
chemical	JJ	O
modifications	NNS	O
(	(	O
Fire	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
1998	CD	I
,	,	I
391	CD	I
,	,	I
806-811	CD	I
;	:	O
Timmons	NNS	B
and	CC	I
Fire	NNP	I
,	,	I
Nature	NNP	I
1998	CD	I
,	,	I
395	CD	I
,	,	I
854	CD	I
;	:	O
Timmons	NNP	B
et	FW	I
al.	NN	I
,	,	I
Gene	NNP	I
,	,	I
2001	CD	I
,	,	I
263	CD	I
,	,	I
103-112	CD	I
;	:	O
Tabara	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
1998	CD	I
,	,	I
282	CD	I
,	,	I
430-431	JJ	I
;	:	O
Montgomery	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
,	,	I
1998	CD	I
,	,	I
95	CD	I
,	,	I
15502-15507	CD	I
;	:	O
Tuschl	NNP	B
et	FW	I
al.	NN	I
,	,	I
Genes	NNP	I
Dev.	NNP	I
,	,	I
1999	CD	I
,	,	I
13	CD	I
,	,	I
3191-3197	CD	I
;	:	O
Elbashir	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
,	,	I
2001	CD	I
,	,	I
411	CD	I
,	,	I
494-498	JJ	I
;	:	O
Elbashir	NNP	B
et	FW	I
al.	NN	I
,	,	I
Genes	NNP	I
Dev	NNP	I
.	.	I
2001	CD	I
,	,	I
15	CD	I
,	,	I
188-200	CD	I
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
such	JJ	O
double-stranded	JJ	O
moieties	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
inhibit	VB	O
the	DT	O
target	NN	O
by	IN	O
the	DT	O
classical	JJ	O
hybridization	NN	O
of	IN	O
the	DT	O
antisense	JJ	O
strand	NN	O
of	IN	O
the	DT	O
duplex	NN	O
to	TO	O
the	DT	O
target	NN	O
,	,	O
thereby	RB	O
triggering	VBG	O
enzymatic	JJ	O
degradation	NN	O
of	IN	O
the	DT	O
target	NN	O
(	(	O
Tijsterman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
2002	CD	I
,	,	I
295	CD	I
,	,	I
694-697	JJ	I
)	)	O
.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
applied	VBN	O
in	IN	O
the	DT	O
areas	NNS	O
of	IN	O
drug	NN	O
discovery	NN	O
and	CC	O
target	NN	O
validation	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
comprehends	VBZ	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
and	CC	O
preferred	JJ	O
target	NN	O
segments	NNS	O
identified	VBN	O
herein	NN	O
in	IN	O
drug	NN	O
discovery	NN	O
efforts	NNS	O
to	TO	O
elucidate	VB	O
relationships	NNS	O
that	WDT	O
exist	VBP	O
between	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and	CC	O
a	DT	O
disease	NN	O
state	NN	O
,	,	O
phenotype	NN	O
,	,	O
or	CC	O
condition	NN	O
.	.	O
These	DT	O
methods	NNS	O
include	VBP	O
detecting	VBG	O
or	CC	O
modulating	VBG	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
comprising	VBG	O
contacting	VBG	O
a	DT	O
sample	NN	O
,	,	O
tissue	NN	O
,	,	O
cell	NN	O
,	,	O
or	CC	O
organism	NN	O
with	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
measuring	VBG	O
the	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
protein	JJ	O
level	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and/or	NN	O
a	DT	O
related	JJ	O
phenotypic	NN	O
or	CC	O
chemical	NN	O
endpoint	NN	O
at	IN	O
some	DT	O
time	NN	O
after	IN	O
treatment	NN	O
,	,	O
and	CC	O
optionally	RB	O
comparing	VBG	O
the	DT	O
measured	VBN	O
value	NN	O
to	TO	O
a	DT	O
non-treated	JJ	O
sample	NN	O
or	CC	O
sample	NN	O
treated	VBN	O
with	IN	O
a	DT	O
further	JJ	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
These	DT	O
methods	NNS	O
can	MD	O
also	RB	O
be	VB	O
performed	VBN	O
in	IN	O
parallel	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
experiments	NNS	O
to	TO	O
determine	VB	O
the	DT	O
function	NN	O
of	IN	O
unknown	JJ	O
genes	NNS	O
for	IN	O
the	DT	O
process	NN	O
of	IN	O
target	NN	O
validation	NN	O
or	CC	O
to	TO	O
determine	VB	O
the	DT	O
validity	NN	O
of	IN	O
a	DT	O
particular	JJ	O
gene	NN	O
product	NN	O
as	IN	O
a	DT	O
target	NN	O
for	IN	O
treatment	NN	O
or	CC	O
prevention	NN	O
of	IN	O
a	DT	O
particular	JJ	O
disease	NN	O
,	,	O
condition	NN	O
,	,	O
or	CC	O
phenotype	NN	O
.	.	O
E.	NNP	O
Kits	NNP	O
,	,	O
Research	NNP	O
Reagents	NNP	O
,	,	O
Diagnostics	NNP	O
,	,	O
and	CC	O
Therapeutics	NNPS	O
The	DT	O
antisense	NN	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
utilized	VBN	O
for	IN	O
diagnostics	NNS	O
,	,	O
therapeutics	NNS	O
,	,	O
prophylaxis	NN	O
and	CC	O
as	IN	O
research	NN	O
reagents	NNS	O
and	CC	O
kits	NNS	O
.	.	O
Furthermore	RB	O
,	,	O
antisense	JJ	O
oligonucleotides	NNS	O
,	,	O
which	WDT	O
are	VBP	O
able	JJ	O
to	TO	O
inhibit	VB	O
gene	NN	O
expression	NN	O
with	IN	O
exquisite	JJ	O
specificity	NN	O
,	,	O
are	VBP	O
often	RB	O
used	VBN	O
by	IN	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
to	TO	O
elucidate	VB	O
the	DT	O
function	NN	O
of	IN	O
particular	JJ	O
genes	NNS	O
or	CC	O
to	TO	O
distinguish	VB	O
between	IN	O
functions	NNS	O
of	IN	O
various	JJ	O
members	NNS	O
of	IN	O
a	DT	O
biological	JJ	O
pathway	NN	O
.	.	O
For	IN	O
use	NN	O
in	IN	O
kits	NNS	O
and	CC	O
diagnostics	NNS	O
,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
either	CC	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
compounds	NNS	O
or	CC	O
therapeutics	NNS	O
,	,	O
are	VBP	O
used	VBN	O
as	IN	O
tools	NNS	O
in	IN	O
differential	JJ	O
and/or	JJ	O
combinatorial	JJ	O
analyses	NNS	O
to	TO	O
elucidate	VB	O
expression	NN	O
patterns	NNS	O
of	IN	O
a	DT	O
portion	NN	O
or	CC	O
the	DT	O
entire	JJ	O
complement	NN	O
of	IN	O
genes	NNS	O
expressed	VBN	O
within	IN	O
cells	NNS	O
and	CC	O
tissues	NNS	O
.	.	O
As	IN	O
one	CD	O
nonlimiting	VBG	O
example	NN	O
,	,	O
expression	NN	O
patterns	NNS	O
within	IN	O
cells	NNS	O
or	CC	O
tissues	NNS	O
treated	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
antisense	JJ	O
compounds	NNS	O
are	VBP	O
compared	VBN	O
to	TO	O
control	VB	O
cells	NNS	O
or	CC	O
tissues	NNS	O
not	RB	O
treated	VBN	O
with	IN	O
antisense	JJ	O
compounds	NNS	O
and	CC	O
the	DT	O
patterns	NNS	O
produced	VBN	O
are	VBP	O
analyzed	VBN	O
for	IN	O
differential	JJ	O
levels	NNS	O
of	IN	O
gene	NN	O
expression	NN	O
as	IN	O
they	PRP	O
pertain	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
to	TO	O
disease	VB	O
association	NN	O
,	,	O
signaling	VBG	O
pathway	NN	O
,	,	O
cellular	JJ	O
localization	NN	O
,	,	O
expression	NN	O
level	NN	O
,	,	O
size	NN	O
,	,	O
structure	NN	O
or	CC	O
function	NN	O
of	IN	O
the	DT	O
genes	NNS	O
examined	VBD	O
.	.	O
These	DT	O
analyses	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
on	IN	O
stimulated	JJ	O
or	CC	O
unstimulated	JJ	O
cells	NNS	O
and	CC	O
in	IN	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
other	JJ	O
compounds	NNS	O
which	WDT	O
affect	VBP	O
expression	NN	O
patterns	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
methods	NNS	O
of	IN	O
gene	NN	O
expression	NN	O
analysis	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
include	VBP	O
DNA	NNP	O
arrays	NNS	O
or	CC	O
microarrays	NNS	O
(	(	O
Brazma	NNP	B
and	CC	I
Vilo	NNP	I
,	,	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
2000	CD	I
,	,	I
480	CD	I
,	,	I
17-24	CD	I
;	:	O
Celis	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
2000	CD	I
,	,	I
480	CD	I
,	,	I
2-16	JJ	I
)	)	O
,	,	O
SAGE	NNP	O
(	(	O
serial	JJ	O
analysis	NN	O
of	IN	O
gene	NN	O
expression	NN	O
)	)	O
(	(	O
Madden	NNP	B
,	,	I
et	FW	I
al.	RB	I
,	,	I
Drug	NNP	I
Discov	NNP	I
.	.	I
Today	NN	I
,	,	I
2000	CD	I
,	,	I
5	CD	I
,	,	I
415-425	JJ	I
)	)	O
,	,	O
READS	NNP	O
(	(	O
restriction	NN	O
enzyme	DT	O
amplification	NN	O
of	IN	O
digested	JJ	O
cDNAs	NN	O
)	)	O
(	(	O
Prashar	NNP	B
and	CC	I
Weissman	NNP	I
,	,	I
Methods	NNP	I
Enzymol.	NNP	I
,	,	I
1999	CD	I
,	,	I
303	CD	I
,	,	I
258-72	JJ	I
)	)	O
,	,	O
TOGA	NNP	O
(	(	O
total	JJ	O
gene	NN	O
expression	NN	O
analysis	NN	O
)	)	O
(	(	O
Sutcliffe	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
2000	CD	I
,	,	I
97	CD	I
,	,	I
1976-81	JJ	I
)	)	O
,	,	O
protein	JJ	O
arrays	NNS	O
and	CC	O
proteomics	NNS	O
(	(	O
Celis	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
2000	CD	I
,	,	I
480	CD	I
,	,	I
2-16	JJ	I
;	:	O
Jungblut	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Electrophoresis	NNP	I
,	,	I
1999	CD	I
,	,	I
20	CD	I
,	,	I
2100-10	JJ	I
)	)	O
,	,	O
expressed	VBD	O
sequence	NN	O
tag	NN	O
(	(	O
EST	NNP	O
)	)	O
sequencing	NN	O
(	(	O
Celis	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
2000	CD	I
,	,	I
480	CD	I
,	,	I
2-16	JJ	I
;	:	O
Larsson	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Biotechnol.	NNP	I
,	,	I
2000	CD	I
,	,	I
80	CD	I
,	,	I
143-57	JJ	I
)	)	O
,	,	O
subtractive	JJ	O
RNA	NNP	O
fingerprinting	NN	O
(	(	O
SuRF	NNP	O
)	)	O
(	(	O
Fuchs	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Anal	NNP	I
.	.	I
Biochem.	NNP	I
,	,	I
2000	CD	I
,	,	I
286	CD	I
,	,	I
91-98	CD	I
;	:	O
Larson	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Cytometry	NNP	I
,	,	I
2000	CD	I
,	,	I
41	CD	I
,	,	I
203-208	JJ	I
)	)	O
,	,	O
subtractive	JJ	O
cloning	NN	O
,	,	O
differential	JJ	O
display	NN	O
(	(	O
DD	NNP	O
)	)	O
(	(	O
Jurecic	NNP	B
and	CC	I
Belmont	NNP	I
,	,	I
Curr	NNP	I
.	.	I
Opin	NNP	I
.	.	I
Microbiol.	NNP	I
,	,	I
2000	CD	I
,	,	I
3	CD	I
,	,	I
316-21	JJ	I
)	)	O
,	,	O
comparative	JJ	O
genomic	JJ	O
hybridization	NN	O
(	(	O
Carulli	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Cell	NNP	I
Biochem	NNP	I
.	.	I
Suppl.	NNP	I
,	,	I
1998	CD	I
,	,	I
31	CD	I
,	,	I
286-96	JJ	I
)	)	O
,	,	O
FISH	NNP	O
(	(	O
fluorescent	NN	O
in	IN	O
situ	JJ	O
hybridization	NN	O
)	)	O
techniques	NNS	O
(	(	O
Going	VBG	B
and	CC	I
Gusterson	NNP	I
,	,	I
Eur	NNP	I
.	.	I
J	NNP	I
.	.	I
Cancer	NN	I
,	,	I
1999	CD	I
,	,	I
35	CD	I
,	,	I
1895-904	JJ	I
)	)	O
and	CC	O
mass	$	O
spectrometry	NN	O
methods	NNS	O
(	(	O
To	TO	B
,	,	I
Comb	NNP	I
.	.	I
Chem	NNP	I
.	.	I
High	JJ	I
Throughput	NNP	I
Screen	NNP	I
,	,	I
2000	CD	I
,	,	I
3	CD	I
,	,	I
235-41	JJ	I
)	)	O
.	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
useful	JJ	O
for	IN	O
research	NN	O
and	CC	O
diagnostics	NNS	O
,	,	O
because	IN	O
these	DT	O
compounds	NNS	O
hybridize	VBP	O
to	TO	O
nucleic	VB	O
acids	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
The	DT	O
primers	NNS	O
and	CC	O
probes	NNS	O
disclosed	VBN	O
herein	NNS	O
are	VBP	O
useful	JJ	O
in	IN	O
methods	NNS	O
requiring	VBG	O
the	DT	O
specific	JJ	O
detection	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
and	CC	O
in	IN	O
the	DT	O
amplification	NN	O
of	IN	O
said	VBD	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
for	IN	O
detection	NN	O
or	CC	O
for	IN	O
use	NN	O
in	IN	O
further	JJ	O
studies	NNS	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
Hybridization	NN	O
of	IN	O
the	DT	O
primers	NNS	O
and	CC	O
probes	NNS	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
can	MD	O
be	VB	O
detected	VBN	O
by	IN	O
means	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Such	JJ	O
means	NNS	O
may	MD	O
include	VB	O
conjugation	NN	O
of	IN	O
an	DT	O
enzyme	NN	O
to	TO	O
the	DT	O
primer	NN	O
or	CC	O
probe	NN	O
or	CC	O
any	DT	O
other	JJ	O
suitable	JJ	O
detection	NN	O
means	NNS	O
.	.	O
Kits	NNS	O
using	VBG	O
such	JJ	O
detection	NN	O
means	NNS	O
for	IN	O
detecting	VBG	O
the	DT	O
level	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
a	DT	O
sample	NN	O
may	MD	O
also	RB	O
be	VB	O
prepared	VBN	O
.	.	O
The	DT	O
invention	NN	O
further	RBR	O
provides	VBZ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
compound	NN	O
or	CC	O
composition	NN	O
of	IN	O
the	DT	O
invention	NN	O
in	IN	O
the	DT	O
manufacture	NN	O
of	IN	O
a	DT	O
medicament	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
any	DT	O
and	CC	O
all	DT	O
conditions	NNS	O
disclosed	VBD	O
herein	NN	O
.	.	O
The	DT	O
specificity	NN	O
and	CC	O
sensitivity	NN	O
of	IN	O
antisense	NN	O
are	VBP	O
also	RB	O
harnessed	VBN	O
by	IN	O
those	DT	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
for	IN	O
therapeutic	JJ	O
uses	NNS	O
.	.	O
Antisense	NNP	O
compounds	NNS	O
have	VBP	O
been	VBN	O
employed	VBN	O
as	IN	O
therapeutic	JJ	O
moieties	NNS	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
disease	NN	O
states	NNS	O
in	IN	O
animals	NNS	O
,	,	O
including	VBG	O
humans	NNS	O
.	.	O
Antisense	NNP	O
oligonucleotide	MD	O
drugs	NNS	O
,	,	O
including	VBG	O
ribozymes	NNS	O
,	,	O
have	VBP	O
been	VBN	O
safely	RB	O
and	CC	O
effectively	RB	O
administered	VBN	O
to	TO	O
humans	NNS	O
and	CC	O
numerous	JJ	O
clinical	JJ	O
trials	NNS	O
are	VBP	O
underway	RB	O
.	.	O
It	PRP	O
is	VBZ	O
thus	RB	O
established	VBN	O
that	IN	O
antisense	JJ	O
compounds	NNS	O
can	MD	O
be	VB	O
useful	JJ	O
therapeutic	JJ	O
modalities	NNS	O
that	WDT	O
can	MD	O
be	VB	O
configured	VBN	O
to	TO	O
be	VB	O
useful	JJ	O
in	IN	O
treatment	NN	O
regimes	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cells	NNS	O
,	,	O
tissues	NNS	O
and	CC	O
animals	NNS	O
,	,	O
especially	RB	O
humans	NNS	O
.	.	O
For	IN	O
therapeutics	NNS	O
,	,	O
an	DT	O
animal	NN	O
,	,	O
preferably	RB	O
a	DT	O
human	JJ	O
,	,	O
suspected	VBN	O
of	IN	O
having	VBG	O
a	DT	O
disease	NN	O
or	CC	O
disorder	NN	O
which	WDT	O
can	MD	O
be	VB	O
treated	VBN	O
by	IN	O
modulating	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
is	VBZ	O
treated	VBN	O
by	IN	O
administering	VBG	O
antisense	JJ	O
compounds	NNS	O
in	IN	O
accordance	NN	O
with	IN	O
this	DT	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
one	CD	O
non-limiting	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
methods	NNS	O
comprise	VBP	O
the	DT	O
step	NN	O
of	IN	O
administering	VBG	O
to	TO	O
the	DT	O
animal	NN	O
in	IN	O
need	NN	O
of	IN	O
treatment	NN	O
,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
inhibitor	NN	O
.	.	O
The	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
inhibitors	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
effectively	RB	O
inhibit	VB	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
protein	NN	O
or	CC	O
inhibit	VB	O
the	DT	O
expression	NN	O
of	IN	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
protein	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
an	DT	O
animal	NN	O
is	VBZ	O
inhibited	VBN	O
by	IN	O
about	IN	O
10	CD	O
%	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
an	DT	O
animal	NN	O
is	VBZ	O
inhibited	VBN	O
by	IN	O
about	IN	O
30	CD	O
%	NN	O
.	.	O
More	RBR	O
preferably	RB	O
,	,	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
an	DT	O
animal	NN	O
is	VBZ	O
inhibited	VBN	O
by	IN	O
50	CD	O
%	NN	O
or	CC	O
more	JJR	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
antisense	NN	O
compounds	VBZ	O
modulate	JJ	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
by	IN	O
at	IN	O
least	JJS	O
10	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
20	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
25	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
30	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
40	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
50	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
60	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
70	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
75	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
80	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
85	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
95	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
98	CD	O
%	NN	O
,	,	O
by	IN	O
at	IN	O
least	JJS	O
99	CD	O
%	NN	O
,	,	O
or	CC	O
by	IN	O
100	CD	O
%	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
reduction	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
may	MD	O
be	VB	O
measured	VBN	O
in	IN	O
serum	NN	O
,	,	O
adipose	JJ	O
tissue	NN	O
,	,	O
liver	RB	O
or	CC	O
any	DT	O
other	JJ	O
body	NN	O
fluid	NN	O
,	,	O
tissue	NN	O
or	CC	O
organ	NN	O
of	IN	O
the	DT	O
animal	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
cells	NNS	O
contained	VBN	O
within	IN	O
said	VBD	O
fluids	NNS	O
,	,	O
tissues	NNS	O
or	CC	O
organs	NNS	O
being	VBG	O
analyzed	VBN	O
contain	VBP	O
a	DT	O
nucleic	JJ	O
acid	NN	O
molecule	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
protein	NN	O
and/or	VBD	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
protein	NN	O
itself	PRP	O
.	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
utilized	VBN	O
in	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
by	IN	O
adding	VBG	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
compound	NN	O
to	TO	O
a	DT	O
suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
diluent	NN	O
or	CC	O
carrier	NN	O
.	.	O
The	DT	O
compounds	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
useful	JJ	O
prophylactically	RB	O
.	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
also	RB	O
useful	JJ	O
for	IN	O
identifying	VBG	O
diseased	JJ	O
states	NNS	O
associated	VBN	O
with	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
.	.	O
The	DT	O
methods	NNS	O
include	VBP	O
identifying	VBG	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
a	DT	O
sample	NN	O
using	VBG	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
primers	NNS	O
comprising	VBG	O
SEQ	NNP	O
ID	NNP	O
NOs	NNP	O
:	:	O
6	CD	O
or	CC	O
7	CD	O
,	,	O
or	CC	O
the	DT	O
probe	NN	O
comprising	VBG	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
8	CD	O
.	.	O
The	DT	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
further	JJ	O
useful	JJ	O
for	IN	O
treating	VBG	O
or	CC	O
preventing	VBG	O
a	DT	O
variety	NN	O
of	IN	O
conditions	NNS	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
utilized	VBN	O
to	TO	O
ameliorate	VB	O
or	CC	O
lessen	VB	O
the	DT	O
severity	NN	O
of	IN	O
a	DT	O
condition	NN	O
in	IN	O
an	DT	O
animal	NN	O
.	.	O
The	DT	O
conditions	NNS	O
can	MD	O
include	VB	O
cardiovascular	JJ	O
disorder	NN	O
,	,	O
obesity	NN	O
such	JJ	O
as	IN	O
diet	JJ	O
induced	JJ	O
obesity	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
cholesterolemia	NN	O
,	,	O
and	CC	O
liver	RB	O
steatosis	NN	O
,	,	O
among	IN	O
others	NNS	O
.	.	O
There	EX	O
are	VBP	O
several	JJ	O
physical	JJ	O
indicia	NN	O
of	IN	O
obesity	NN	O
and	CC	O
include	VBP	O
increased	VBN	O
fat	JJ	O
,	,	O
among	IN	O
others	NNS	O
.	.	O
The	DT	O
treatment	NN	O
or	CC	O
prevention	NN	O
of	IN	O
a	DT	O
condition	NN	O
using	VBG	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
include	VB	O
contacting	VBG	O
an	DT	O
animal	NN	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Preferably	RB	O
,	,	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
is	VBZ	O
inhibited	VBN	O
and	CC	O
the	DT	O
measurement	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
physical	JJ	O
indicia	NN	O
of	IN	O
the	DT	O
condition	NN	O
indicates	VBZ	O
a	DT	O
lessening	NN	O
of	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
obese	JJ	O
.	.	O
The	DT	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
additionally	RB	O
utilized	JJ	O
for	IN	O
lowering	VBG	O
certain	JJ	O
components	NNS	O
of	IN	O
blood	NN	O
from	IN	O
an	DT	O
animal	NN	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
useful	JJ	O
for	IN	O
lowering	VBG	O
serum	JJ	O
free	JJ	O
fatty	NN	O
acids	NNS	O
,	,	O
serum	NN	O
triglycerides	NNS	O
,	,	O
lowering	VBG	O
HDL	NNP	O
cholesterol	NN	O
,	,	O
lowering	VBG	O
total	JJ	O
serum	NN	O
cholesterol	NN	O
,	,	O
plasma	NN	O
or	CC	O
serum	NN	O
insulin	NN	O
,	,	O
or	CC	O
hepatic	JJ	O
triglycerides	NNS	O
in	IN	O
an	DT	O
animal	NN	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
contacted	VBN	O
with	IN	O
an	DT	O
effective	JJ	O
amount	NN	O
of	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
plasma	JJ	O
insulin	NN	O
levels	NNS	O
are	VBP	O
lowered	VBN	O
at	IN	O
about	RB	O
two	CD	O
or	CC	O
four	CD	O
weeks	NNS	O
after	IN	O
contacting	VBG	O
the	DT	O
animal	NN	O
with	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
also	RB	O
useful	JJ	O
in	IN	O
inhibiting	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
a	DT	O
cell	NN	O
or	CC	O
tissue	NN	O
of	IN	O
an	DT	O
animal	NN	O
.	.	O
The	DT	O
method	NN	O
includes	VBZ	O
contacting	VBG	O
the	DT	O
cell	NN	O
or	CC	O
tissue	NN	O
with	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Preferably	RB	O
,	,	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
is	VBZ	O
inhibited	VBN	O
in	IN	O
the	DT	O
present	JJ	O
method	NN	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
tissue	NN	O
of	IN	O
the	DT	O
animal	NN	O
is	VBZ	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
or	CC	O
brown	NN	O
adipose	JJ	O
tissue	NN	O
.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
further	JJ	O
useful	JJ	O
in	IN	O
methods	NNS	O
for	IN	O
modulating	VBG	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
,	,	O
lipogenesis	NN	O
,	,	O
or	CC	O
gluconeogenesis	NN	O
,	,	O
among	IN	O
others	NNS	O
,	,	O
in	IN	O
an	DT	O
animal	NN	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
contacted	VBN	O
with	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
modulation	NN	O
of	IN	O
lipogenesis	NN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
a	DT	O
change	NN	O
in	IN	O
the	DT	O
mRNA	JJ	O
level	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
lipogenic	JJ	O
gene	NN	O
.	.	O
The	DT	O
lipogenic	JJ	O
gene	NN	O
is	VBZ	O
selected	VBN	O
from	IN	O
among	IN	O
glycerol	JJ	O
kinase	NN	O
,	,	O
ATP-citrate	NNP	O
lyase	NN	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
1	CD	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
2	CD	O
,	,	O
fatty	JJ	O
acid	JJ	O
synthase	NN	O
,	,	O
carnitine	JJ	O
palmitoyltransferase	NN	O
I	PRP	O
,	,	O
stearoyl-CoA	JJ	O
desaturase	NN	O
,	,	O
HMG-CoA	NNP	O
reductase	NN	O
,	,	O
lipoprotein	JJ	O
lipase	NN	O
and	CC	O
sterol	NN	O
regulatory	JJ	O
binding	NN	O
element	NN	O
protein	NN	O
1	CD	O
.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
additionally	RB	O
useful	JJ	O
for	IN	O
reducing	VBG	O
the	DT	O
liver	NN	O
weight	NN	O
of	IN	O
an	DT	O
animal	NN	O
.	.	O
For	IN	O
this	DT	O
use	NN	O
,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
contacted	VBN	O
with	IN	O
a	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Typically	RB	O
,	,	O
the	DT	O
animal	NN	O
is	VBZ	O
obese	JJ	O
or	CC	O
diabetic	JJ	O
.	.	O
F.	NNP	O
Modifications	NNP	O
As	NNP	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
a	DT	O
nucleoside	NN	O
is	VBZ	O
a	DT	O
base-sugar	JJ	O
combination	NN	O
.	.	O
The	DT	O
base	JJ	O
portion	NN	O
of	IN	O
the	DT	O
nucleoside	NN	O
is	VBZ	O
normally	RB	O
a	DT	O
heterocyclic	JJ	O
base	NN	O
sometimes	RB	O
referred	VBD	O
to	TO	O
as	IN	O
a	DT	O
“	JJ	O
nucleobase	NN	O
”	NN	O
or	CC	O
simply	RB	O
a	DT	O
“	JJ	O
base	NN	O
”	NN	O
.	.	O
The	DT	O
two	CD	O
most	JJS	O
common	JJ	O
classes	NNS	O
of	IN	O
such	JJ	O
heterocyclic	JJ	O
bases	NNS	O
are	VBP	O
the	DT	O
purines	NNS	O
and	CC	O
the	DT	O
pyrimidines	NNS	O
.	.	O
Nucleotides	NNS	O
are	VBP	O
nucleosides	NNS	O
that	IN	O
further	JJ	O
include	VBP	O
a	DT	O
phosphate	JJ	O
group	NN	O
covalently	RB	O
linked	VBN	O
to	TO	O
the	DT	O
sugar	NN	O
portion	NN	O
of	IN	O
the	DT	O
nucleoside	NN	O
.	.	O
For	IN	O
those	DT	O
nucleosides	NNS	O
that	WDT	O
include	VBP	O
a	DT	O
pentofuranosyl	NN	O
sugar	NN	O
,	,	O
the	DT	O
phosphate	NN	O
group	NN	O
can	MD	O
be	VB	O
linked	VBN	O
to	TO	O
the	DT	O
2′	CD	O
,	,	O
3′	CD	O
or	CC	O
5′	CD	O
hydroxyl	JJ	O
moiety	NN	O
of	IN	O
the	DT	O
sugar	NN	O
.	.	O
In	IN	O
forming	VBG	O
oligonucleotides	NNS	O
,	,	O
the	DT	O
phosphate	NN	O
groups	NNS	O
covalently	RB	O
link	VBP	O
adjacent	JJ	O
nucleosides	NNS	O
to	TO	O
one	CD	O
another	DT	O
to	TO	O
form	VB	O
a	DT	O
linear	JJ	O
polymeric	JJ	O
compound	NN	O
.	.	O
In	IN	O
turn	NN	O
,	,	O
the	DT	O
respective	JJ	O
ends	NNS	O
of	IN	O
this	DT	O
linear	JJ	O
polymeric	JJ	O
compound	NN	O
can	MD	O
be	VB	O
further	RB	O
joined	VBN	O
to	TO	O
form	VB	O
a	DT	O
circular	JJ	O
compound	NN	O
,	,	O
however	RB	O
,	,	O
linear	JJ	O
compounds	NNS	O
are	VBP	O
generally	RB	O
preferred	VBN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
linear	JJ	O
compounds	NNS	O
may	MD	O
have	VB	O
internal	JJ	O
nucleobase	NN	O
complementarity	NN	O
and	CC	O
may	MD	O
therefore	VB	O
fold	NN	O
in	IN	O
a	DT	O
manner	NN	O
as	IN	O
to	TO	O
produce	VB	O
a	DT	O
fully	RB	O
or	CC	O
partially	RB	O
double-stranded	JJ	O
compound	NN	O
.	.	O
Within	IN	O
oligonucleotides	NNS	O
,	,	O
the	DT	O
phosphate	NN	O
groups	NNS	O
are	VBP	O
commonly	RB	O
referred	VBN	O
to	TO	O
as	IN	O
forming	VBG	O
the	DT	O
internucleoside	JJ	O
backbone	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
The	DT	O
normal	JJ	O
linkage	NN	O
or	CC	O
backbone	NN	O
of	IN	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
is	VBZ	O
a	DT	O
3′	CD	O
to	TO	O
5′	CD	O
phosphodiester	NN	O
linkage	NN	O
.	.	O
Modified	NNP	O
Internucleoside	NNP	O
Linkages	NNP	O
(	(	O
Backbones	NNP	O
)	)	O
Antisense	NNP	O
compounds	VBZ	O
useful	JJ	O
in	IN	O
this	DT	O
invention	NN	O
include	VBP	O
oligonucleotides	NNS	O
containing	VBG	O
modified	JJ	O
backbones	NNS	O
or	CC	O
non-natural	JJ	O
internucleoside	NN	O
linkages	NNS	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
and	CC	O
“	NNP	O
oligonucleotide	RB	O
mimetic	JJ	O
”	NN	O
or	CC	O
“	JJ	O
mimetic	JJ	O
”	NN	O
refers	NNS	O
to	TO	O
any	DT	O
compound	NN	O
of	IN	O
the	DT	O
invention	NN	O
which	WDT	O
is	VBZ	O
modified	VBN	O
from	IN	O
the	DT	O
naturally	RB	O
occurring	VBG	O
RNA	NNP	O
or	CC	O
DNA	NNP	O
nucleic	JJ	O
acids	NNS	O
.	.	O
As	IN	O
defined	VBN	O
herein	NN	O
,	,	O
oligonucleotides	IN	O
having	VBG	O
modified	VBN	O
backbones	NNS	O
include	VBP	O
those	DT	O
that	WDT	O
retain	VBP	O
a	DT	O
phosphorus	NN	O
atom	NN	O
in	IN	O
the	DT	O
backbone	NN	O
and	CC	O
those	DT	O
that	WDT	O
do	VBP	O
not	RB	O
have	VB	O
a	DT	O
phosphorus	NN	O
atom	NN	O
in	IN	O
the	DT	O
backbone	NN	O
.	.	O
For	IN	O
the	DT	O
purposes	NNS	O
of	IN	O
this	DT	O
specification	NN	O
,	,	O
and	CC	O
as	IN	O
sometimes	RB	O
referenced	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
modified	VBD	O
oligonucleotides	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
have	VB	O
a	DT	O
phosphorus	NN	O
atom	NN	O
in	IN	O
their	PRP$	O
internucleoside	JJ	O
backbone	NN	O
can	MD	O
also	RB	O
be	VB	O
considered	VBN	O
to	TO	O
be	VB	O
oligonucleosides	NNS	O
.	.	O
Preferred	NNP	O
modified	VBD	O
oligonucleotide	JJ	O
backbones	NNS	O
containing	VBG	O
a	DT	O
phosphorus	NN	O
atom	NN	O
therein	NN	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
phosphorothioates	VBZ	O
,	,	O
chiral	JJ	O
phosphorothioates	NNS	O
,	,	O
phosphorodithioates	NNS	O
,	,	O
phosphotriesters	NNS	O
,	,	O
aminoalkyl-phosphotriesters	NNS	O
,	,	O
methyl	NN	O
and	CC	O
other	JJ	O
alkyl	NN	O
phosphonates	NNS	O
including	VBG	O
3′-alkylene	JJ	O
phosphonates	NNS	O
,	,	O
5′-alkylene	JJ	O
phosphonates	NNS	O
and	CC	O
chiral	JJ	O
phosphonates	NNS	O
,	,	O
phosphinates	NNS	O
,	,	O
phosphoramidates	NNS	O
including	VBG	O
3′-amino	JJ	O
phosphoramidate	NN	O
and	CC	O
aminoalkylphosphoramidates	NNS	O
,	,	O
thionophosphoramidates	NNS	O
,	,	O
thionoalkylphosphonates	NNS	O
,	,	O
thionoalkylphosphotriesters	NNS	O
,	,	O
selenophosphates	NNS	O
and	CC	O
boranophosphates	NNS	O
having	VBG	O
normal	JJ	O
3′-5′	JJ	O
linkages	NNS	O
,	,	O
2′-5′	JJ	O
linked	VBD	O
analogs	NNS	O
of	IN	O
these	DT	O
,	,	O
and	CC	O
those	DT	O
having	VBG	O
inverted	VBN	O
polarity	NN	O
wherein	VBP	O
one	CD	O
or	CC	O
more	JJR	O
internucleotide	JJ	O
linkages	NNS	O
is	VBZ	O
a	DT	O
3′	CD	O
to	TO	O
3′	CD	O
,	,	O
5′	CD	O
to	TO	O
5′	CD	O
or	CC	O
2′	CD	O
to	TO	O
2′	CD	O
linkage	NN	O
.	.	O
Preferred	NNP	O
oligonucleotides	VBZ	O
having	VBG	O
inverted	VBN	O
polarity	NN	O
comprise	NN	O
a	DT	O
single	JJ	O
3′	CD	O
to	TO	O
3′	CD	O
linkage	NN	O
at	IN	O
the	DT	O
3′-most	JJ	O
internucleotide	JJ	O
linkage	NN	O
i.e	NN	O
.	.	O
a	DT	O
single	JJ	O
inverted	JJ	O
nucleoside	NN	O
residue	NN	O
which	WDT	O
may	MD	O
be	VB	O
abasic	JJ	O
(	(	O
the	DT	O
nucleobase	NN	O
is	VBZ	O
missing	VBG	O
or	CC	O
has	VBZ	O
a	DT	O
hydroxyl	NN	O
group	NN	O
in	IN	O
place	NN	O
thereof	NN	O
)	)	O
.	.	O
Various	JJ	O
salts	NNS	O
,	,	O
mixed	JJ	O
salts	NNS	O
and	CC	O
free	JJ	O
acid	NN	O
forms	NNS	O
are	VBP	O
also	RB	O
included	VBN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
the	DT	O
above	JJ	O
phosphorus-containing	NN	O
linkages	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
3,687,808	CD	O
;	:	O
4,469,863	CD	O
;	:	O
4,476,301	CD	O
;	:	O
5,023,243	CD	O
;	:	O
5,177,196	CD	O
;	:	O
5,188,897	CD	O
;	:	O
5,264,423	CD	O
;	:	O
5,276,019	CD	O
;	:	O
5,278,302	CD	O
;	:	O
5,286,717	CD	O
;	:	O
5,321,131	CD	O
;	:	O
5,399,676	CD	O
;	:	O
5,405,939	CD	O
;	:	O
5,453,496	CD	O
;	:	O
5,455,233	CD	O
;	:	O
5,466,677	CD	O
;	:	O
5,476,925	CD	O
;	:	O
5,519,126	CD	O
;	:	O
5,536,821	CD	O
;	:	O
5,541,306	CD	O
;	:	O
5,550,111	CD	O
;	:	O
5,563,253	CD	O
;	:	O
5,571,799	CD	O
;	:	O
5,587,361	CD	O
;	:	O
5,194,599	CD	O
;	:	O
5,565,555	CD	O
;	:	O
5,527,899	CD	O
;	:	O
5,721,218	CD	O
;	:	O
5,672,697	CD	O
and	CC	O
5,625,050	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Preferred	NNP	O
modified	VBD	O
oligonucleotide	JJ	O
backbones	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
include	VB	O
a	DT	O
phosphorus	JJ	O
atom	NN	O
therein	NNS	O
have	VBP	O
backbones	NNS	O
that	WDT	O
are	VBP	O
formed	VBN	O
by	IN	O
short	JJ	O
chain	NN	O
alkyl	NN	O
or	CC	O
cycloalkyl	NN	O
internucleoside	NN	O
linkages	NNS	O
,	,	O
mixed	JJ	O
heteroatom	NN	O
and	CC	O
alkyl	NN	O
or	CC	O
cycloalkyl	NN	O
internucleoside	NN	O
linkages	VBZ	O
,	,	O
or	CC	O
one	CD	O
or	CC	O
more	JJR	O
short	JJ	O
chain	NN	O
heteroatomic	VBD	O
or	CC	O
heterocyclic	JJ	O
internucleoside	NN	O
linkages	NNS	O
.	.	O
These	DT	O
include	VBP	O
those	DT	O
having	VBG	O
morpholino	NN	O
linkages	NNS	O
(	(	O
formed	VBN	O
in	IN	O
part	NN	O
from	IN	O
the	DT	O
sugar	NN	O
portion	NN	O
of	IN	O
a	DT	O
nucleoside	NN	O
)	)	O
;	:	O
siloxane	JJ	O
backbones	NNS	O
;	:	O
sulfide	RB	O
,	,	O
sulfoxide	NN	O
and	CC	O
sulfone	NN	O
backbones	NNS	O
;	:	O
formacetyl	NNS	O
and	CC	O
thioformacetyl	JJ	O
backbones	NNS	O
;	:	O
methylene	CC	O
formacetyl	NN	O
and	CC	O
thioformacetyl	JJ	O
backbones	NNS	O
;	:	O
riboacetyl	VB	O
backbones	NNS	O
;	:	O
alkene	VBZ	O
containing	VBG	O
backbones	NNS	O
;	:	O
sulfamate	VB	O
backbones	NNS	O
;	:	O
methyleneimino	NN	O
and	CC	O
methylenehydrazino	NN	O
backbones	NNS	O
;	:	O
sulfonate	NN	O
and	CC	O
sulfonamide	JJ	O
backbones	NNS	O
;	:	O
amide	IN	O
backbones	NNS	O
;	:	O
and	CC	O
others	NNS	O
having	VBG	O
mixed	JJ	O
N	NNP	O
,	,	O
O	NNP	O
,	,	O
S	NNP	O
and	CC	O
CH2	NNP	O
component	NN	O
parts	NNS	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
the	DT	O
above	JJ	O
oligonucleosides	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,034,506	CD	O
;	:	O
5,166,315	CD	O
;	:	O
5,185,444	CD	O
;	:	O
5,214,134	CD	O
;	:	O
5,216,141	CD	O
;	:	O
5,235,033	CD	O
;	:	O
5,264,562	CD	O
;	:	O
5,264,564	CD	O
;	:	O
5,405,938	CD	O
;	:	O
5,434,257	CD	O
;	:	O
5,466,677	CD	O
;	:	O
5,470,967	CD	O
;	:	O
5,489,677	CD	O
;	:	O
5,541,307	CD	O
;	:	O
5,561,225	CD	O
;	:	O
5,596,086	CD	O
;	:	O
5,602,240	CD	O
;	:	O
5,610,289	CD	O
;	:	O
5,602,240	CD	O
;	:	O
5,608,046	CD	O
;	:	O
5,610,289	CD	O
;	:	O
5,618,704	CD	O
;	:	O
5,623,070	CD	O
;	:	O
5,663,312	CD	O
;	:	O
5,633,360	CD	O
;	:	O
5,677,437	CD	O
;	:	O
5,792,608	CD	O
;	:	O
5,646,269	CD	O
and	CC	O
5,677,439	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Modified	VBN	O
Sugar	NNP	O
and	CC	O
Internucleoside	NNP	O
Linkages-Mimetics	NNP	O
In	IN	O
other	JJ	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
,	,	O
e.g.	NN	O
,	,	O
oligonucleotide	IN	O
mimetics	NNS	O
,	,	O
both	CC	O
the	DT	O
sugar	NN	O
and	CC	O
the	DT	O
internucleoside	JJ	O
linkage	NN	O
(	(	O
i.e	NN	O
.	.	O
the	DT	O
backbone	NN	O
)	)	O
of	IN	O
the	DT	O
nucleotide	JJ	O
units	NNS	O
are	VBP	O
replaced	VBN	O
with	IN	O
novel	JJ	O
groups	NNS	O
.	.	O
The	DT	O
nucleobase	JJ	O
units	NNS	O
are	VBP	O
maintained	VBN	O
for	IN	O
hybridization	NN	O
with	IN	O
an	DT	O
appropriate	JJ	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
One	CD	O
such	JJ	O
oligonucleotide	JJ	O
mimetic	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
excellent	JJ	O
hybridization	NN	O
properties	NNS	O
,	,	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
a	DT	O
peptide	NN	O
nucleic	JJ	O
acid	NN	O
(	(	O
PNA	NNP	O
)	)	O
.	.	O
In	IN	O
PNA	NNP	O
compounds	NNS	O
,	,	O
the	DT	O
sugar-backbone	NN	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
is	VBZ	O
replaced	VBN	O
with	IN	O
an	DT	O
amide	NN	O
containing	VBG	O
backbone	NN	O
,	,	O
in	IN	O
particular	JJ	O
an	DT	O
aminoethylglycine	JJ	O
backbone	NN	O
.	.	O
The	DT	O
nucleobases	NNS	O
are	VBP	O
retained	VBN	O
and	CC	O
are	VBP	O
bound	VBN	O
directly	RB	O
or	CC	O
indirectly	RB	O
to	TO	O
aza	VB	O
nitrogen	NN	O
atoms	NNS	O
of	IN	O
the	DT	O
amide	JJ	O
portion	NN	O
of	IN	O
the	DT	O
backbone	NN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
PNA	NNP	O
compounds	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,539,082	CD	O
;	:	O
5,714,331	CD	O
;	:	O
and	CC	O
5,719,262	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Further	RB	O
teaching	NN	O
of	IN	O
PNA	NNP	O
compounds	NNS	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
Nielsen	NNP	B
et	CC	I
al.	NN	I
,	,	I
Science	NNP	I
,	,	I
1991	CD	I
,	,	I
254	CD	I
,	,	I
1497-1500	CD	I
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
oligonucleotides	NNS	O
with	IN	O
phosphorothioate	JJ	O
backbones	NNS	O
and	CC	O
oligonucleotides	NNS	O
with	IN	O
heteroatom	JJ	O
backbones	NNS	O
,	,	O
and	CC	O
in	IN	O
particular	JJ	O
—CH2—NH—O—CH2—	NN	O
,	,	O
—CH2—N	NNP	O
(	(	O
CH3	NNP	O
)	)	O
—O—CH2—	VBP	O
[	JJ	O
known	VBN	O
as	IN	O
a	DT	O
methylene	NN	O
(	(	O
methylimino	NN	O
)	)	O
or	CC	O
MMI	NNP	O
backbone	NN	O
]	NN	O
,	,	O
—CH2—O—N	NNP	O
(	(	O
CH3	NNP	O
)	)	O
—CH2—	NN	O
,	,	O
—CH2—N	NNP	O
(	(	O
CH3	NNP	O
)	)	O
—N	NN	O
(	(	O
CH3	NNP	O
)	)	O
—CH2—	NN	O
and	CC	O
—O—N	NNP	O
(	(	O
CH3	NNP	O
)	)	O
—CH2—CH2—	VBP	O
[	JJ	O
wherein	IN	O
the	DT	O
native	JJ	O
phosphodiester	NN	O
backbone	NN	O
is	VBZ	O
represented	VBN	O
as	IN	O
—O—P—O—CH2—	JJ	O
]	NN	O
of	IN	O
the	DT	O
above	NN	O
referenced	VBD	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,489,677	CD	O
,	,	O
and	CC	O
the	DT	O
amide	JJ	O
backbones	NNS	O
of	IN	O
the	DT	O
above	NN	O
referenced	VBD	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,602,240	CD	O
.	.	O
Also	RB	O
included	VBN	O
are	VBP	O
oligonucleotides	NNS	O
having	VBG	O
morpholino	NN	O
backbone	NN	O
structures	NNS	O
of	IN	O
the	DT	O
above-referenced	JJ	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,034,506	CD	O
.	.	O
Modified	NNP	O
Sugars	NNP	O
Oligonucleotide	NNP	O
mimetics	NNS	O
may	MD	O
also	RB	O
contain	VB	O
one	CD	O
or	CC	O
more	JJR	O
substituted	JJ	O
sugar	NN	O
moieties	NNS	O
.	.	O
As	IN	O
such	JJ	O
these	DT	O
may	MD	O
comprise	VB	O
one	CD	O
of	IN	O
the	DT	O
following	VBG	O
at	IN	O
the	DT	O
2′	CD	O
position	NN	O
:	:	O
OH	NN	O
;	:	O
F	NNP	O
;	:	O
O—	NNP	O
,	,	O
S—	NNP	O
,	,	O
or	CC	O
N-alkyl	NNP	O
;	:	O
O—	NNP	O
,	,	O
S—	NNP	O
,	,	O
or	CC	O
N-alkenyl	NNP	O
;	:	O
O—	NNP	O
,	,	O
S—	NNP	O
or	CC	O
N-alkynyl	NNP	O
;	:	O
or	CC	O
O-alkyl-O-alkyl	NNP	O
,	,	O
wherein	VBZ	O
the	DT	O
alkyl	NN	O
,	,	O
alkenyl	NN	O
and	CC	O
alkynyl	NN	O
may	MD	O
be	VB	O
substituted	VBN	O
or	CC	O
unsubstituted	VBN	O
C1	NNP	O
to	TO	O
C10	NNP	O
alkyl	NN	O
or	CC	O
C2	NNP	O
to	TO	O
C10	NNP	O
alkenyl	NN	O
and	CC	O
alkynyl	NN	O
.	.	O
Particularly	RB	O
preferred	VBN	O
are	VBP	O
O	NNP	O
[	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nO	DT	O
]	NNP	O
mCH3	NN	O
,	,	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nOCH3	NN	O
,	,	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nNH2	NN	O
,	,	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nCH3	NN	O
,	,	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nONH2	NN	O
,	,	O
and	CC	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
nON	FW	O
[	FW	O
(	(	O
CH2	NNP	O
)	)	O
nCH3	VBP	O
]	$	O
2	CD	O
,	,	O
where	WRB	O
n	NN	O
and	CC	O
m	NN	O
are	VBP	O
from	IN	O
1	CD	O
to	TO	O
about	IN	O
10	CD	O
.	.	O
Other	JJ	O
oligonucleotide	IN	O
mimetics	NNS	O
may	MD	O
comprise	VB	O
one	CD	O
of	IN	O
the	DT	O
following	VBG	O
at	IN	O
the	DT	O
2′	CD	O
position	NN	O
:	:	O
C1	NN	O
to	TO	O
C10	NNP	O
lower	JJR	O
alkyl	NN	O
,	,	O
substituted	VBD	O
lower	JJR	O
alkyl	NN	O
,	,	O
alkenyl	NN	O
,	,	O
alkynyl	NN	O
,	,	O
alkaryl	NN	O
,	,	O
aralkyl	NN	O
,	,	O
O-alkaryl	NNP	O
or	CC	O
O-aralkyl	NNP	O
,	,	O
SH	NNP	O
,	,	O
SCH3	NNP	O
,	,	O
OCN	NNP	O
,	,	O
Cl	NNP	O
,	,	O
Br	NNP	O
,	,	O
CN	NNP	O
,	,	O
CF3	NNP	O
,	,	O
OCF3	NNP	O
,	,	O
SOCH3	NNP	O
,	,	O
SO2CH3	NNP	O
,	,	O
ONO2	NNP	O
,	,	O
NO2	NNP	O
,	,	O
N3	NNP	O
,	,	O
NH2	NNP	O
,	,	O
heterocycloalkyl	NN	O
,	,	O
heterocycloalkaryl	NN	O
,	,	O
aminoalkylamino	NN	O
,	,	O
polyalkylamino	NN	O
,	,	O
substituted	VBD	O
silyl	NN	O
,	,	O
an	DT	O
RNA	NNP	O
cleaving	NN	O
group	NN	O
,	,	O
a	DT	O
reporter	NN	O
group	NN	O
,	,	O
an	DT	O
intercalator	NN	O
,	,	O
a	DT	O
group	NN	O
for	IN	O
improving	VBG	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
,	,	O
or	CC	O
a	DT	O
group	NN	O
for	IN	O
improving	VBG	O
the	DT	O
pharmacodynamic	JJ	O
properties	NNS	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
,	,	O
and	CC	O
other	JJ	O
substituents	NNS	O
having	VBG	O
similar	JJ	O
properties	NNS	O
.	.	O
One	CD	O
modification	NN	O
includes	VBZ	O
2′-methoxyethoxy	JJ	O
(	(	O
2′-O—CH2CH2OCH3	JJ	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
or	CC	O
2′-O-methoxyethyl	JJ	O
or	CC	O
2′-MOE	JJ	O
)	)	O
(	(	O
Martin	NNP	B
et	RB	I
al.	RB	I
,	,	I
Helv	NNP	I
.	.	I
Chim	NNP	I
.	.	I
Acta	NNP	I
,	,	I
1995	CD	I
,	,	I
78	CD	I
,	,	I
486-504	JJ	I
)	)	O
i.e.	NN	O
,	,	O
an	DT	O
alkoxyalkoxy	JJ	O
group	NN	O
.	.	O
A	DT	O
further	JJ	O
modification	NN	O
includes	VBZ	O
2′-dimethylaminooxyethoxy	JJ	O
,	,	O
i.e.	FW	O
,	,	O
a	DT	O
O	NNP	O
(	(	O
CH2	NNP	O
)	)	O
2ON	CD	O
(	(	O
CH3	NNP	O
)	)	O
2	CD	O
group	NN	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
2′-DMAOE	JJ	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
examples	NNS	O
hereinbelow	VBP	O
,	,	O
and	CC	O
2′-dimethylaminoethoxyethoxy	JJ	O
(	(	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
2′-O-dimethyl-amino-ethoxy-ethyl	JJ	O
or	CC	O
2′-DMAEOE	JJ	O
)	)	O
,	,	O
i.e.	FW	O
,	,	O
2′-O—CH2—O—CH2—N	JJ	O
(	(	O
CH3	NNP	O
)	)	O
2	CD	O
,	,	O
also	RB	O
described	VBN	O
in	IN	O
examples	NNS	O
hereinbelow	VBP	O
.	.	O
Other	JJ	O
modifications	NNS	O
include	VBP	O
2′-methoxy	JJ	O
(	(	O
2′-O—CH3	JJ	O
)	)	O
,	,	O
2′-amino	JJ	O
(	(	O
2′—NH2	CD	O
)	)	O
2′-aminopropoxy	JJ	O
(	(	O
2′-OCH2CH2CH2NH2	JJ	O
)	)	O
,	,	O
2′-allyl	JJ	O
(	(	O
2′-CH2—CH═CH2	JJ	O
)	)	O
,	,	O
2′-O-allyl	JJ	O
(	(	O
2′-O—CH2—CH═CH2	JJ	O
)	)	O
and	CC	O
2′-fluoro	JJ	O
(	(	O
2′-F	JJ	O
)	)	O
.	.	O
The	DT	O
2′modification	CD	O
may	MD	O
be	VB	O
in	IN	O
the	DT	O
arabino	NN	O
(	(	O
up	RP	O
)	)	O
position	NN	O
or	CC	O
ribo	NN	O
(	(	O
down	RP	O
)	)	O
position	NN	O
.	.	O
One	CD	O
2′-arabino	JJ	O
modification	NN	O
is	VBZ	O
2′-F	JJ	O
.	.	O
Similar	JJ	O
modifications	NNS	O
may	MD	O
also	RB	O
be	VB	O
made	VBN	O
at	IN	O
other	JJ	O
positions	NNS	O
on	IN	O
the	DT	O
oligonucleotide	NN	O
,	,	O
particularly	RB	O
the	DT	O
3′	CD	O
position	NN	O
of	IN	O
the	DT	O
sugar	NN	O
on	IN	O
the	DT	O
3′	CD	O
terminal	JJ	O
nucleotide	NN	O
or	CC	O
in	IN	O
2′-5′	JJ	O
linked	VBN	O
oligonucleotides	NNS	O
and	CC	O
the	DT	O
5′	CD	O
position	NN	O
of	IN	O
5′	CD	O
terminal	JJ	O
nucleotide	NN	O
.	.	O
Oligonucleotide	IN	O
mimetics	NNS	O
involving	VBG	O
the	DT	O
sugar	NN	O
,	,	O
such	JJ	O
as	IN	O
cyclobutyl	NN	O
moieties	NNS	O
in	IN	O
place	NN	O
of	IN	O
the	DT	O
pentofuranosyl	NN	O
sugar	NN	O
,	,	O
are	VBP	O
also	RB	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
modified	VBN	O
sugar	NN	O
structures	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,981,957	CD	O
;	:	O
5,118,800	CD	O
;	:	O
5,319,080	CD	O
;	:	O
5,359,044	CD	O
;	:	O
5,393,878	CD	O
;	:	O
5,446,137	CD	O
;	:	O
5,466,786	CD	O
;	:	O
5,514,785	CD	O
;	:	O
5,519,134	CD	O
;	:	O
5,567,811	CD	O
;	:	O
5,576,427	CD	O
;	:	O
5,591,722	CD	O
;	:	O
5,597,909	CD	O
;	:	O
5,610,300	CD	O
;	:	O
5,627,053	CD	O
;	:	O
5,639,873	CD	O
;	:	O
5,646,265	CD	O
;	:	O
5,658,873	CD	O
;	:	O
5,670,633	CD	O
;	:	O
5,792,747	CD	O
;	:	O
and	CC	O
5,700,920	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
A	DT	O
further	JJ	O
modification	NN	O
of	IN	O
the	DT	O
sugar	NN	O
includes	VBZ	O
Locked	NNP	O
Nucleic	NNP	O
Acids	NNP	O
(	(	O
LNAs	NNP	O
)	)	O
in	IN	O
which	WDT	O
the	DT	O
2′-hydroxyl	JJ	O
group	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
the	DT	O
3′	CD	O
or	CC	O
4′	CD	O
carbon	NN	O
atom	NN	O
of	IN	O
the	DT	O
sugar	NN	O
ring	NN	O
,	,	O
thereby	RB	O
forming	VBG	O
a	DT	O
bicyclic	JJ	O
sugar	NN	O
moiety	NN	O
.	.	O
The	DT	O
linkage	NN	O
is	VBZ	O
preferably	RB	O
a	DT	O
methylene	NN	O
(	(	O
—CH2—	NNP	O
)	)	O
n	FW	O
group	NN	O
bridging	VBG	O
the	DT	O
2′	CD	O
oxygen	NN	O
atom	NN	O
and	CC	O
the	DT	O
4′	CD	O
carbon	NN	O
atom	NN	O
wherein	NN	O
n	NN	O
is	VBZ	O
1	CD	O
or	CC	O
2	CD	O
.	.	O
However	RB	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
comprehends	NNS	O
ethylene	JJ	O
linkages	NNS	O
as	RB	O
well	RB	O
.	.	O
LNAs	NNP	O
and	CC	O
preparation	NN	O
thereof	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO	$	O
98/39352	CD	O
and	CC	O
WO	NNP	O
99/14226	CD	O
.	.	O
Natural	NNP	O
and	CC	O
Modified	NNP	O
Nucleobases	NNP	O
Oligonucleotide	NNP	O
mimetics	NNS	O
also	RB	O
include	VBP	O
nucleobase	JJ	O
(	(	O
often	RB	O
referred	VBN	O
to	TO	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
heterocyclic	JJ	O
base	NN	O
or	CC	O
simply	RB	O
as	IN	O
“	JJ	O
base	NN	O
”	NN	O
)	)	O
modifications	NNS	O
or	CC	O
substitutions	NNS	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
“	NNP	O
unmodified	VBD	O
”	NNP	O
or	CC	O
“	NNP	O
natural	JJ	O
”	NNP	O
nucleobases	NNS	O
include	VBP	O
the	DT	O
purine	NN	O
bases	VBZ	O
adenine	NN	O
(	(	O
A	DT	O
)	)	O
and	CC	O
guanine	NN	O
(	(	O
G	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
pyrimidine	NN	O
bases	VBZ	O
thymine	NN	O
(	(	O
T	NNP	O
)	)	O
,	,	O
cytosine	NN	O
(	(	O
C	NNP	O
)	)	O
and	CC	O
uracil	JJ	O
(	(	O
U	NNP	O
)	)	O
.	.	O
Modified	VBN	O
nucleobases	NNS	O
include	VBP	O
other	JJ	O
synthetic	JJ	O
and	CC	O
natural	JJ	O
nucleobases	NNS	O
such	JJ	O
as	IN	O
5-methylcytosine	JJ	O
(	(	O
5-me-C	JJ	O
)	)	O
,	,	O
5-hydroxymethyl	JJ	O
cytosine	NN	O
,	,	O
xanthine	NN	O
,	,	O
hypoxanthine	NN	O
,	,	O
2-aminoadenine	JJ	O
,	,	O
6-methyl	JJ	O
and	CC	O
other	JJ	O
alkyl	JJ	O
derivatives	NNS	O
of	IN	O
adenine	NN	O
and	CC	O
guanine	NN	O
,	,	O
2-propyl	JJ	O
and	CC	O
other	JJ	O
alkyl	JJ	O
derivatives	NNS	O
of	IN	O
adenine	NN	O
and	CC	O
guanine	NN	O
,	,	O
2-thiouracil	JJ	O
,	,	O
2-thiothymine	JJ	O
and	CC	O
2-thiocytosine	JJ	O
,	,	O
5-halouracil	JJ	O
and	CC	O
cytosine	JJ	O
,	,	O
5-propynyl	JJ	O
(	(	O
—C≡C—CH3	NNP	O
)	)	O
uracil	NN	O
and	CC	O
cytosine	NN	O
and	CC	O
other	JJ	O
alkynyl	JJ	O
derivatives	NNS	O
of	IN	O
pyrimidine	NN	O
bases	NNS	O
,	,	O
6-azo	JJ	O
uracil	NN	O
,	,	O
cytosine	NN	O
and	CC	O
thymine	NN	O
,	,	O
5-uracil	JJ	O
(	(	O
pseudouracil	NN	O
)	)	O
,	,	O
4-thiouracil	JJ	O
,	,	O
8-halo	JJ	O
,	,	O
8-amino	JJ	O
,	,	O
8-thiol	JJ	O
,	,	O
8-thioalkyl	JJ	O
,	,	O
8-hydroxyl	JJ	O
and	CC	O
other	JJ	O
8-substituted	JJ	O
adenines	NNS	O
and	CC	O
guanines	NNS	O
,	,	O
5-halo	JJ	O
particularly	RB	O
5-bromo	JJ	O
,	,	O
5-trifluoromethyl	JJ	O
and	CC	O
other	JJ	O
5-substituted	JJ	O
uracils	NNS	O
and	CC	O
cytosines	NNS	O
,	,	O
7-methylguanine	JJ	O
and	CC	O
7-methyladenine	JJ	O
,	,	O
2-F-adenine	JJ	O
,	,	O
2-amino-adenine	JJ	O
,	,	O
8-azaguanine	JJ	O
and	CC	O
8-azaadenine	JJ	O
,	,	O
7-deazaguanine	JJ	O
and	CC	O
7-deazaadenine	JJ	O
and	CC	O
3-deazaguanine	JJ	O
and	CC	O
3-deazaadenine	JJ	O
.	.	O
Further	RB	O
modified	VBN	O
nucleobases	NNS	O
include	VBP	O
tricyclic	JJ	O
pyrimidines	NNS	O
such	JJ	O
as	IN	O
phenoxazine	JJ	O
cytidine	NN	O
(	(	O
1H-pyrimido	JJ	O
[	NNP	O
5,4-b	JJ	O
]	NNP	O
[	NNP	O
1,4	CD	O
]	NNP	O
benzoxazin-2	NN	O
(	(	O
3H	CD	O
)	)	O
-one	NN	O
)	)	O
,	,	O
phenothiazine	JJ	O
cytidine	NN	O
(	(	O
1H-pyrimido	JJ	O
[	NNP	O
5,4-b	JJ	O
]	NNP	O
[	NNP	O
1,4	CD	O
]	NNP	O
benzothiazin-2	NN	O
(	(	O
3H	CD	O
)	)	O
-one	NN	O
)	)	O
,	,	O
G-clamps	NNP	O
such	JJ	O
as	IN	O
a	DT	O
substituted	JJ	O
phenoxazine	NN	O
cytidine	NN	O
(	(	O
e.g	NN	O
.	.	O
9-	CD	O
(	(	O
2-aminoethoxy	JJ	O
)	)	O
-H-pyrimido	FW	O
[	JJ	O
5,4-b	JJ	O
]	NN	O
[	$	O
1,4	CD	O
]	JJ	O
benzoxazin-2	NN	O
(	(	O
3H	CD	O
)	)	O
-one	NN	O
)	)	O
,	,	O
carbazole	JJ	O
cytidine	NN	O
(	(	O
2H-pyrimido	JJ	O
[	NNP	O
4,5-b	JJ	O
]	NNP	O
indol-2-one	NN	O
)	)	O
,	,	O
pyridoindole	JJ	O
cytidine	NN	O
(	(	O
H-pyrido	NNP	O
[	NNP	O
3′,2′:4,5	CD	O
]	NNP	O
pyrrolo	NN	O
[	NNP	O
2,3-d	JJ	O
]	NNP	O
pyrimidin-2-one	NN	O
)	)	O
.	.	O
Modified	VBN	O
nucleobases	NNS	O
may	MD	O
also	RB	O
include	VB	O
those	DT	O
in	IN	O
which	WDT	O
the	DT	O
purine	NN	O
or	CC	O
pyrimidine	JJ	O
base	NN	O
is	VBZ	O
replaced	VBN	O
with	IN	O
other	JJ	O
heterocycles	NNS	O
,	,	O
for	IN	O
example	NN	O
7-deaza-adenine	CD	O
,	,	O
7-deazaguanosine	CD	O
,	,	O
2-aminopyridine	JJ	O
and	CC	O
2-pyridone	CD	O
.	.	O
Further	JJ	O
nucleobases	NNS	O
include	VBP	O
those	DT	O
disclosed	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
3,687,808	CD	O
,	,	O
those	DT	O
disclosed	VBN	O
in	IN	O
The	DT	O
Concise	NNP	O
Encyclopedia	NNP	O
Of	IN	O
Polymer	NNP	O
Science	NNP	O
And	CC	O
Engineering	NNP	O
,	,	O
pages	VBZ	O
858-859	CD	O
,	,	O
Kroschwitz	NNP	O
,	,	O
J.	NNP	O
I.	NNP	O
,	,	O
ed	NN	O
.	.	O
John	NNP	O
Wiley	NNP	O
&	CC	O
Sons	NNP	O
,	,	O
1990	CD	O
,	,	O
those	DT	O
disclosed	VBN	O
by	IN	O
Englisch	NNP	O
et	FW	O
al.	NN	O
,	,	O
Angewandte	NNP	O
Chemie	NNP	O
,	,	O
International	NNP	O
Edition	NNP	O
,	,	O
1991	CD	O
,	,	O
30	CD	O
,	,	O
613	CD	O
,	,	O
and	CC	O
those	DT	O
disclosed	VBN	O
by	IN	O
Sanghvi	NNP	B
,	,	I
Y.	NNP	I
S.	NNP	I
,	,	I
Chapter	NNP	I
15	CD	I
,	,	I
Antisense	NNP	I
Research	NNP	I
and	CC	I
Applications	NNP	I
,	,	I
pages	VBZ	I
289-302	JJ	I
,	,	I
Crooke	NNP	I
,	,	I
S.	NNP	I
T.	NNP	I
and	CC	I
Lebleu	NNP	I
,	,	I
B.	NNP	I
,	,	I
ed.	NN	I
,	,	I
CRC	NNP	I
Press	NNP	I
,	,	I
1993	CD	I
.	.	O
Certain	NN	O
of	IN	O
these	DT	O
nucleobases	NNS	O
are	VBP	O
particularly	RB	O
useful	JJ	O
for	IN	O
increasing	VBG	O
the	DT	O
binding	NN	O
affinity	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
These	DT	O
include	VBP	O
5-substituted	JJ	O
pyrimidines	NNS	O
,	,	O
6-azapyrimidines	NNS	O
and	CC	O
N-2	NNP	O
,	,	O
N-6	NNP	O
and	CC	O
O-6	NNP	O
substituted	VBD	O
purines	NNS	O
,	,	O
including	VBG	O
2-aminopropyladenine	JJ	O
,	,	O
5-propynyluracil	JJ	O
and	CC	O
5-propynylcytosine	JJ	O
.	.	O
5-methylcytosine	JJ	O
substitutions	NNS	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
nucleic	JJ	O
acid	JJ	O
duplex	JJ	O
stability	NN	O
by	IN	O
0.6-1.2°	JJ	O
C.	NNP	O
and	CC	O
are	VBP	O
presently	RB	O
preferred	JJ	O
base	NN	O
substitutions	NNS	O
,	,	O
even	RB	O
more	RBR	O
particularly	RB	O
when	WRB	O
combined	VBN	O
with	IN	O
2′-O-methoxyethyl	JJ	O
sugar	NN	O
modifications	NNS	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
certain	JJ	O
of	IN	O
the	DT	O
above	NN	O
noted	VBD	O
modified	JJ	O
nucleobases	NNS	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
modified	JJ	O
nucleobases	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
the	DT	O
above	NN	O
noted	VBD	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
3,687,808	CD	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,845,205	CD	O
;	:	O
5,130,302	CD	O
;	:	O
5,134,066	CD	O
;	:	O
5,175,273	CD	O
;	:	O
5,367,066	CD	O
;	:	O
5,432,272	CD	O
;	:	O
5,457,187	CD	O
;	:	O
5,459,255	CD	O
;	:	O
5,484,908	CD	O
;	:	O
5,502,177	CD	O
;	:	O
5,525,711	CD	O
;	:	O
5,552,540	CD	O
;	:	O
5,587,469	CD	O
;	:	O
5,594,121	CD	O
,	,	O
5,596,091	CD	O
;	:	O
5,614,617	CD	O
;	:	O
5,645,985	CD	O
;	:	O
5,830,653	CD	O
;	:	O
5,763,588	CD	O
;	:	O
6,005,096	CD	O
;	:	O
5,681,941	CD	O
;	:	O
and	CC	O
5,570,692	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Conjugates	VBZ	O
Another	DT	O
modification	NN	O
of	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
involves	VBZ	O
chemically	RB	O
linking	VBG	O
to	TO	O
the	DT	O
antisense	NN	O
compound	NN	O
one	CD	O
or	CC	O
more	JJR	O
moieties	NNS	O
or	CC	O
conjugates	NNS	O
which	WDT	O
enhance	VBP	O
the	DT	O
activity	NN	O
,	,	O
cellular	JJ	O
distribution	NN	O
or	CC	O
cellular	JJ	O
uptake	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
These	DT	O
moieties	NNS	O
or	CC	O
conjugates	NNS	O
can	MD	O
include	VB	O
conjugate	JJ	O
groups	NNS	O
covalently	RB	O
bound	IN	O
to	TO	O
functional	JJ	O
groups	NNS	O
such	JJ	O
as	IN	O
primary	JJ	O
or	CC	O
secondary	JJ	O
hydroxyl	NN	O
groups	NNS	O
.	.	O
Conjugate	NNP	O
groups	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
intercalators	NNS	O
,	,	O
reporter	NN	O
molecules	NNS	O
,	,	O
polyamines	NNS	O
,	,	O
polyamides	NNS	O
,	,	O
polyethylene	NN	O
glycols	NNS	O
,	,	O
polyethers	NNS	O
,	,	O
groups	NNS	O
that	WDT	O
enhance	VBP	O
the	DT	O
pharmacodynamic	JJ	O
properties	NNS	O
of	IN	O
oligomers	NNS	O
,	,	O
and	CC	O
groups	NNS	O
that	WDT	O
enhance	VBP	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
of	IN	O
oligomers	NNS	O
.	.	O
Typical	JJ	O
conjugate	NN	O
groups	NNS	O
include	VBP	O
cholesterol	NN	O
,	,	O
lipids	NNS	O
,	,	O
phospholipids	NNS	O
,	,	O
biotin	NN	O
,	,	O
phenazine	NN	O
,	,	O
folate	NN	O
,	,	O
phenanthridine	NN	O
,	,	O
anthraquinone	NN	O
,	,	O
acridine	NN	O
,	,	O
fluoresceins	NNS	O
,	,	O
rhodamines	NNS	O
,	,	O
coumarins	NNS	O
,	,	O
and	CC	O
dyes	NNS	O
.	.	O
Groups	NNS	O
that	WDT	O
enhance	VBP	O
the	DT	O
pharmacodynamic	JJ	O
properties	NNS	O
,	,	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
include	VBP	O
groups	NNS	O
that	WDT	O
improve	VBP	O
uptake	NN	O
,	,	O
enhance	NN	O
resistance	NN	O
to	TO	O
degradation	NN	O
,	,	O
and/or	JJ	O
strengthen	NN	O
sequence-specific	JJ	O
hybridization	NN	O
with	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
Groups	NNS	O
that	WDT	O
enhance	VBP	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
,	,	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
include	VBP	O
groups	NNS	O
that	WDT	O
improve	VBP	O
uptake	NN	O
,	,	O
distribution	NN	O
,	,	O
metabolism	NN	O
or	CC	O
excretion	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Representative	JJ	O
conjugate	NN	O
groups	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
International	NNP	O
Patent	NNP	O
Application	NNP	O
No	NNP	O
.	.	O
PCT/US92/09196	NNP	O
,	,	O
filed	VBD	O
Oct.	NNP	O
23	CD	O
,	,	O
1992	CD	O
,	,	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
,	,	O
the	DT	O
entire	JJ	O
disclosures	NNS	O
of	IN	O
which	WDT	O
are	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
Conjugate	NNP	O
moieties	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
lipid	VB	O
moieties	NNS	O
such	JJ	O
as	IN	O
a	DT	O
cholesterol	NN	O
moiety	NN	O
,	,	O
cholic	JJ	O
acid	NN	O
,	,	O
a	DT	O
thioether	NN	O
,	,	O
e.g.	NN	O
,	,	O
hexyl-5-tritylthiol	NN	O
,	,	O
a	DT	O
thiocholesterol	NN	O
,	,	O
an	DT	O
aliphatic	JJ	O
chain	NN	O
,	,	O
e.g.	NN	O
,	,	O
dodecandiol	NN	O
or	CC	O
undecyl	JJ	O
residues	NNS	O
,	,	O
a	DT	O
phospholipid	NN	O
,	,	O
e.g.	NN	O
,	,	O
di-hexadecyl-rac-glycerol	NN	O
or	CC	O
triethylammonium	NN	O
1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate	JJ	O
,	,	O
a	DT	O
polyamine	NN	O
or	CC	O
a	DT	O
polyethylene	JJ	O
glycol	NN	O
chain	NN	O
,	,	O
or	CC	O
adamantane	RB	O
acetic	JJ	O
acid	NN	O
,	,	O
a	DT	O
palmityl	NN	O
moiety	NN	O
,	,	O
or	CC	O
an	DT	O
octadecylamine	JJ	O
or	CC	O
hexylamino-carbonyl-oxycholesterol	JJ	O
moiety	NN	O
.	.	O
Antisense	NNP	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
conjugated	VBN	O
to	TO	O
drug	NN	O
substances	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
aspirin	NN	O
,	,	O
warfarin	NN	O
,	,	O
phenylbutazone	NN	O
,	,	O
ibuprofen	NN	O
,	,	O
suprofen	NN	O
,	,	O
fenbufen	NN	O
,	,	O
ketoprofen	NN	O
,	,	O
(	(	O
S	NNP	O
)	)	O
-	:	O
(	(	O
+	NN	O
)	)	O
-pranoprofen	NN	O
,	,	O
carprofen	NN	O
,	,	O
dansylsarcosine	NN	O
,	,	O
2,3,5-triiodobenzoic	JJ	O
acid	NN	O
,	,	O
flufenamic	JJ	O
acid	NN	O
,	,	O
folinic	JJ	O
acid	NN	O
,	,	O
a	DT	O
benzothiadiazide	NN	O
,	,	O
chlorothiazide	NN	O
,	,	O
a	DT	O
diazepine	NN	O
,	,	O
indomethicin	NN	O
,	,	O
a	DT	O
barbiturate	NN	O
,	,	O
a	DT	O
cephalosporin	NN	O
,	,	O
a	DT	O
sulfa	JJ	O
drug	NN	O
,	,	O
an	DT	O
antidiabetic	JJ	O
,	,	O
an	DT	O
antibacterial	NN	O
or	CC	O
an	DT	O
antibiotic	JJ	O
.	.	O
Oligonucleotide-drug	JJ	O
conjugates	NNS	O
and	CC	O
their	PRP$	O
preparation	NN	O
are	VBP	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,656,730	CD	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
oligonucleotide	JJ	O
conjugates	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,828,979	CD	O
;	:	O
4,948,882	CD	O
;	:	O
5,218,105	CD	O
;	:	O
5,525,465	CD	O
;	:	O
5,541,313	CD	O
;	:	O
5,545,730	CD	O
;	:	O
5,552,538	CD	O
;	:	O
5,578,717	CD	O
,	,	O
5,580,731	CD	O
;	:	O
5,580,731	CD	O
;	:	O
5,591,584	CD	O
;	:	O
5,109,124	CD	O
;	:	O
5,118,802	CD	O
;	:	O
5,138,045	CD	O
;	:	O
5,414,077	CD	O
;	:	O
5,486,603	CD	O
;	:	O
5,512,439	CD	O
;	:	O
5,578,718	CD	O
;	:	O
5,608,046	CD	O
;	:	O
4,587,044	CD	O
;	:	O
4,605,735	CD	O
;	:	O
4,667,025	CD	O
;	:	O
4,762,779	CD	O
;	:	O
4,789,737	CD	O
;	:	O
4,824,941	CD	O
;	:	O
4,835,263	CD	O
;	:	O
4,876,335	CD	O
;	:	O
4,904,582	CD	O
;	:	O
4,958,013	CD	O
;	:	O
5,082,830	CD	O
;	:	O
5,112,963	CD	O
;	:	O
5,214,136	CD	O
;	:	O
5,082,830	CD	O
;	:	O
5,112,963	CD	O
;	:	O
5,214,136	CD	O
;	:	O
5,245,022	CD	O
;	:	O
5,254,469	CD	O
;	:	O
5,258,506	CD	O
;	:	O
5,262,536	CD	O
;	:	O
5,272,250	CD	O
;	:	O
5,292,873	CD	O
;	:	O
5,317,098	CD	O
;	:	O
5,371,241	CD	O
,	,	O
5,391,723	CD	O
;	:	O
5,416,203	CD	O
,	,	O
5,451,463	CD	O
;	:	O
5,510,475	CD	O
;	:	O
5,512,667	CD	O
;	:	O
5,514,785	CD	O
;	:	O
5,565,552	CD	O
;	:	O
5,567,810	CD	O
;	:	O
5,574,142	CD	O
;	:	O
5,585,481	CD	O
;	:	O
5,587,371	CD	O
;	:	O
5,595,726	CD	O
;	:	O
5,597,696	CD	O
;	:	O
5,599,923	CD	O
;	:	O
5,599,928	CD	O
and	CC	O
5,688,941	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Oligomeric	NNP	O
compounds	NNS	O
used	VBN	O
in	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
modified	VBN	O
to	TO	O
have	VB	O
one	CD	O
or	CC	O
more	JJR	O
stabilizing	VBG	O
groups	NNS	O
that	WDT	O
are	VBP	O
generally	RB	O
attached	VBN	O
to	TO	O
one	CD	O
or	CC	O
both	DT	O
termini	NNS	O
of	IN	O
oligomeric	JJ	O
compounds	NNS	O
to	TO	O
enhance	VB	O
properties	NNS	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
nuclease	NN	O
stability	NN	O
.	.	O
Included	VBN	O
in	IN	O
stabilizing	VBG	O
groups	NNS	O
are	VBP	O
cap	JJ	O
structures	NNS	O
.	.	O
By	IN	O
“	JJ	O
cap	NN	O
structure	NN	O
or	CC	O
terminal	JJ	O
cap	NN	O
moiety	NN	O
”	NN	O
is	VBZ	O
meant	JJ	O
chemical	JJ	O
modifications	NNS	O
,	,	O
which	WDT	O
have	VBP	O
been	VBN	O
incorporated	VBN	O
at	IN	O
either	DT	O
terminus	NN	O
of	IN	O
oligonucleotides	NNS	O
(	(	O
see	VB	O
for	IN	O
example	NN	O
Wincott	NNP	B
et	VBZ	I
al	NN	I
.	.	I
and	CC	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
97/26270	CD	O
,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
herein	NN	O
)	)	O
.	.	O
These	DT	O
terminal	JJ	O
modifications	NNS	O
protect	VBP	O
the	DT	O
oligomeric	JJ	O
compounds	NNS	O
having	VBG	O
terminal	JJ	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
from	IN	O
exonuclease	JJ	O
degradation	NN	O
,	,	O
and	CC	O
can	MD	O
help	VB	O
in	IN	O
delivery	NN	O
and/or	NN	O
localization	NN	O
within	IN	O
a	DT	O
cell	NN	O
.	.	O
The	DT	O
cap	NN	O
can	MD	O
be	VB	O
present	JJ	O
at	IN	O
the	DT	O
5′-terminus	JJ	O
(	(	O
5′-cap	JJ	O
)	)	O
or	CC	O
at	IN	O
the	DT	O
3′-terminus	JJ	O
(	(	O
3′-cap	JJ	O
)	)	O
or	CC	O
at	IN	O
both	DT	O
termini	NN	O
.	.	O
In	IN	O
non-limiting	JJ	O
examples	NNS	O
,	,	O
the	DT	O
5′-cap	JJ	O
includes	VBZ	O
inverted	JJ	O
abasic	JJ	O
residue	NN	O
(	(	O
moiety	NN	O
)	)	O
,	,	O
4′,5′-methylene	JJ	O
nucleotide	NN	O
;	:	O
1-	JJ	O
(	(	O
beta-D-erythrofuranosyl	JJ	O
)	)	O
nucleotide	RB	O
,	,	O
4′-thio	JJ	O
nucleotide	NN	O
,	,	O
carbocyclic	JJ	O
nucleotide	RB	O
;	:	O
1,5-anhydrohexitol	JJ	O
nucleotide	NN	O
;	:	O
L-nucleotides	NNP	O
;	:	O
alpha-nucleotides	NNS	O
;	:	O
modified	VBN	O
base	NN	O
nucleotide	NN	O
;	:	O
phosphorodithioate	JJ	O
linkage	NN	O
;	:	O
threo-pentofuranosyl	JJ	O
nucleotide	NN	O
;	:	O
acyclic	JJ	O
3′,4′-seco	JJ	O
nucleotide	NN	O
;	:	O
acyclic	JJ	O
3,4-dihydroxybutyl	JJ	O
nucleotide	NN	O
;	:	O
acyclic	JJ	O
3,5-dihydroxypentyl	JJ	O
ribonucleotide	NN	O
,	,	O
3′-3′-inverted	JJ	O
nucleotide	JJ	O
moiety	NN	O
;	:	O
3′-3′-inverted	JJ	O
abasic	JJ	O
moiety	NN	O
;	:	O
3′-2′-inverted	JJ	O
nucleotide	IN	O
moiety	NN	O
;	:	O
3′-2′-inverted	JJ	O
abasic	JJ	O
moiety	NN	O
;	:	O
1,4-butanediol	JJ	O
phosphate	NN	O
;	:	O
3′-phosphoramidate	JJ	O
;	:	O
hexylphosphate	NN	O
;	:	O
aminohexyl	JJ	O
phosphate	NN	O
;	:	O
3′-phosphate	JJ	O
;	:	O
3′-phosphorothioate	JJ	O
;	:	O
phosphorodithioate	NN	O
;	:	O
or	CC	O
bridging	VBG	O
or	CC	O
non-bridging	JJ	O
methylphosphonate	NN	O
moiety	NN	O
(	(	O
for	IN	O
more	JJR	O
details	NNS	O
see	VBP	O
Wincott	NNP	O
et	FW	O
al.	NN	O
,	,	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
97/26270	CD	O
,	,	O
incorporated	VBN	O
by	IN	O
reference	NN	O
herein	NN	O
)	)	O
.	.	O
Particularly	RB	O
preferred	VBN	O
3′-cap	JJ	O
structures	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
4′,5′-methylene	JJ	O
nucleotide	RB	O
;	:	O
1-	JJ	O
(	(	O
beta-D-erythrofuranosyl	JJ	O
)	)	O
nucleotide	RB	O
;	:	O
4′-thio	JJ	O
nucleotide	NN	O
,	,	O
carbocyclic	JJ	O
nucleotide	RB	O
;	:	O
5′-amino-alkyl	JJ	O
phosphate	NN	O
;	:	O
1,3-diamino-2-propyl	JJ	O
phosphate	NN	O
,	,	O
3-aminopropyl	JJ	O
phosphate	NN	O
;	:	O
6-aminohexyl	JJ	O
phosphate	NN	O
;	:	O
1,2-aminododecyl	JJ	O
phosphate	NN	O
;	:	O
hydroxypropyl	JJ	O
phosphate	NN	O
;	:	O
1,5-anhydrohexitol	JJ	O
nucleotide	NN	O
;	:	O
L-nucleotide	NNP	O
;	:	O
alpha-nucleotide	JJ	O
;	:	O
modified	VBN	O
base	NN	O
nucleotide	NN	O
;	:	O
phosphorodithioate	NN	O
;	:	O
threo-pentofuranosyl	JJ	O
nucleotide	NN	O
;	:	O
acyclic	JJ	O
3′,4′-seco	JJ	O
nucleotide	NN	O
;	:	O
3,4-dihydroxybutyl	JJ	O
nucleotide	NN	O
;	:	O
3,5-dihydroxypentyl	JJ	O
nucleotide	NN	O
,	,	O
5′-5′-inverted	JJ	O
nucleotide	JJ	O
moiety	NN	O
;	:	O
5′-5′-inverted	JJ	O
abasic	JJ	O
moiety	NN	O
;	:	O
5′-phosphoramidate	JJ	O
;	:	O
5′-phosphorothioate	JJ	O
;	:	O
1,4-butanediol	JJ	O
phosphate	NN	O
;	:	O
5′-amino	JJ	O
;	:	O
bridging	VBG	O
and/or	IN	O
non-bridging	JJ	O
5′-phosphoramidate	JJ	O
,	,	O
phosphorothioate	JJ	O
and/or	NN	O
phosphorodithioate	NN	O
,	,	O
bridging	VBG	O
or	CC	O
non	JJ	O
bridging	NN	O
methylphosphonate	NN	O
and	CC	O
5′-mercapto	JJ	O
moieties	NNS	O
(	(	O
for	IN	O
more	JJR	O
details	NNS	O
see	VBP	O
Beaucage	NNP	B
and	CC	I
Tyer	NNP	I
,	,	I
1993	CD	I
,	,	I
Tetrahedron	NNP	I
49	CD	I
,	,	I
1925	CD	I
;	:	O
incorporated	VBN	O
by	IN	O
reference	NN	O
herein	NN	O
)	)	O
.	.	O
Further	RB	O
3′	CD	O
and	CC	O
5′-stabilizing	JJ	O
groups	NNS	O
that	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
cap	VB	O
one	CD	O
or	CC	O
both	DT	O
ends	NNS	O
of	IN	O
an	DT	O
oligomeric	JJ	O
compound	NN	O
to	TO	O
impart	VB	O
nuclease	JJ	O
stability	NN	O
include	VBP	O
those	DT	O
disclosed	VBN	O
in	IN	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
03/004602	CD	O
,	,	O
published	VBN	O
Jan.	NNP	O
16	CD	O
,	,	O
2003	CD	O
.	.	O
Chimeric	NNP	O
Compounds	NNP	O
It	PRP	O
is	VBZ	O
not	RB	O
necessary	JJ	O
for	IN	O
all	DT	O
positions	NNS	O
in	IN	O
a	DT	O
given	VBN	O
compound	NN	O
or	CC	O
oligonucleotide	JJ	O
mimetic	JJ	O
to	TO	O
be	VB	O
uniformly	RB	O
modified	VBN	O
,	,	O
and	CC	O
in	IN	O
fact	NN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
aforementioned	JJ	O
modifications	NNS	O
may	MD	O
be	VB	O
incorporated	VBN	O
in	IN	O
a	DT	O
single	JJ	O
compound	NN	O
or	CC	O
even	RB	O
at	IN	O
a	DT	O
single	JJ	O
nucleoside	NN	O
within	IN	O
an	DT	O
oligonucleotide	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
includes	VBZ	O
antisense	JJ	O
compounds	NNS	O
or	CC	O
mimetics	NNS	O
which	WDT	O
are	VBP	O
chimeric	JJ	O
compounds	NNS	O
.	.	O
“	JJ	O
Chimeric	NNP	O
”	NNP	O
antisense	JJ	O
compounds	NNS	O
or	CC	O
“	JJ	O
chimeras	NNS	O
,	,	O
”	NN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
are	VBP	O
antisense	JJ	O
compounds	NNS	O
,	,	O
particularly	RB	O
oligonucleotides	NNS	O
,	,	O
which	WDT	O
contain	VBP	O
at	IN	O
least	JJS	O
two	CD	O
chemically	RB	O
distinct	JJ	O
regions	NNS	O
,	,	O
each	DT	O
made	VBD	O
up	IN	O
of	IN	O
at	IN	O
least	JJS	O
one	CD	O
monomer	NN	O
unit	NN	O
,	,	O
i.e.	FW	O
,	,	O
a	DT	O
nucleotide	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
an	DT	O
oligonucleotide	JJ	O
compound	NN	O
.	.	O
Chimeric	NNP	O
antisense	NN	O
oligonucleotides	NNS	O
are	VBP	O
thus	RB	O
a	DT	O
form	NN	O
of	IN	O
antisense	JJ	O
compound	NN	O
.	.	O
These	DT	O
oligonucleotides	NNS	O
typically	RB	O
contain	VBP	O
at	IN	O
least	JJS	O
one	CD	O
chemically	RB	O
distinct	JJ	O
region	NN	O
wherein	IN	O
the	DT	O
oligonucleotide	NN	O
is	VBZ	O
modified	VBN	O
so	RB	O
as	IN	O
to	TO	O
confer	VB	O
upon	IN	O
the	DT	O
oligonucleotide	NN	O
increased	VBD	O
resistance	NN	O
to	TO	O
nuclease	VB	O
degradation	NN	O
,	,	O
increased	VBD	O
cellular	JJ	O
uptake	NN	O
,	,	O
increased	VBN	O
stability	NN	O
and/or	NN	O
increased	VBD	O
binding	JJ	O
affinity	NN	O
for	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
An	DT	O
additional	JJ	O
chemically	NN	O
distinct	JJ	O
region	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
may	MD	O
serve	VB	O
as	IN	O
a	DT	O
substrate	NN	O
for	IN	O
enzymes	NNS	O
capable	JJ	O
of	IN	O
cleaving	VBG	O
RNA	NNP	O
:	:	O
DNA	NN	O
or	CC	O
RNA	NN	O
:	:	O
RNA	JJ	O
hybrids	NNS	O
.	.	O
By	IN	O
way	NN	O
of	IN	O
example	NN	O
,	,	O
RNase	NNP	O
H	NNP	O
is	VBZ	O
a	DT	O
cellular	JJ	O
endonuclease	NN	O
which	WDT	O
cleaves	VBZ	O
the	DT	O
RNA	NNP	O
strand	NN	O
of	IN	O
an	DT	O
RNA	NN	O
:	:	O
DNA	NN	O
duplex	NN	O
.	.	O
Modifications	NNS	O
that	WDT	O
activate	VBP	O
,	,	O
recruit	NN	O
or	CC	O
trigger	NN	O
RNase	NNP	O
H	NNP	O
and	CC	O
result	NN	O
in	IN	O
cleavage	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
target	NN	O
thereby	RB	O
greatly	RB	O
enhance	VB	O
the	DT	O
efficiency	NN	O
of	IN	O
oligonucleotide-mediated	JJ	O
inhibition	NN	O
of	IN	O
gene	NN	O
expression	NN	O
.	.	O
The	DT	O
cleavage	NN	O
of	IN	O
RNA	NNP	O
:	:	O
RNA	JJ	O
hybrids	NNS	O
can	MD	O
,	,	O
in	IN	O
like	JJ	O
fashion	NN	O
,	,	O
be	VB	O
accomplished	VBN	O
through	IN	O
the	DT	O
actions	NNS	O
of	IN	O
endoribonucleases	NNS	O
such	JJ	O
as	IN	O
RnaseL	NNP	O
,	,	O
which	WDT	O
cleaves	VBZ	O
both	DT	O
cellular	JJ	O
and	CC	O
viral	JJ	O
RNA	NNP	O
.	.	O
Cleavage	NN	O
of	IN	O
the	DT	O
RNA	NNP	O
target	NN	O
can	MD	O
be	VB	O
routinely	RB	O
detected	VBN	O
by	IN	O
gel	JJ	O
electrophoresis	NN	O
and	CC	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
associated	VBN	O
nucleic	JJ	O
acid	JJ	O
hybridization	NN	O
techniques	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Preferred	NNP	O
chimeric	JJ	O
oligonucleotides	NNS	O
are	VBP	O
those	DT	O
disclosed	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
herein	NN	O
.	.	O
Particularly	RB	O
preferred	VBN	O
chimeric	JJ	O
oligonucleotides	NNS	O
are	VBP	O
those	DT	O
referred	JJ	O
to	TO	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NOS	NNP	O
:	:	O
65	CD	O
,	,	O
26	CD	O
,	,	O
29	CD	O
,	,	O
and	CC	O
35	CD	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
those	DT	O
chimeric	JJ	O
oligonucleotides	NNS	O
set	VBD	O
forth	NN	O
in	IN	O
Tables	NNP	O
2	CD	O
,	,	O
3	CD	O
,	,	O
14	CD	O
,	,	O
and	CC	O
15	CD	O
and	CC	O
specified	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
below	IN	O
.	.	O
Preferred	VBN	O
siRNAs	NNS	O
are	VBP	O
those	DT	O
referred	JJ	O
to	TO	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
Nos	NNP	O
:	:	O
238	CD	O
,	,	O
242	CD	O
,	,	O
243	CD	O
,	,	O
251	CD	O
,	,	O
and	CC	O
252	CD	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
those	DT	O
set	VBN	O
forth	NN	O
in	IN	O
Table	JJ	O
11	CD	O
and	CC	O
specified	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
below	IN	O
.	.	O
Chimeric	NNP	O
antisense	NN	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
formed	VBN	O
as	IN	O
composite	JJ	O
structures	NNS	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
oligonucleotides	NNS	O
,	,	O
modified	VBD	O
oligonucleotides	NNS	O
,	,	O
oligonucleosides	NNS	O
and/or	VBP	O
oligonucleotide	RB	O
mimetics	NNS	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Chimeric	NNP	O
antisense	NN	O
compounds	NNS	O
can	MD	O
be	VB	O
of	IN	O
several	JJ	O
different	JJ	O
types	NNS	O
.	.	O
These	DT	O
include	VBP	O
a	DT	O
first	JJ	O
type	NN	O
wherein	VBP	O
the	DT	O
“	NNP	O
gap	NN	O
”	NNP	O
segment	NN	O
of	IN	O
linked	VBN	O
nucleosides	NNS	O
is	VBZ	O
positioned	VBN	O
between	IN	O
5′	CD	O
and	CC	O
3′	CD	O
“	NNS	O
wing	VBG	O
”	JJ	O
segments	NNS	O
of	IN	O
linked	VBN	O
nucleosides	NNS	O
and	CC	O
a	DT	O
second	JJ	O
“	NN	O
open	JJ	O
end	NN	O
”	NN	O
type	NN	O
wherein	VBD	O
the	DT	O
“	NNP	O
gap	NN	O
”	NNP	O
segment	NN	O
is	VBZ	O
located	VBN	O
at	IN	O
either	CC	O
the	DT	O
3′	CD	O
or	CC	O
the	DT	O
5′	CD	O
terminus	NN	O
of	IN	O
the	DT	O
chimeric	JJ	O
antisense	NN	O
compound	NN	O
.	.	O
Compounds	NNS	O
of	IN	O
the	DT	O
first	JJ	O
type	NN	O
are	VBP	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
or	CC	O
gapped	VBD	O
oligonucleotides	NNS	O
.	.	O
Compounds	NNS	O
of	IN	O
the	DT	O
second	JJ	O
type	NN	O
are	VBP	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
“	JJ	O
hemimers	NNS	O
”	VBP	O
or	CC	O
“	VBP	O
wingmers	NNS	O
”	VBP	O
.	.	O
Such	JJ	O
compounds	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
referred	VBN	O
to	TO	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
hybrids	NNS	O
.	.	O
In	IN	O
a	DT	O
gapmer	NN	O
that	WDT	O
is	VBZ	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
a	DT	O
gap	NN	O
or	CC	O
wing	NN	O
can	MD	O
be	VB	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
or	CC	O
18	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
a	DT	O
20-nucleotide	JJ	O
gapmer	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
gap	NN	O
8	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
flanked	VBN	O
on	IN	O
both	DT	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
sides	NNS	O
by	IN	O
wings	NNS	O
6	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
a	DT	O
20-nucleotide	JJ	O
gapmer	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
gap	NN	O
10	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
flanked	VBN	O
on	IN	O
both	DT	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
sides	NNS	O
by	IN	O
wings	NNS	O
5	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
a	DT	O
20-nucleotide	JJ	O
gapmer	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
gap	NN	O
12	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
flanked	VBN	O
on	IN	O
both	DT	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
sides	NNS	O
by	IN	O
wings	NNS	O
4	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
a	DT	O
20-nucleotide	JJ	O
gapmer	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
gap	NN	O
14	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
flanked	VBN	O
on	IN	O
both	DT	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
sides	NNS	O
by	IN	O
wings	NNS	O
3	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
a	DT	O
20-nucleotide	JJ	O
gapmer	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
gap	NN	O
16	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
flanked	VBN	O
on	IN	O
both	DT	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
sides	NNS	O
by	IN	O
wings	NNS	O
2	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
a	DT	O
20-nucleotide	JJ	O
gapmer	NN	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
gap	NN	O
18	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
flanked	VBN	O
on	IN	O
both	DT	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
ends	NNS	O
by	IN	O
wings	NNS	O
1	CD	O
nucleotide	RB	O
in	IN	O
length	NN	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
wings	NNS	O
are	VBP	O
of	IN	O
different	JJ	O
lengths	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
20-nucleotide	JJ	O
gapmer	NN	O
may	MD	O
be	VB	O
comprised	VBN	O
of	IN	O
a	DT	O
gap	NN	O
10	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
flanked	VBN	O
by	IN	O
a	DT	O
6-nucleotide	JJ	O
wing	NN	O
on	IN	O
one	CD	O
side	NN	O
(	(	O
5′	CD	O
or	CC	O
3′	CD	O
)	)	O
and	CC	O
a	DT	O
4-nucleotide	JJ	O
wing	NN	O
on	IN	O
the	DT	O
other	JJ	O
side	NN	O
(	(	O
5′	CD	O
or	CC	O
3′	CD	O
)	)	O
.	.	O
In	IN	O
a	DT	O
hemimer	NN	O
,	,	O
an	DT	O
“	NN	O
open	JJ	O
end	NN	O
”	NN	O
chimeric	JJ	O
antisense	NN	O
compound	NN	O
having	VBG	O
two	CD	O
chemically	RB	O
distinct	JJ	O
regions	NNS	O
,	,	O
a	DT	O
first	JJ	O
chemically	RB	O
distinct	JJ	O
region	NN	O
,	,	O
or	CC	O
the	DT	O
gap	NN	O
segment	NN	O
,	,	O
in	IN	O
a	DT	O
compound	NN	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
can	MD	O
be	VB	O
located	VBN	O
at	IN	O
either	CC	O
the	DT	O
5′	CD	O
or	CC	O
3′	CD	O
terminus	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
,	,	O
can	MD	O
be	VB	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
or	CC	O
19	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
A	DT	O
second	JJ	O
chemically	RB	O
distinct	JJ	O
region	NN	O
in	IN	O
a	DT	O
compound	NN	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
can	MD	O
be	VB	O
located	VBN	O
at	IN	O
the	DT	O
3′	CD	O
terminus	NN	O
of	IN	O
the	DT	O
compound	NN	O
and	CC	O
can	MD	O
be	VB	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
,	,	O
8	CD	O
,	,	O
9	CD	O
,	,	O
10	CD	O
,	,	O
11	CD	O
,	,	O
12	CD	O
,	,	O
13	CD	O
,	,	O
14	CD	O
,	,	O
15	CD	O
,	,	O
16	CD	O
,	,	O
17	CD	O
,	,	O
18	CD	O
or	CC	O
19	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
20-nucleotide	JJ	O
hemimer	NN	O
can	MD	O
have	VB	O
a	DT	O
first	JJ	O
chemically	RB	O
distinct	JJ	O
region	NN	O
,	,	O
or	CC	O
a	DT	O
gap	NN	O
segment	NN	O
,	,	O
of	IN	O
10	CD	O
nucleotides	NNS	O
at	IN	O
the	DT	O
5′	CD	O
end	NN	O
and	CC	O
a	DT	O
second	JJ	O
segment	NN	O
of	IN	O
10	CD	O
nucleotides	NNS	O
at	IN	O
the	DT	O
3′	CD	O
end	NN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
hybrid	JJ	O
structures	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,013,830	CD	O
;	:	O
5,149,797	CD	O
;	:	O
5,220,007	CD	O
;	:	O
5,256,775	CD	O
;	:	O
5,366,878	CD	O
;	:	O
5,403,711	CD	O
;	:	O
5,491,133	CD	O
;	:	O
5,565,350	CD	O
;	:	O
5,623,065	CD	O
;	:	O
5,652,355	CD	O
;	:	O
5,652,356	CD	O
;	:	O
and	CC	O
5,700,922	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
G.	NNP	O
Formulations	NNP	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
admixed	VBN	O
,	,	O
encapsulated	VBN	O
,	,	O
conjugated	VBD	O
or	CC	O
otherwise	RB	O
associated	VBN	O
with	IN	O
other	JJ	O
molecules	NNS	O
,	,	O
molecule	NN	O
structures	NNS	O
or	CC	O
mixtures	NNS	O
of	IN	O
compounds	NNS	O
,	,	O
as	IN	O
for	IN	O
example	NN	O
,	,	O
liposomes	RB	O
,	,	O
receptor-targeted	JJ	O
molecules	NNS	O
,	,	O
oral	JJ	O
,	,	O
rectal	JJ	O
,	,	O
topical	JJ	O
or	CC	O
other	JJ	O
formulations	NNS	O
,	,	O
for	IN	O
assisting	VBG	O
in	IN	O
uptake	NN	O
,	,	O
distribution	NN	O
and/or	NN	O
absorption	NN	O
.	.	O
Representative	JJ	O
United	NNP	O
States	NNPS	O
patents	NNS	O
that	WDT	O
teach	VBP	O
the	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
uptake	JJ	O
,	,	O
distribution	NN	O
and/or	IN	O
absorption-assisting	JJ	O
formulations	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,108,921	CD	O
;	:	O
5,354,844	CD	O
;	:	O
5,416,016	CD	O
;	:	O
5,459,127	CD	O
;	:	O
5,521,291	CD	O
;	:	O
5,543,158	CD	O
;	:	O
5,547,932	CD	O
;	:	O
5,583,020	CD	O
;	:	O
5,591,721	CD	O
;	:	O
4,426,330	CD	O
;	:	O
4,534,899	CD	O
;	:	O
5,013,556	CD	O
;	:	O
5,108,921	CD	O
;	:	O
5,213,804	CD	O
;	:	O
5,227,170	CD	O
;	:	O
5,264,221	CD	O
;	:	O
5,356,633	CD	O
;	:	O
5,395,619	CD	O
;	:	O
5,416,016	CD	O
;	:	O
5,417,978	CD	O
;	:	O
5,462,854	CD	O
;	:	O
5,469,854	CD	O
;	:	O
5,512,295	CD	O
;	:	O
5,527,528	CD	O
;	:	O
5,534,259	CD	O
;	:	O
5,543,152	CD	O
;	:	O
5,556,948	CD	O
;	:	O
5,580,575	CD	O
;	:	O
and	CC	O
5,595,756	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
The	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
encompass	NN	O
any	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
,	,	O
esters	NNS	O
,	,	O
or	CC	O
salts	NNS	O
of	IN	O
such	JJ	O
esters	NNS	O
,	,	O
or	CC	O
any	DT	O
other	JJ	O
compound	NN	O
which	WDT	O
,	,	O
upon	IN	O
administration	NN	O
to	TO	O
an	DT	O
animal	NN	O
,	,	O
including	VBG	O
a	DT	O
human	JJ	O
,	,	O
is	VBZ	O
capable	JJ	O
of	IN	O
providing	VBG	O
(	(	O
directly	RB	O
or	CC	O
indirectly	RB	O
)	)	O
the	DT	O
biologically	RB	O
active	JJ	O
metabolite	NN	O
or	CC	O
residue	JJ	O
thereof	NN	O
.	.	O
Accordingly	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
disclosure	NN	O
is	VBZ	O
also	RB	O
drawn	VBN	O
to	TO	O
prodrugs	NNS	O
and	CC	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
of	IN	O
such	JJ	O
prodrugs	NNS	O
,	,	O
and	CC	O
other	JJ	O
bioequivalents	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
prodrug	NN	O
”	NNP	O
indicates	VBZ	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
that	WDT	O
is	VBZ	O
prepared	VBN	O
in	IN	O
an	DT	O
inactive	JJ	O
form	NN	O
that	WDT	O
is	VBZ	O
converted	VBN	O
to	TO	O
an	DT	O
active	JJ	O
form	NN	O
(	(	O
i.e.	JJ	O
,	,	O
drug	NN	O
)	)	O
within	IN	O
the	DT	O
body	NN	O
or	CC	O
cells	NNS	O
thereof	VBN	O
by	IN	O
the	DT	O
action	NN	O
of	IN	O
endogenous	JJ	O
enzymes	NNS	O
or	CC	O
other	JJ	O
chemicals	NNS	O
and/or	JJ	O
conditions	NNS	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
prodrug	JJ	O
versions	NNS	O
of	IN	O
the	DT	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
prepared	VBN	O
as	IN	O
SATE	NNP	O
[	NNP	O
(	(	O
S-acetyl-2-thioethyl	NNP	O
)	)	O
phosphate	NN	O
]	NN	O
derivatives	NNS	O
according	VBG	O
to	TO	O
the	DT	O
methods	NNS	O
disclosed	VBN	O
in	IN	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
93/24510	CD	O
to	TO	O
Gosselin	NNP	O
et	FW	O
al.	NN	O
,	,	O
published	VBN	O
Dec.	NNP	O
9	CD	O
,	,	O
1993	CD	O
or	CC	O
in	IN	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
94/26764	CD	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,770,713	CD	O
to	TO	O
Imbach	NNP	O
et	FW	O
al	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
”	JJ	O
refers	NNS	O
to	TO	O
physiologically	RB	O
and	CC	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
of	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
:	:	O
i.e.	NN	O
,	,	O
salts	NNS	O
that	WDT	O
retain	VBP	O
the	DT	O
desired	JJ	O
biological	JJ	O
activity	NN	O
of	IN	O
the	DT	O
parent	NN	O
compound	NN	O
and	CC	O
do	VBP	O
not	RB	O
impart	VB	O
undesired	JJ	O
toxicological	JJ	O
effects	NNS	O
thereto	NN	O
.	.	O
For	IN	O
oligonucleotides	NNS	O
,	,	O
preferred	JJ	O
examples	NNS	O
of	IN	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Pharmaceutically	RB	O
acceptable	JJ	O
base	NN	O
addition	NN	O
salts	NNS	O
are	VBP	O
formed	VBN	O
with	IN	O
metals	NNS	O
or	CC	O
amines	NNS	O
,	,	O
such	JJ	O
as	IN	O
alkali	NN	O
and	CC	O
alkaline	JJ	O
earth	NN	O
metals	NNS	O
or	CC	O
organic	JJ	O
amines	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
metals	NNS	O
used	VBN	O
as	IN	O
cations	NNS	O
are	VBP	O
sodium	JJ	O
,	,	O
potassium	NN	O
,	,	O
magnesium	NN	O
,	,	O
calcium	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
Examples	NNS	O
of	IN	O
suitable	JJ	O
amines	NNS	O
are	VBP	O
N	NNP	O
,	,	O
N′-dibenzylethylenediamine	NNP	O
,	,	O
chloroprocaine	NN	O
,	,	O
choline	NN	O
,	,	O
diethanolamine	NN	O
,	,	O
dicyclohexylamine	NN	O
,	,	O
ethylenediamine	NN	O
,	,	O
N-methylglucamine	NNP	O
,	,	O
and	CC	O
procaine	NN	O
(	(	O
see	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Berge	NNP	B
et	FW	I
al.	NN	I
,	,	I
“	NNP	I
Pharmaceutical	NNP	I
Salts	NNP	I
,	,	I
”	NNP	I
J.	NNP	I
of	IN	I
Pharma	NNP	I
Sci.	NNP	I
,	,	I
1977	CD	I
,	,	I
66	CD	I
,	,	I
1-19	JJ	I
)	)	O
.	.	O
The	DT	O
base	NN	O
addition	NN	O
salts	NNS	O
of	IN	O
said	VBD	O
acidic	JJ	O
compounds	NNS	O
are	VBP	O
prepared	VBN	O
by	IN	O
contacting	VBG	O
the	DT	O
free	JJ	O
acid	NN	O
form	NN	O
with	IN	O
a	DT	O
sufficient	JJ	O
amount	NN	O
of	IN	O
the	DT	O
desired	JJ	O
base	NN	O
to	TO	O
produce	VB	O
the	DT	O
salt	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
manner	NN	O
.	.	O
The	DT	O
free	JJ	O
acid	NN	O
form	NN	O
may	MD	O
be	VB	O
regenerated	VBN	O
by	IN	O
contacting	VBG	O
the	DT	O
salt	NN	O
form	NN	O
with	IN	O
an	DT	O
acid	NN	O
and	CC	O
isolating	VBG	O
the	DT	O
free	JJ	O
acid	NN	O
in	IN	O
the	DT	O
conventional	JJ	O
manner	NN	O
.	.	O
The	DT	O
free	JJ	O
acid	NN	O
forms	NNS	O
differ	VBP	O
from	IN	O
their	PRP$	O
respective	JJ	O
salt	NN	O
forms	NNS	O
somewhat	RB	O
in	IN	O
certain	JJ	O
physical	JJ	O
properties	NNS	O
such	JJ	O
as	IN	O
solubility	NN	O
in	IN	O
polar	JJ	O
solvents	NNS	O
,	,	O
but	CC	O
otherwise	RB	O
the	DT	O
salts	NNS	O
are	VBP	O
equivalent	JJ	O
to	TO	O
their	PRP$	O
respective	JJ	O
free	JJ	O
acid	NN	O
for	IN	O
purposes	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
a	DT	O
“	JJ	O
pharmaceutical	JJ	O
addition	NN	O
salt	NN	O
”	NNP	O
includes	VBZ	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
salt	NN	O
of	IN	O
an	DT	O
acid	JJ	O
form	NN	O
of	IN	O
one	CD	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
These	DT	O
include	VBP	O
organic	JJ	O
or	CC	O
inorganic	JJ	O
acid	NN	O
salts	NNS	O
of	IN	O
the	DT	O
amines	NNS	O
.	.	O
Preferred	NNP	O
acid	NN	O
salts	NNS	O
are	VBP	O
the	DT	O
hydrochlorides	NNS	O
,	,	O
acetates	NNS	O
,	,	O
salicylates	NNS	O
,	,	O
nitrates	NNS	O
and	CC	O
phosphates	NNS	O
.	.	O
Other	JJ	O
suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
include	VBP	O
basic	JJ	O
salts	NNS	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
inorganic	JJ	O
and	CC	O
organic	JJ	O
acids	NNS	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
with	IN	O
inorganic	JJ	O
acids	NNS	O
,	,	O
such	JJ	O
as	IN	O
for	IN	O
example	NN	O
hydrochloric	JJ	O
acid	NN	O
,	,	O
hydrobromic	JJ	O
acid	NN	O
,	,	O
sulfuric	JJ	O
acid	NN	O
or	CC	O
phosphoric	JJ	O
acid	NN	O
;	:	O
with	IN	O
organic	JJ	O
carboxylic	NN	O
,	,	O
sulfonic	JJ	O
,	,	O
sulfo	JJ	O
or	CC	O
phospho	JJ	O
acids	NNS	O
or	CC	O
N-substituted	JJ	O
sulfamic	JJ	O
acids	NNS	O
,	,	O
for	IN	O
example	NN	O
acetic	JJ	O
acid	NN	O
,	,	O
propionic	JJ	O
acid	NN	O
,	,	O
glycolic	JJ	O
acid	NN	O
,	,	O
succinic	JJ	O
acid	NN	O
,	,	O
maleic	JJ	O
acid	NN	O
,	,	O
hydroxymaleic	JJ	O
acid	NN	O
,	,	O
methylmaleic	JJ	O
acid	NN	O
,	,	O
fumaric	JJ	O
acid	NN	O
,	,	O
malic	JJ	O
acid	NN	O
,	,	O
tartaric	JJ	O
acid	NN	O
,	,	O
lactic	JJ	O
acid	NN	O
,	,	O
oxalic	JJ	O
acid	NN	O
,	,	O
gluconic	JJ	O
acid	NN	O
,	,	O
glucaric	JJ	O
acid	NN	O
,	,	O
glucuronic	JJ	O
acid	NN	O
,	,	O
citric	JJ	O
acid	NN	O
,	,	O
benzoic	NN	O
acid	NN	O
,	,	O
cinnamic	JJ	O
acid	NN	O
,	,	O
mandelic	JJ	O
acid	NN	O
,	,	O
salicylic	JJ	O
acid	NN	O
,	,	O
4-aminosalicylic	JJ	O
acid	NN	O
,	,	O
2-phenoxybenzoic	JJ	O
acid	NN	O
,	,	O
2-acetoxybenzoic	JJ	O
acid	NN	O
,	,	O
embonic	JJ	O
acid	NN	O
,	,	O
nicotinic	JJ	O
acid	NN	O
or	CC	O
isonicotinic	JJ	O
acid	NN	O
;	:	O
and	CC	O
with	IN	O
amino	JJ	O
acids	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
20	CD	O
alpha-amino	JJ	O
acids	NNS	O
involved	VBN	O
in	IN	O
the	DT	O
synthesis	NN	O
of	IN	O
proteins	NNS	O
in	IN	O
nature	NN	O
,	,	O
for	IN	O
example	NN	O
glutamic	JJ	O
acid	NN	O
or	CC	O
aspartic	JJ	O
acid	NN	O
,	,	O
and	CC	O
also	RB	O
with	IN	O
phenylacetic	JJ	O
acid	NN	O
,	,	O
methanesulfonic	JJ	O
acid	NN	O
,	,	O
ethanesulfonic	JJ	O
acid	NN	O
,	,	O
2-hydroxyethanesulfonic	JJ	O
acid	NN	O
,	,	O
ethane-1,2-disulfonic	JJ	O
acid	NN	O
,	,	O
benzenesulfonic	JJ	O
acid	NN	O
,	,	O
4-methylbenzenesulfonic	JJ	O
acid	NN	O
,	,	O
naphthalene-2-sulfonic	JJ	O
acid	NN	O
,	,	O
naphthalene-1,5-disulfonic	JJ	O
acid	NN	O
,	,	O
2-	JJ	O
or	CC	O
3-phosphoglycerate	JJ	O
,	,	O
glucose-6-phosphate	JJ	O
,	,	O
N-cyclohexylsulfamic	JJ	O
acid	NN	O
(	(	O
with	IN	O
the	DT	O
formation	NN	O
of	IN	O
cyclamates	NNS	O
)	)	O
,	,	O
or	CC	O
with	IN	O
other	JJ	O
acid	JJ	O
organic	JJ	O
compounds	NNS	O
,	,	O
such	JJ	O
as	IN	O
ascorbic	JJ	O
acid	NN	O
.	.	O
Pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
of	IN	O
compounds	NNS	O
may	MD	O
also	RB	O
be	VB	O
prepared	VBN	O
with	IN	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
cation	NN	O
.	.	O
Suitable	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
cations	NNS	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
include	VBP	O
alkaline	NN	O
,	,	O
alkaline	JJ	O
earth	NN	O
,	,	O
ammonium	NN	O
and	CC	O
quaternary	JJ	O
ammonium	NN	O
cations	NNS	O
.	.	O
Carbonates	NNS	O
or	CC	O
hydrogen	NN	O
carbonates	NNS	O
are	VBP	O
also	RB	O
possible	JJ	O
.	.	O
For	IN	O
oligonucleotides	NNS	O
,	,	O
preferred	JJ	O
examples	NNS	O
of	IN	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
(	(	O
a	DT	O
)	)	O
salts	NNS	O
formed	VBN	O
with	IN	O
cations	NNS	O
such	JJ	O
as	IN	O
sodium	NN	O
,	,	O
potassium	NN	O
,	,	O
ammonium	NN	O
,	,	O
magnesium	NN	O
,	,	O
calcium	NN	O
,	,	O
polyamines	NNS	O
such	JJ	O
as	IN	O
spermine	NN	O
and	CC	O
spermidine	NN	O
,	,	O
etc	FW	O
.	.	O
;	:	O
(	(	O
b	NN	O
)	)	O
acid	NN	O
addition	NN	O
salts	NNS	O
formed	VBN	O
with	IN	O
inorganic	JJ	O
acids	NNS	O
,	,	O
for	IN	O
example	NN	O
hydrochloric	JJ	O
acid	NN	O
,	,	O
hydrobromic	JJ	O
acid	NN	O
,	,	O
sulfuric	JJ	O
acid	NN	O
,	,	O
phosphoric	JJ	O
acid	NN	O
,	,	O
nitric	JJ	O
acid	NN	O
and	CC	O
the	DT	O
like	JJ	O
;	:	O
(	(	O
c	NN	O
)	)	O
salts	NNS	O
formed	VBN	O
with	IN	O
organic	JJ	O
acids	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
acetic	JJ	O
acid	NN	O
,	,	O
oxalic	JJ	O
acid	NN	O
,	,	O
tartaric	JJ	O
acid	NN	O
,	,	O
succinic	JJ	O
acid	NN	O
,	,	O
maleic	JJ	O
acid	NN	O
,	,	O
fumaric	JJ	O
acid	NN	O
,	,	O
gluconic	JJ	O
acid	NN	O
,	,	O
citric	JJ	O
acid	NN	O
,	,	O
malic	JJ	O
acid	NN	O
,	,	O
ascorbic	JJ	O
acid	NN	O
,	,	O
benzoic	NN	O
acid	NN	O
,	,	O
tannic	JJ	O
acid	NN	O
,	,	O
palmitic	JJ	O
acid	NN	O
,	,	O
alginic	JJ	O
acid	NN	O
,	,	O
polyglutamic	JJ	O
acid	NN	O
,	,	O
naphthalenesulfonic	JJ	O
acid	NN	O
,	,	O
methanesulfonic	JJ	O
acid	NN	O
,	,	O
p-toluenesulfonic	JJ	O
acid	NN	O
,	,	O
naphthalenedisulfonic	JJ	O
acid	NN	O
,	,	O
polygalacturonic	JJ	O
acid	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
;	:	O
and	CC	O
(	(	O
d	NN	O
)	)	O
salts	NNS	O
formed	VBN	O
from	IN	O
elemental	JJ	O
anions	NNS	O
such	JJ	O
as	IN	O
chlorine	NN	O
,	,	O
bromine	NN	O
,	,	O
and	CC	O
iodine	NN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
includes	VBZ	O
pharmaceutical	JJ	O
compositions	NNS	O
and	CC	O
formulations	NNS	O
which	WDT	O
include	VBP	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
administered	VBN	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
ways	NNS	O
depending	VBG	O
upon	IN	O
whether	IN	O
local	JJ	O
or	CC	O
systemic	JJ	O
treatment	NN	O
is	VBZ	O
desired	VBN	O
and	CC	O
upon	IN	O
the	DT	O
area	NN	O
to	TO	O
be	VB	O
treated	VBN	O
.	.	O
Administration	NN	O
may	MD	O
be	VB	O
topical	JJ	O
(	(	O
including	VBG	O
ophthalmic	JJ	O
and	CC	O
to	TO	O
mucous	JJ	O
membranes	NNS	O
including	VBG	O
vaginal	JJ	O
and	CC	O
rectal	JJ	O
delivery	NN	O
)	)	O
,	,	O
pulmonary	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
by	IN	O
inhalation	NN	O
or	CC	O
insufflation	NN	O
of	IN	O
powders	NNS	O
or	CC	O
aerosols	NNS	O
,	,	O
including	VBG	O
by	IN	O
nebulizer	NN	O
;	:	O
intratracheal	NN	O
,	,	O
intranasal	NN	O
,	,	O
epidermal	JJ	O
and	CC	O
transdermal	JJ	O
)	)	O
,	,	O
oral	JJ	O
or	CC	O
parenteral	JJ	O
.	.	O
Parenteral	JJ	O
administration	NN	O
includes	VBZ	O
intravenous	JJ	O
,	,	O
intraarterial	JJ	O
,	,	O
subcutaneous	JJ	O
,	,	O
intraperitoneal	JJ	O
or	CC	O
intramuscular	JJ	O
injection	NN	O
or	CC	O
infusion	NN	O
;	:	O
or	CC	O
intracranial	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
intrathecal	JJ	O
or	CC	O
intraventricular	JJ	O
,	,	O
administration	NN	O
.	.	O
Oligonucleotides	NNS	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
2′-O-methoxyethyl	JJ	O
modification	NN	O
are	VBP	O
believed	VBN	O
to	TO	O
be	VB	O
particularly	RB	O
useful	JJ	O
for	IN	O
oral	JJ	O
administration	NN	O
.	.	O
Pharmaceutical	JJ	O
compositions	NNS	O
and	CC	O
formulations	NNS	O
for	IN	O
topical	JJ	O
administration	NN	O
may	MD	O
include	VB	O
transdermal	JJ	O
patches	NNS	O
,	,	O
ointments	NNS	O
,	,	O
lotions	NNS	O
,	,	O
creams	NNS	O
,	,	O
gels	NNS	O
,	,	O
drops	NNS	O
,	,	O
suppositories	NNS	O
,	,	O
sprays	NNS	O
,	,	O
liquids	NNS	O
and	CC	O
powders	NNS	O
.	.	O
Conventional	JJ	O
pharmaceutical	JJ	O
carriers	NNS	O
,	,	O
aqueous	JJ	O
,	,	O
powder	NN	O
or	CC	O
oily	RB	O
bases	NNS	O
,	,	O
thickeners	NNS	O
and	CC	O
the	DT	O
like	JJ	O
may	MD	O
be	VB	O
necessary	JJ	O
or	CC	O
desirable	JJ	O
.	.	O
Coated	VBN	O
condoms	NNS	O
,	,	O
gloves	NNS	O
and	CC	O
the	DT	O
like	JJ	O
may	MD	O
also	RB	O
be	VB	O
useful	JJ	O
.	.	O
Preferred	NNP	O
topical	JJ	O
formulations	NNS	O
include	VBP	O
those	DT	O
in	IN	O
which	WDT	O
the	DT	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
in	IN	O
admixture	NN	O
with	IN	O
a	DT	O
topical	JJ	O
delivery	NN	O
agent	NN	O
such	JJ	O
as	IN	O
lipids	NNS	O
,	,	O
liposomes	NNS	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
fatty	JJ	O
acid	NN	O
esters	NNS	O
,	,	O
steroids	NNS	O
,	,	O
chelating	VBG	O
agents	NNS	O
and	CC	O
surfactants	NNS	O
.	.	O
Preferred	NNP	O
lipids	NNS	O
and	CC	O
liposomes	NNS	O
include	VBP	O
neutral	JJ	O
(	(	O
e.g	NN	O
.	.	O
dioleoylphosphatidyl	NNS	O
DOPE	NNP	O
ethanolamine	NN	O
,	,	O
dimyristoylphosphatidyl	JJ	O
choline	NN	O
DMPC	NNP	O
,	,	O
distearolyphosphatidyl	JJ	O
choline	NN	O
)	)	O
negative	NN	O
(	(	O
e.g	NN	O
.	.	O
dimyristoylphosphatidyl	NN	O
glycerol	NN	O
DMPG	NNP	O
)	)	O
and	CC	O
cationic	JJ	O
(	(	O
e.g	NN	O
.	.	O
dioleoyltetramethylaminopropyl	NN	O
DOTAP	NNP	O
and	CC	O
dioleoylphosphatidyl	JJ	O
ethanolamine	NN	O
DOTMA	NNP	O
)	)	O
.	.	O
Oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
encapsulated	VBN	O
within	IN	O
liposomes	NNS	O
or	CC	O
may	MD	O
form	VB	O
complexes	NNS	O
thereto	NN	O
,	,	O
in	IN	O
particular	JJ	O
to	TO	O
cationic	JJ	O
liposomes	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
oligonucleotides	NNS	O
may	MD	O
be	VB	O
complexed	VBN	O
to	TO	O
lipids	NNS	O
,	,	O
in	IN	O
particular	JJ	O
to	TO	O
cationic	JJ	O
lipids	NNS	O
.	.	O
Preferred	NNP	O
fatty	JJ	O
acids	NNS	O
and	CC	O
esters	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	JJ	O
arachidonic	JJ	O
acid	NN	O
,	,	O
oleic	JJ	O
acid	NN	O
,	,	O
eicosanoic	JJ	O
acid	NN	O
,	,	O
lauric	JJ	O
acid	NN	O
,	,	O
caprylic	JJ	O
acid	NN	O
,	,	O
capric	JJ	O
acid	NN	O
,	,	O
myristic	JJ	O
acid	NN	O
,	,	O
palmitic	JJ	O
acid	NN	O
,	,	O
stearic	JJ	O
acid	NN	O
,	,	O
linoleic	JJ	O
acid	NN	O
,	,	O
linolenic	JJ	O
acid	NN	O
,	,	O
dicaprate	NN	O
,	,	O
tricaprate	NN	O
,	,	O
monoolein	NN	O
,	,	O
dilaurin	NN	O
,	,	O
glyceryl	JJ	O
1-monocaprate	JJ	O
,	,	O
1-dodecylazacycloheptan-2-one	JJ	O
,	,	O
an	DT	O
acylcarnitine	NN	O
,	,	O
an	DT	O
acylcholine	NN	O
,	,	O
or	CC	O
a	DT	O
C1-10alkyl	JJ	O
ester	NN	O
(	(	O
e.g	NN	O
.	.	O
isopropylmyristate	VB	O
IPM	NNP	O
)	)	O
,	,	O
monoglyceride	RB	O
,	,	O
diglyceride	NN	O
or	CC	O
pharmaceutically	RB	O
acceptable	JJ	O
salt	NN	O
thereof	NN	O
.	.	O
Topical	JJ	O
formulations	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
detail	NN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,747,014	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
an	DT	O
oligonucleotide	NN	O
may	MD	O
be	VB	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
via	IN	O
an	DT	O
oral	JJ	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O
The	DT	O
subjects	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
comprise	NN	O
animals	NNS	O
.	.	O
An	DT	O
animal	JJ	O
subject	NN	O
may	MD	O
be	VB	O
a	DT	O
mammal	JJ	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
mouse	NN	O
,	,	O
a	DT	O
rat	NN	O
,	,	O
a	DT	O
dog	NN	O
,	,	O
a	DT	O
guinea	NN	O
pig	NN	O
,	,	O
a	DT	O
human	JJ	O
,	,	O
a	DT	O
non-human	JJ	O
primate	NN	O
,	,	O
a	DT	O
cat	NN	O
or	CC	O
a	DT	O
pig	NN	O
.	.	O
Non-human	JJ	O
primates	NNS	O
include	VBP	O
monkeys	NNS	O
and	CC	O
chimpanzees	NNS	O
.	.	O
A	DT	O
suitable	JJ	O
animal	NN	O
subject	NN	O
may	MD	O
be	VB	O
an	DT	O
experimental	JJ	O
animal	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
mouse	NN	O
,	,	O
a	DT	O
rat	NN	O
,	,	O
a	DT	O
dog	NN	O
,	,	O
a	DT	O
non-human	JJ	O
primate	NN	O
,	,	O
a	DT	O
cat	NN	O
or	CC	O
a	DT	O
pig	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
subject	NN	O
may	MD	O
be	VB	O
a	DT	O
human	JJ	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
subject	NN	O
may	MD	O
be	VB	O
a	DT	O
human	JJ	O
patient	NN	O
as	IN	O
discussed	VBN	O
in	IN	O
more	JJR	O
detail	NN	O
herein	NN	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
modulate	VB	O
the	DT	O
expression	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
genes	NNS	O
of	IN	O
the	DT	O
human	JJ	O
patient	NN	O
.	.	O
In	IN	O
some	DT	O
particular	JJ	O
embodiments	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
inhibit	VB	O
expression	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
genes	NNS	O
of	IN	O
the	DT	O
human	JJ	O
patient	NN	O
.	.	O
In	IN	O
particular	JJ	O
embodiments	NNS	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
modulate	VB	O
,	,	O
i.e	NN	O
.	.	O
inhibit	NN	O
or	CC	O
enhance	NN	O
,	,	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
order	NN	O
to	TO	O
obtain	VB	O
therapeutic	JJ	O
outcomes	NNS	O
discussed	VBN	O
herein	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
non-parenteral	JJ	O
(	(	O
e.g	NN	O
.	.	O
oral	JJ	O
)	)	O
oligonucleotide	IN	O
formulations	NNS	O
according	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
result	NN	O
in	IN	O
enhanced	JJ	O
bioavailability	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
In	IN	O
this	DT	O
context	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
bioavailability	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
measurement	NN	O
of	IN	O
that	DT	O
portion	NN	O
of	IN	O
an	DT	O
administered	VBN	O
drug	NN	O
which	WDT	O
reaches	VBZ	O
the	DT	O
circulatory	NN	O
system	NN	O
(	(	O
e.g	UH	O
.	.	O
blood	NN	O
,	,	O
especially	RB	O
blood	JJ	O
plasma	NN	O
)	)	O
when	WRB	O
a	DT	O
particular	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
deliver	VB	O
the	DT	O
drug	NN	O
.	.	O
Enhanced	NNP	O
bioavailability	NN	O
refers	NNS	O
to	TO	O
a	DT	O
particular	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
's	POS	O
ability	NN	O
to	TO	O
deliver	VB	O
oligonucleotide	RB	O
to	TO	O
the	DT	O
peripheral	JJ	O
blood	NN	O
plasma	NN	O
of	IN	O
a	DT	O
subject	JJ	O
relative	NN	O
to	TO	O
another	DT	O
mode	NN	O
of	IN	O
administration	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
when	WRB	O
a	DT	O
non-parenteral	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
(	(	O
e.g	UH	O
.	.	O
an	DT	O
oral	JJ	O
mode	NN	O
)	)	O
is	VBZ	O
used	VBN	O
to	TO	O
introduce	VB	O
the	DT	O
drug	NN	O
into	IN	O
a	DT	O
subject	NN	O
,	,	O
the	DT	O
bioavailability	NN	O
for	IN	O
that	DT	O
mode	NN	O
of	IN	O
administration	NN	O
may	MD	O
be	VB	O
compared	VBN	O
to	TO	O
a	DT	O
different	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
,	,	O
e.g	NN	O
.	.	O
an	DT	O
IV	NNP	O
mode	NN	O
of	IN	O
administration	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
area	NN	O
under	IN	O
a	DT	O
compound	NN	O
's	POS	O
blood	NN	O
plasma	NN	O
concentration	NN	O
curve	NN	O
(	(	O
AUC0	NNP	O
)	)	O
after	IN	O
non-parenteral	JJ	O
administration	NN	O
may	MD	O
be	VB	O
divided	VBN	O
by	IN	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
drug	NN	O
's	POS	O
plasma	JJ	O
concentration	NN	O
curve	NN	O
after	IN	O
intravenous	JJ	O
(	(	O
i.v	JJ	O
.	.	O
)	)	O
administration	NN	O
(	(	O
AUCiv	NNP	O
)	)	O
to	TO	O
provide	VB	O
a	DT	O
dimensionless	JJ	O
quotient	NN	O
(	(	O
relative	JJ	O
bioavailability	NN	O
,	,	O
RB	NNP	O
)	)	O
that	WDT	O
represents	VBZ	O
fraction	NN	O
of	IN	O
compound	NN	O
absorbed	VBN	O
via	IN	O
the	DT	O
non-parenteral	JJ	O
route	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
IV	NNP	O
route	NN	O
.	.	O
A	DT	O
composition	NN	O
's	POS	O
bioavailability	NN	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
enhanced	VBN	O
in	IN	O
comparison	NN	O
to	TO	O
another	DT	O
composition	NN	O
's	POS	O
bioavailability	NN	O
when	WRB	O
the	DT	O
first	JJ	O
composition	NN	O
's	POS	O
relative	JJ	O
bioavailability	NN	O
(	(	O
RB1	NNP	O
)	)	O
is	VBZ	O
greater	JJR	O
than	IN	O
the	DT	O
second	JJ	O
composition	NN	O
's	POS	O
relative	JJ	O
bioavailability	NN	O
(	(	O
RB2	NNP	O
)	)	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
bioavailability	NN	O
correlates	NNS	O
with	IN	O
therapeutic	JJ	O
efficacy	NN	O
when	WRB	O
a	DT	O
compound	NN	O
's	POS	O
therapeutic	JJ	O
efficacy	NN	O
is	VBZ	O
related	VBN	O
to	TO	O
the	DT	O
blood	NN	O
concentration	NN	O
achieved	VBD	O
,	,	O
even	RB	O
if	IN	O
the	DT	O
drug	NN	O
's	POS	O
ultimate	JJ	O
site	NN	O
of	IN	O
action	NN	O
is	VBZ	O
intracellular	JJ	O
(	(	O
van	JJ	B
Berge-Henegouwen	NNP	I
et	NN	I
al.	NN	I
,	,	I
Gastroenterol.	NNP	I
,	,	I
1977	CD	I
,	,	I
73	CD	I
,	,	I
300	CD	I
)	)	O
.	.	O
Bioavailability	NNP	O
studies	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
degree	NN	O
of	IN	O
intestinal	JJ	O
absorption	NN	O
of	IN	O
a	DT	O
drug	NN	O
by	IN	O
measuring	VBG	O
the	DT	O
change	NN	O
in	IN	O
peripheral	JJ	O
blood	NN	O
levels	NNS	O
of	IN	O
the	DT	O
drug	NN	O
after	IN	O
an	DT	O
oral	JJ	O
dose	NN	O
(	(	O
DiSanto	NNP	B
,	,	I
Chapter	NNP	I
76	CD	I
In	IN	I
:	:	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Ed.	NNP	I
,	,	I
Gennaro	NNP	I
,	,	I
ed.	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1990	CD	I
,	,	I
pages	VBZ	I
1451-1458	JJ	I
)	)	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
bioavailability	NN	O
of	IN	O
an	DT	O
oral	JJ	O
composition	NN	O
(	(	O
comprising	VBG	O
an	DT	O
oligonucleotide	NN	O
)	)	O
is	VBZ	O
said	VBD	O
to	TO	O
be	VB	O
“	RB	O
enhanced	VBN	O
”	NN	O
when	WRB	O
its	PRP$	O
relative	JJ	O
bioavailability	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
the	DT	O
bioavailability	NN	O
of	IN	O
a	DT	O
composition	NN	O
substantially	RB	O
consisting	VBG	O
of	IN	O
pure	JJ	O
oligonucleotide	NN	O
,	,	O
i.e	NN	O
.	.	O
oligonucleotide	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
penetration	NN	O
enhancer	NN	O
.	.	O
Organ	NNP	O
bioavailability	NN	O
refers	NNS	O
to	TO	O
the	DT	O
concentration	NN	O
of	IN	O
compound	NN	O
in	IN	O
an	DT	O
organ	NN	O
.	.	O
Organ	NNP	O
bioavailability	NN	O
may	MD	O
be	VB	O
measured	VBN	O
in	IN	O
test	NN	O
subjects	NNS	O
by	IN	O
a	DT	O
number	NN	O
of	IN	O
means	NNS	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
whole-body	NN	O
radiography	NN	O
.	.	O
Organ	NNP	O
bioavailability	NN	O
may	MD	O
be	VB	O
modified	VBN	O
,	,	O
e.g	NN	O
.	.	O
enhanced	VBN	O
,	,	O
by	IN	O
one	CD	O
or	CC	O
more	JJR	O
modifications	NNS	O
to	TO	O
the	DT	O
oligonucleotide	NN	O
,	,	O
by	IN	O
use	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
carrier	NN	O
compounds	NNS	O
or	CC	O
excipients	NNS	O
,	,	O
etc	FW	O
.	.	O
as	IN	O
discussed	VBN	O
in	IN	O
more	JJR	O
detail	NN	O
herein	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
an	DT	O
increase	NN	O
in	IN	O
bioavailability	NN	O
will	MD	O
result	VB	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
organ	JJ	O
bioavailability	NN	O
.	.	O
Oral	NNP	O
oligonucleotide	NN	O
compositions	NNS	O
according	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
comprise	VB	O
one	CD	O
or	CC	O
more	JJR	O
“	JJ	O
mucosal	NN	O
penetration	NN	O
enhancers	NNS	O
,	,	O
”	NNP	O
also	RB	O
known	VBN	O
as	IN	O
“	JJ	O
absorption	NN	O
enhancers	NNS	O
”	VBP	O
or	CC	O
simply	RB	O
as	IN	O
“	JJ	O
penetration	NN	O
enhancers.	NN	O
”	NNP	O
Accordingly	NNP	O
,	,	O
some	DT	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
comprise	NN	O
at	IN	O
least	JJS	O
one	CD	O
oligonucleotide	NN	O
in	IN	O
combination	NN	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
a	DT	O
penetration	NN	O
enhancer	NN	O
is	VBZ	O
a	DT	O
substance	NN	O
that	WDT	O
facilitates	VBZ	O
the	DT	O
transport	NN	O
of	IN	O
a	DT	O
drug	NN	O
across	IN	O
mucous	JJ	O
membrane	NN	O
(	(	O
s	PRP	O
)	)	O
associated	VBN	O
with	IN	O
the	DT	O
desired	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
,	,	O
e.g	NN	O
.	.	O
intestinal	JJ	O
epithelial	JJ	O
membranes	NNS	O
.	.	O
Accordingly	RB	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
select	VB	O
one	CD	O
or	CC	O
more	JJR	O
penetration	NN	O
enhancers	NNS	O
that	WDT	O
facilitate	VBP	O
the	DT	O
uptake	NN	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
,	,	O
without	IN	O
interfering	VBG	O
with	IN	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
,	,	O
and	CC	O
in	IN	O
such	JJ	O
a	DT	O
manner	NN	O
the	DT	O
oligonucleotide	NN	O
can	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
the	DT	O
body	NN	O
of	IN	O
an	DT	O
animal	NN	O
without	IN	O
unacceptable	JJ	O
degrees	NNS	O
of	IN	O
side-effects	NNS	O
such	JJ	O
as	IN	O
toxicity	NN	O
,	,	O
irritation	NN	O
or	CC	O
allergic	JJ	O
response	NN	O
.	.	O
Embodiments	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
provide	VBP	O
compositions	NNS	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
pharmaceutically	RB	O
acceptable	JJ	O
penetration	NN	O
enhancers	NNS	O
,	,	O
and	CC	O
methods	NNS	O
of	IN	O
using	VBG	O
such	JJ	O
compositions	NNS	O
,	,	O
which	WDT	O
result	VBP	O
in	IN	O
the	DT	O
improved	JJ	O
bioavailability	NN	O
of	IN	O
oligonucleotides	NNS	O
administered	VBN	O
via	IN	O
non-parenteral	JJ	O
modes	NNS	O
of	IN	O
administration	NN	O
.	.	O
Heretofore	NNP	O
,	,	O
certain	JJ	O
penetration	NN	O
enhancers	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
improve	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
certain	JJ	O
drugs	NNS	O
.	.	O
See	NNP	O
Muranishi	NNP	B
,	,	I
Crit	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Ther	DT	I
.	.	I
Drug	NN	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1	CD	I
and	CC	O
Lee	NNP	B
et	NNP	I
al.	NN	I
,	,	I
Crit	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Ther	DT	I
.	.	I
Drug	NN	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
8	CD	I
,	,	I
91	CD	I
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
found	VBN	O
that	IN	O
the	DT	O
uptake	NN	O
and	CC	O
delivery	NN	O
of	IN	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
greatly	RB	O
improved	VBN	O
even	RB	O
when	WRB	O
administered	VBN	O
by	IN	O
non-parenteral	JJ	O
means	NNS	O
through	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
different	JJ	O
classes	NNS	O
of	IN	O
penetration	NN	O
enhancers	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
compositions	NNS	O
for	IN	O
non-parenteral	JJ	O
administration	NN	O
include	VBP	O
one	CD	O
or	CC	O
more	JJR	O
modifications	NNS	O
to	TO	O
naturally-occurring	JJ	O
oligonucleotides	NNS	O
(	(	O
i.e	NN	O
.	.	O
full-phosphodiester	JJ	O
deoxyribosyl	NN	O
or	CC	O
full-phosphodiester	JJ	O
ribosyl	NN	O
oligonucleotides	NNS	O
)	)	O
.	.	O
Such	JJ	O
modifications	NNS	O
may	MD	O
increase	VB	O
binding	VBG	O
affinity	NN	O
,	,	O
nuclease	JJ	O
stability	NN	O
,	,	O
cell	NN	O
or	CC	O
tissue	NN	O
permeability	NN	O
,	,	O
tissue	NN	O
distribution	NN	O
,	,	O
or	CC	O
other	JJ	O
biological	JJ	O
or	CC	O
pharmacokinetic	JJ	O
property	NN	O
.	.	O
Modifications	NNS	O
may	MD	O
be	VB	O
made	VBN	O
to	TO	O
the	DT	O
base	NN	O
,	,	O
the	DT	O
linker	NN	O
,	,	O
or	CC	O
the	DT	O
sugar	NN	O
,	,	O
in	IN	O
general	JJ	O
,	,	O
as	IN	O
discussed	VBN	O
in	IN	O
more	JJR	O
detail	NN	O
herein	NN	O
with	IN	O
regards	NNS	O
to	TO	O
oligonucleotide	VB	O
chemistry	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
compositions	NNS	O
for	IN	O
administration	NN	O
to	TO	O
a	DT	O
subject	NN	O
,	,	O
and	CC	O
in	IN	O
particular	JJ	O
oral	JJ	O
compositions	NNS	O
for	IN	O
administration	NN	O
to	TO	O
an	DT	O
animal	NN	O
(	(	O
human	JJ	O
or	CC	O
non-human	JJ	O
)	)	O
subject	NN	O
,	,	O
will	MD	O
comprise	VB	O
modified	VBN	O
oligonucleotides	IN	O
having	VBG	O
one	CD	O
or	CC	O
more	JJR	O
modifications	NNS	O
for	IN	O
enhancing	VBG	O
affinity	NN	O
,	,	O
stability	NN	O
,	,	O
tissue	NN	O
distribution	NN	O
,	,	O
or	CC	O
other	JJ	O
biological	JJ	O
property	NN	O
.	.	O
Suitable	JJ	O
modified	VBD	O
linkers	NNS	O
include	VBP	O
phosphorothioate	JJ	O
linkers	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
phosphorothioate	NN	O
linker	NN	O
.	.	O
Phosphorothioate	NNP	O
linkers	NNS	O
provide	VBP	O
nuclease	JJ	O
stability	NN	O
as	RB	O
well	RB	O
as	IN	O
plasma	NN	O
protein	NN	O
binding	VBG	O
characteristics	NNS	O
to	TO	O
the	DT	O
oligonucleotide	NN	O
.	.	O
Nuclease	NNP	O
stability	NN	O
is	VBZ	O
useful	JJ	O
for	IN	O
increasing	VBG	O
the	DT	O
in	IN	O
vivo	JJ	O
lifetime	NN	O
of	IN	O
oligonucleotides	NNS	O
,	,	O
while	IN	O
plasma	JJ	O
protein	NN	O
binding	NN	O
decreases	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
first	JJ	O
pass	NN	O
clearance	NN	O
of	IN	O
oligonucleotide	JJ	O
via	IN	O
renal	JJ	O
excretion	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
according	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
at	IN	O
least	JJS	O
two	CD	O
phosphorothioate	JJ	O
linkers	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
wherein	VBP	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
exactly	RB	O
n	VBN	O
nucleosides	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
from	IN	O
one	CD	O
to	TO	O
n−1	VB	O
phosphorothioate	NN	O
linkages	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
wherein	VBP	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
exactly	RB	O
n	VBN	O
nucleosides	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
n−1	VBN	O
phosphorothioate	JJ	O
linkages	NNS	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
wherein	IN	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
exactly	RB	O
n	VBN	O
nucleoside	RB	O
,	,	O
and	CC	O
n	NN	O
is	VBZ	O
even	RB	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
from	IN	O
1	CD	O
to	TO	O
n/2	VB	O
phosphorothioate	NN	O
linkages	NNS	O
,	,	O
or	CC	O
,	,	O
when	WRB	O
n	NN	O
is	VBZ	O
odd	JJ	O
,	,	O
from	IN	O
1	CD	O
to	TO	O
(	(	O
n−1	NN	O
)	)	O
/2	NN	O
phosphorothioate	NN	O
linkages	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
alternating	VBG	O
phosphodiester	NN	O
(	(	O
PO	NNP	O
)	)	O
and	CC	O
phosphorothioate	NN	O
(	(	O
PS	NNP	O
)	)	O
linkages	VBZ	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
stretch	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
consecutive	JJ	O
PO	NNP	O
linkages	NNS	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
stretch	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
PS	NNP	O
linkages	NNS	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
at	IN	O
least	JJS	O
two	CD	O
stretches	NNS	O
of	IN	O
PO	NNP	O
linkages	NNS	O
interrupted	VBN	O
by	IN	O
at	IN	O
least	JJS	O
one	CD	O
PS	NNP	O
linkage	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
nucleosides	NNS	O
is	VBZ	O
modified	VBN	O
on	IN	O
the	DT	O
ribosyl	NN	O
sugar	NN	O
unit	NN	O
by	IN	O
a	DT	O
modification	NN	O
that	WDT	O
imparts	VBZ	O
nuclease	DT	O
stability	NN	O
,	,	O
binding	VBG	O
affinity	NN	O
or	CC	O
some	DT	O
other	JJ	O
beneficial	JJ	O
biological	JJ	O
property	NN	O
to	TO	O
the	DT	O
sugar	NN	O
.	.	O
In	IN	O
some	DT	O
cases	NNS	O
,	,	O
the	DT	O
sugar	NN	O
modification	NN	O
includes	VBZ	O
a	DT	O
2′-modification	JJ	O
,	,	O
e.g	NN	O
.	.	O
the	DT	O
2′-OH	CD	O
of	IN	O
the	DT	O
ribosyl	NN	O
sugar	NN	O
is	VBZ	O
replaced	VBN	O
or	CC	O
substituted	VBN	O
.	.	O
Suitable	JJ	O
replacements	NNS	O
for	IN	O
2′-OH	JJ	O
include	VBP	O
2′-F	JJ	O
and	CC	O
2′-arabino-F	JJ	O
.	.	O
Suitable	JJ	O
substitutions	NNS	O
for	IN	O
OH	NNP	O
include	VBP	O
2′-O-alkyl	JJ	O
,	,	O
e.g	NN	O
.	.	O
2-O-methyl	JJ	O
,	,	O
and	CC	O
2′-O-substituted	JJ	O
alkyl	NN	O
,	,	O
e.g	NN	O
.	.	O
2′-O-methoxyethyl	JJ	O
,	,	O
2′-NH2	JJ	O
,	,	O
2′-O-aminopropyl	JJ	O
,	,	O
etc	FW	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
2′-modification	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
contains	VBZ	O
at	IN	O
least	JJS	O
two	CD	O
2′-modifications	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
2′-modification	NN	O
at	IN	O
each	DT	O
of	IN	O
the	DT	O
termini	NN	O
(	(	O
i.e	NN	O
.	.	O
the	DT	O
3′-	JJ	O
and	CC	O
5′-terminal	JJ	O
nucleosides	NNS	O
each	DT	O
have	VBP	O
the	DT	O
same	JJ	O
or	CC	O
different	JJ	O
2′-modifications	NNS	O
)	)	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
oligonucleotide	NN	O
has	VBZ	O
at	IN	O
least	JJS	O
two	CD	O
sequential	JJ	O
2′-modifications	NNS	O
at	IN	O
each	DT	O
end	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
oligonucleotides	IN	O
further	JJ	O
comprise	NN	O
at	IN	O
least	JJS	O
one	CD	O
deoxynucleoside	NN	O
.	.	O
In	IN	O
particular	JJ	O
embodiments	NNS	O
,	,	O
oligonucleotides	NNS	O
comprise	VBP	O
a	DT	O
stretch	NN	O
of	IN	O
deoxynucleosides	NNS	O
such	JJ	O
that	IN	O
the	DT	O
stretch	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
activating	VBG	O
RNase	NNP	O
(	(	O
e.g	NN	O
.	.	O
RNase	NNP	O
H	NNP	O
)	)	O
cleavage	NN	O
of	IN	O
an	DT	O
RNA	NNP	O
to	TO	O
which	WDT	O
the	DT	O
oligonucleotide	NN	O
is	VBZ	O
capable	JJ	O
of	IN	O
hybridizing	VBG	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
a	DT	O
stretch	NN	O
of	IN	O
deoxynucleosides	NNS	O
capable	JJ	O
of	IN	O
activating	VBG	O
RNase-mediated	JJ	O
cleavage	NN	O
of	IN	O
RNA	NNP	O
comprises	VBZ	O
about	RB	O
6	CD	O
to	TO	O
about	IN	O
16	CD	O
,	,	O
e.g	NN	O
.	.	O
about	RB	O
8	CD	O
to	TO	O
about	IN	O
16	CD	O
consecutive	JJ	O
deoxynucleosides	NNS	O
.	.	O
In	IN	O
further	JJ	O
embodiments	NNS	O
,	,	O
oligonucleotides	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
eliciting	VBG	O
cleaveage	NN	O
by	IN	O
dsRNAse	NN	O
enzymes	NNS	O
which	WDT	O
act	VBP	O
on	IN	O
RNA	NNP	O
:	:	O
RNA	NNP	O
hybrids	NNS	O
.	.	O
Oligonucleotide	NNP	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
formulated	VBN	O
in	IN	O
various	JJ	O
dosage	NN	O
forms	NNS	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
tablets	NNS	O
,	,	O
capsules	NNS	O
,	,	O
liquid	NN	O
syrups	NNS	O
,	,	O
soft	JJ	O
gels	NNS	O
,	,	O
suppositories	NNS	O
,	,	O
and	CC	O
enemas	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
alimentary	JJ	O
delivery	NN	O
”	NN	O
encompasses	VBZ	O
e.g	NN	O
.	.	O
oral	JJ	O
,	,	O
rectal	JJ	O
,	,	O
endoscopic	NN	O
and	CC	O
sublingual/buccal	JJ	O
administration	NN	O
.	.	O
A	DT	O
common	JJ	O
requirement	NN	O
for	IN	O
these	DT	O
modes	NNS	O
of	IN	O
administration	NN	O
is	VBZ	O
absorption	NN	O
over	IN	O
some	DT	O
portion	NN	O
or	CC	O
all	DT	O
of	IN	O
the	DT	O
alimentary	JJ	O
tract	NN	O
and	CC	O
a	DT	O
need	NN	O
for	IN	O
efficient	JJ	O
mucosal	JJ	O
penetration	NN	O
of	IN	O
the	DT	O
oligonucleotides	NNS	O
or	CC	O
mimetics	NNS	O
thereof	VBP	O
so	RB	O
administered	VBN	O
.	.	O
Delivery	NN	O
of	IN	O
a	DT	O
drug	NN	O
via	IN	O
the	DT	O
oral	JJ	O
mucosa	NN	O
,	,	O
as	IN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
buccal	JJ	O
and	CC	O
sublingual	JJ	O
administration	NN	O
,	,	O
has	VBZ	O
several	JJ	O
desirable	JJ	O
features	NNS	O
,	,	O
including	VBG	O
,	,	O
in	IN	O
many	JJ	O
instances	NNS	O
,	,	O
a	DT	O
more	RBR	O
rapid	JJ	O
rise	NN	O
in	IN	O
plasma	JJ	O
concentration	NN	O
of	IN	O
the	DT	O
drug	NN	O
(	(	O
Harvey	NNP	B
,	,	I
Chapter	NNP	I
35	CD	I
In	IN	I
:	:	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Ed.	NNP	I
,	,	I
Gennaro	NNP	I
,	,	I
ed.	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1990	CD	I
,	,	I
page	VB	I
711	CD	I
)	)	O
.	.	O
Endoscopy	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
drug	NN	O
delivery	NN	O
directly	RB	O
to	TO	O
an	DT	O
interior	JJ	O
portion	NN	O
of	IN	O
the	DT	O
alimentary	JJ	O
tract	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
endoscopic	FW	O
retrograde	NN	O
cystopancreatography	NN	O
(	(	O
ERCP	NNP	O
)	)	O
takes	VBZ	O
advantage	NN	O
of	IN	O
extended	VBN	O
gastroscopy	NN	O
and	CC	O
permits	NNS	O
selective	JJ	O
access	NN	O
to	TO	O
the	DT	O
biliary	JJ	O
tract	NN	O
and	CC	O
the	DT	O
pancreatic	JJ	O
duct	NN	O
(	(	O
Hirahata	NNP	B
et	RB	I
al.	RB	I
,	,	I
Gan	NNP	I
To	TO	I
Kagaku	NNP	I
Ryoho	NNP	I
,	,	I
1992	CD	I
,	,	I
19	CD	I
(	(	I
10	CD	I
Suppl	NNP	I
.	.	I
)	)	I
,	,	I
1591	CD	I
)	)	O
.	.	O
Pharmaceutical	JJ	O
compositions	NNS	O
,	,	O
including	VBG	O
liposomal	JJ	O
formulations	NNS	O
,	,	O
can	MD	O
be	VB	O
delivered	VBN	O
directly	RB	O
into	IN	O
portions	NNS	O
of	IN	O
the	DT	O
alimentary	JJ	O
canal	NN	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
e.g.	UH	O
,	,	O
the	DT	O
duodenum	NN	O
(	(	O
Somogyi	NNP	B
et	RB	I
al.	RB	I
,	,	I
Pharm	NNP	I
.	.	I
Res.	NNP	I
,	,	I
1995	CD	I
,	,	I
12	CD	I
,	,	I
149	CD	I
)	)	O
or	CC	O
the	DT	O
gastric	JJ	O
submucosa	NN	O
(	(	O
Akamo	NNP	B
et	RB	I
al.	RB	I
,	,	I
Japanese	JJ	I
J	NNP	I
.	.	I
Cancer	NNP	I
Res.	NNP	I
,	,	I
1994	CD	I
,	,	I
85	CD	I
,	,	I
652	CD	I
)	)	O
via	IN	O
endoscopic	NN	O
means	NNS	O
.	.	O
Gastric	NNP	O
lavage	NN	O
devices	NNS	O
(	(	O
Inoue	NNP	B
et	RB	I
al.	RB	I
,	,	I
Artif	NNP	I
.	.	I
Organs	NNS	I
,	,	I
1997	CD	I
,	,	I
21	CD	I
,	,	I
28	CD	I
)	)	O
and	CC	O
percutaneous	JJ	O
endoscopic	NN	O
feeding	VBG	O
devices	NNS	O
(	(	O
Pennington	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Ailment	NNP	I
Pharmacol	NNP	I
.	.	I
Ther.	NNP	I
,	,	I
1995	CD	I
,	,	I
9	CD	I
,	,	I
471	CD	I
)	)	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
for	IN	O
direct	JJ	O
alimentary	JJ	O
delivery	NN	O
of	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
oligonucleotide	IN	O
formulations	NNS	O
may	MD	O
be	VB	O
administered	VBN	O
through	IN	O
the	DT	O
anus	NN	O
into	IN	O
the	DT	O
rectum	NN	O
or	CC	O
lower	JJR	O
intestine	NN	O
.	.	O
Rectal	JJ	O
suppositories	NNS	O
,	,	O
retention	NN	O
enemas	NN	O
or	CC	O
rectal	JJ	O
catheters	NNS	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
this	DT	O
purpose	NN	O
and	CC	O
may	MD	O
be	VB	O
preferred	VBN	O
when	WRB	O
patient	JJ	O
compliance	NN	O
might	MD	O
otherwise	RB	O
be	VB	O
difficult	JJ	O
to	TO	O
achieve	VB	O
(	(	O
e.g.	NN	O
,	,	O
in	IN	O
pediatric	JJ	O
and	CC	O
geriatric	JJ	O
applications	NNS	O
,	,	O
or	CC	O
when	WRB	O
the	DT	O
patient	NN	O
is	VBZ	O
vomiting	VBG	O
or	CC	O
unconscious	JJ	O
)	)	O
.	.	O
Rectal	JJ	O
administration	NN	O
can	MD	O
result	VB	O
in	IN	O
more	JJR	O
prompt	NN	O
and	CC	O
higher	JJR	O
blood	NN	O
levels	NNS	O
than	IN	O
the	DT	O
oral	JJ	O
route	NN	O
.	.	O
(	(	O
Harvey	NNP	B
,	,	I
Chapter	NNP	I
35	CD	I
In	IN	I
:	:	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Ed.	NNP	I
,	,	I
Gennaro	NNP	I
,	,	I
ed.	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1990	CD	I
,	,	I
page	VB	I
711	CD	I
)	)	O
.	.	O
Because	IN	O
about	RB	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
drug	NN	O
that	WDT	O
is	VBZ	O
absorbed	VBN	O
from	IN	O
the	DT	O
rectum	NN	O
will	MD	O
likely	RB	O
bypass	VB	O
the	DT	O
liver	NN	O
,	,	O
administration	NN	O
by	IN	O
this	DT	O
route	NN	O
significantly	RB	O
reduces	VBZ	O
the	DT	O
potential	JJ	O
for	IN	O
first-pass	JJ	O
metabolism	NN	O
(	(	O
Benet	NNP	B
et	RB	I
al.	RB	I
,	,	I
Chapter	NNP	I
1	CD	I
In	IN	I
:	:	I
Goodman	NNP	I
&	CC	I
Gilman	NNP	I
's	POS	I
The	DT	I
Pharmacological	JJ	I
Basis	NNP	I
of	IN	I
Therapeutics	NNP	I
,	,	I
9th	CD	I
Ed.	NNP	I
,	,	I
Hardman	NNP	I
et	VBZ	I
al.	NN	I
,	,	I
eds.	NN	I
,	,	I
McGraw-Hill	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
1996	CD	I
)	)	O
.	.	O
Some	DT	O
embodiments	NNS	O
employ	VBP	O
various	JJ	O
penetration	NN	O
enhancers	NNS	O
in	IN	O
order	NN	O
to	TO	O
effect	NN	O
transport	NN	O
of	IN	O
oligonucleotides	NNS	O
and	CC	O
other	JJ	O
nucleic	JJ	O
acids	NNS	O
across	IN	O
mucosal	NN	O
and	CC	O
epithelial	JJ	O
membranes	NNS	O
.	.	O
Penetration	NN	O
enhancers	NNS	O
may	MD	O
be	VB	O
classified	VBN	O
as	IN	O
belonging	NN	O
to	TO	O
one	CD	O
of	IN	O
five	CD	O
broad	JJ	O
categories—surfactants	NNS	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
bile	NN	O
salts	NNS	O
,	,	O
chelating	VBG	O
agents	NNS	O
,	,	O
and	CC	O
non-chelating	JJ	O
non-surfactants	NNS	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
p.	VBZ	I
92	CD	I
)	)	O
.	.	O
Accordingly	RB	O
,	,	O
some	DT	O
embodiments	NNS	O
comprise	VBP	O
oral	JJ	O
oligonucleotide	IN	O
compositions	NNS	O
comprising	VBG	O
at	IN	O
least	JJS	O
one	CD	O
member	NN	O
of	IN	O
the	DT	O
group	NN	O
consisting	VBG	O
of	IN	O
surfactants	NNS	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
bile	NN	O
salts	NNS	O
,	,	O
chelating	VBG	O
agents	NNS	O
,	,	O
and	CC	O
non-chelating	JJ	O
surfactants	NNS	O
.	.	O
Further	JJ	O
embodiments	NNS	O
comprise	VB	O
oral	JJ	O
oligonucleotide	IN	O
compositions	NNS	O
comprising	VBG	O
at	IN	O
least	JJS	O
one	CD	O
fatty	JJ	O
acid	NN	O
,	,	O
e.g	NN	O
.	.	O
capric	NN	O
or	CC	O
lauric	JJ	O
acid	NN	O
,	,	O
or	CC	O
combinations	NNS	O
or	CC	O
salts	NNS	O
thereof	NNS	O
.	.	O
Other	JJ	O
embodiments	NNS	O
comprise	VBP	O
methods	NNS	O
of	IN	O
enhancing	VBG	O
the	DT	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
,	,	O
the	DT	O
method	NN	O
comprising	VBG	O
co-administering	VBG	O
the	DT	O
oligonucleotide	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
.	.	O
Other	JJ	O
excipients	NNS	O
that	WDT	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
oral	JJ	O
oligonucleotide	JJ	O
compositions	NNS	O
include	VBP	O
surfactants	NNS	O
(	(	O
or	CC	O
“	VB	O
surface-active	JJ	O
agents	NNS	O
”	POS	O
)	)	O
.	.	O
These	DT	O
are	VBP	O
chemical	NN	O
entities	NNS	O
which	WDT	O
,	,	O
when	WRB	O
dissolved	VBN	O
in	IN	O
an	DT	O
aqueous	JJ	O
solution	NN	O
,	,	O
reduce	VB	O
the	DT	O
surface	NN	O
tension	NN	O
of	IN	O
the	DT	O
solution	NN	O
or	CC	O
the	DT	O
interfacial	JJ	O
tension	NN	O
between	IN	O
the	DT	O
aqueous	JJ	O
solution	NN	O
and	CC	O
another	DT	O
liquid	NN	O
,	,	O
with	IN	O
the	DT	O
result	NN	O
that	IN	O
absorption	NN	O
of	IN	O
oligonucleotides	NNS	O
through	IN	O
the	DT	O
alimentary	JJ	O
mucosa	NN	O
and	CC	O
other	JJ	O
epithelial	JJ	O
membranes	NNS	O
is	VBZ	O
enhanced	VBN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
bile	VB	O
salts	NNS	O
and	CC	O
fatty	JJ	O
acids	NNS	O
,	,	O
surfactants	NNS	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
sodium	NN	O
lauryl	NN	O
sulfate	NN	O
,	,	O
polyoxyethylene-9-lauryl	JJ	O
ether	NN	O
and	CC	O
polyoxyethylene-20-cetyl	NN	O
ether	NN	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	VB	I
92	CD	I
)	)	O
;	:	O
and	CC	O
perfluorohemical	JJ	O
emulsions	NNS	O
,	,	O
such	JJ	O
as	IN	O
FC-43	NNP	O
(	(	O
Takahashi	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Phamacol.	NNP	I
,	,	I
1988	CD	I
,	,	I
40	CD	I
,	,	I
252	CD	I
)	)	O
.	.	O
Fatty	NNP	O
acids	NNS	O
and	CC	O
their	PRP$	O
derivatives	NNS	O
which	WDT	O
act	VBP	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
and	CC	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
oleic	JJ	O
acid	NN	O
,	,	O
lauric	JJ	O
acid	NN	O
,	,	O
capric	JJ	O
acid	NN	O
(	(	O
n-decanoic	JJ	O
acid	NN	O
)	)	O
,	,	O
myristic	JJ	O
acid	NN	O
,	,	O
palmitic	JJ	O
acid	NN	O
,	,	O
stearic	JJ	O
acid	NN	O
,	,	O
linoleic	JJ	O
acid	NN	O
,	,	O
linolenic	JJ	O
acid	NN	O
,	,	O
dicaprate	NN	O
,	,	O
tricaprate	NN	O
,	,	O
monoolein	NN	O
(	(	O
1-monooleoyl-rac-glycerol	JJ	O
)	)	O
,	,	O
dilaurin	UH	O
,	,	O
caprylic	JJ	O
acid	NN	O
,	,	O
arachidonic	JJ	O
acid	NN	O
,	,	O
glyceryl	JJ	O
1-monocaprate	JJ	O
,	,	O
1-dodecylazacycloheptan-2-one	JJ	O
,	,	O
acylcarnitines	NNS	O
,	,	O
acylcholines	NNS	O
and	CC	O
mono-	JJ	O
and	CC	O
di-glycerides	JJ	O
thereof	NN	O
and/or	NN	O
physiologically	RB	O
acceptable	JJ	O
salts	NNS	O
thereof	NN	O
(	(	O
i.e.	FW	O
,	,	O
oleate	NN	O
,	,	O
laurate	NN	O
,	,	O
caprate	NN	O
,	,	O
myristate	NN	O
,	,	O
palmitate	NN	O
,	,	O
stearate	NN	O
,	,	O
linoleate	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	NN	I
92	CD	I
;	:	O
Muranishi	NNP	B
,	,	I
Critical	NNP	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1	CD	I
;	:	O
El-Hariri	JJ	B
et	NN	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
1992	CD	I
,	,	I
44	CD	I
,	,	I
651	CD	I
)	)	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
bile	NN	O
salts	NNS	O
also	RB	O
function	VBP	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
to	TO	O
facilitate	VB	O
the	DT	O
uptake	NN	O
and	CC	O
bioavailability	NN	O
of	IN	O
drugs	NNS	O
.	.	O
The	DT	O
physiological	JJ	O
roles	NNS	O
of	IN	O
bile	NN	O
include	VBP	O
the	DT	O
facilitation	NN	O
of	IN	O
dispersion	NN	O
and	CC	O
absorption	NN	O
of	IN	O
lipids	NNS	O
and	CC	O
fat-soluble	JJ	O
vitamins	NNS	O
(	(	O
Brunton	NNP	B
,	,	I
Chapter	NNP	I
38	CD	I
In	IN	I
Goodman	NNP	I
&	CC	I
Gilman	NNP	I
's	POS	I
The	DT	I
Pharmacological	JJ	I
Basis	NNP	I
of	IN	I
Therapeutics	NNP	I
,	,	I
9th	CD	I
Ed.	NNP	I
,	,	I
Hardman	NNP	I
et	VBZ	I
al.	NN	I
,	,	I
eds.	NN	I
,	,	I
McGraw-Hill	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
1996	CD	I
,	,	I
pages	VBZ	I
934-935	CD	I
)	)	O
.	.	O
Various	JJ	O
natural	JJ	O
bile	NN	O
salts	NNS	O
,	,	O
and	CC	O
their	PRP$	O
synthetic	JJ	O
derivatives	NNS	O
,	,	O
act	NN	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
bile	NN	O
salt	NN	O
”	NNP	O
includes	VBZ	O
any	DT	O
of	IN	O
the	DT	O
naturally	RB	O
occurring	VBG	O
components	NNS	O
of	IN	O
bile	NN	O
as	RB	O
well	RB	O
as	IN	O
any	DT	O
of	IN	O
their	PRP$	O
synthetic	JJ	O
derivatives	NNS	O
.	.	O
The	DT	O
bile	NN	O
salts	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
cholic	JJ	O
acid	NN	O
(	(	O
or	CC	O
its	PRP$	O
pharmaceutically	RB	O
acceptable	JJ	O
sodium	NN	O
salt	NN	O
,	,	O
sodium	NN	O
cholate	NN	O
)	)	O
,	,	O
dehydrocholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
dehydrocholate	NN	O
)	)	O
,	,	O
deoxycholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
deoxycholate	NN	O
)	)	O
,	,	O
glucholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
glucholate	NN	O
)	)	O
,	,	O
glycholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
glycocholate	NN	O
)	)	O
,	,	O
glycodeoxycholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
glycodeoxycholate	NN	O
)	)	O
,	,	O
taurocholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
taurocholate	NN	O
)	)	O
,	,	O
taurodeoxycholic	JJ	O
acid	NN	O
(	(	O
sodium	JJ	O
taurodeoxycholate	NN	O
)	)	O
,	,	O
chenodeoxycholic	JJ	O
acid	NN	O
(	(	O
CDCA	NNP	O
,	,	O
sodium	NN	O
chenodeoxycholate	NN	O
)	)	O
,	,	O
ursodeoxycholic	JJ	O
acid	NN	O
(	(	O
UDCA	NNP	O
)	)	O
,	,	O
sodium	JJ	O
tauro-24,25-dihydro-fusidate	NN	O
(	(	O
STDHF	NNP	O
)	)	O
,	,	O
sodium	JJ	O
glycodihydrofusidate	NN	O
and	CC	O
polyoxyethylene-9-lauryl	NN	O
ether	NN	O
(	(	O
POE	NNP	O
)	)	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	NN	I
92	CD	I
;	:	O
Swinyard	NNP	B
,	,	I
Chapter	NNP	I
39	CD	I
In	IN	I
:	:	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
18th	CD	I
Ed.	NNP	I
,	,	I
Gennaro	NNP	I
,	,	I
ed.	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1990	CD	I
,	,	I
pages	VBZ	I
782-783	CD	I
;	:	O
Muranishi	NNP	B
,	,	I
Critical	NNP	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1	CD	I
;	:	O
Yamamoto	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Exp	NNP	I
.	.	I
Ther.	NNP	I
,	,	I
1992	CD	I
,	,	I
263	CD	I
,	,	I
25	CD	I
;	:	O
Yamashita	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
1990	CD	I
,	,	I
79	CD	I
,	,	I
579	CD	I
)	)	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
penetration	NN	O
enhancers	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
are	VBP	O
mixtures	NNS	O
of	IN	O
penetration	NN	O
enhancing	VBG	O
compounds	NNS	O
.	.	O
One	CD	O
such	JJ	O
penetration	NN	O
mixture	NN	O
is	VBZ	O
UDCA	NNP	O
(	(	O
and/or	JJ	O
CDCA	NNP	O
)	)	O
with	IN	O
capric	JJ	O
and/or	NN	O
lauric	JJ	O
acids	NNS	O
or	CC	O
salts	NNS	O
thereof	JJ	O
e.g	NN	O
.	.	O
sodium	NN	O
.	.	O
Such	JJ	O
mixtures	NNS	O
are	VBP	O
useful	JJ	O
for	IN	O
enhancing	VBG	O
the	DT	O
delivery	NN	O
of	IN	O
biologically	RB	O
active	JJ	O
substances	NNS	O
across	IN	O
mucosal	NN	O
membranes	NNS	O
,	,	O
in	IN	O
particular	JJ	O
intestinal	JJ	O
mucosa	NN	O
.	.	O
Other	JJ	O
penetration	NN	O
enhancer	NN	O
mixtures	NNS	O
comprise	VBP	O
about	IN	O
5-95	CD	O
%	NN	O
of	IN	O
bile	JJ	O
acid	NN	O
or	CC	O
salt	NN	O
(	(	O
s	PRP	O
)	)	O
UDCA	NNP	O
and/or	VBZ	O
CDCA	NNP	O
with	IN	O
5-95	JJ	O
%	NN	O
capric	JJ	O
and/or	NN	O
lauric	JJ	O
acid	NN	O
.	.	O
Particular	JJ	O
penetration	NN	O
enhancers	NNS	O
are	VBP	O
mixtures	NNS	O
of	IN	O
the	DT	O
sodium	NN	O
salts	NNS	O
of	IN	O
UDCA	NNP	O
,	,	O
capric	JJ	O
acid	NN	O
and	CC	O
lauric	JJ	O
acid	NN	O
in	IN	O
a	DT	O
ratio	NN	O
of	IN	O
about	IN	O
1:2:2	CD	O
respectively	RB	O
.	.	O
Another	DT	O
such	JJ	O
penetration	NN	O
enhancer	NN	O
is	VBZ	O
a	DT	O
mixture	NN	O
of	IN	O
capric	NN	O
and	CC	O
lauric	JJ	O
acid	NN	O
(	(	O
or	CC	O
salts	VB	O
thereof	NN	O
)	)	O
in	IN	O
a	DT	O
0.01:1	CD	O
to	TO	O
1:0.01	CD	O
ratio	NN	O
(	(	O
mole	JJ	O
basis	NN	O
)	)	O
.	.	O
In	IN	O
particular	JJ	O
embodiments	NNS	O
capric	JJ	O
acid	NN	O
and	CC	O
lauric	JJ	O
acid	NN	O
are	VBP	O
present	JJ	O
in	IN	O
molar	JJ	O
ratios	NNS	O
of	IN	O
e.g	NN	O
.	.	O
about	RB	O
0.1:1	CD	O
to	TO	O
about	IN	O
1:0.1	CD	O
,	,	O
in	IN	O
particular	JJ	O
about	IN	O
0.5:1	CD	O
to	TO	O
about	IN	O
1:0.5	CD	O
.	.	O
Other	JJ	O
excipients	NNS	O
include	VBP	O
chelating	VBG	O
agents	NNS	O
,	,	O
i.e	NN	O
.	.	O
compounds	NNS	O
that	WDT	O
remove	VBP	O
metallic	JJ	O
ions	NNS	O
from	IN	O
solution	NN	O
by	IN	O
forming	VBG	O
complexes	NNS	O
therewith	NN	O
,	,	O
with	IN	O
the	DT	O
result	NN	O
that	IN	O
absorption	NN	O
of	IN	O
oligonucleotides	NNS	O
through	IN	O
the	DT	O
alimentary	JJ	O
and	CC	O
other	JJ	O
mucosa	NN	O
is	VBZ	O
enhanced	VBN	O
.	.	O
With	IN	O
regards	NNS	O
to	TO	O
their	PRP$	O
use	NN	O
as	IN	O
penetration	NN	O
enhancers	NNS	O
in	IN	O
compositions	NNS	O
containing	VBG	O
DNA-like	NNP	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
chelating	VBG	O
agents	NNS	O
have	VBP	O
the	DT	O
added	JJ	O
advantage	NN	O
of	IN	O
also	RB	O
serving	VBG	O
as	IN	O
DNase	NNP	O
inhibitors	NNS	O
,	,	O
as	IN	O
most	JJS	O
characterized	JJ	O
DNA	NN	O
nucleases	NNS	O
require	VBP	O
a	DT	O
divalent	NN	O
metal	NN	O
ion	NN	O
for	IN	O
catalysis	NN	O
and	CC	O
are	VBP	O
thus	RB	O
inhibited	VBN	O
by	IN	O
chelating	VBG	O
agents	NNS	O
(	(	O
Jarrett	NNP	B
,	,	I
J	NNP	I
.	.	I
Chromatogr.	NNP	I
,	,	I
1993	CD	I
,	,	I
618	CD	I
,	,	I
315	CD	I
)	)	O
.	.	O
Chelating	VBG	O
agents	NNS	O
of	IN	O
the	DT	O
invention	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
disodium	NN	O
ethylenediaminetetraacetate	NN	O
(	(	O
EDTA	NNP	O
)	)	O
,	,	O
citric	JJ	O
acid	NN	O
,	,	O
salicylates	NNS	O
(	(	O
e.g.	NN	O
,	,	O
sodium	NN	O
salicylate	NN	O
,	,	O
5-methoxysalicylate	JJ	O
and	CC	O
homovanilate	NN	O
)	)	O
,	,	O
N-acyl	JJ	O
derivatives	NNS	O
of	IN	O
collagen	NN	O
,	,	O
laureth-9	JJ	O
and	CC	O
N-amino	JJ	O
acyl	NN	O
derivatives	NNS	O
of	IN	O
beta-diketones	NNS	O
(	(	O
enamines	NNS	O
)	)	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	NN	I
92	CD	I
;	:	O
Muranishi	NNP	B
,	,	I
Critical	NNP	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1	CD	I
;	:	O
Buur	NNP	B
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Control	NNP	I
Rel.	NNP	I
,	,	I
1990	CD	I
,	,	I
14	CD	I
,	,	I
43	CD	I
)	)	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
non-chelating	JJ	O
non-surfactant	JJ	O
penetration	NN	O
enhancers	NNS	O
may	MD	O
be	VB	O
defined	VBN	O
as	IN	O
compounds	NNS	O
that	WDT	O
demonstrate	VBP	O
insignificant	JJ	O
activity	NN	O
as	IN	O
chelating	VBG	O
agents	NNS	O
or	CC	O
as	IN	O
surfactants	NNS	O
but	CC	O
that	DT	O
nonetheless	RB	O
enhance	JJ	O
absorption	NN	O
of	IN	O
oligonucleotides	NNS	O
through	IN	O
the	DT	O
alimentary	JJ	O
and	CC	O
other	JJ	O
mucosal	NN	O
membranes	NNS	O
(	(	O
Muranishi	NNP	B
,	,	I
Critical	NNP	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1990	CD	I
,	,	I
7	CD	I
,	,	I
1	CD	I
)	)	O
.	.	O
This	DT	O
class	NN	O
of	IN	O
penetration	NN	O
enhancers	NNS	O
includes	VBZ	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
unsaturated	JJ	O
cyclic	JJ	O
ureas	NNS	O
,	,	O
1-alkyl-	JJ	O
and	CC	O
1-alkenylazacyclo-alkanone	JJ	O
derivatives	NNS	O
(	(	O
Lee	NNP	B
et	RB	I
al.	RB	I
,	,	I
Critical	JJ	I
Reviews	NNP	I
in	IN	I
Therapeutic	NNP	I
Drug	NNP	I
Carrier	NNP	I
Systems	NNPS	I
,	,	I
1991	CD	I
,	,	I
page	VB	I
92	CD	I
)	)	O
;	:	O
and	CC	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
agents	NNS	O
such	JJ	O
as	IN	O
diclofenac	JJ	O
sodium	NN	O
,	,	O
indomethacin	NN	O
and	CC	O
phenylbutazone	NN	O
(	(	O
Yamashita	NNP	B
et	RB	I
al.	RB	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
1987	CD	I
,	,	I
39	CD	I
,	,	I
621	CD	I
)	)	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
oligonucleotide	JJ	O
compositions	NNS	O
for	IN	O
oral	JJ	O
delivery	NN	O
comprise	NN	O
at	IN	O
least	JJS	O
two	CD	O
discrete	JJ	O
phases	NNS	O
,	,	O
which	WDT	O
phases	VBZ	O
may	MD	O
comprise	VB	O
particles	NNS	O
,	,	O
capsules	NNS	O
,	,	O
gel-capsules	NNS	O
,	,	O
microspheres	NNS	O
,	,	O
etc	FW	O
.	.	O
Each	DT	O
phase	NN	O
may	MD	O
contain	VB	O
one	CD	O
or	CC	O
more	JJR	O
oligonucleotides	NNS	O
,	,	O
penetration	NN	O
enhancers	NNS	O
,	,	O
surfactants	NNS	O
,	,	O
bioadhesives	NNS	O
,	,	O
effervescent	JJ	O
agents	NNS	O
,	,	O
or	CC	O
other	JJ	O
adjuvant	NN	O
,	,	O
excipient	NN	O
or	CC	O
diluent	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
one	CD	O
phase	NN	O
comprises	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
oligonucleotide	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
a	DT	O
first	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
oligonucleotide	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
,	,	O
while	IN	O
a	DT	O
second	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
a	DT	O
first	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
oligonucleotide	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
,	,	O
while	IN	O
a	DT	O
second	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
and	CC	O
substantially	RB	O
no	DT	O
oligonucleotide	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
at	IN	O
least	JJS	O
one	CD	O
phase	NN	O
is	VBZ	O
compounded	VBN	O
with	IN	O
at	IN	O
least	JJS	O
one	CD	O
degradation	NN	O
retardant	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
coating	NN	O
or	CC	O
a	DT	O
matrix	NN	O
,	,	O
which	WDT	O
delays	VBZ	O
release	NN	O
of	IN	O
the	DT	O
contents	NNS	O
of	IN	O
that	DT	O
phase	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
a	DT	O
first	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
oligonucleotide	NN	O
and	CC	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
,	,	O
while	IN	O
a	DT	O
second	JJ	O
phase	NN	O
comprises	NNS	O
at	IN	O
least	JJS	O
one	CD	O
penetration	NN	O
enhancer	NN	O
and	CC	O
a	DT	O
release-retardant	JJ	O
.	.	O
In	IN	O
particular	JJ	O
embodiments	NNS	O
,	,	O
an	DT	O
oral	JJ	O
oligonucleotide	NN	O
composition	NN	O
comprises	VBZ	O
a	DT	O
first	JJ	O
phase	NN	O
comprising	VBG	O
particles	NNS	O
containing	VBG	O
an	DT	O
oligonucleotide	NN	O
and	CC	O
a	DT	O
penetration	NN	O
enhancer	NN	O
,	,	O
and	CC	O
a	DT	O
second	JJ	O
phase	NN	O
comprising	VBG	O
particles	NNS	O
coated	VBN	O
with	IN	O
a	DT	O
release-retarding	JJ	O
agent	NN	O
and	CC	O
containing	VBG	O
penetration	NN	O
enhancer	NN	O
.	.	O
Agents	NNS	O
that	WDT	O
enhance	VBP	O
uptake	NN	O
of	IN	O
oligonucleotides	NNS	O
at	IN	O
the	DT	O
cellular	JJ	O
level	NN	O
may	MD	O
also	RB	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
pharmaceutical	JJ	O
,	,	O
therapeutic	JJ	O
and	CC	O
other	JJ	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
cationic	JJ	O
lipids	NNS	O
,	,	O
such	JJ	O
as	IN	O
LIPOFECTIN™	NNP	O
reagent	NN	O
(	(	O
Junichi	NNP	O
et	RB	O
al	RB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,705,188	CD	O
)	)	O
,	,	O
cationic	JJ	O
glycerol	NN	O
derivatives	NNS	O
,	,	O
and	CC	O
polycationic	JJ	O
molecules	NNS	O
,	,	O
such	JJ	O
as	IN	O
polylysine	NN	O
(	(	O
Lollo	NNP	O
et	RB	O
al.	RB	O
,	,	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
97/30731	CD	O
)	)	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
A	DT	O
“	JJ	O
pharmaceutical	JJ	O
carrier	NN	O
”	NN	O
or	CC	O
“	JJ	O
excipient	JJ	O
”	NN	O
may	MD	O
be	VB	O
a	DT	O
pharmaceutically	RB	O
acceptable	JJ	O
solvent	NN	O
,	,	O
suspending	VBG	O
agent	NN	O
or	CC	O
any	DT	O
other	JJ	O
pharmacologically	RB	O
inert	JJ	O
vehicle	NN	O
for	IN	O
delivering	VBG	O
one	CD	O
or	CC	O
more	JJR	O
nucleic	JJ	O
acids	NNS	O
to	TO	O
an	DT	O
animal	NN	O
.	.	O
The	DT	O
excipient	NN	O
may	MD	O
be	VB	O
liquid	JJ	O
or	CC	O
solid	JJ	O
and	CC	O
is	VBZ	O
selected	VBN	O
,	,	O
with	IN	O
the	DT	O
planned	JJ	O
manner	NN	O
of	IN	O
administration	NN	O
in	IN	O
mind	NN	O
,	,	O
so	RB	O
as	IN	O
to	TO	O
provide	VB	O
for	IN	O
the	DT	O
desired	JJ	O
bulk	NN	O
,	,	O
consistency	NN	O
,	,	O
etc.	FW	O
,	,	O
when	WRB	O
combined	VBN	O
with	IN	O
a	DT	O
an	DT	O
oligonucleotide	NN	O
and	CC	O
the	DT	O
other	JJ	O
components	NNS	O
of	IN	O
a	DT	O
given	VBN	O
pharmaceutical	JJ	O
composition	NN	O
.	.	O
Typical	JJ	O
pharmaceutical	JJ	O
carriers	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
binding	VBG	O
agents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
pregelatinised	VBD	O
maize	NN	O
starch	NN	O
,	,	O
polyvinylpyrrolidone	NN	O
or	CC	O
hydroxypropyl	NN	O
methylcellulose	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
fillers	NNS	O
(	(	O
e.g.	NN	O
,	,	O
lactose	JJ	O
and	CC	O
other	JJ	O
sugars	NNS	O
,	,	O
microcrystalline	NN	O
cellulose	NN	O
,	,	O
pectin	NN	O
,	,	O
gelatin	NN	O
,	,	O
calcium	NN	O
sulfate	NN	O
,	,	O
ethyl	FW	O
cellulose	NN	O
,	,	O
polyacrylates	VBZ	O
or	CC	O
calcium	NN	O
hydrogen	NN	O
phosphate	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
lubricants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
magnesium	NN	O
stearate	NN	O
,	,	O
talc	NN	O
,	,	O
silica	NN	O
,	,	O
colloidal	JJ	O
silicon	NN	O
dioxide	NN	O
,	,	O
stearic	JJ	O
acid	NN	O
,	,	O
metallic	JJ	O
stearates	NNS	O
,	,	O
hydrogenated	VBD	O
vegetable	JJ	O
oils	NNS	O
,	,	O
corn	NN	O
starch	NN	O
,	,	O
polyethylene	NN	O
glycols	NNS	O
,	,	O
sodium	NN	O
benzoate	NN	O
,	,	O
sodium	NN	O
acetate	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
;	:	O
disintegrants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
starch	NN	O
,	,	O
sodium	NN	O
starch	NN	O
glycolate	NN	O
,	,	O
EXPLOTAB™	NNP	O
)	)	O
;	:	O
and	CC	O
wetting	VBG	O
agents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
sodium	NN	O
lauryl	NN	O
sulphate	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O
Oral	NNP	O
oligonucleotide	IN	O
compositions	NNS	O
may	MD	O
additionally	RB	O
contain	VB	O
other	JJ	O
adjunct	JJ	O
components	NNS	O
conventionally	RB	O
found	VBN	O
in	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
,	,	O
at	IN	O
their	PRP$	O
art-established	JJ	O
usage	NN	O
levels	NNS	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
compositions	NNS	O
may	MD	O
contain	VB	O
additional	JJ	O
,	,	O
compatible	JJ	O
,	,	O
pharmaceutically-active	JJ	O
materials	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
antipruritics	NNS	O
,	,	O
astringents	NNS	O
,	,	O
local	JJ	O
anesthetics	NNS	O
or	CC	O
anti-inflammatory	JJ	O
agents	NNS	O
,	,	O
or	CC	O
may	MD	O
contain	VB	O
additional	JJ	O
materials	NNS	O
useful	JJ	O
in	IN	O
physically	RB	O
formulating	VBG	O
various	JJ	O
dosage	NN	O
forms	NNS	O
of	IN	O
the	DT	O
composition	NN	O
of	IN	O
present	JJ	O
invention	NN	O
,	,	O
such	JJ	O
as	IN	O
dyes	NNS	O
,	,	O
flavoring	VBG	O
agents	NNS	O
,	,	O
preservatives	NNS	O
,	,	O
antioxidants	NNS	O
,	,	O
opacifiers	NNS	O
,	,	O
thickening	VBG	O
agents	NNS	O
and	CC	O
stabilizers	NNS	O
.	.	O
However	RB	O
,	,	O
such	JJ	O
materials	NNS	O
,	,	O
when	WRB	O
added	VBD	O
,	,	O
should	MD	O
not	RB	O
unduly	VB	O
interfere	RB	O
with	IN	O
the	DT	O
biological	JJ	O
activities	NNS	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Compositions	NNS	O
and	CC	O
formulations	NNS	O
for	IN	O
parenteral	JJ	O
,	,	O
intrathecal	JJ	O
or	CC	O
intraventricular	JJ	O
administration	NN	O
may	MD	O
include	VB	O
sterile	JJ	O
aqueous	JJ	O
solutions	NNS	O
which	WDT	O
may	MD	O
also	RB	O
contain	VB	O
buffers	NNS	O
,	,	O
diluents	NNS	O
and	CC	O
other	JJ	O
suitable	JJ	O
additives	NNS	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
penetration	NN	O
enhancers	NNS	O
,	,	O
carrier	NN	O
compounds	NNS	O
and	CC	O
other	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
carriers	NNS	O
or	CC	O
excipients	NNS	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
which	WDT	O
may	MD	O
conveniently	RB	O
be	VB	O
presented	VBN	O
in	IN	O
unit	NN	O
dosage	NN	O
form	NN	O
,	,	O
may	MD	O
be	VB	O
prepared	VBN	O
according	VBG	O
to	TO	O
conventional	JJ	O
techniques	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
pharmaceutical	JJ	O
industry	NN	O
.	.	O
Such	JJ	O
techniques	NNS	O
include	VBP	O
the	DT	O
step	NN	O
of	IN	O
bringing	VBG	O
into	IN	O
association	NN	O
the	DT	O
active	JJ	O
ingredients	NNS	O
with	IN	O
the	DT	O
pharmaceutical	JJ	O
carrier	NN	O
(	(	O
s	NN	O
)	)	O
or	CC	O
excipient	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
formulations	NNS	O
are	VBP	O
prepared	VBN	O
by	IN	O
uniformly	JJ	O
and	CC	O
intimately	RB	O
bringing	VBG	O
into	IN	O
association	NN	O
the	DT	O
active	JJ	O
ingredients	NNS	O
with	IN	O
liquid	JJ	O
carriers	NNS	O
or	CC	O
finely	RB	O
divided	VBN	O
solid	JJ	O
carriers	NNS	O
or	CC	O
both	DT	O
,	,	O
and	CC	O
then	RB	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
shaping	VBG	O
the	DT	O
product	NN	O
.	.	O
The	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
formulated	VBN	O
into	IN	O
any	DT	O
of	IN	O
many	JJ	O
possible	JJ	O
dosage	NN	O
forms	NNS	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
tablets	NNS	O
,	,	O
capsules	NNS	O
,	,	O
gel	NN	O
capsules	NNS	O
,	,	O
liquid	NN	O
syrups	NNS	O
,	,	O
soft	JJ	O
gels	NNS	O
,	,	O
suppositories	NNS	O
,	,	O
and	CC	O
enemas	NN	O
.	.	O
The	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
formulated	VBN	O
as	IN	O
suspensions	NNS	O
in	IN	O
aqueous	JJ	O
,	,	O
non-aqueous	JJ	O
or	CC	O
mixed	JJ	O
media	NNS	O
.	.	O
Aqueous	JJ	O
suspensions	NNS	O
may	MD	O
further	RB	O
contain	VB	O
substances	NNS	O
which	WDT	O
increase	VBP	O
the	DT	O
viscosity	NN	O
of	IN	O
the	DT	O
suspension	NN	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
sodium	NN	O
carboxymethylcellulose	NN	O
,	,	O
sorbitol	JJ	O
and/or	NN	O
dextran	NN	O
.	.	O
The	DT	O
suspension	NN	O
may	MD	O
also	RB	O
contain	VB	O
stabilizers	NNS	O
.	.	O
Pharmaceutical	JJ	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
foams	NNS	O
,	,	O
solutions	NNS	O
,	,	O
emulsions	NNS	O
,	,	O
and	CC	O
liposome-containing	JJ	O
formulations	NNS	O
.	.	O
These	DT	O
compositions	NNS	O
may	MD	O
be	VB	O
generated	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
components	NNS	O
that	WDT	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
preformed	JJ	O
liquids	NNS	O
,	,	O
self-emulsifying	JJ	O
solids	NNS	O
and	CC	O
self-emulsifying	JJ	O
semisolids	NNS	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
and	CC	O
formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
comprise	VB	O
one	CD	O
or	CC	O
more	JJR	O
penetration	NN	O
enhancers	NNS	O
,	,	O
carriers	NNS	O
,	,	O
excipients	NNS	O
or	CC	O
other	JJ	O
active	JJ	O
or	CC	O
inactive	JJ	O
ingredients	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
the	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
may	MD	O
be	VB	O
formulated	VBN	O
and	CC	O
used	VBN	O
as	IN	O
foams	NNS	O
.	.	O
Pharmaceutical	JJ	O
foams	NNS	O
include	VBP	O
formulations	NNS	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
emulsions	NNS	O
,	,	O
microemulsions	NNS	O
,	,	O
creams	NNS	O
,	,	O
jellies	NNS	O
and	CC	O
liposomes	NNS	O
.	.	O
While	IN	O
basically	RB	O
similar	JJ	O
in	IN	O
nature	NN	O
these	DT	O
formulations	NNS	O
vary	VBP	O
in	IN	O
the	DT	O
components	NNS	O
and	CC	O
the	DT	O
consistency	NN	O
of	IN	O
the	DT	O
final	JJ	O
product	NN	O
.	.	O
The	DT	O
preparation	NN	O
of	IN	O
such	JJ	O
compositions	NNS	O
and	CC	O
formulations	NNS	O
is	VBZ	O
generally	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
pharmaceutical	JJ	O
and	CC	O
formulation	NN	O
arts	NNS	O
and	CC	O
may	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
formulation	NN	O
of	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
prepared	VBN	O
and	CC	O
formulated	VBN	O
as	IN	O
emulsions	NNS	O
.	.	O
Emulsions	NNS	O
are	VBP	O
typically	RB	O
heterogeneous	JJ	O
systems	NNS	O
of	IN	O
one	CD	O
liquid	NN	O
dispersed	VBN	O
in	IN	O
another	DT	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
droplets	NNS	O
usually	RB	O
exceeding	VBG	O
0.1	CD	O
μm	NN	O
in	IN	O
diameter	NN	O
(	(	O
Idson	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
199	CD	I
;	:	O
Rosoff	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
Volume	NN	I
1	CD	I
,	,	I
p.	RB	I
245	CD	I
;	:	O
Block	NNP	B
in	IN	I
Pharmaceutical	NNP	I
Dosage	NNP	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
2	CD	I
,	,	I
p.	RB	I
335	CD	I
;	:	O
Higuchi	NNP	B
et	FW	I
al.	NN	I
,	,	I
in	IN	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1985	CD	I
,	,	I
p.	VBZ	I
301	CD	I
)	)	O
.	.	O
Emulsions	NNS	O
are	VBP	O
often	RB	O
biphasic	JJ	O
systems	NNS	O
comprising	VBG	O
of	IN	O
two	CD	O
immiscible	JJ	O
liquid	NN	O
phases	NNS	O
intimately	RB	O
mixed	JJ	O
and	CC	O
dispersed	JJ	O
with	IN	O
each	DT	O
other	JJ	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
emulsions	NNS	O
may	MD	O
be	VB	O
either	CC	O
water-in-oil	JJ	O
(	(	O
w/o	NN	O
)	)	O
or	CC	O
of	IN	O
the	DT	O
oil-in-water	NN	O
(	(	O
o/w	NN	O
)	)	O
variety	NN	O
.	.	O
When	WRB	O
an	DT	O
aqueous	JJ	O
phase	NN	O
is	VBZ	O
finely	RB	O
divided	VBN	O
into	IN	O
and	CC	O
dispersed	VBD	O
as	IN	O
minute	JJ	O
droplets	NNS	O
into	IN	O
a	DT	O
bulk	NN	O
oily	RB	O
phase	VBZ	O
the	DT	O
resulting	VBG	O
composition	NN	O
is	VBZ	O
called	VBN	O
a	DT	O
water-in-oil	NN	O
(	(	O
w/o	NN	O
)	)	O
emulsion	NN	O
.	.	O
Alternatively	RB	O
,	,	O
when	WRB	O
an	DT	O
oily	JJ	O
phase	NN	O
is	VBZ	O
finely	RB	O
divided	VBN	O
into	IN	O
and	CC	O
dispersed	VBD	O
as	IN	O
minute	JJ	O
droplets	NNS	O
into	IN	O
a	DT	O
bulk	NN	O
aqueous	JJ	O
phase	NN	O
the	DT	O
resulting	VBG	O
composition	NN	O
is	VBZ	O
called	VBN	O
an	DT	O
oil-in-water	NN	O
(	(	O
o/w	NN	O
)	)	O
emulsion	NN	O
.	.	O
Emulsions	NNS	O
may	MD	O
contain	VB	O
additional	JJ	O
components	NNS	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
dispersed	JJ	O
phases	NNS	O
and	CC	O
the	DT	O
active	JJ	O
drug	NN	O
which	WDT	O
may	MD	O
be	VB	O
present	JJ	O
as	IN	O
a	DT	O
solution	NN	O
in	IN	O
either	CC	O
the	DT	O
aqueous	JJ	O
phase	NN	O
,	,	O
oily	RB	O
phase	NN	O
or	CC	O
itself	PRP	O
as	IN	O
a	DT	O
separate	JJ	O
phase	NN	O
.	.	O
Pharmaceutical	JJ	O
excipients	NNS	O
such	JJ	O
as	IN	O
emulsifiers	NNS	O
,	,	O
stabilizers	NNS	O
,	,	O
dyes	NNS	O
,	,	O
and	CC	O
anti-oxidants	NNS	O
may	MD	O
also	RB	O
be	VB	O
present	JJ	O
in	IN	O
emulsions	NNS	O
as	IN	O
needed	VBN	O
.	.	O
Pharmaceutical	JJ	O
emulsions	NNS	O
may	MD	O
also	RB	O
be	VB	O
multiple	JJ	O
emulsions	NNS	O
that	WDT	O
are	VBP	O
comprised	VBN	O
of	IN	O
more	JJR	O
than	IN	O
two	CD	O
phases	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
oil-in-water-in-oil	NN	O
(	(	O
o/w/o	NN	O
)	)	O
and	CC	O
water-in-oil-in-water	NN	O
(	(	O
w/o/w	NN	O
)	)	O
emulsions	NNS	O
.	.	O
Such	JJ	O
complex	JJ	O
formulations	NNS	O
often	RB	O
provide	VBP	O
certain	JJ	O
advantages	NNS	O
that	WDT	O
simple	VBP	O
binary	JJ	O
emulsions	NNS	O
do	VBP	O
not	RB	O
.	.	O
Multiple	JJ	O
emulsions	NNS	O
in	IN	O
which	WDT	O
individual	JJ	O
oil	NN	O
droplets	NNS	O
of	IN	O
an	DT	O
o/w	JJ	O
emulsion	NN	O
enclose	VB	O
small	JJ	O
water	NN	O
droplets	NNS	O
constitute	VBP	O
a	DT	O
w/o/w	JJ	O
emulsion	NN	O
.	.	O
Likewise	RB	O
a	DT	O
system	NN	O
of	IN	O
oil	NN	O
droplets	NNS	O
enclosed	VBD	O
in	IN	O
globules	NNS	O
of	IN	O
water	NN	O
stabilized	VBN	O
in	IN	O
an	DT	O
oily	RB	O
continuous	JJ	O
provides	VBZ	O
an	DT	O
o/w/o	JJ	O
emulsion	NN	O
.	.	O
Often	RB	O
,	,	O
the	DT	O
dispersed	JJ	O
or	CC	O
discontinuous	JJ	O
phase	NN	O
of	IN	O
the	DT	O
emulsion	NN	O
is	VBZ	O
well	RB	O
dispersed	VBN	O
into	IN	O
the	DT	O
external	JJ	O
or	CC	O
continuous	JJ	O
phase	NN	O
and	CC	O
maintained	VBN	O
in	IN	O
this	DT	O
form	NN	O
through	IN	O
the	DT	O
means	NNS	O
of	IN	O
emulsifiers	NNS	O
or	CC	O
the	DT	O
viscosity	NN	O
of	IN	O
the	DT	O
formulation	NN	O
.	.	O
Either	DT	O
of	IN	O
the	DT	O
phases	NNS	O
of	IN	O
the	DT	O
emulsion	NN	O
may	MD	O
be	VB	O
a	DT	O
semisolid	JJ	O
or	CC	O
a	DT	O
solid	JJ	O
,	,	O
as	IN	O
is	VBZ	O
the	DT	O
case	NN	O
of	IN	O
emulsion-style	JJ	O
ointment	NN	O
bases	NNS	O
and	CC	O
creams	NNS	O
.	.	O
Other	JJ	O
means	NNS	O
of	IN	O
stabilizing	VBG	O
emulsions	NNS	O
entail	VBP	O
the	DT	O
use	NN	O
of	IN	O
emulsifiers	NNS	O
that	WDT	O
may	MD	O
be	VB	O
incorporated	VBN	O
into	IN	O
either	DT	O
phase	NN	O
of	IN	O
the	DT	O
emulsion	NN	O
.	.	O
Emulsifiers	NNS	O
may	MD	O
broadly	RB	O
be	VB	O
classified	VBN	O
into	IN	O
four	CD	O
categories	NNS	O
:	:	O
synthetic	JJ	O
surfactants	NNS	O
,	,	O
naturally	RB	O
occurring	VBG	O
emulsifiers	NNS	O
,	,	O
absorption	NN	O
bases	NNS	O
,	,	O
and	CC	O
finely	RB	O
dispersed	JJ	O
solids	NNS	O
(	(	O
Idson	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
199	CD	I
)	)	O
.	.	O
Synthetic	JJ	O
surfactants	NNS	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
surface	NN	O
active	JJ	O
agents	NNS	O
,	,	O
have	VBP	O
found	VBN	O
wide	JJ	O
applicability	NN	O
in	IN	O
the	DT	O
formulation	NN	O
of	IN	O
emulsions	NNS	O
and	CC	O
have	VBP	O
been	VBN	O
reviewed	VBN	O
in	IN	O
the	DT	O
literature	NN	O
(	(	O
Rieger	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
285	CD	I
;	:	O
Idson	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
1988	CD	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
199	CD	I
)	)	O
.	.	O
Surfactants	NNS	O
are	VBP	O
typically	RB	O
amphiphilic	JJ	O
and	CC	O
comprise	VB	O
a	DT	O
hydrophilic	NN	O
and	CC	O
a	DT	O
hydrophobic	JJ	O
portion	NN	O
.	.	O
The	DT	O
ratio	NN	O
of	IN	O
the	DT	O
hydrophilic	NN	O
to	TO	O
the	DT	O
hydrophobic	JJ	O
nature	NN	O
of	IN	O
the	DT	O
surfactant	NN	O
has	VBZ	O
been	VBN	O
termed	VBN	O
the	DT	O
hydrophile/lipophile	NN	O
balance	NN	O
(	(	O
HLB	NNP	O
)	)	O
and	CC	O
is	VBZ	O
a	DT	O
valuable	JJ	O
tool	NN	O
in	IN	O
categorizing	VBG	O
and	CC	O
selecting	VBG	O
surfactants	NNS	O
in	IN	O
the	DT	O
preparation	NN	O
of	IN	O
formulations	NNS	O
.	.	O
Surfactants	NNS	O
may	MD	O
be	VB	O
classified	VBN	O
into	IN	O
different	JJ	O
classes	NNS	O
based	VBN	O
on	IN	O
the	DT	O
nature	NN	O
of	IN	O
the	DT	O
hydrophilic	JJ	O
group	NN	O
:	:	O
nonionic	JJ	O
,	,	O
anionic	JJ	O
,	,	O
cationic	JJ	O
and	CC	O
amphoteric	JJ	O
(	(	O
Rieger	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
285	CD	I
)	)	O
.	.	O
Naturally	RB	O
occurring	VBG	O
emulsifiers	NNS	O
used	VBN	O
in	IN	O
emulsion	NN	O
formulations	NNS	O
include	VBP	O
lanolin	NN	O
,	,	O
beeswax	NN	O
,	,	O
phosphatides	NNS	O
,	,	O
lecithin	NN	O
and	CC	O
acacia	NN	O
.	.	O
Absorption	NN	O
bases	NNS	O
possess	VBP	O
hydrophilic	JJ	O
properties	NNS	O
such	JJ	O
that	IN	O
they	PRP	O
can	MD	O
soak	VB	O
up	RP	O
water	NN	O
to	TO	O
form	VB	O
w/o	JJ	O
emulsions	NNS	O
yet	RB	O
retain	VBP	O
their	PRP$	O
semisolid	JJ	O
consistencies	NNS	O
,	,	O
such	JJ	O
as	IN	O
anhydrous	JJ	O
lanolin	NN	O
and	CC	O
hydrophilic	JJ	O
petrolatum	NN	O
.	.	O
Finely	RB	O
divided	VBN	O
solids	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
used	VBN	O
as	IN	O
good	JJ	O
emulsifiers	NNS	O
especially	RB	O
in	IN	O
combination	NN	O
with	IN	O
surfactants	NNS	O
and	CC	O
in	IN	O
viscous	JJ	O
preparations	NNS	O
.	.	O
These	DT	O
include	VBP	O
polar	JJ	O
inorganic	JJ	O
solids	NNS	O
,	,	O
such	JJ	O
as	IN	O
heavy	JJ	O
metal	NN	O
hydroxides	NNS	O
,	,	O
nonswelling	VBG	O
clays	NNS	O
such	JJ	O
as	IN	O
bentonite	NN	O
,	,	O
attapulgite	RB	O
,	,	O
hectorite	NN	O
,	,	O
kaolin	NN	O
,	,	O
montmorillonite	NN	O
,	,	O
colloidal	JJ	O
aluminum	NN	O
silicate	NN	O
and	CC	O
colloidal	JJ	O
magnesium	NN	O
aluminum	NN	O
silicate	NN	O
,	,	O
pigments	NNS	O
and	CC	O
nonpolar	JJ	O
solids	NNS	O
such	JJ	O
as	IN	O
carbon	NN	O
or	CC	O
glyceryl	NN	O
tristearate	NN	O
.	.	O
A	DT	O
large	JJ	O
variety	NN	O
of	IN	O
non-emulsifying	JJ	O
materials	NNS	O
are	VBP	O
also	RB	O
included	VBN	O
in	IN	O
emulsion	NN	O
formulations	NNS	O
and	CC	O
contribute	NN	O
to	TO	O
the	DT	O
properties	NNS	O
of	IN	O
emulsions	NNS	O
.	.	O
These	DT	O
include	VBP	O
fats	NNS	O
,	,	O
oils	NNS	O
,	,	O
waxes	NNS	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
fatty	JJ	O
alcohols	NNS	O
,	,	O
fatty	JJ	O
esters	NNS	O
,	,	O
humectants	NNS	O
,	,	O
hydrophilic	JJ	O
colloids	NNS	O
,	,	O
preservatives	NNS	O
and	CC	O
antioxidants	NNS	O
(	(	O
Block	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
335	CD	I
;	:	O
Idson	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
199	CD	I
)	)	I
.	.	O
Hydrophilic	JJ	O
colloids	NNS	O
or	CC	O
hydrocolloids	NNS	O
include	VBP	O
naturally	RB	O
occurring	VBG	O
gums	NNS	O
and	CC	O
synthetic	JJ	O
polymers	NNS	O
such	JJ	O
as	IN	O
polysaccharides	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
acacia	NN	O
,	,	O
agar	NN	O
,	,	O
alginic	JJ	O
acid	NN	O
,	,	O
carrageenan	NN	O
,	,	O
guar	NN	O
gum	NN	O
,	,	O
karaya	FW	O
gum	NN	O
,	,	O
and	CC	O
tragacanth	NN	O
)	)	O
,	,	O
cellulose	JJ	O
derivatives	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
carboxymethylcellulose	NN	O
and	CC	O
carboxypropylcellulose	NN	O
)	)	O
,	,	O
and	CC	O
synthetic	JJ	O
polymers	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
carbomers	NNS	O
,	,	O
cellulose	JJ	O
ethers	NNS	O
,	,	O
and	CC	O
carboxyvinyl	JJ	O
polymers	NNS	O
)	)	O
.	.	O
These	DT	O
disperse	NN	O
or	CC	O
swell	NN	O
in	IN	O
water	NN	O
to	TO	O
form	VB	O
colloidal	JJ	O
solutions	NNS	O
that	WDT	O
stabilize	VBP	O
emulsions	NNS	O
by	IN	O
forming	VBG	O
strong	JJ	O
interfacial	JJ	O
films	NNS	O
around	IN	O
the	DT	O
dispersed-phase	JJ	O
droplets	NNS	O
and	CC	O
by	IN	O
increasing	VBG	O
the	DT	O
viscosity	NN	O
of	IN	O
the	DT	O
external	JJ	O
phase	NN	O
.	.	O
Since	IN	O
emulsions	NNS	O
often	RB	O
contain	VBP	O
a	DT	O
number	NN	O
of	IN	O
ingredients	NNS	O
such	JJ	O
as	IN	O
carbohydrates	NNS	O
,	,	O
proteins	NNS	O
,	,	O
sterols	NNS	O
and	CC	O
phosphatides	NNS	O
that	WDT	O
may	MD	O
readily	VB	O
support	VB	O
the	DT	O
growth	NN	O
of	IN	O
microbes	NNS	O
,	,	O
these	DT	O
formulations	NNS	O
often	RB	O
incorporate	VBP	O
preservatives	NNS	O
.	.	O
Commonly	RB	O
used	VBN	O
preservatives	NNS	O
included	VBD	O
in	IN	O
emulsion	NN	O
formulations	NNS	O
include	VBP	O
methyl	JJ	O
paraben	NN	O
,	,	O
propyl	NN	O
paraben	NN	O
,	,	O
quaternary	JJ	O
ammonium	NN	O
salts	NNS	O
,	,	O
benzalkonium	NN	O
chloride	NN	O
,	,	O
esters	NNS	O
of	IN	O
p-hydroxybenzoic	JJ	O
acid	NN	O
,	,	O
and	CC	O
boric	JJ	O
acid	NN	O
.	.	O
Antioxidants	NNS	O
are	VBP	O
also	RB	O
commonly	RB	O
added	VBD	O
to	TO	O
emulsion	VB	O
formulations	NNS	O
to	TO	O
prevent	VB	O
deterioration	NN	O
of	IN	O
the	DT	O
formulation	NN	O
.	.	O
Antioxidants	NNS	O
used	VBN	O
may	MD	O
be	VB	O
free	JJ	O
radical	JJ	O
scavengers	NNS	O
such	JJ	O
as	IN	O
tocopherols	NNS	O
,	,	O
alkyl	NN	O
gallates	NNS	O
,	,	O
butylated	VBD	O
hydroxyanisole	NN	O
,	,	O
butylated	VBN	O
hydroxytoluene	NN	O
,	,	O
or	CC	O
reducing	VBG	O
agents	NNS	O
such	JJ	O
as	IN	O
ascorbic	JJ	O
acid	NN	O
and	CC	O
sodium	NN	O
metabisulfite	NN	O
,	,	O
and	CC	O
antioxidant	JJ	O
synergists	NNS	O
such	JJ	O
as	IN	O
citric	JJ	O
acid	NN	O
,	,	O
tartaric	JJ	O
acid	NN	O
,	,	O
and	CC	O
lecithin	NN	O
.	.	O
The	DT	O
application	NN	O
of	IN	O
emulsion	NN	O
formulations	NNS	O
via	IN	O
dermatological	JJ	O
,	,	O
oral	JJ	O
and	CC	O
parenteral	JJ	O
routes	NNS	O
and	CC	O
methods	NNS	O
for	IN	O
their	PRP$	O
manufacture	NN	O
have	VBP	O
been	VBN	O
reviewed	VBN	O
in	IN	O
the	DT	O
literature	NN	O
(	(	O
Idson	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
199	CD	I
)	)	O
.	.	O
Emulsion	NN	O
formulations	NNS	O
for	IN	O
oral	JJ	O
delivery	NN	O
have	VBP	O
been	VBN	O
very	RB	O
widely	RB	O
used	VBN	O
because	IN	O
of	IN	O
reasons	NNS	O
of	IN	O
ease	NN	O
of	IN	O
formulation	NN	O
,	,	O
efficacy	NN	O
from	IN	O
an	DT	O
absorption	NN	O
and	CC	O
bioavailability	NN	O
standpoint	NN	O
.	.	O
(	(	O
Rosoff	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
245	CD	I
;	:	O
Idson	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
199	CD	I
)	)	O
.	.	O
Mineral-oil	JJ	O
base	NN	O
laxatives	NNS	O
,	,	O
oil-soluble	JJ	O
vitamins	NNS	O
and	CC	O
high	JJ	O
fat	NN	O
nutritive	JJ	O
preparations	NNS	O
are	VBP	O
among	IN	O
the	DT	O
materials	NNS	O
that	WDT	O
have	VBP	O
commonly	RB	O
been	VBN	O
administered	VBN	O
orally	RB	O
as	IN	O
o/w	JJ	O
emulsions	NNS	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
compositions	NNS	O
of	IN	O
oligonucleotides	NNS	O
are	VBP	O
formulated	VBN	O
as	IN	O
microemulsions	NNS	O
.	.	O
A	DT	O
microemulsion	NN	O
may	MD	O
be	VB	O
defined	VBN	O
as	IN	O
a	DT	O
system	NN	O
of	IN	O
water	NN	O
,	,	O
oil	NN	O
and	CC	O
amphiphile	NN	O
which	WDT	O
is	VBZ	O
a	DT	O
single	JJ	O
optically	RB	O
isotropic	JJ	O
and	CC	O
thermodynamically	RB	O
stable	JJ	O
liquid	JJ	O
solution	NN	O
(	(	O
Rosoff	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
245	CD	I
)	)	O
.	.	O
Typically	RB	O
microemulsions	NNS	O
are	VBP	O
systems	NNS	O
that	WDT	O
are	VBP	O
prepared	VBN	O
by	IN	O
first	JJ	O
dispersing	VBG	O
an	DT	O
oil	NN	O
in	IN	O
an	DT	O
aqueous	JJ	O
surfactant	JJ	O
solution	NN	O
and	CC	O
then	RB	O
adding	VBG	O
a	DT	O
sufficient	JJ	O
amount	NN	O
of	IN	O
a	DT	O
fourth	JJ	O
component	NN	O
,	,	O
generally	RB	O
an	DT	O
intermediate	JJ	O
chain-length	NN	O
alcohol	NN	O
to	TO	O
form	VB	O
a	DT	O
transparent	NN	O
system	NN	O
.	.	O
Therefore	RB	O
,	,	O
microemulsions	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
described	VBN	O
as	IN	O
thermodynamically	RB	O
stable	JJ	O
,	,	O
isotropically	RB	O
clear	JJ	O
dispersions	NNS	O
of	IN	O
two	CD	O
immiscible	JJ	O
liquids	NNS	O
that	WDT	O
are	VBP	O
stabilized	VBN	O
by	IN	O
interfacial	JJ	O
films	NNS	O
of	IN	O
surface-active	JJ	O
molecules	NNS	O
(	(	O
Leung	NNP	B
and	CC	I
Shah	NNP	I
,	,	I
in	IN	I
:	:	I
Controlled	JJ	I
Release	NNP	I
of	IN	I
Drugs	NNP	I
:	:	I
Polymers	NNS	I
and	CC	I
Aggregate	NNP	I
Systems	NNP	I
,	,	I
Rosoff	NNP	I
,	,	I
M.	NNP	I
,	,	I
Ed.	NNP	I
,	,	I
1989	CD	I
,	,	I
VCH	NNP	I
Publishers	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
pages	VBZ	I
185-215	JJ	I
)	)	O
.	.	O
Microemulsions	NNS	O
commonly	RB	O
are	VBP	O
prepared	JJ	O
via	IN	O
a	DT	O
combination	NN	O
of	IN	O
three	CD	O
to	TO	O
five	CD	O
components	NNS	O
that	WDT	O
include	VBP	O
oil	NN	O
,	,	O
water	NN	O
,	,	O
surfactant	NN	O
,	,	O
cosurfactant	NN	O
and	CC	O
electrolyte	NN	O
.	.	O
Whether	IN	O
the	DT	O
microemulsion	NN	O
is	VBZ	O
of	IN	O
the	DT	O
water-in-oil	NN	O
(	(	O
w/o	NN	O
)	)	O
or	CC	O
an	DT	O
oil-in-water	JJ	O
(	(	O
o/w	MD	O
)	)	O
type	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
properties	NNS	O
of	IN	O
the	DT	O
oil	NN	O
and	CC	O
surfactant	NN	O
used	VBN	O
and	CC	O
on	IN	O
the	DT	O
structure	NN	O
and	CC	O
geometric	JJ	O
packing	NN	O
of	IN	O
the	DT	O
polar	JJ	O
heads	NNS	O
and	CC	O
hydrocarbon	NN	O
tails	NNS	O
of	IN	O
the	DT	O
surfactant	JJ	O
molecules	NNS	O
(	(	O
Schott	NNP	B
,	,	I
in	IN	I
Remington	NNP	I
's	POS	I
Pharmaceutical	NNP	I
Sciences	NNPS	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Co.	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1985	CD	I
,	,	I
p.	VBZ	I
271	CD	I
)	)	O
.	.	O
The	DT	O
phenomenological	JJ	O
approach	NN	O
utilizing	VBG	O
phase	NN	O
diagrams	NN	O
has	VBZ	O
been	VBN	O
extensively	RB	O
studied	VBN	O
and	CC	O
has	VBZ	O
yielded	VBN	O
a	DT	O
comprehensive	JJ	O
knowledge	NN	O
,	,	O
to	TO	O
one	CD	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
of	IN	O
how	WRB	O
to	TO	O
formulate	VB	O
microemulsions	NNS	O
(	(	O
Rosoff	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
245	CD	I
;	:	O
Block	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
335	CD	I
)	)	O
.	.	O
Compared	VBN	O
to	TO	O
conventional	JJ	O
emulsions	NNS	O
,	,	O
microemulsions	NNS	O
offer	VBP	O
the	DT	O
advantage	NN	O
of	IN	O
solubilizing	VBG	O
water-insoluble	JJ	O
drugs	NNS	O
in	IN	O
a	DT	O
formulation	NN	O
of	IN	O
thermodynamically	RB	O
stable	JJ	O
droplets	NNS	O
that	WDT	O
are	VBP	O
formed	VBN	O
spontaneously	RB	O
.	.	O
Surfactants	NNS	O
used	VBN	O
in	IN	O
the	DT	O
preparation	NN	O
of	IN	O
microemulsions	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
ionic	JJ	O
surfactants	NNS	O
,	,	O
non-ionic	JJ	O
surfactants	NNS	O
,	,	O
Brij	NNP	O
96	CD	O
,	,	O
polyoxyethylene	NN	O
oleyl	NN	O
ethers	NNS	O
,	,	O
polyglycerol	NN	O
fatty	JJ	O
acid	NN	O
esters	NNS	O
,	,	O
tetraglycerol	NN	O
monolaurate	NN	O
(	(	O
ML310	NNP	O
)	)	O
,	,	O
tetraglycerol	JJ	O
monooleate	NN	O
(	(	O
MO310	NNP	O
)	)	O
,	,	O
hexaglycerol	JJ	O
monooleate	NN	O
(	(	O
PO310	NNP	O
)	)	O
,	,	O
hexaglycerol	JJ	O
pentaoleate	NN	O
(	(	O
PO500	NNP	O
)	)	O
,	,	O
decaglycerol	JJ	O
monocaprate	NN	O
(	(	O
MCA750	NNP	O
)	)	O
,	,	O
decaglycerol	JJ	O
monooleate	NN	O
(	(	O
MO750	NNP	O
)	)	O
,	,	O
decaglycerol	JJ	O
sequioleate	NN	O
(	(	O
SO750	NNP	O
)	)	O
,	,	O
decaglycerol	JJ	O
decaoleate	NN	O
(	(	O
DAO750	NNP	O
)	)	O
,	,	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
cosurfactants	NNS	O
.	.	O
The	DT	O
cosurfactant	NN	O
,	,	O
usually	RB	O
a	DT	O
short-chain	JJ	O
alcohol	NN	O
such	JJ	O
as	IN	O
ethanol	NN	O
,	,	O
1-propanol	JJ	O
,	,	O
and	CC	O
1-butanol	JJ	O
,	,	O
serves	VBZ	O
to	TO	O
increase	VB	O
the	DT	O
interfacial	JJ	O
fluidity	NN	O
by	IN	O
penetrating	VBG	O
into	IN	O
the	DT	O
surfactant	JJ	O
film	NN	O
and	CC	O
consequently	RB	O
creating	VBG	O
a	DT	O
disordered	JJ	O
film	NN	O
because	IN	O
of	IN	O
the	DT	O
void	JJ	O
space	NN	O
generated	VBD	O
among	IN	O
surfactant	JJ	O
molecules	NNS	O
.	.	O
Microemulsions	NNS	O
may	MD	O
,	,	O
however	RB	O
,	,	O
be	VB	O
prepared	VBN	O
without	IN	O
the	DT	O
use	NN	O
of	IN	O
cosurfactants	NNS	O
and	CC	O
alcohol-free	JJ	O
self-emulsifying	JJ	O
microemulsion	NN	O
systems	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
aqueous	JJ	O
phase	NN	O
may	MD	O
typically	RB	O
be	VB	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
water	NN	O
,	,	O
an	DT	O
aqueous	JJ	O
solution	NN	O
of	IN	O
the	DT	O
drug	NN	O
,	,	O
glycerol	NN	O
,	,	O
PEG300	NNP	O
,	,	O
PEG400	NNP	O
,	,	O
polyglycerols	NNS	O
,	,	O
propylene	NN	O
glycols	NNS	O
,	,	O
and	CC	O
derivatives	NNS	O
of	IN	O
ethylene	NN	O
glycol	NN	O
.	.	O
The	DT	O
oil	NN	O
phase	NN	O
may	MD	O
include	VB	O
,	,	O
but	CC	O
is	VBZ	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
materials	NNS	O
such	JJ	O
as	IN	O
Captex	NNP	O
300	CD	O
,	,	O
Captex	NNP	O
355	CD	O
,	,	O
Capmul	NNP	O
MCM	NNP	O
,	,	O
fatty	JJ	O
acid	NN	O
esters	NNS	O
,	,	O
medium	NN	O
chain	NN	O
(	(	O
C8-C12	NNP	O
)	)	O
mono	NN	O
,	,	O
di	NN	O
,	,	O
and	CC	O
tri-glycerides	NNS	O
,	,	O
polyoxyethylated	VBD	O
glyceryl	JJ	O
fatty	JJ	O
acid	NN	O
esters	NNS	O
,	,	O
fatty	JJ	O
alcohols	NNS	O
,	,	O
polyglycolized	VBN	O
glycerides	NNS	O
,	,	O
saturated	VBD	O
polyglycolized	JJ	O
C8-C10	NNP	O
glycerides	NNS	O
,	,	O
vegetable	NN	O
oils	NNS	O
and	CC	O
silicone	NN	O
oil	NN	O
.	.	O
Microemulsions	NNS	O
are	VBP	O
particularly	RB	O
of	IN	O
interest	NN	O
from	IN	O
the	DT	O
standpoint	NN	O
of	IN	O
drug	NN	O
solubilization	NN	O
and	CC	O
the	DT	O
enhanced	JJ	O
absorption	NN	O
of	IN	O
drugs	NNS	O
.	.	O
Lipid	NNP	O
based	VBN	O
microemulsions	NNS	O
(	(	O
both	DT	O
o/w	NN	O
and	CC	O
w/o	NN	O
)	)	O
have	VBP	O
been	VBN	O
proposed	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
oral	JJ	O
bioavailability	NN	O
of	IN	O
drugs	NNS	O
,	,	O
including	VBG	O
peptides	NNS	O
(	(	O
Constantinides	NNP	B
et	RB	I
al.	RB	I
,	,	I
Pharmaceutical	NNP	I
Research	NNP	I
,	,	I
1994	CD	I
,	,	I
11	CD	I
,	,	I
1385-1390	CD	I
;	:	O
Ritschel	NNP	B
,	,	I
Meth	NNP	I
.	.	I
Find	NNP	I
.	.	I
Exp	NNP	I
.	.	I
Clin	NNP	I
.	.	I
Pharmacol.	NNP	I
,	,	I
1993	CD	I
,	,	I
13	CD	I
,	,	I
205	CD	I
)	)	O
.	.	O
Microemulsions	NNS	O
afford	VBP	O
advantages	NNS	O
of	IN	O
improved	JJ	O
drug	NN	O
solubilization	NN	O
,	,	O
protection	NN	O
of	IN	O
drug	NN	O
from	IN	O
enzymatic	JJ	O
hydrolysis	NN	O
,	,	O
possible	JJ	O
enhancement	NN	O
of	IN	O
drug	NN	O
absorption	NN	O
due	JJ	O
to	TO	O
surfactant-induced	JJ	O
alterations	NNS	O
in	IN	O
membrane	NN	O
fluidity	NN	O
and	CC	O
permeability	NN	O
,	,	O
ease	NN	O
of	IN	O
preparation	NN	O
,	,	O
ease	NN	O
of	IN	O
oral	JJ	O
administration	NN	O
over	IN	O
solid	JJ	O
dosage	NN	O
forms	NNS	O
,	,	O
improved	JJ	O
clinical	JJ	O
potency	NN	O
,	,	O
and	CC	O
decreased	JJ	O
toxicity	NN	O
(	(	O
Constantinides	NNP	B
et	RB	I
al.	RB	I
,	,	I
Pharmaceutical	NNP	I
Research	NNP	I
,	,	I
1994	CD	I
,	,	I
11	CD	I
,	,	I
1385	CD	I
;	:	O
Ho	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Pharm	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
1996	CD	I
,	,	I
85	CD	I
,	,	I
138-143	JJ	I
)	)	O
.	.	O
Often	NNP	O
microemulsions	NNS	O
may	MD	O
form	VB	O
spontaneously	RB	O
when	WRB	O
their	PRP$	O
components	NNS	O
are	VBP	O
brought	VBN	O
together	RB	O
at	IN	O
ambient	JJ	O
temperature	NN	O
.	.	O
This	DT	O
may	MD	O
be	VB	O
particularly	RB	O
advantageous	JJ	O
when	WRB	O
formulating	VBG	O
thermolabile	NN	O
drugs	NNS	O
,	,	O
peptides	NNS	O
or	CC	O
oligonucleotides	NNS	O
.	.	O
Microemulsions	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
effective	JJ	O
in	IN	O
the	DT	O
transdermal	JJ	O
delivery	NN	O
of	IN	O
active	JJ	O
components	NNS	O
in	IN	O
both	DT	O
cosmetic	JJ	O
and	CC	O
pharmaceutical	JJ	O
applications	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
expected	VBN	O
that	IN	O
the	DT	O
microemulsion	NN	O
compositions	NNS	O
and	CC	O
formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
will	MD	O
facilitate	VB	O
the	DT	O
increased	JJ	O
systemic	JJ	O
absorption	NN	O
of	IN	O
oligonucleotides	NNS	O
from	IN	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
improve	VB	O
the	DT	O
local	JJ	O
cellular	JJ	O
uptake	NN	O
of	IN	O
oligonucleotides	NNS	O
within	IN	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
,	,	O
vagina	NN	O
,	,	O
buccal	JJ	O
cavity	NN	O
and	CC	O
other	JJ	O
areas	NNS	O
of	IN	O
administration	NN	O
.	.	O
Microemulsions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
contain	VB	O
additional	JJ	O
components	NNS	O
and	CC	O
additives	NNS	O
such	JJ	O
as	IN	O
sorbitan	JJ	O
monostearate	NN	O
(	(	O
Grill	NNP	O
3	CD	O
)	)	O
,	,	O
Labrasol	NNP	O
,	,	O
and	CC	O
penetration	NN	O
enhancers	NNS	O
to	TO	O
improve	VB	O
the	DT	O
properties	NNS	O
of	IN	O
the	DT	O
formulation	NN	O
and	CC	O
to	TO	O
enhance	VB	O
the	DT	O
absorption	NN	O
of	IN	O
the	DT	O
oligonucleotides	NNS	O
and	CC	O
nucleic	JJ	O
acids	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Penetration	NN	O
enhancers	NNS	O
used	VBN	O
in	IN	O
the	DT	O
microemulsions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
be	VB	O
classified	VBN	O
as	IN	O
belonging	NN	O
to	TO	O
one	CD	O
of	IN	O
five	CD	O
broad	JJ	O
categories	NNS	O
described	VBD	O
herein	NN	O
.	.	O
There	EX	O
are	VBP	O
many	JJ	O
organized	VBN	O
surfactant	JJ	O
structures	NNS	O
besides	IN	O
microemulsions	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
studied	VBN	O
and	CC	O
used	VBN	O
in	IN	O
the	DT	O
formulation	NN	O
of	IN	O
drugs	NNS	O
.	.	O
These	DT	O
include	VBP	O
monolayers	NNS	O
,	,	O
micelles	NNS	O
,	,	O
bilayers	NNS	O
and	CC	O
vesicles	NNS	O
.	.	O
Vesicles	NNS	O
,	,	O
such	JJ	O
as	IN	O
liposomes	NNS	O
,	,	O
have	VBP	O
attracted	VBN	O
great	JJ	O
interest	NN	O
because	IN	O
of	IN	O
their	PRP$	O
specificity	NN	O
and	CC	O
the	DT	O
duration	NN	O
of	IN	O
action	NN	O
they	PRP	O
offer	VBP	O
from	IN	O
the	DT	O
standpoint	NN	O
of	IN	O
drug	NN	O
delivery	NN	O
.	.	O
Formulations	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
include	VBP	O
liposomal	JJ	O
formulations	NNS	O
.	.	O
As	IN	O
used	VBN	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
term	NN	O
“	NNP	O
liposome	VBZ	O
”	NNP	O
means	VBZ	O
a	DT	O
vesicle	NN	O
composed	VBN	O
of	IN	O
amphiphilic	JJ	O
lipids	NNS	O
arranged	VBN	O
in	IN	O
a	DT	O
spherical	JJ	O
bilayer	NN	O
or	CC	O
bilayers	NNS	O
.	.	O
Liposomes	NNS	O
are	VBP	O
unilamellar	JJ	O
or	CC	O
multilamellar	JJ	O
vesicles	NNS	O
which	WDT	O
have	VBP	O
a	DT	O
membrane	NN	O
formed	VBN	O
from	IN	O
a	DT	O
lipophilic	JJ	O
material	NN	O
and	CC	O
an	DT	O
aqueous	JJ	O
interior	NN	O
that	WDT	O
contains	VBZ	O
the	DT	O
composition	NN	O
to	TO	O
be	VB	O
delivered	VBN	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
cross	VB	O
intact	JJ	O
mammalian	JJ	O
skin	NN	O
,	,	O
lipid	JJ	O
vesicles	NNS	O
must	MD	O
pass	VB	O
through	IN	O
a	DT	O
series	NN	O
of	IN	O
fine	JJ	O
pores	NNS	O
,	,	O
each	DT	O
with	IN	O
a	DT	O
diameter	NN	O
less	JJR	O
than	IN	O
50	CD	O
nm	JJ	O
,	,	O
under	IN	O
the	DT	O
influence	NN	O
of	IN	O
a	DT	O
suitable	JJ	O
transdermal	JJ	O
gradient	NN	O
.	.	O
Therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
use	VB	O
a	DT	O
liposome	NN	O
which	WDT	O
is	VBZ	O
highly	RB	O
deformable	JJ	O
and	CC	O
able	JJ	O
to	TO	O
pass	VB	O
through	IN	O
such	JJ	O
fine	JJ	O
pores	NNS	O
.	.	O
Further	JJ	O
advantages	NNS	O
of	IN	O
liposomes	NNS	O
include	VBP	O
:	:	O
liposomes	NNS	O
obtained	VBN	O
from	IN	O
natural	JJ	O
phospholipids	NNS	O
are	VBP	O
biocompatible	JJ	O
and	CC	O
biodegradable	JJ	O
;	:	O
liposomes	NNS	O
can	MD	O
incorporate	VB	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
water	NN	O
and	CC	O
lipid	JJ	O
soluble	JJ	O
drugs	NNS	O
;	:	O
and	CC	O
liposomes	NNS	O
can	MD	O
protect	VB	O
encapsulated	JJ	O
drugs	NNS	O
in	IN	O
their	PRP$	O
internal	JJ	O
compartments	NNS	O
from	IN	O
metabolism	NN	O
and	CC	O
degradation	NN	O
(	(	O
Rosoff	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Lieberman	NNP	I
,	,	I
Rieger	NNP	I
and	CC	I
Banker	NNP	I
(	(	I
Eds	NNP	I
.	.	I
)	)	I
,	,	I
1988	CD	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
volume	NN	I
1	CD	I
,	,	I
p.	RB	I
245	CD	I
)	)	O
.	.	O
Important	JJ	O
considerations	NNS	O
in	IN	O
the	DT	O
preparation	NN	O
of	IN	O
liposome	JJ	O
formulations	NNS	O
are	VBP	O
the	DT	O
lipid	JJ	O
surface	NN	O
charge	NN	O
,	,	O
vesicle	NN	O
size	NN	O
and	CC	O
the	DT	O
aqueous	JJ	O
volume	NN	O
of	IN	O
the	DT	O
liposomes	NNS	O
.	.	O
Liposomes	NNS	O
are	VBP	O
useful	JJ	O
for	IN	O
the	DT	O
transfer	NN	O
and	CC	O
delivery	NN	O
of	IN	O
active	JJ	O
ingredients	NNS	O
to	TO	O
the	DT	O
site	NN	O
of	IN	O
action	NN	O
.	.	O
Because	IN	O
the	DT	O
liposomal	JJ	O
membrane	NN	O
is	VBZ	O
structurally	RB	O
similar	JJ	O
to	TO	O
biological	JJ	O
membranes	NNS	O
,	,	O
when	WRB	O
liposomes	NNS	O
are	VBP	O
applied	VBN	O
to	TO	O
a	DT	O
tissue	NN	O
,	,	O
the	DT	O
liposomes	NNS	O
start	VBP	O
to	TO	O
merge	VB	O
with	IN	O
the	DT	O
cellular	JJ	O
membranes	NNS	O
.	.	O
As	IN	O
the	DT	O
merging	NN	O
of	IN	O
the	DT	O
liposome	NN	O
and	CC	O
cell	NN	O
progresses	NNS	O
,	,	O
the	DT	O
liposomal	JJ	O
contents	NNS	O
are	VBP	O
emptied	VBN	O
into	IN	O
the	DT	O
cell	NN	O
where	WRB	O
the	DT	O
active	JJ	O
agent	NN	O
may	MD	O
act	VB	O
.	.	O
Liposomal	JJ	O
formulations	NNS	O
have	VBP	O
been	VBN	O
the	DT	O
focus	NN	O
of	IN	O
extensive	JJ	O
investigation	NN	O
as	IN	O
the	DT	O
mode	NN	O
of	IN	O
delivery	NN	O
for	IN	O
many	JJ	O
drugs	NNS	O
.	.	O
There	EX	O
is	VBZ	O
growing	VBG	O
evidence	NN	O
that	IN	O
for	IN	O
topical	JJ	O
administration	NN	O
,	,	O
liposomes	VBZ	O
present	JJ	O
several	JJ	O
advantages	NNS	O
over	IN	O
other	JJ	O
formulations	NNS	O
.	.	O
Such	JJ	O
advantages	NNS	O
include	VBP	O
reduced	VBN	O
side-effects	NNS	O
related	VBN	O
to	TO	O
high	JJ	O
systemic	JJ	O
absorption	NN	O
of	IN	O
the	DT	O
administered	JJ	O
drug	NN	O
,	,	O
increased	JJ	O
accumulation	NN	O
of	IN	O
the	DT	O
administered	JJ	O
drug	NN	O
at	IN	O
the	DT	O
desired	JJ	O
target	NN	O
,	,	O
and	CC	O
the	DT	O
ability	NN	O
to	TO	O
administer	VB	O
a	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
drugs	NNS	O
,	,	O
both	DT	O
hydrophilic	JJ	O
and	CC	O
hydrophobic	JJ	O
,	,	O
into	IN	O
the	DT	O
skin	NN	O
.	.	O
Several	JJ	O
reports	NNS	O
have	VBP	O
detailed	VBN	O
the	DT	O
ability	NN	O
of	IN	O
liposomes	NNS	O
to	TO	O
deliver	VB	O
agents	NNS	O
including	VBG	O
high-molecular	JJ	O
weight	NN	O
DNA	NNP	O
into	IN	O
the	DT	O
skin	NN	O
.	.	O
Compounds	NNS	O
including	VBG	O
analgesics	NNS	O
,	,	O
antibodies	NNS	O
,	,	O
hormones	NNS	O
and	CC	O
high-molecular	JJ	O
weight	NN	O
DNAs	NNP	O
have	VBP	O
been	VBN	O
administered	VBN	O
to	TO	O
the	DT	O
skin	NN	O
.	.	O
The	DT	O
majority	NN	O
of	IN	O
applications	NNS	O
resulted	VBN	O
in	IN	O
the	DT	O
targeting	NN	O
of	IN	O
the	DT	O
upper	JJ	O
epidermis	NN	O
.	.	O
Liposomes	RB	O
fall	VB	O
into	IN	O
two	CD	O
broad	JJ	O
classes	NNS	O
,	,	O
cationic	JJ	O
and	CC	O
non-cationic	JJ	O
,	,	O
both	DT	O
of	IN	O
which	WDT	O
are	VBP	O
useful	JJ	O
for	IN	O
the	DT	O
delivery	NN	O
of	IN	O
DNA	NNP	O
,	,	O
RNA	NNP	O
or	CC	O
any	DT	O
nucleic	JJ	O
acid-based	JJ	O
construct	NN	O
into	IN	O
cells	NNS	O
.	.	O
Cationic	JJ	O
liposomes	NNS	O
are	VBP	O
positively	RB	O
charged	VBN	O
liposomes	NNS	O
which	WDT	O
interact	VBP	O
with	IN	O
negatively	RB	O
charged	VBN	O
DNA	NNP	O
molecules	NNS	O
to	TO	O
form	VB	O
a	DT	O
stable	JJ	O
complex	NN	O
.	.	O
The	DT	O
positively	RB	O
charged	VBN	O
DNA/liposome	NNP	O
complex	JJ	O
binds	NNS	O
to	TO	O
the	DT	O
negatively	RB	O
charged	VBN	O
cell	NN	O
surface	NN	O
and	CC	O
is	VBZ	O
internalized	VBN	O
in	IN	O
an	DT	O
endosome	NN	O
.	.	O
Due	JJ	O
to	TO	O
the	DT	O
acidic	JJ	O
pH	NN	O
within	IN	O
the	DT	O
endosome	NN	O
,	,	O
the	DT	O
liposomes	NNS	O
are	VBP	O
ruptured	VBN	O
,	,	O
releasing	VBG	O
their	PRP$	O
contents	NNS	O
into	IN	O
the	DT	O
cell	NN	O
cytoplasm	NN	O
(	(	O
Wang	NNP	B
et	RB	I
al.	RB	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun.	NNP	I
,	,	I
1987	CD	I
,	,	I
147	CD	I
,	,	I
980-985	CD	I
)	)	O
.	.	O
Liposomes	NNS	O
which	WDT	O
are	VBP	O
pH-sensitive	JJ	O
or	CC	O
negatively-charged	JJ	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
non-cationic	JJ	O
liposomes	NNS	O
,	,	O
entrap	VBP	O
DNA	NNP	O
rather	RB	O
than	IN	O
complex	JJ	O
with	IN	O
it	PRP	O
.	.	O
Since	IN	O
both	DT	O
the	DT	O
DNA	NN	O
and	CC	O
the	DT	O
lipid	NN	O
are	VBP	O
similarly	RB	O
charged	VBN	O
,	,	O
repulsion	NN	O
rather	RB	O
than	IN	O
complex	JJ	O
formation	NN	O
occurs	VBZ	O
.	.	O
Nevertheless	RB	O
,	,	O
some	DT	O
DNA	NN	O
is	VBZ	O
entrapped	VBN	O
within	IN	O
the	DT	O
aqueous	JJ	O
interior	NN	O
of	IN	O
these	DT	O
liposomes	NNS	O
.	.	O
pH-sensitive	JJ	O
liposomes	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
deliver	VB	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
thymidine	NN	O
kinase	NN	O
gene	NN	O
to	TO	O
cell	VB	O
monolayers	NNS	O
in	IN	O
culture	NN	O
.	.	O
Expression	NN	O
of	IN	O
the	DT	O
exogenous	JJ	O
gene	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
target	NN	O
cells	NNS	O
(	(	O
Zhou	NNP	B
et	RB	I
al.	RB	I
,	,	I
Journal	NNP	I
of	IN	I
Controlled	NNP	I
Release	NNP	I
,	,	I
1992	CD	I
,	,	I
19	CD	I
,	,	I
269-274	JJ	I
)	)	O
.	.	O
One	CD	O
major	JJ	O
type	NN	O
of	IN	O
liposomal	JJ	O
composition	NN	O
includes	VBZ	O
phospholipids	IN	O
other	JJ	O
than	IN	O
naturally-derived	JJ	O
phosphatidylcholine	NN	O
.	.	O
Neutral	JJ	O
liposome	NN	O
compositions	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
can	MD	O
be	VB	O
formed	VBN	O
from	IN	O
dimyristoyl	JJ	O
phosphatidylcholine	NN	O
(	(	O
DMPC	NNP	O
)	)	O
or	CC	O
dipalmitoyl	JJ	O
phosphatidylcholine	NN	O
(	(	O
DPPC	NNP	O
)	)	O
.	.	O
Anionic	NNP	O
liposome	NN	O
compositions	NNS	O
generally	RB	O
are	VBP	O
formed	VBN	O
from	IN	O
dimyristoyl	NN	O
phosphatidylglycerol	NN	O
,	,	O
while	IN	O
anionic	JJ	O
fusogenic	JJ	O
liposomes	NNS	O
are	VBP	O
formed	VBN	O
primarily	RB	O
from	IN	O
dioleoyl	JJ	O
phosphatidylethanolamine	NN	O
(	(	O
DOPE	NNP	O
)	)	O
.	.	O
Another	DT	O
type	NN	O
of	IN	O
liposomal	JJ	O
composition	NN	O
is	VBZ	O
formed	VBN	O
from	IN	O
phosphatidylcholine	NN	O
(	(	O
PC	NN	O
)	)	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
soybean	JJ	O
PC	NN	O
,	,	O
and	CC	O
egg	JJ	O
PC	NN	O
.	.	O
Another	DT	O
type	NN	O
is	VBZ	O
formed	VBN	O
from	IN	O
mixtures	NNS	O
of	IN	O
phospholipid	JJ	O
and/or	JJ	O
phosphatidylcholine	NN	O
and/or	NN	O
cholesterol	NN	O
.	.	O
Several	JJ	O
studies	NNS	O
have	VBP	O
assessed	VBN	O
the	DT	O
topical	JJ	O
delivery	NN	O
of	IN	O
liposomal	JJ	O
drug	NN	O
formulations	NNS	O
to	TO	O
the	DT	O
skin	NN	O
.	.	O
Application	NN	O
of	IN	O
liposomes	NNS	O
containing	VBG	O
interferon	NN	O
to	TO	O
guinea	VB	O
pig	JJ	O
skin	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
reduction	NN	O
of	IN	O
skin	NN	O
herpes	NNS	O
sores	NNS	O
while	IN	O
delivery	NN	O
of	IN	O
interferon	NN	O
via	IN	O
other	JJ	O
means	NNS	O
(	(	O
e.g	NN	O
.	.	O
as	IN	O
a	DT	O
solution	NN	O
or	CC	O
as	IN	O
an	DT	O
emulsion	NN	O
)	)	O
were	VBD	O
ineffective	JJ	O
(	(	O
Weiner	NNP	B
et	RB	I
al.	RB	I
,	,	I
Journal	NNP	I
of	IN	I
Drug	NNP	I
Targeting	NNP	I
,	,	I
1992	CD	I
,	,	I
2	CD	I
,	,	I
405-410	JJ	I
)	)	O
.	.	O
Further	RB	O
,	,	O
an	DT	O
additional	JJ	O
study	NN	O
tested	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
interferon	NN	O
administered	VBN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
liposomal	JJ	O
formulation	NN	O
to	TO	O
the	DT	O
administration	NN	O
of	IN	O
interferon	NN	O
using	VBG	O
an	DT	O
aqueous	JJ	O
system	NN	O
,	,	O
and	CC	O
concluded	VBD	O
that	IN	O
the	DT	O
liposomal	JJ	O
formulation	NN	O
was	VBD	O
superior	JJ	O
to	TO	O
aqueous	JJ	O
administration	NN	O
(	(	O
du	JJ	B
Plessis	NNP	I
et	NN	I
al.	NN	I
,	,	I
Antiviral	NNP	I
Research	NNP	I
,	,	I
1992	CD	I
,	,	I
18	CD	I
,	,	I
259-265	JJ	I
)	)	O
.	.	O
Non-ionic	JJ	O
liposomal	JJ	O
systems	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
examined	VBN	O
to	TO	O
determine	VB	O
their	PRP$	O
utility	NN	O
in	IN	O
the	DT	O
delivery	NN	O
of	IN	O
drugs	NNS	O
to	TO	O
the	DT	O
skin	NN	O
,	,	O
in	IN	O
particular	JJ	O
systems	NNS	O
comprising	VBG	O
non-ionic	JJ	O
surfactant	NN	O
and	CC	O
cholesterol	NN	O
.	.	O
Non-ionic	JJ	O
liposomal	JJ	O
formulations	NNS	O
comprising	VBG	O
the	DT	O
Novasome™	NNP	O
I	PRP	O
(	(	O
glyceryl	JJ	O
dilaurate/cholesterol/polyoxyethylene-10-stearyl	NN	O
ether	NN	O
)	)	O
and	CC	O
Novasome™	NNP	O
II	NNP	O
(	(	O
glyceryl	JJ	O
distearate/cholesterol/polyoxyethylene-10-stearyl	NN	O
ether	NN	O
)	)	O
reagents	NNS	O
were	VBD	O
used	VBN	O
to	TO	O
deliver	VB	O
cyclosporin-A	JJ	O
into	IN	O
the	DT	O
dermis	NN	O
of	IN	O
mouse	NN	O
skin	NN	O
.	.	O
Results	NNS	O
indicated	VBD	O
that	IN	O
such	JJ	O
non-ionic	JJ	O
liposomal	JJ	O
systems	NNS	O
were	VBD	O
effective	JJ	O
in	IN	O
facilitating	VBG	O
the	DT	O
deposition	NN	O
of	IN	O
cyclosporin-A	JJ	O
into	IN	O
different	JJ	O
layers	NNS	O
of	IN	O
the	DT	O
skin	NN	O
(	(	O
Hu	NNP	B
et	RB	I
al	RB	I
.	.	I
S.T.P	NNP	I
.	.	I
Pharma	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
1994	CD	I
,	,	I
4	CD	I
,	,	I
6	CD	I
,	,	I
466	CD	I
)	)	O
.	.	O
Liposomes	NNS	O
also	RB	O
include	VBP	O
“	NNP	O
sterically	RB	O
stabilized	VBD	O
”	JJ	O
liposomes	NNS	O
,	,	O
a	DT	O
term	NN	O
which	WDT	O
,	,	O
as	IN	O
used	VBN	O
herein	NN	O
,	,	O
refers	NNS	O
to	TO	O
liposomes	VB	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
specialized	JJ	O
lipids	NNS	O
that	IN	O
,	,	O
when	WRB	O
incorporated	VBN	O
into	IN	O
liposomes	NNS	O
,	,	O
result	NN	O
in	IN	O
enhanced	JJ	O
circulation	NN	O
lifetimes	NNS	O
relative	VBP	O
to	TO	O
liposomes	VB	O
lacking	VBG	O
such	JJ	O
specialized	JJ	O
lipids	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
sterically	RB	O
stabilized	VBN	O
liposomes	NNS	O
are	VBP	O
those	DT	O
in	IN	O
which	WDT	O
part	NN	O
of	IN	O
the	DT	O
vesicle-forming	JJ	O
lipid	JJ	O
portion	NN	O
of	IN	O
the	DT	O
liposome	NN	O
(	(	O
A	DT	O
)	)	O
comprises	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
glycolipids	NNS	O
,	,	O
such	JJ	O
as	IN	O
monosialoganglioside	NN	O
GM1	NNP	O
,	,	O
or	CC	O
(	(	O
B	NNP	O
)	)	O
is	VBZ	O
derivatized	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
hydrophilic	JJ	O
polymers	NNS	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
moiety	NN	O
.	.	O
While	IN	O
not	RB	O
wishing	VBG	O
to	TO	O
be	VB	O
bound	VBN	O
by	IN	O
any	DT	O
particular	JJ	O
theory	NN	O
,	,	O
it	PRP	O
is	VBZ	O
thought	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
,	,	O
at	IN	O
least	JJS	O
for	IN	O
sterically	RB	O
stabilized	VBN	O
liposomes	NNS	O
containing	VBG	O
gangliosides	NNS	O
,	,	O
sphingomyelin	NN	O
,	,	O
or	CC	O
PEG-derivatized	JJ	O
lipids	NNS	O
,	,	O
the	DT	O
enhanced	JJ	O
circulation	NN	O
half-life	NN	O
of	IN	O
these	DT	O
sterically	RB	O
stabilized	VBN	O
liposomes	NNS	O
derives	VBZ	O
from	IN	O
a	DT	O
reduced	JJ	O
uptake	NN	O
into	IN	O
cells	NNS	O
of	IN	O
the	DT	O
reticuloendothelial	JJ	O
system	NN	O
(	(	O
RES	NNP	O
)	)	O
(	(	O
Allen	NNP	B
et	RB	I
al.	RB	I
,	,	I
FEBS	NNP	I
Letters	NNP	I
,	,	I
1987	CD	I
,	,	I
223	CD	I
,	,	I
42	CD	I
;	:	O
Wu	NNP	B
et	FW	I
al.	NN	I
,	,	I
Cancer	NNP	I
Research	NNP	I
,	,	I
1993	CD	I
,	,	I
53	CD	I
,	,	I
3765	CD	I
)	)	O
.	.	O
Liposomes	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Various	JJ	O
liposomes	NNS	O
comprising	VBG	O
one	CD	O
or	CC	O
more	JJR	O
glycolipids	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Papahadjopoulos	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
Ann	NNP	I
.	.	I
N.Y.	NNP	I
Acad	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
1987	CD	I
,	,	I
507	CD	I
,	,	I
64	CD	I
)	)	I
reported	VBD	O
the	DT	O
ability	NN	O
of	IN	O
monosialoganglioside	NN	O
GM1	NNP	O
,	,	O
galactocerebroside	NN	O
sulfate	NN	O
and	CC	O
phosphatidylinositol	NN	O
to	TO	O
improve	VB	O
blood	NN	O
half-lives	NNS	O
of	IN	O
liposomes	NNS	O
.	.	O
These	DT	O
findings	NNS	O
were	VBD	O
expounded	VBN	O
upon	IN	O
by	IN	O
Gabizon	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
1988	CD	I
,	,	I
85	CD	I
,	,	I
6949	CD	I
)	)	I
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,837,028	CD	O
and	CC	O
WO	NNP	O
88/04924	CD	O
,	,	O
both	DT	O
to	TO	O
Allen	NNP	O
et	FW	O
al.	NN	O
,	,	O
disclose	VB	O
liposomes	NNS	O
comprising	VBG	O
(	(	O
1	CD	O
)	)	O
sphingomyelin	NN	O
and	CC	O
(	(	O
2	CD	O
)	)	O
the	DT	O
ganglioside	JJ	O
GM1	NNP	O
or	CC	O
a	DT	O
galactocerebroside	JJ	O
sulfate	NN	O
ester	NN	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,543,152	CD	O
(	(	O
Webb	NNP	O
et	RB	O
al	RB	O
.	.	O
)	)	O
discloses	NNS	O
liposomes	VBZ	O
comprising	VBG	O
sphingomyelin	NN	O
.	.	O
Liposomes	NNS	O
comprising	VBG	O
1,2-sn-dimyristoylphosphatidylcholine	JJ	O
are	VBP	O
disclosed	VBN	O
in	IN	O
WO	NNP	O
97/13499	CD	O
(	(	O
Lim	NNP	O
et	RB	O
al	RB	O
.	.	O
)	)	O
.	.	O
Many	JJ	O
liposomes	NNS	O
comprising	VBG	O
lipids	NNS	O
derivatized	VBN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
hydrophilic	JJ	O
polymers	NNS	O
,	,	O
and	CC	O
methods	NNS	O
of	IN	O
preparation	NN	O
thereof	NN	O
,	,	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Sunamoto	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
Bull	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc	NNP	I
.	.	I
Jpn.	NNP	I
,	,	I
1980	CD	I
,	,	I
53	CD	I
,	,	I
2778	CD	I
)	)	I
described	VBD	O
liposomes	NNS	O
comprising	VBG	O
a	DT	O
nonionic	JJ	O
detergent	NN	O
,	,	O
2C1215G	CD	O
,	,	O
that	WDT	O
contains	VBZ	O
a	DT	O
PEG	NNP	O
moiety	NN	O
.	.	O
Illum	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
1984	CD	I
,	,	I
167	CD	I
,	,	I
79	CD	I
)	)	I
noted	VBD	O
that	IN	O
hydrophilic	JJ	O
coating	NN	O
of	IN	O
polystyrene	NN	O
particles	NNS	O
with	IN	O
polymeric	JJ	O
glycols	NNS	O
results	NNS	O
in	IN	O
significantly	RB	O
enhanced	VBN	O
blood	NN	O
half-lives	NNS	O
.	.	O
Synthetic	JJ	O
phospholipids	NNS	O
modified	VBN	O
by	IN	O
the	DT	O
attachment	NN	O
of	IN	O
carboxylic	JJ	O
groups	NNS	O
of	IN	O
polyalkylene	NN	O
glycols	NNS	O
(	(	O
e.g.	NN	O
,	,	O
PEG	NNP	O
)	)	O
are	VBP	O
described	VBN	O
by	IN	O
Sears	NNP	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
4,426,330	CD	O
and	CC	O
4,534,899	CD	O
)	)	O
.	.	O
Klibanov	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
FEBS	NNP	I
Lett.	NNP	I
,	,	I
1990	CD	I
,	,	I
268	CD	I
,	,	I
235	CD	I
)	)	I
described	VBD	O
experiments	NNS	O
demonstrating	VBG	O
that	IN	O
liposomes	VBZ	O
comprising	VBG	O
phosphatidylethanolamine	NN	O
(	(	O
PE	NNP	O
)	)	O
derivatized	VBD	O
with	IN	O
PEG	NNP	O
or	CC	O
PEG	NNP	O
stearate	VBP	O
have	VBP	O
significant	JJ	O
increases	NNS	O
in	IN	O
blood	NN	O
circulation	NN	O
half-lives	NNS	O
.	.	O
Blume	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
Biochimica	NNP	I
et	VBZ	I
Biophysica	NNP	I
Acta	NNP	I
,	,	I
1990	CD	I
,	,	I
1029	CD	I
,	,	I
91	CD	I
)	)	I
extended	VBD	O
such	JJ	O
observations	NNS	O
to	TO	O
other	JJ	O
PEG-derivatized	JJ	O
phospholipids	NNS	O
,	,	O
e.g.	NN	O
,	,	O
DSPE-PEG	NNP	O
,	,	O
formed	VBN	O
from	IN	O
the	DT	O
combination	NN	O
of	IN	O
distearoylphosphatidylethanolamine	NN	O
(	(	O
DSPE	NNP	O
)	)	O
and	CC	O
PEG	NNP	O
.	.	O
Liposomes	NNS	O
having	VBG	O
covalently	RB	O
bound	VBN	O
PEG	NNP	O
moieties	NNS	O
on	IN	O
their	PRP$	O
external	JJ	O
surface	NN	O
are	VBP	O
described	VBN	O
in	IN	O
European	JJ	O
Patent	NNP	O
No	NNP	O
.	.	O
EP	NNP	O
0	CD	O
445	CD	O
131	CD	O
B1	NNP	O
and	CC	O
WO	NNP	O
90/04384	CD	O
to	TO	O
Fisher	NNP	O
.	.	O
Liposome	NNP	O
compositions	NNS	O
containing	VBG	O
1-20	JJ	O
mole	JJ	O
percent	NN	O
of	IN	O
PE	NNP	O
derivatized	VBD	O
with	IN	O
PEG	NNP	O
,	,	O
and	CC	O
methods	NNS	O
of	IN	O
use	NN	O
thereof	NN	O
,	,	O
are	VBP	O
described	VBN	O
by	IN	O
Woodle	NNP	O
et	CC	O
al	NN	O
.	.	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,013,556	CD	O
and	CC	O
5,356,633	CD	O
)	)	O
and	CC	O
Martin	NNP	O
et	VBP	O
al	NN	O
.	.	O
(	(	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,213,804	CD	O
and	CC	O
European	JJ	O
Patent	NNP	O
No	NNP	O
.	.	O
EP	NNP	O
0	CD	O
496	CD	O
813	CD	O
B1	NNP	O
)	)	O
.	.	O
Liposomes	RB	O
comprising	VBG	O
a	DT	O
number	NN	O
of	IN	O
other	JJ	O
lipid-polymer	JJ	O
conjugates	NNS	O
are	VBP	O
disclosed	VBN	O
in	IN	O
WO	NNP	O
91/05545	CD	O
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,225,212	CD	O
(	(	O
both	DT	O
to	TO	O
Martin	NNP	B
et	FW	I
al	NN	I
.	.	I
)	)	O
and	CC	O
in	IN	O
WO	NNP	O
94/20073	CD	O
(	(	O
Zalipsky	NNP	B
et	VBZ	I
al	RB	I
.	.	I
)	)	O
Liposomes	NNS	O
comprising	VBG	O
PEG-modified	JJ	O
ceramide	NN	O
lipids	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
WO	NNP	O
96/10391	CD	O
(	(	O
Choi	NNP	O
et	RB	O
al	RB	O
.	.	O
)	)	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,540,935	CD	O
(	(	O
Miyazaki	NNP	O
et	RB	O
al	RB	O
.	.	O
)	)	O
and	CC	O
5,556,948	CD	O
(	(	O
Tagawa	NNP	O
et	RB	O
al	RB	O
.	.	O
)	)	O
describe	JJ	O
PEG-containing	NNP	O
liposomes	NNS	O
that	WDT	O
can	MD	O
be	VB	O
further	JJ	O
derivatized	VBN	O
with	IN	O
functional	JJ	O
moieties	NNS	O
on	IN	O
their	PRP$	O
surfaces	NNS	O
.	.	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
96/40062	CD	O
to	TO	O
Thierry	NNP	O
et	NNP	O
al	NN	O
.	.	O
refers	NNS	O
to	TO	O
methods	NNS	O
for	IN	O
encapsulating	VBG	O
high	JJ	O
molecular	JJ	O
weight	NN	O
nucleic	JJ	O
acids	NNS	O
in	IN	O
liposomes	NNS	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,264,221	CD	O
to	TO	O
Tagawa	NNP	O
et	FW	O
al	NN	O
.	.	O
refers	NNS	O
to	TO	O
protein-bonded	JJ	O
liposomes	NNS	O
and	CC	O
asserts	VBZ	O
that	IN	O
the	DT	O
contents	NNS	O
of	IN	O
such	JJ	O
liposomes	NNS	O
may	MD	O
include	VB	O
an	DT	O
antisense	JJ	O
RNA	NNP	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,665,710	CD	O
to	TO	O
Rahman	NNP	O
et	FW	O
al	NN	O
.	.	O
refers	NNS	O
to	TO	O
certain	JJ	O
methods	NNS	O
of	IN	O
encapsulating	VBG	O
oligodeoxynucleotides	NNS	O
in	IN	O
liposomes	NNS	O
.	.	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	$	O
97/04787	CD	O
to	TO	O
Love	NNP	O
et	FW	O
al	NN	O
.	.	O
refers	NNS	O
to	TO	O
liposomes	NNS	O
comprising	VBG	O
antisense	NN	O
oligonucleotides	NNS	O
targeted	VBD	O
to	TO	O
the	DT	O
raf	NN	O
gene	NN	O
.	.	O
Transfersomes	NNS	O
are	VBP	O
yet	RB	O
another	DT	O
type	NN	O
of	IN	O
liposome	NN	O
,	,	O
and	CC	O
are	VBP	O
highly	RB	O
deformable	JJ	O
lipid	NN	O
aggregates	NNS	O
which	WDT	O
are	VBP	O
attractive	JJ	O
candidates	NNS	O
for	IN	O
drug	NN	O
delivery	NN	O
vehicles	NNS	O
.	.	O
Transfersomes	NNS	O
may	MD	O
be	VB	O
described	VBN	O
as	IN	O
lipid	JJ	O
droplets	NNS	O
which	WDT	O
are	VBP	O
so	RB	O
highly	RB	O
deformable	JJ	O
that	IN	O
they	PRP	O
are	VBP	O
easily	RB	O
able	JJ	O
to	TO	O
penetrate	VB	O
through	IN	O
pores	NNS	O
which	WDT	O
are	VBP	O
smaller	JJR	O
than	IN	O
the	DT	O
droplet	NN	O
.	.	O
Transfersomes	NNS	O
are	VBP	O
adaptable	JJ	O
to	TO	O
the	DT	O
environment	NN	O
in	IN	O
which	WDT	O
they	PRP	O
are	VBP	O
used	VBN	O
,	,	O
e.g	FW	O
.	.	O
they	PRP	O
are	VBP	O
self-optimizing	JJ	O
(	(	O
adaptive	JJ	O
to	TO	O
the	DT	O
shape	NN	O
of	IN	O
pores	NNS	O
in	IN	O
the	DT	O
skin	NN	O
)	)	O
,	,	O
self-repairing	JJ	O
,	,	O
frequently	RB	O
reach	VBP	O
their	PRP$	O
targets	NNS	O
without	IN	O
fragmenting	NN	O
,	,	O
and	CC	O
often	RB	O
self-loading	JJ	O
.	.	O
To	TO	O
make	VB	O
transfersomes	NNS	O
it	PRP	O
is	VBZ	O
possible	JJ	O
to	TO	O
add	VB	O
surface	JJ	O
edge-activators	NNS	O
,	,	O
usually	RB	O
surfactants	NNS	O
,	,	O
to	TO	O
a	DT	O
standard	JJ	O
liposomal	JJ	O
composition	NN	O
.	.	O
Transfersomes	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
deliver	VB	O
serum	JJ	O
albumin	NN	O
to	TO	O
the	DT	O
skin	NN	O
.	.	O
The	DT	O
transfersome-mediated	JJ	O
delivery	NN	O
of	IN	O
serum	NN	O
albumin	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
as	RB	O
effective	JJ	O
as	IN	O
subcutaneous	JJ	O
injection	NN	O
of	IN	O
a	DT	O
solution	NN	O
containing	VBG	O
serum	NN	O
albumin	NN	O
.	.	O
Surfactants	NNS	O
find	VBP	O
wide	JJ	O
application	NN	O
in	IN	O
formulations	NNS	O
such	JJ	O
as	IN	O
emulsions	NNS	O
(	(	O
including	VBG	O
microemulsions	NNS	O
)	)	O
and	CC	O
liposomes	NNS	O
.	.	O
The	DT	O
most	RBS	O
common	JJ	O
way	NN	O
of	IN	O
classifying	NN	O
and	CC	O
ranking	VBG	O
the	DT	O
properties	NNS	O
of	IN	O
the	DT	O
many	JJ	O
different	JJ	O
types	NNS	O
of	IN	O
surfactants	NNS	O
,	,	O
both	DT	O
natural	JJ	O
and	CC	O
synthetic	JJ	O
,	,	O
is	VBZ	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
hydrophile/lipophile	JJ	O
balance	NN	O
(	(	O
HLB	NNP	O
)	)	O
.	.	O
The	DT	O
nature	NN	O
of	IN	O
the	DT	O
hydrophilic	JJ	O
group	NN	O
(	(	O
also	RB	O
known	VBN	O
as	IN	O
the	DT	O
“	NNP	O
head	NN	O
”	NN	O
)	)	O
provides	VBZ	O
the	DT	O
most	RBS	O
useful	JJ	O
means	NNS	O
for	IN	O
categorizing	VBG	O
the	DT	O
different	JJ	O
surfactants	NNS	O
used	VBN	O
in	IN	O
formulations	NNS	O
(	(	O
Rieger	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
1988	CD	I
,	,	I
p.	VBZ	I
285	CD	I
)	)	O
.	.	O
If	IN	O
the	DT	O
surfactant	NN	O
molecule	NN	O
is	VBZ	O
not	RB	O
ionized	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
classified	VBN	O
as	IN	O
a	DT	O
nonionic	JJ	O
surfactant	NN	O
.	.	O
Nonionic	JJ	O
surfactants	NNS	O
find	VBP	O
wide	JJ	O
application	NN	O
in	IN	O
pharmaceutical	JJ	O
and	CC	O
cosmetic	JJ	O
products	NNS	O
and	CC	O
are	VBP	O
usable	JJ	O
over	IN	O
a	DT	O
wide	JJ	O
range	NN	O
of	IN	O
pH	NN	O
values	NNS	O
.	.	O
In	IN	O
general	JJ	O
their	PRP$	O
HLB	NN	O
values	NNS	O
range	VBP	O
from	IN	O
2	CD	O
to	TO	O
about	IN	O
18	CD	O
depending	VBG	O
on	IN	O
their	PRP$	O
structure	NN	O
.	.	O
Nonionic	JJ	O
surfactants	NNS	O
include	VBP	O
nonionic	JJ	O
esters	NNS	O
such	JJ	O
as	IN	O
ethylene	JJ	O
glycol	NN	O
esters	NNS	O
,	,	O
propylene	NN	O
glycol	NN	O
esters	NNS	O
,	,	O
glyceryl	NN	O
esters	NNS	O
,	,	O
polyglyceryl	NN	O
esters	NNS	O
,	,	O
sorbitan	JJ	O
esters	NNS	O
,	,	O
sucrose	JJ	O
esters	NNS	O
,	,	O
and	CC	O
ethoxylated	VBD	O
esters	NNS	O
.	.	O
Nonionic	NNP	O
alkanolamides	NNS	O
and	CC	O
ethers	NNS	O
such	JJ	O
as	IN	O
fatty	JJ	O
alcohol	NN	O
ethoxylates	NNS	O
,	,	O
propoxylated	VBD	O
alcohols	NNS	O
,	,	O
and	CC	O
ethoxylated/propoxylated	VBD	O
block	NN	O
polymers	NNS	O
are	VBP	O
also	RB	O
included	VBN	O
in	IN	O
this	DT	O
class	NN	O
.	.	O
The	DT	O
polyoxyethylene	NN	O
surfactants	NNS	O
are	VBP	O
the	DT	O
most	RBS	O
popular	JJ	O
members	NNS	O
of	IN	O
the	DT	O
nonionic	JJ	O
surfactant	JJ	O
class	NN	O
.	.	O
If	IN	O
the	DT	O
surfactant	NN	O
molecule	NN	O
carries	VBZ	O
a	DT	O
negative	JJ	O
charge	NN	O
when	WRB	O
it	PRP	O
is	VBZ	O
dissolved	VBN	O
or	CC	O
dispersed	VBN	O
in	IN	O
water	NN	O
,	,	O
the	DT	O
surfactant	NN	O
is	VBZ	O
classified	VBN	O
as	IN	O
anionic	NN	O
.	.	O
Anionic	JJ	O
surfactants	NNS	O
include	VBP	O
carboxylates	NNS	O
such	JJ	O
as	IN	O
soaps	NNS	O
,	,	O
acyl	NN	O
lactylates	NNS	O
,	,	O
acyl	JJ	O
amides	NNS	O
of	IN	O
amino	NN	O
acids	NNS	O
,	,	O
esters	NNS	O
of	IN	O
sulfuric	JJ	O
acid	NNS	O
such	JJ	O
as	IN	O
alkyl	NN	O
sulfates	NNS	O
and	CC	O
ethoxylated	VBD	O
alkyl	NN	O
sulfates	NNS	O
,	,	O
sulfonates	NNS	O
such	JJ	O
as	IN	O
alkyl	JJ	O
benzene	NN	O
sulfonates	NNS	O
,	,	O
acyl	NN	O
isethionates	NNS	O
,	,	O
acyl	NN	O
taurates	NNS	O
and	CC	O
sulfosuccinates	NNS	O
,	,	O
and	CC	O
phosphates	NNS	O
.	.	O
The	DT	O
most	RBS	O
important	JJ	O
members	NNS	O
of	IN	O
the	DT	O
anionic	JJ	O
surfactant	JJ	O
class	NN	O
are	VBP	O
the	DT	O
alkyl	JJ	O
sulfates	NNS	O
and	CC	O
the	DT	O
soaps	NNS	O
.	.	O
If	IN	O
the	DT	O
surfactant	NN	O
molecule	NN	O
carries	VBZ	O
a	DT	O
positive	JJ	O
charge	NN	O
when	WRB	O
it	PRP	O
is	VBZ	O
dissolved	VBN	O
or	CC	O
dispersed	VBN	O
in	IN	O
water	NN	O
,	,	O
the	DT	O
surfactant	NN	O
is	VBZ	O
classified	VBN	O
as	IN	O
cationic	NN	O
.	.	O
Cationic	JJ	O
surfactants	NNS	O
include	VBP	O
quaternary	JJ	O
ammonium	NN	O
salts	NNS	O
and	CC	O
ethoxylated	VBN	O
amines	NNS	O
.	.	O
The	DT	O
quaternary	JJ	O
ammonium	NN	O
salts	NNS	O
are	VBP	O
the	DT	O
most	RBS	O
used	JJ	O
members	NNS	O
of	IN	O
this	DT	O
class	NN	O
.	.	O
If	IN	O
the	DT	O
surfactant	NN	O
molecule	NN	O
has	VBZ	O
the	DT	O
ability	NN	O
to	TO	O
carry	VB	O
either	RB	O
a	DT	O
positive	JJ	O
or	CC	O
negative	JJ	O
charge	NN	O
,	,	O
the	DT	O
surfactant	NN	O
is	VBZ	O
classified	VBN	O
as	IN	O
amphoteric	NN	O
.	.	O
Amphoteric	JJ	O
surfactants	NNS	O
include	VBP	O
acrylic	JJ	O
acid	JJ	O
derivatives	NNS	O
,	,	O
substituted	VBD	O
alkylamides	NNS	O
,	,	O
N-alkylbetaines	NNS	O
and	CC	O
phosphatides	NNS	O
.	.	O
The	DT	O
use	NN	O
of	IN	O
surfactants	NNS	O
in	IN	O
drug	NN	O
products	NNS	O
,	,	O
formulations	NNS	O
and	CC	O
in	IN	O
emulsions	NNS	O
has	VBZ	O
been	VBN	O
reviewed	VBN	O
(	(	O
Rieger	NNP	B
,	,	I
in	IN	I
Pharmaceutical	JJ	I
Dosage	NN	I
Forms	NNP	I
,	,	I
Marcel	NNP	I
Dekker	NNP	I
,	,	I
Inc.	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
1988	CD	I
,	,	I
p.	VBZ	I
285	CD	I
)	)	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
,	,	O
the	DT	O
present	JJ	O
invention	NN	O
employs	VBZ	O
various	JJ	O
penetration	NN	O
enhancers	NNS	O
to	TO	O
effect	NN	O
the	DT	O
efficient	JJ	O
delivery	NN	O
of	IN	O
nucleic	JJ	O
acids	NNS	O
,	,	O
particularly	RB	O
oligonucleotides	NNS	O
,	,	O
to	TO	O
the	DT	O
skin	NN	O
of	IN	O
animals	NNS	O
.	.	O
Most	JJS	O
drugs	NNS	O
are	VBP	O
present	JJ	O
in	IN	O
solution	NN	O
in	IN	O
both	DT	O
ionized	JJ	O
and	CC	O
nonionized	JJ	O
forms	NNS	O
.	.	O
However	RB	O
,	,	O
usually	RB	O
only	RB	O
lipid	JJ	O
soluble	JJ	O
or	CC	O
lipophilic	JJ	O
drugs	NNS	O
readily	RB	O
cross	VBP	O
cell	NN	O
membranes	NNS	O
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
discovered	VBN	O
that	IN	O
even	RB	O
non-lipophilic	JJ	O
drugs	NNS	O
may	MD	O
cross	VB	O
cell	NN	O
membranes	NNS	O
if	IN	O
the	DT	O
membrane	NN	O
to	TO	O
be	VB	O
crossed	VBN	O
is	VBZ	O
treated	VBN	O
with	IN	O
a	DT	O
penetration	NN	O
enhancer	NN	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
aiding	VBG	O
the	DT	O
diffusion	NN	O
of	IN	O
non-lipophilic	JJ	O
drugs	NNS	O
across	IN	O
cell	NN	O
membranes	NNS	O
,	,	O
penetration	NN	O
enhancers	NNS	O
also	RB	O
enhance	VBP	O
the	DT	O
permeability	NN	O
of	IN	O
lipophilic	JJ	O
drugs	NNS	O
.	.	O
Other	JJ	O
agents	NNS	O
may	MD	O
be	VB	O
utilized	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
penetration	NN	O
of	IN	O
the	DT	O
administered	JJ	O
nucleic	JJ	O
acids	NNS	O
,	,	O
including	VBG	O
glycols	NNS	O
such	JJ	O
as	IN	O
ethylene	NN	O
glycol	NN	O
and	CC	O
propylene	NN	O
glycol	NN	O
,	,	O
pyrrols	NNS	O
such	JJ	O
as	IN	O
2-pyrrol	JJ	O
,	,	O
azones	NNS	O
,	,	O
and	CC	O
terpenes	NNS	O
such	JJ	O
as	IN	O
limonene	NN	O
and	CC	O
menthone	NN	O
.	.	O
The	DT	O
pharmaceutical	JJ	O
formulations	NNS	O
and	CC	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
include	VB	O
surfactants	NNS	O
.	.	O
The	DT	O
use	NN	O
of	IN	O
surfactants	NNS	O
in	IN	O
drug	NN	O
products	NNS	O
,	,	O
formulations	NNS	O
and	CC	O
in	IN	O
emulsions	NNS	O
is	VBZ	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Surfactants	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
One	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
that	IN	O
formulations	NNS	O
are	VBP	O
routinely	RB	O
designed	VBN	O
according	VBG	O
to	TO	O
their	PRP$	O
intended	VBN	O
use	NN	O
,	,	O
i.e.	NN	O
,	,	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O
Preferred	JJ	O
formulations	NNS	O
for	IN	O
topical	JJ	O
administration	NN	O
include	VBP	O
those	DT	O
in	IN	O
which	WDT	O
the	DT	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
in	IN	O
admixture	NN	O
with	IN	O
a	DT	O
topical	JJ	O
delivery	NN	O
agent	NN	O
such	JJ	O
as	IN	O
lipids	NNS	O
,	,	O
liposomes	NNS	O
,	,	O
fatty	JJ	O
acids	NNS	O
,	,	O
fatty	JJ	O
acid	NN	O
esters	NNS	O
,	,	O
steroids	NNS	O
,	,	O
chelating	VBG	O
agents	NNS	O
and	CC	O
surfactants	NNS	O
.	.	O
Preferred	NNP	O
lipids	NNS	O
and	CC	O
liposomes	NNS	O
include	VBP	O
neutral	JJ	O
(	(	O
e.g	NN	O
.	.	O
dioleoylphosphatidyl	NNS	O
DOPE	NNP	O
ethanolamine	NN	O
,	,	O
dimyristoylphosphatidyl	JJ	O
choline	NN	O
DMPC	NNP	O
,	,	O
distearolyphosphatidyl	JJ	O
choline	NN	O
)	)	O
negative	NN	O
(	(	O
e.g	NN	O
.	.	O
dimyristoylphosphatidyl	NN	O
glycerol	NN	O
DMPG	NNP	O
)	)	O
and	CC	O
cationic	JJ	O
(	(	O
e.g	NN	O
.	.	O
dioleoyltetramethylaminopropyl	NN	O
DOTAP	NNP	O
and	CC	O
dioleoylphosphatidyl	JJ	O
ethanolamine	NN	O
DOTMA	NNP	O
)	)	O
.	.	O
For	IN	O
topical	JJ	O
or	CC	O
other	JJ	O
administration	NN	O
,	,	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
encapsulated	VBN	O
within	IN	O
liposomes	NNS	O
or	CC	O
may	MD	O
form	VB	O
complexes	NNS	O
thereto	NN	O
,	,	O
in	IN	O
particular	JJ	O
to	TO	O
cationic	JJ	O
liposomes	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
oligonucleotides	NNS	O
may	MD	O
be	VB	O
complexed	VBN	O
to	TO	O
lipids	NNS	O
,	,	O
in	IN	O
particular	JJ	O
to	TO	O
cationic	JJ	O
lipids	NNS	O
.	.	O
Preferred	NNP	O
fatty	JJ	O
acids	NNS	O
and	CC	O
esters	NNS	O
,	,	O
pharmaceutically	RB	O
acceptable	JJ	O
salts	NNS	O
thereof	NN	O
,	,	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
Topical	JJ	O
formulations	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
detail	NN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,747,014	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Compositions	NNS	O
and	CC	O
formulations	NNS	O
for	IN	O
oral	JJ	O
administration	NN	O
include	VBP	O
powders	NNS	O
or	CC	O
granules	NNS	O
,	,	O
microparticulates	NNS	O
,	,	O
nanoparticulates	NNS	O
,	,	O
suspensions	NNS	O
or	CC	O
solutions	NNS	O
in	IN	O
water	NN	O
or	CC	O
non-aqueous	JJ	O
media	NNS	O
,	,	O
capsules	NNS	O
,	,	O
gel	NN	O
capsules	NNS	O
,	,	O
sachets	NNS	O
,	,	O
tablets	NNS	O
or	CC	O
minitablets	NNS	O
.	.	O
Thickeners	NNS	O
,	,	O
flavoring	VBG	O
agents	NNS	O
,	,	O
diluents	NNS	O
,	,	O
emulsifiers	NNS	O
,	,	O
dispersing	VBG	O
aids	NNS	O
or	CC	O
binders	NNS	O
may	MD	O
be	VB	O
desirable	JJ	O
.	.	O
Preferred	NNP	O
oral	JJ	O
formulations	NNS	O
are	VBP	O
those	DT	O
in	IN	O
which	WDT	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
administered	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
penetration	NN	O
enhancers	NNS	O
surfactants	NNS	O
and	CC	O
chelators	NNS	O
.	.	O
Preferred	JJ	O
surfactants	NNS	O
include	VBP	O
fatty	JJ	O
acids	NNS	O
and/or	VBP	O
esters	NNS	O
or	CC	O
salts	NNS	O
thereof	NNS	O
,	,	O
bile	JJ	O
acids	NNS	O
and/or	VBP	O
salts	NNS	O
thereof	NNS	O
.	.	O
Preferred	NNP	O
bile	NN	O
acids/salts	NNS	O
and	CC	O
fatty	JJ	O
acids	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Also	RB	O
preferred	VBN	O
are	VBP	O
combinations	NNS	O
of	IN	O
penetration	NN	O
enhancers	NNS	O
,	,	O
for	IN	O
example	NN	O
,	,	O
fatty	JJ	O
acids/salts	NNS	O
in	IN	O
combination	NN	O
with	IN	O
bile	JJ	O
acids/salts	NNS	O
.	.	O
A	DT	O
particularly	RB	O
preferred	JJ	O
combination	NN	O
is	VBZ	O
the	DT	O
sodium	NN	O
salt	NN	O
of	IN	O
lauric	JJ	O
acid	NN	O
,	,	O
capric	JJ	O
acid	NN	O
and	CC	O
UDCA	NNP	O
.	.	O
Further	JJ	O
penetration	NN	O
enhancers	NNS	O
include	VBP	O
polyoxyethylene-9-lauryl	JJ	O
ether	NN	O
,	,	O
polyoxyethylene-20-cetyl	JJ	O
ether	NN	O
.	.	O
Oligonucleotides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
be	VB	O
delivered	VBN	O
orally	RB	O
,	,	O
in	IN	O
granular	JJ	O
form	NN	O
including	VBG	O
sprayed	VBN	O
dried	JJ	O
particles	NNS	O
,	,	O
or	CC	O
complexed	VBN	O
to	TO	O
form	VB	O
micro	NN	O
or	CC	O
nanoparticles	NNS	O
.	.	O
Oligonucleotide	IN	O
complexing	VBG	O
agents	NNS	O
and	CC	O
their	PRP$	O
uses	NNS	O
are	VBP	O
further	JJ	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,287,860	CD	O
,	,	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Oral	JJ	O
formulations	NNS	O
for	IN	O
oligonucleotides	NNS	O
and	CC	O
their	PRP$	O
preparation	NN	O
are	VBP	O
described	VBN	O
in	IN	O
detail	NN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,747,014	CD	O
;	:	O
U.S.	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
2003/0027780	CD	O
(	(	O
Feb.	NNP	O
6	CD	O
,	,	O
2003	CD	O
)	)	O
and	CC	O
its	PRP$	O
parent	NN	O
applications	NNS	O
;	:	O
and	CC	O
U.S.	NNP	O
patent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
09/082,624	CD	O
(	(	O
filed	VBN	O
May	NNP	O
21	CD	O
,	,	O
1998	CD	O
)	)	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
Compositions	NNS	O
and	CC	O
formulations	NNS	O
for	IN	O
parenteral	JJ	O
,	,	O
intrathecal	JJ	O
or	CC	O
intraventricular	JJ	O
administration	NN	O
may	MD	O
include	VB	O
sterile	JJ	O
aqueous	JJ	O
solutions	NNS	O
which	WDT	O
may	MD	O
also	RB	O
contain	VB	O
buffers	NNS	O
,	,	O
diluents	NNS	O
and	CC	O
other	JJ	O
suitable	JJ	O
additives	NNS	O
such	JJ	O
as	IN	O
,	,	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
,	,	O
penetration	NN	O
enhancers	NNS	O
,	,	O
carrier	NN	O
compounds	NNS	O
and	CC	O
other	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
carriers	NNS	O
or	CC	O
excipients	NNS	O
.	.	O
Oligonucleotides	NNS	O
may	MD	O
be	VB	O
formulated	VBN	O
for	IN	O
delivery	NN	O
in	IN	O
vivo	NN	O
in	IN	O
an	DT	O
acceptable	JJ	O
dosage	NN	O
form	NN	O
,	,	O
e.g	NN	O
.	.	O
as	IN	O
parenteral	JJ	O
or	CC	O
non-parenteral	JJ	O
formulations	NNS	O
.	.	O
Parenteral	JJ	O
formulations	NNS	O
include	VBP	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
,	,	O
subcutaneous	JJ	O
(	(	O
SC	NNP	O
)	)	O
,	,	O
intraperitoneal	JJ	O
(	(	O
IP	NNP	O
)	)	O
,	,	O
intravitreal	JJ	O
and	CC	O
intramuscular	JJ	O
(	(	O
IM	NNP	O
)	)	O
formulations	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
formulations	NNS	O
for	IN	O
delivery	NN	O
via	IN	O
pulmonary	JJ	O
inhalation	NN	O
,	,	O
intranasal	JJ	O
administration	NN	O
,	,	O
topical	JJ	O
administration	NN	O
,	,	O
etc	FW	O
.	.	O
Non-parenteral	JJ	O
formulations	NNS	O
include	VBP	O
formulations	NNS	O
for	IN	O
delivery	NN	O
via	IN	O
the	DT	O
alimentary	JJ	O
canal	NN	O
,	,	O
e.g	NN	O
.	.	O
oral	JJ	O
administration	NN	O
,	,	O
rectal	JJ	O
administration	NN	O
,	,	O
intrajejunal	JJ	O
instillation	NN	O
,	,	O
etc	FW	O
.	.	O
Rectal	JJ	O
administration	NN	O
includes	VBZ	O
administration	NN	O
as	IN	O
an	DT	O
enema	NN	O
or	CC	O
a	DT	O
suppository	NN	O
.	.	O
Oral	JJ	O
administration	NN	O
includes	VBZ	O
administration	NN	O
as	IN	O
a	DT	O
capsule	NN	O
,	,	O
a	DT	O
gel	NN	O
capsule	NN	O
,	,	O
a	DT	O
pill	NN	O
,	,	O
an	DT	O
elixir	NN	O
,	,	O
etc	FW	O
.	.	O
The	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
also	RB	O
be	VB	O
administered	VBN	O
by	IN	O
pulsatile	JJ	O
delivery	NN	O
.	.	O
“	NNS	O
Pulsatile	NNP	O
delivery	NN	O
”	NN	O
refers	NNS	O
to	TO	O
a	DT	O
pharmaceutical	JJ	O
formulation	NN	O
that	IN	O
delivers	VBZ	O
a	DT	O
first	JJ	O
pulse	NN	O
of	IN	O
drug	NN	O
(	(	O
e.g	NN	O
.	.	O
an	DT	O
antisense	JJ	O
compound	NN	O
)	)	O
combined	VBN	O
with	IN	O
a	DT	O
penetration	NN	O
enhancer	NN	O
and	CC	O
a	DT	O
second	JJ	O
pulse	NN	O
of	IN	O
penetration	NN	O
enhancer	NN	O
to	TO	O
promote	VB	O
absorption	NN	O
of	IN	O
drug	NN	O
which	WDT	O
is	VBZ	O
not	RB	O
absorbed	VBN	O
upon	IN	O
release	NN	O
with	IN	O
the	DT	O
first	JJ	O
pulse	NN	O
of	IN	O
penetration	NN	O
enhancer	NN	O
.	.	O
One	CD	O
embodiment	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
a	DT	O
delayed	JJ	O
release	NN	O
oral	JJ	O
formulation	NN	O
for	IN	O
enhanced	JJ	O
intestinal	JJ	O
drug	NN	O
absorption	NN	O
,	,	O
comprising	NN	O
:	:	O
(	(	O
a	DT	O
)	)	O
a	DT	O
first	JJ	O
population	NN	O
of	IN	O
carrier	NN	O
particles	NNS	O
comprising	VBG	O
said	VBD	O
drug	NN	O
and	CC	O
a	DT	O
penetration	NN	O
enhancer	NN	O
,	,	O
wherein	NN	O
said	VBD	O
drug	NN	O
and	CC	O
said	VBD	O
penetration	NN	O
enhancer	NN	O
are	VBP	O
released	VBN	O
at	IN	O
a	DT	O
first	JJ	O
location	NN	O
in	IN	O
the	DT	O
intestine	NN	O
;	:	O
and	CC	O
(	(	O
b	NN	O
)	)	O
a	DT	O
second	JJ	O
population	NN	O
of	IN	O
carrier	NN	O
particles	NNS	O
comprising	VBG	O
a	DT	O
penetration	NN	O
enhancer	NN	O
and	CC	O
a	DT	O
delayed	JJ	O
release	NN	O
coating	NN	O
or	CC	O
matrix	NN	O
,	,	O
wherein	VBP	O
the	DT	O
penetration	NN	O
enhancer	NN	O
is	VBZ	O
released	VBN	O
at	IN	O
a	DT	O
second	JJ	O
location	NN	O
in	IN	O
the	DT	O
intestine	JJ	O
downstream	NN	O
from	IN	O
the	DT	O
first	JJ	O
location	NN	O
,	,	O
whereby	WRB	O
absorption	NN	O
of	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
enhanced	VBN	O
when	WRB	O
the	DT	O
drug	NN	O
reaches	VBZ	O
the	DT	O
second	JJ	O
location	NN	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
penetration	NN	O
enhancer	NN	O
in	IN	O
(	(	O
a	DT	O
)	)	O
and	CC	O
(	(	O
b	NN	O
)	)	O
is	VBZ	O
different	JJ	O
.	.	O
This	DT	O
enhancement	NN	O
is	VBZ	O
obtained	VBN	O
by	IN	O
encapsulating	VBG	O
at	IN	O
least	JJS	O
two	CD	O
populations	NNS	O
of	IN	O
carrier	NN	O
particles	NNS	O
.	.	O
The	DT	O
first	JJ	O
population	NN	O
of	IN	O
carrier	NN	O
particles	NNS	O
comprises	VBZ	O
a	DT	O
biologically	RB	O
active	JJ	O
substance	NN	O
and	CC	O
a	DT	O
penetration	NN	O
enhancer	NN	O
,	,	O
and	CC	O
the	DT	O
second	JJ	O
(	(	O
and	CC	O
optionally	RB	O
additional	JJ	O
)	)	O
population	NN	O
of	IN	O
carrier	NN	O
particles	NNS	O
comprises	VBZ	O
a	DT	O
penetration	NN	O
enhancer	NN	O
and	CC	O
a	DT	O
delayed	JJ	O
release	NN	O
coating	NN	O
or	CC	O
matrix	NN	O
.	.	O
A	DT	O
“	NN	O
first	RB	O
pass	JJ	O
effect	NN	O
”	NN	O
that	WDT	O
applies	VBZ	O
to	TO	O
orally	RB	O
administered	VBN	O
drugs	NNS	O
is	VBZ	O
degradation	NN	O
due	JJ	O
to	TO	O
the	DT	O
action	NN	O
of	IN	O
gastric	JJ	O
acid	NN	O
and	CC	O
various	JJ	O
digestive	JJ	O
enzymes	NNS	O
.	.	O
One	CD	O
means	VBZ	O
of	IN	O
ameliorating	VBG	O
first	JJ	O
pass	NN	O
clearance	NN	O
effects	NNS	O
is	VBZ	O
to	TO	O
increase	VB	O
the	DT	O
dose	NN	O
of	IN	O
administered	JJ	O
drug	NN	O
,	,	O
thereby	RB	O
compensating	VBG	O
for	IN	O
proportion	NN	O
of	IN	O
drug	NN	O
lost	VBN	O
to	TO	O
first	JJ	O
pass	NN	O
clearance	NN	O
.	.	O
This	DT	O
may	MD	O
be	VB	O
readily	RB	O
achieved	VBN	O
with	IN	O
i.v	NN	O
.	.	O
administration	NN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
simply	RB	O
providing	VBG	O
more	JJR	O
of	IN	O
the	DT	O
drug	NN	O
to	TO	O
an	DT	O
animal	NN	O
.	.	O
However	RB	O
,	,	O
other	JJ	O
factors	NNS	O
influence	VBP	O
the	DT	O
bioavailability	NN	O
of	IN	O
drugs	NNS	O
administered	VBN	O
via	IN	O
non-parenteral	JJ	O
means	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
drug	NN	O
may	MD	O
be	VB	O
enzymatically	RB	O
or	CC	O
chemically	RB	O
degraded	VBN	O
in	IN	O
the	DT	O
alimentary	JJ	O
canal	NN	O
or	CC	O
blood	NN	O
stream	NN	O
and/or	NN	O
may	MD	O
be	VB	O
impermeable	JJ	O
or	CC	O
semipermeable	JJ	O
to	TO	O
various	JJ	O
mucosal	JJ	O
membranes	NNS	O
.	.	O
These	DT	O
pharmaceutical	JJ	O
compositions	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
enhancing	VBG	O
absorption	NN	O
of	IN	O
biologically	RB	O
active	JJ	O
substances	NNS	O
when	WRB	O
administered	VBN	O
via	IN	O
the	DT	O
rectal	NN	O
,	,	O
vaginal	JJ	O
,	,	O
nasal	JJ	O
or	CC	O
pulmonary	JJ	O
routes	NNS	O
.	.	O
Release	NN	O
of	IN	O
the	DT	O
biologically	RB	O
active	JJ	O
substance	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
in	IN	O
any	DT	O
part	NN	O
of	IN	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
.	.	O
Liquid	NNP	O
pharmaceutical	JJ	O
compositions	NNS	O
of	IN	O
oligonucleotide	NN	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
combining	VBG	O
the	DT	O
oligonucleotide	NN	O
with	IN	O
a	DT	O
suitable	JJ	O
vehicle	NN	O
,	,	O
for	IN	O
example	NN	O
sterile	JJ	O
pyrogen	NN	O
free	JJ	O
water	NN	O
,	,	O
or	CC	O
saline	JJ	O
solution	NN	O
.	.	O
Other	JJ	O
therapeutic	JJ	O
compounds	NNS	O
may	MD	O
optionally	RB	O
be	VB	O
included	VBN	O
.	.	O
The	DT	O
present	JJ	O
invention	NN	O
also	RB	O
contemplates	VBZ	O
the	DT	O
use	NN	O
of	IN	O
solid	JJ	O
particulate	NN	O
compositions	NNS	O
.	.	O
Such	JJ	O
compositions	NNS	O
preferably	RB	O
comprise	VBP	O
particles	NNS	O
of	IN	O
oligonucleotide	NN	O
that	WDT	O
are	VBP	O
of	IN	O
respirable	JJ	O
size	NN	O
.	.	O
Such	JJ	O
particles	NNS	O
can	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
grinding	VBG	O
dry	JJ	O
oligonucleotide	NN	O
by	IN	O
conventional	JJ	O
means	NNS	O
,	,	O
fore	RB	O
example	NN	O
with	IN	O
a	DT	O
mortar	NN	O
and	CC	O
pestle	NN	O
,	,	O
and	CC	O
then	RB	O
passing	VBG	O
the	DT	O
resulting	VBG	O
powder	NN	O
composition	NN	O
through	IN	O
a	DT	O
400	CD	O
mesh	NN	O
screen	NN	O
to	TO	O
segregate	VB	O
large	JJ	O
particles	NNS	O
and	CC	O
agglomerates	NNS	O
.	.	O
A	DT	O
solid	JJ	O
particulate	NN	O
composition	NN	O
comprised	VBD	O
of	IN	O
an	DT	O
active	JJ	O
oligonucleotide	NN	O
can	MD	O
optionally	RB	O
contain	VB	O
a	DT	O
dispersant	NN	O
which	WDT	O
serves	VBZ	O
to	TO	O
facilitate	VB	O
the	DT	O
formation	NN	O
of	IN	O
an	DT	O
aerosol	NN	O
,	,	O
for	IN	O
example	NN	O
lactose	NN	O
.	.	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
oligonucleotide	IN	O
compositions	NNS	O
can	MD	O
be	VB	O
aerosolized	VBN	O
.	.	O
Aerosolization	NN	O
of	IN	O
liquid	JJ	O
particles	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
by	IN	O
any	DT	O
suitable	JJ	O
means	NNS	O
,	,	O
such	JJ	O
as	IN	O
with	IN	O
a	DT	O
nebulizer	NN	O
.	.	O
See	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,501,729	CD	O
.	.	O
Nebulizers	NNS	O
are	VBP	O
commercially	RB	O
available	JJ	O
devices	NNS	O
which	WDT	O
transform	VBP	O
solutions	NNS	O
or	CC	O
suspensions	NNS	O
into	IN	O
a	DT	O
therapeutic	JJ	O
aerosol	NN	O
mist	NN	O
either	CC	O
by	IN	O
means	NNS	O
of	IN	O
acceleration	NN	O
of	IN	O
a	DT	O
compressed	JJ	O
gas	NN	O
,	,	O
typically	RB	O
air	NN	O
or	CC	O
oxygen	NN	O
,	,	O
through	IN	O
a	DT	O
narrow	JJ	O
venturi	NN	O
orifice	NN	O
or	CC	O
by	IN	O
means	NNS	O
of	IN	O
ultrasonic	JJ	O
agitation	NN	O
.	.	O
Suitable	JJ	O
nebulizers	NNS	O
include	VBP	O
those	DT	O
sold	VBN	O
by	IN	O
Blairex®	NNP	O
under	IN	O
the	DT	O
name	NN	O
PARI	NNP	O
LC	NNP	O
PLUS	NNP	O
,	,	O
PARI	NNP	O
DURA-NEB	NNP	O
2000	CD	O
,	,	O
PARI-BABY	NNP	O
Size	NNP	O
,	,	O
PARI	NNP	O
PRONEB	NNP	O
Compressor	NNP	O
with	IN	O
LC	NNP	O
PLUS	NNP	O
,	,	O
PARI	NNP	O
WALKHALER	NNP	O
Compressor/Nebulizer	NNP	O
System	NNP	O
,	,	O
PARI	NNP	O
LC	NNP	O
PLUS	NNP	O
Reusable	NNP	O
Nebulizer	NNP	O
,	,	O
and	CC	O
PARI	NNP	O
LC	NNP	O
Jet+	NNP	O
®Nebulizer	NNP	O
.	.	O
Formulations	NNS	O
for	IN	O
use	NN	O
in	IN	O
nebulizers	NNS	O
may	MD	O
consist	VB	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
in	IN	O
a	DT	O
liquid	NN	O
,	,	O
such	JJ	O
as	IN	O
sterile	JJ	O
,	,	O
pyragen	JJ	O
free	JJ	O
water	NN	O
,	,	O
or	CC	O
saline	JJ	O
solution	NN	O
,	,	O
wherein	VBP	O
the	DT	O
oligonucleotide	NN	O
comprises	VBZ	O
up	RP	O
to	TO	O
about	IN	O
40	CD	O
%	NN	O
w/w	NN	O
of	IN	O
the	DT	O
formulation	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
oligonucleotide	JJ	O
comprises	VBZ	O
less	JJR	O
than	IN	O
20	CD	O
%	NN	O
w/w	NN	O
.	.	O
If	IN	O
desired	VBN	O
,	,	O
further	JJ	O
additives	NNS	O
such	JJ	O
as	IN	O
preservatives	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
methyl	VB	O
hydroxybenzoate	NN	O
)	)	O
antioxidants	NNS	O
,	,	O
and	CC	O
flavoring	VBG	O
agents	NNS	O
can	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
composition	NN	O
.	.	O
Solid	JJ	O
particles	NNS	O
comprising	VBG	O
an	DT	O
oligonucleotide	NN	O
can	MD	O
also	RB	O
be	VB	O
aerosolized	VBN	O
using	VBG	O
any	DT	O
solid	JJ	O
particulate	NN	O
medicament	NN	O
aerosol	JJ	O
generator	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Such	JJ	O
aerosol	JJ	O
generators	NNS	O
produce	VBP	O
respirable	JJ	O
particles	NNS	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
and	CC	O
further	RB	O
produce	VB	O
reproducible	JJ	O
metered	VBN	O
dose	JJ	O
per	IN	O
unit	NN	O
volume	NN	O
of	IN	O
aerosol	NN	O
.	.	O
Suitable	JJ	O
solid	JJ	O
particulate	NN	O
aerosol	JJ	O
generators	NNS	O
include	VBP	O
insufflators	NNS	O
and	CC	O
metered	VBD	O
dose	JJ	O
inhalers	NNS	O
.	.	O
Metered	NNP	O
dose	NN	O
inhalers	NNS	O
are	VBP	O
used	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
are	VBP	O
useful	JJ	O
in	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
Preferably	RB	O
,	,	O
liquid	NN	O
or	CC	O
solid	JJ	O
aerosols	NNS	O
are	VBP	O
produced	VBN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
from	IN	O
about	IN	O
10	CD	O
to	TO	O
150	CD	O
liters	NNS	O
per	IN	O
minute	NN	O
,	,	O
more	JJR	O
preferably	RB	O
from	IN	O
about	RB	O
30	CD	O
to	TO	O
150	CD	O
liters	NNS	O
per	IN	O
minute	NN	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
about	IN	O
60	CD	O
liters	NNS	O
per	IN	O
minute	NN	O
.	.	O
Enhanced	NNP	O
bioavailability	NN	O
of	IN	O
biologically	RB	O
active	JJ	O
substances	NNS	O
is	VBZ	O
also	RB	O
achieved	VBN	O
via	IN	O
the	DT	O
oral	JJ	O
administration	NN	O
of	IN	O
the	DT	O
compositions	NNS	O
and	CC	O
methods	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
may	MD	O
additionally	RB	O
contain	VB	O
other	JJ	O
adjunct	JJ	O
components	NNS	O
conventionally	RB	O
found	VBN	O
in	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
,	,	O
at	IN	O
their	PRP$	O
art-established	JJ	O
usage	NN	O
levels	NNS	O
.	.	O
Thus	RB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
the	DT	O
compositions	NNS	O
may	MD	O
contain	VB	O
additional	JJ	O
,	,	O
compatible	JJ	O
,	,	O
pharmaceutically-active	JJ	O
materials	NNS	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
antipruritics	NNS	O
,	,	O
astringents	NNS	O
,	,	O
local	JJ	O
anesthetics	NNS	O
or	CC	O
anti-inflammatory	JJ	O
agents	NNS	O
,	,	O
or	CC	O
may	MD	O
contain	VB	O
additional	JJ	O
materials	NNS	O
useful	JJ	O
in	IN	O
physically	RB	O
formulating	VBG	O
various	JJ	O
dosage	NN	O
forms	NNS	O
of	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
such	JJ	O
as	IN	O
dyes	NNS	O
,	,	O
flavoring	VBG	O
agents	NNS	O
,	,	O
preservatives	NNS	O
,	,	O
antioxidants	NNS	O
,	,	O
opacifiers	NNS	O
,	,	O
thickening	VBG	O
agents	NNS	O
and	CC	O
stabilizers	NNS	O
.	.	O
However	RB	O
,	,	O
such	JJ	O
materials	NNS	O
,	,	O
when	WRB	O
added	VBD	O
,	,	O
should	MD	O
not	RB	O
unduly	VB	O
interfere	RB	O
with	IN	O
the	DT	O
biological	JJ	O
activities	NNS	O
of	IN	O
the	DT	O
components	NNS	O
of	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
The	DT	O
formulations	NNS	O
can	MD	O
be	VB	O
sterilized	VBN	O
and	CC	O
,	,	O
if	IN	O
desired	VBN	O
,	,	O
mixed	JJ	O
with	IN	O
auxiliary	JJ	O
agents	NNS	O
,	,	O
e.g.	NN	O
,	,	O
lubricants	NNS	O
,	,	O
preservatives	NNS	O
,	,	O
stabilizers	NNS	O
,	,	O
wetting	VBG	O
agents	NNS	O
,	,	O
emulsifiers	NNS	O
,	,	O
salts	NNS	O
for	IN	O
influencing	VBG	O
osmotic	JJ	O
pressure	NN	O
,	,	O
buffers	NNS	O
,	,	O
colorings	NNS	O
,	,	O
flavorings	NNS	O
and/or	VBP	O
aromatic	JJ	O
substances	NNS	O
and	CC	O
the	DT	O
like	JJ	O
which	WDT	O
do	VBP	O
not	RB	O
deleteriously	RB	O
interact	JJ	O
with	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
the	DT	O
formulation	NN	O
.	.	O
Aqueous	JJ	O
suspensions	NNS	O
may	MD	O
contain	VB	O
substances	NNS	O
which	WDT	O
increase	VBP	O
the	DT	O
viscosity	NN	O
of	IN	O
the	DT	O
suspension	NN	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
sodium	NN	O
carboxymethylcellulose	NN	O
,	,	O
sorbitol	JJ	O
and/or	NN	O
dextran	NN	O
.	.	O
The	DT	O
suspension	NN	O
may	MD	O
also	RB	O
contain	VB	O
stabilizers	NNS	O
.	.	O
Certain	NNP	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
provide	RB	O
pharmaceutical	JJ	O
compositions	NNS	O
containing	VBG	O
one	CD	O
or	CC	O
more	JJR	O
oligomeric	JJ	O
compounds	NNS	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
chemotherapeutic	JJ	O
agents	NNS	O
which	WDT	O
function	NN	O
by	IN	O
a	DT	O
non-antisense	JJ	O
mechanism	NN	O
.	.	O
Examples	NNS	O
of	IN	O
such	JJ	O
chemotherapeutic	JJ	O
agents	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
cancer	NN	O
chemotherapeutic	JJ	O
drugs	NNS	O
such	JJ	O
as	IN	O
daunorubicin	NN	O
,	,	O
daunomycin	NN	O
,	,	O
dactinomycin	NN	O
,	,	O
doxorubicin	NN	O
,	,	O
epirubicin	NN	O
,	,	O
idarubicin	NN	O
,	,	O
esorubicin	NN	O
,	,	O
bleomycin	NN	O
,	,	O
mafosfamide	NN	O
,	,	O
ifosfamide	NN	O
,	,	O
cytosine	NN	O
arabinoside	NN	O
,	,	O
bis-chloroethylnitrosurea	JJ	O
,	,	O
busulfan	NN	O
,	,	O
mitomycin	FW	O
C	NNP	O
,	,	O
actinomycin	JJ	O
D	NNP	O
,	,	O
mithramycin	NN	O
,	,	O
prednisone	NN	O
,	,	O
hydroxyprogesterone	NN	O
,	,	O
testosterone	NN	O
,	,	O
tamoxifen	NN	O
,	,	O
dacarbazine	NN	O
,	,	O
procarbazine	NN	O
,	,	O
hexamethylmelamine	NN	O
,	,	O
pentamethylmelamine	NN	O
,	,	O
mitoxantrone	NN	O
,	,	O
amsacrine	NN	O
,	,	O
chlorambucil	NN	O
,	,	O
methylcyclohexylnitrosurea	NN	O
,	,	O
nitrogen	NN	O
mustards	NNS	O
,	,	O
melphalan	NN	O
,	,	O
cyclophosphamide	NN	O
,	,	O
6-mercaptopurine	JJ	O
,	,	O
6-thioguanine	JJ	O
,	,	O
cytarabine	JJ	O
,	,	O
5-azacytidine	JJ	O
,	,	O
hydroxyurea	JJ	O
,	,	O
deoxycoformycin	JJ	O
,	,	O
4-hydroxyperoxycyclophosphoramide	JJ	O
,	,	O
5-fluorouracil	JJ	O
(	(	O
5-FU	JJ	O
)	)	O
,	,	O
5-fluorodeoxyuridine	JJ	O
(	(	O
5-FUdR	JJ	O
)	)	O
,	,	O
methotrexate	NN	O
(	(	O
MTX	NNP	O
)	)	O
,	,	O
colchicine	NN	O
,	,	O
taxol	NN	O
,	,	O
vincristine	NN	O
,	,	O
vinblastine	NN	O
,	,	O
etoposide	RB	O
(	(	O
VP-16	NNP	O
)	)	O
,	,	O
trimetrexate	NN	O
,	,	O
irinotecan	JJ	O
,	,	O
topotecan	JJ	O
,	,	O
gemcitabine	NN	O
,	,	O
teniposide	NN	O
,	,	O
cisplatin	NN	O
and	CC	O
diethylstilbestrol	NN	O
(	(	O
DES	NNP	O
)	)	O
.	.	O
When	WRB	O
used	VBN	O
with	IN	O
the	DT	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
such	JJ	O
chemotherapeutic	JJ	O
agents	NNS	O
may	MD	O
be	VB	O
used	VBN	O
individually	RB	O
(	(	O
e.g.	UH	O
,	,	O
5-FU	JJ	O
and	CC	O
oligonucleotide	NN	O
)	)	O
,	,	O
sequentially	RB	O
(	(	O
e.g.	UH	O
,	,	O
5-FU	JJ	O
and	CC	O
oligonucleotide	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
followed	VBN	O
by	IN	O
MTX	NNP	O
and	CC	O
oligonucleotide	RB	O
)	)	O
,	,	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
such	JJ	O
chemotherapeutic	JJ	O
agents	NNS	O
(	(	O
e.g.	NN	O
,	,	O
5-FU	JJ	O
,	,	O
MTX	NNP	O
and	CC	O
oligonucleotide	RB	O
,	,	O
or	CC	O
5-FU	JJ	O
,	,	O
radiotherapy	NN	O
and	CC	O
oligonucleotide	NN	O
)	)	O
.	.	O
Anti-inflammatory	JJ	O
drugs	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
nonsteroidal	VB	O
anti-inflammatory	JJ	O
drugs	NNS	O
and	CC	O
corticosteroids	NNS	O
,	,	O
and	CC	O
antiviral	JJ	O
drugs	NNS	O
,	,	O
including	VBG	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
ribivirin	VB	O
,	,	O
vidarabine	NN	O
,	,	O
acyclovir	NN	O
and	CC	O
ganciclovir	NN	O
,	,	O
may	MD	O
also	RB	O
be	VB	O
combined	VBN	O
in	IN	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Combinations	NNS	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
and	CC	O
other	JJ	O
non-antisense	JJ	O
drugs	NNS	O
are	VBP	O
also	RB	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
this	DT	O
invention	NN	O
.	.	O
Two	CD	O
or	CC	O
more	JJR	O
combined	JJ	O
compounds	NNS	O
may	MD	O
be	VB	O
used	VBN	O
together	RB	O
or	CC	O
sequentially	RB	O
.	.	O
In	IN	O
another	DT	O
related	JJ	O
embodiment	NN	O
,	,	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
contain	VB	O
one	CD	O
or	CC	O
more	JJR	O
antisense	JJ	O
compounds	NNS	O
,	,	O
particularly	RB	O
oligonucleotides	NNS	O
,	,	O
targeted	VBN	O
to	TO	O
a	DT	O
first	JJ	O
nucleic	JJ	O
acid	NN	O
and	CC	O
one	CD	O
or	CC	O
more	JJR	O
additional	JJ	O
antisense	NN	O
compounds	NNS	O
targeted	VBN	O
to	TO	O
a	DT	O
second	JJ	O
nucleic	JJ	O
acid	NN	O
target	NN	O
.	.	O
Alternatively	RB	O
,	,	O
compositions	NNS	O
of	IN	O
the	DT	O
invention	NN	O
may	MD	O
contain	VB	O
two	CD	O
or	CC	O
more	JJR	O
antisense	JJ	O
compounds	NNS	O
targeted	VBN	O
to	TO	O
different	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
same	JJ	O
nucleic	JJ	O
acid	NN	O
target	NN	O
.	.	O
Numerous	JJ	O
examples	NNS	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
are	VBP	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Two	CD	O
or	CC	O
more	JJR	O
combined	JJ	O
compounds	NNS	O
may	MD	O
be	VB	O
used	VBN	O
together	RB	O
or	CC	O
sequentially	RB	O
.	.	O
H.	NNP	O
Dosing	VBG	O
The	DT	O
formulation	NN	O
of	IN	O
therapeutic	JJ	O
compositions	NNS	O
and	CC	O
their	PRP$	O
subsequent	JJ	O
administration	NN	O
(	(	O
dosing	VBG	O
)	)	O
is	VBZ	O
believed	VBN	O
to	TO	O
be	VB	O
within	IN	O
the	DT	O
skill	NN	O
of	IN	O
those	DT	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Dosing	VBG	O
is	VBZ	O
dependent	JJ	O
on	IN	O
severity	NN	O
and	CC	O
responsiveness	NN	O
of	IN	O
the	DT	O
disease	NN	O
state	NN	O
to	TO	O
be	VB	O
treated	VBN	O
,	,	O
with	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
lasting	VBG	O
from	IN	O
several	JJ	O
days	NNS	O
to	TO	O
several	JJ	O
months	NNS	O
,	,	O
or	CC	O
until	IN	O
a	DT	O
cure	NN	O
is	VBZ	O
effected	VBN	O
or	CC	O
a	DT	O
diminution	NN	O
of	IN	O
the	DT	O
disease	NN	O
state	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O
Optimal	JJ	O
dosing	VBG	O
schedules	NNS	O
can	MD	O
be	VB	O
calculated	VBN	O
from	IN	O
measurements	NNS	O
of	IN	O
drug	NN	O
accumulation	NN	O
in	IN	O
the	DT	O
body	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O
Persons	NNS	O
of	IN	O
ordinary	JJ	O
skill	NN	O
can	MD	O
easily	RB	O
determine	VB	O
optimum	JJ	O
dosages	NNS	O
,	,	O
dosing	VBG	O
methodologies	NNS	O
and	CC	O
repetition	NN	O
rates	NNS	O
.	.	O
Optimum	NNP	O
dosages	NNS	O
may	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
the	DT	O
relative	JJ	O
potency	NN	O
of	IN	O
individual	JJ	O
oligonucleotides	NNS	O
,	,	O
and	CC	O
can	MD	O
generally	RB	O
be	VB	O
estimated	VBN	O
based	VBN	O
on	IN	O
EC50s	NNP	O
found	VBD	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
vivo	NN	O
animal	NN	O
models	NNS	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
dosage	NN	O
is	VBZ	O
from	IN	O
0.01	CD	O
μg	NNS	O
to	TO	O
100	CD	O
g	NNS	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
from	IN	O
0.1	CD	O
μg	NNS	O
to	TO	O
10	CD	O
g	NNS	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
from	IN	O
1.0	CD	O
μg	NNS	O
to	TO	O
1	CD	O
g	NNS	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
from	IN	O
10.0	CD	O
μg	NNS	O
to	TO	O
100	CD	O
mg	NNS	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
from	IN	O
100	CD	O
μg	NNS	O
to	TO	O
10	CD	O
mg	NNS	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
or	CC	O
from	IN	O
1	CD	O
mg	NNS	O
to	TO	O
5	CD	O
mg	NNS	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
given	VBN	O
once	RB	O
or	CC	O
more	JJR	O
daily	JJ	O
,	,	O
weekly	JJ	O
,	,	O
monthly	JJ	O
or	CC	O
yearly	JJ	O
,	,	O
or	CC	O
even	RB	O
once	RB	O
every	DT	O
2	CD	O
to	TO	O
20	CD	O
years	NNS	O
.	.	O
Persons	NNS	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
can	MD	O
easily	RB	O
estimate	VB	O
repetition	NN	O
rates	NNS	O
for	IN	O
dosing	VBG	O
based	VBN	O
on	IN	O
measured	JJ	O
residence	NN	O
times	NNS	O
and	CC	O
concentrations	NNS	O
of	IN	O
the	DT	O
drug	NN	O
in	IN	O
bodily	JJ	O
fluids	NNS	O
or	CC	O
tissues	NNS	O
.	.	O
Following	VBG	O
successful	JJ	O
treatment	NN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
desirable	JJ	O
to	TO	O
have	VB	O
the	DT	O
patient	NN	O
undergo	JJ	O
maintenance	NN	O
therapy	NN	O
to	TO	O
prevent	VB	O
the	DT	O
recurrence	NN	O
of	IN	O
the	DT	O
disease	NN	O
state	NN	O
,	,	O
wherein	VBD	O
the	DT	O
oligonucleotide	NN	O
is	VBZ	O
administered	VBN	O
in	IN	O
maintenance	NN	O
doses	NNS	O
,	,	O
ranging	VBG	O
from	IN	O
0.01	CD	O
ug	NNS	O
to	TO	O
100	CD	O
g	NNS	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
once	RB	O
or	CC	O
more	JJR	O
daily	JJ	O
,	,	O
to	TO	O
once	RB	O
every	DT	O
20	CD	O
years	NNS	O
.	.	O
The	DT	O
effects	NNS	O
of	IN	O
treatments	NNS	O
with	IN	O
therapeutic	JJ	O
compositions	NNS	O
can	MD	O
be	VB	O
assessed	VBN	O
following	VBG	O
collection	NN	O
of	IN	O
tissues	NNS	O
or	CC	O
fluids	NNS	O
from	IN	O
a	DT	O
patient	NN	O
or	CC	O
subject	JJ	O
receiving	NN	O
said	VBD	O
treatments	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
that	IN	O
a	DT	O
biopsy	JJ	O
sample	NN	O
can	MD	O
be	VB	O
procured	VBN	O
from	IN	O
certain	JJ	O
tissues	NNS	O
without	IN	O
resulting	VBG	O
in	IN	O
detrimental	JJ	O
effects	NNS	O
to	TO	O
a	DT	O
patient	NN	O
or	CC	O
subject	NN	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
,	,	O
a	DT	O
tissue	NN	O
and	CC	O
its	PRP$	O
constituent	NN	O
cells	NNS	O
comprise	NN	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
blood	NN	O
(	(	O
e.g.	JJ	O
,	,	O
hematopoietic	JJ	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
human	JJ	O
hematopoietic	JJ	O
progenitor	NN	O
cells	NNS	O
,	,	O
human	JJ	O
hematopoietic	JJ	O
stem	NN	O
cells	NNS	O
,	,	O
CD34+	NNP	O
cells	NNS	O
CD4+	NNP	O
cells	NNS	O
)	)	O
,	,	O
lymphocytes	NNS	O
and	CC	O
other	JJ	O
blood	NN	O
lineage	NN	O
cells	NNS	O
,	,	O
bone	NN	O
marrow	NN	O
,	,	O
breast	NN	O
,	,	O
cervix	NN	O
,	,	O
colon	NN	O
,	,	O
esophagus	NN	O
,	,	O
lymph	JJ	O
node	NN	O
,	,	O
muscle	NN	O
,	,	O
peripheral	JJ	O
blood	NN	O
,	,	O
oral	JJ	O
mucosa	NN	O
and	CC	O
skin	NN	O
.	.	O
In	IN	O
other	JJ	O
embodiments	NNS	O
,	,	O
a	DT	O
fluid	NN	O
and	CC	O
its	PRP$	O
constituent	NN	O
cells	NNS	O
comprise	NN	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
blood	NN	O
,	,	O
urine	NN	O
,	,	O
semen	NNS	O
,	,	O
synovial	JJ	O
fluid	NN	O
,	,	O
lymphatic	JJ	O
fluid	NN	O
and	CC	O
cerebro-spinal	JJ	O
fluid	NN	O
.	.	O
Tissues	NNS	O
or	CC	O
fluids	NNS	O
procured	VBN	O
from	IN	O
patients	NNS	O
can	MD	O
be	VB	O
evaluated	VBN	O
for	IN	O
expression	NN	O
levels	NNS	O
of	IN	O
the	DT	O
target	NN	O
mRNA	NN	O
or	CC	O
protein	NN	O
.	.	O
Additionally	RB	O
,	,	O
the	DT	O
mRNA	NN	O
or	CC	O
protein	JJ	O
expression	NN	O
levels	NNS	O
of	IN	O
other	JJ	O
genes	NNS	O
known	VBN	O
or	CC	O
suspected	VBN	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
the	DT	O
specific	JJ	O
disease	NN	O
state	NN	O
,	,	O
condition	NN	O
or	CC	O
phenotype	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
.	.	O
mRNA	NN	O
levels	NNS	O
can	MD	O
be	VB	O
measured	VBN	O
or	CC	O
evaluated	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
,	,	O
Northern	NNP	O
blot	NN	O
,	,	O
in	IN	O
situ	JJ	O
hybridization	NN	O
or	CC	O
DNA	NNP	O
array	JJ	O
analysis	NN	O
.	.	O
Protein	NNP	O
levels	NNS	O
can	MD	O
be	VB	O
measured	VBN	O
or	CC	O
evaluated	VBN	O
by	IN	O
ELISA	NNP	O
,	,	O
immunoblotting	NN	O
,	,	O
quantitative	JJ	O
protein	NN	O
assays	NNS	O
,	,	O
protein	NN	O
activity	NN	O
assays	NNS	O
(	(	O
for	IN	O
example	NN	O
,	,	O
caspase	NN	O
activity	NN	O
assays	NNS	O
)	)	O
immunohistochemistry	NN	O
or	CC	O
immunocytochemistry	NN	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
treatment	NN	O
can	MD	O
be	VB	O
assessed	VBN	O
by	IN	O
measuring	VBG	O
biomarkers	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
disease	NN	O
or	CC	O
condition	NN	O
in	IN	O
the	DT	O
aforementioned	JJ	O
tissues	NNS	O
and	CC	O
fluids	NNS	O
,	,	O
collected	VBN	O
from	IN	O
a	DT	O
patient	NN	O
or	CC	O
subject	JJ	O
receiving	NN	O
treatment	NN	O
,	,	O
by	IN	O
routine	JJ	O
clinical	JJ	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
These	DT	O
biomarkers	NNS	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
:	:	O
glucose	NN	O
,	,	O
cholesterol	NN	O
,	,	O
lipoproteins	VBZ	O
,	,	O
triglycerides	NNS	O
,	,	O
free	JJ	O
fatty	JJ	O
acids	NNS	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
glucose	NN	O
and	CC	O
lipid	JJ	O
metabolism	NN	O
;	:	O
lipoprotein	CC	O
(	(	O
a	DT	O
)	)	O
or	CC	O
Lp	NNP	O
(	(	O
a	DT	O
)	)	O
or	CC	O
apolipoprotein	JJ	O
B	NNP	O
;	:	O
liver	NN	O
transaminases	NNS	O
,	,	O
bilirubin	NN	O
,	,	O
albumin	NN	O
,	,	O
blood	NN	O
urea	JJ	O
nitrogen	NN	O
,	,	O
creatine	NN	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
kidney	NN	O
and	CC	O
liver	NN	O
function	NN	O
;	:	O
interleukins	NNS	O
,	,	O
tumor	NN	O
necrosis	NN	O
factors	NNS	O
,	,	O
intracellular	JJ	O
adhesion	NN	O
molecules	NNS	O
,	,	O
C-reactive	JJ	O
protein	NN	O
and	CC	O
other	JJ	O
markers	NNS	O
of	IN	O
inflammation	NN	O
;	:	O
testosterone	NN	O
,	,	O
estrogen	NN	O
and	CC	O
other	JJ	O
hormones	NNS	O
;	:	O
tumor	NN	O
markers	NNS	O
;	:	O
vitamins	NNS	O
,	,	O
minerals	NNS	O
and	CC	O
electrolytes	NNS	O
.	.	O
While	IN	O
the	DT	O
present	JJ	O
invention	NN	O
has	VBZ	O
been	VBN	O
described	VBN	O
with	IN	O
specificity	NN	O
in	IN	O
accordance	NN	O
with	IN	O
certain	JJ	O
of	IN	O
its	PRP$	O
preferred	JJ	O
embodiments	NNS	O
,	,	O
the	DT	O
following	JJ	O
examples	NNS	O
serve	VBP	O
only	RB	O
to	TO	O
illustrate	VB	O
the	DT	O
invention	NN	O
and	CC	O
are	VBP	O
not	RB	O
intended	VBN	O
to	TO	O
limit	VB	O
the	DT	O
same	JJ	O
.	.	O
Each	DT	O
of	IN	O
the	DT	O
references	NNS	O
,	,	O
GENBANK®	NNP	O
accession	NN	O
numbers	NNS	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
recited	VBN	O
in	IN	O
the	DT	O
present	JJ	O
application	NN	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O
EXAMPLES	NNP	O
Example	NNP	O
1	CD	O
Synthesis	NNP	O
of	IN	O
Nucleoside	NNP	O
Phosphoramidites	NNP	O
The	DT	O
following	JJ	O
compounds	NNS	O
,	,	O
including	VBG	O
amidites	NNS	O
and	CC	O
their	PRP$	O
intermediates	NNS	O
were	VBD	O
prepared	VBN	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,426,220	CD	O
and	CC	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
WO	NNP	O
02/36743	CD	O
;	:	O
5′-O-Dimethoxytrityl-thymidine	JJ	O
intermediate	NN	O
for	IN	O
5-methyl	JJ	O
dC	NN	O
amidite	NN	O
,	,	O
5′-O-Dimethoxytrityl-2′-deoxy-5-methylcytidine	JJ	O
intermediate	NN	O
for	IN	O
5-methyl-dC	JJ	O
amidite	NN	O
,	,	O
5′-O-Dimethoxytrityl-2′-deoxy-N4-benzoyl-5-methylcytidine	JJ	O
penultimate	NN	O
intermediate	NN	O
for	IN	O
5-methyl	JJ	O
dC	NN	O
amidite	NN	O
,	,	O
[	JJ	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-deoxy-N4-benzoyl-5-methylcytidin-3′-O-yl	FW	O
]	FW	O
-2-cyanoethyl-N	FW	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
5-methyl	JJ	O
dC	NN	O
amidite	NN	O
)	)	O
,	,	O
2′-Fluorodeoxyadenosine	JJ	O
,	,	O
2′-Fluorodeoxyguanosine	JJ	O
,	,	O
2′-Fluorouridine	JJ	O
,	,	O
2′-Fluorodeoxycytidine	JJ	O
,	,	O
2′-O-	JJ	O
(	(	O
2-Methoxyethyl	JJ	O
)	)	O
modified	VBN	O
amidites	NNS	O
,	,	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-5-methyluridine	NN	O
intermediate	JJ	O
,	,	O
5′-O-DMT-2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-5-methyluridine	NN	O
penultimate	NN	O
intermediate	NN	O
,	,	O
[	JJ	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-O-	NN	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-5-methyluridin-3′-O-yl	FW	O
]	FW	O
-2-cyanoethyl-N	FW	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
MOE	NNP	O
T	NNP	O
amidite	NN	O
)	)	O
,	,	O
5′-O-Dimethoxytrityl-2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-5-methylcytidine	NN	O
intermediate	JJ	O
,	,	O
5′-O-dimethoxytrityl-2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-N4-benzoyl-5-methyl-cytidine	NN	O
penultimate	NN	O
intermediate	NN	O
,	,	O
[	JJ	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-O-	NN	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-N4-benzoyl-5-methylcytidin-3′-O-yl	FW	O
]	FW	O
-2-cyanoethyl-N	FW	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
MOE	NNP	O
5-Me-C	NNP	O
amidite	NN	O
)	)	O
,	,	O
[	JJ	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-O-	NN	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-N6-benzoyladenosin-3′-O-yl	FW	O
]	FW	O
-2-cyanoethyl-N	FW	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
MOE	NNP	O
A	NNP	O
amidite	NN	O
)	)	O
,	,	O
[	JJ	O
5′-O-	JJ	O
(	(	O
4,4′-Dimethoxytriphenylmethyl	JJ	O
)	)	O
-2′-O-	NN	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
-N4-isobutyrylguanosin-3′-O-yl	FW	O
]	FW	O
-2-cyanoethyl-N	FW	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
(	(	O
MOE	NNP	O
G	NNP	O
amidite	NN	O
)	)	O
,	,	O
2′-O-	JJ	O
(	(	O
Aminooxyethyl	NNP	O
)	)	O
nucleoside	NN	O
amidites	NNS	O
and	CC	O
2′-O-	JJ	O
(	(	O
dimethylaminooxyethyl	NN	O
)	)	O
nucleoside	NN	O
amidites	NNS	O
,	,	O
2′-	JJ	O
(	(	O
Dimethylaminooxyethoxy	NNP	O
)	)	O
nucleoside	RB	O
amidites	VBZ	O
,	,	O
5′-O-tert-Butyldiphenylsilyl-O2-2′-anhydro-5-methyluridine	JJ	O
,	,	O
5′-O-tert-Butyldiphenylsilyl-2′-O-	JJ	O
(	(	O
2-hydroxyethyl	JJ	O
)	)	O
-5-methyluridine	NN	O
,	,	O
2′-O-	JJ	O
(	(	O
[	JJ	O
2-phthalimidoxy	JJ	O
)	)	O
ethyl	FW	O
]	FW	O
-5′-t-butyldiphenylsilyl-5-methyluridine	NN	O
,	,	O
5′-O-tert-butyldiphenylsilyl-2′-O-	JJ	O
[	NN	O
(	(	O
2-formadoximinooxy	JJ	O
)	)	O
ethyl	FW	O
]	FW	O
-5-methyluridine	NN	O
,	,	O
5′-O-tert-Butyldiphenylsilyl-2′-O-	JJ	O
[	NNP	O
N	NNP	O
,	,	O
N	NNP	O
dimethylaminooxyethyl	VBZ	O
]	NNP	O
-5-methyluridine	NNP	O
,	,	O
2′-O-	JJ	O
(	(	O
dimethylaminooxyethyl	NN	O
)	)	O
-5-methyluridine	NN	O
,	,	O
5′-O-DMT-2′-O-	JJ	O
(	(	O
dimethylaminooxyethyl	NN	O
)	)	O
-5-methyluridine	NN	O
,	,	O
5′-O-DMT-2′-O-	JJ	O
(	(	O
2-N	JJ	O
,	,	O
N-dimethylaminooxyethyl	NNP	O
)	)	O
-5-methyluridine-3′-	FW	O
[	FW	O
(	(	O
2-cyanoethyl	JJ	O
)	)	O
-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
]	NNP	O
,	,	O
2′-	JJ	O
(	(	O
Aminooxyethoxy	NNP	O
)	)	O
nucleoside	RB	O
amidites	VBZ	O
,	,	O
N2-isobutyryl-6-O-diphenylcarbamoyl-2′-O-	NNP	O
(	(	O
2-ethylacetyl	JJ	O
)	)	O
-5′-O-	NN	O
(	(	O
4,4′-dimethoxytrityl	JJ	O
)	)	O
guanosine-3′-	NN	O
[	NN	O
(	(	O
2-cyanoethyl	JJ	O
)	)	O
-N	NN	O
,	,	O
N-diisopropylphosphoramidite	NNP	O
]	NNP	O
,	,	O
2′-dimethylaminoethoxyethoxy	JJ	O
(	(	O
2′-DMAEOE	JJ	O
)	)	O
nucleoside	NN	O
amidites	NNS	O
,	,	O
2′-O-	JJ	O
[	NN	O
2	CD	O
(	(	O
2-N	JJ	O
,	,	O
N-dimethylaminoethoxy	NNP	O
)	)	O
ethyl	VBZ	O
]	JJ	O
-5-methyl	NNP	O
uridine	NN	O
,	,	O
5′-O-dimethoxytrityl-2′-O-	JJ	O
[	NN	O
2	CD	O
(	(	O
2-N	JJ	O
,	,	O
N-dimethylaminoethoxy	NNP	O
)	)	O
-ethyl	NN	O
)	)	O
]	VBZ	O
-5-methyl	JJ	O
uridine	JJ	O
and	CC	O
5′-O-Dimethoxytrityl-2′-O-	JJ	O
[	NN	O
2	CD	O
(	(	O
2-N	JJ	O
,	,	O
N-dimethylaminoethoxy	NNP	O
)	)	O
-ethyl	NN	O
)	)	O
]	VBZ	O
-5-methyl	JJ	O
uridine-3′-O-	JJ	O
(	(	O
cyanoethyl-N	JJ	O
,	,	O
N-diisopropyl	NNP	O
)	)	O
phosphoramidite	NN	O
.	.	O
Example	RB	O
2	CD	O
Oligonucleotide	NNP	O
and	CC	O
Oligonucleoside	NNP	O
Synthesis	NNP	O
The	DT	O
antisense	NN	O
compounds	NNS	O
used	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
this	DT	O
invention	NN	O
may	MD	O
be	VB	O
conveniently	RB	O
and	CC	O
routinely	RB	O
made	VBD	O
through	IN	O
the	DT	O
well-known	JJ	O
technique	NN	O
of	IN	O
solid	JJ	O
phase	NN	O
synthesis	NN	O
.	.	O
Equipment	NN	O
for	IN	O
such	JJ	O
synthesis	NN	O
is	VBZ	O
sold	VBN	O
by	IN	O
several	JJ	O
vendors	NNS	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
Applied	NNP	O
Biosystems	NNP	O
(	(	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Any	DT	O
other	JJ	O
means	NNS	O
for	IN	O
such	JJ	O
synthesis	NN	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
may	MD	O
additionally	RB	O
or	CC	O
alternatively	RB	O
be	VB	O
employed	VBN	O
.	.	O
It	PRP	O
is	VBZ	O
well	RB	O
known	VBN	O
to	TO	O
use	VB	O
similar	JJ	O
techniques	NNS	O
to	TO	O
prepare	VB	O
oligonucleotides	NNS	O
such	JJ	O
as	IN	O
the	DT	O
phosphorothioates	NNS	O
and	CC	O
alkylated	JJ	O
derivatives	NNS	O
.	.	O
Oligonucleotides	NNS	O
:	:	O
Unsubstituted	VBN	O
and	CC	O
substituted	VBN	O
phosphodiester	NN	O
(	(	O
P═O	NNP	O
)	)	O
oligonucleotides	NNS	O
are	VBP	O
synthesized	VBN	O
on	IN	O
an	DT	O
automated	VBN	O
DNA	NNP	O
synthesizer	NN	O
(	(	O
Applied	NNP	O
Biosystems	NNP	O
model	FW	O
394	CD	O
)	)	O
using	VBG	O
standard	JJ	O
phosphoramidite	JJ	O
chemistry	NN	O
with	IN	O
oxidation	NN	O
by	IN	O
iodine	NN	O
.	.	O
Phosphorothioates	NNS	O
(	(	O
P═S	NNP	O
)	)	O
are	VBP	O
synthesized	VBN	O
similar	JJ	O
to	TO	O
phosphodiester	VB	O
oligonucleotides	NNS	O
with	IN	O
the	DT	O
following	JJ	O
exceptions	NNS	O
:	:	O
thiation	NN	O
was	VBD	O
effected	VBN	O
by	IN	O
utilizing	VBG	O
a	DT	O
10	CD	O
%	NN	O
w/v	JJ	O
solution	NN	O
of	IN	O
3	CD	O
,	,	O
H-1,2-benzodithiole-3-one	CD	O
1,1-dioxide	JJ	O
in	IN	O
acetonitrile	NN	O
for	IN	O
the	DT	O
oxidation	NN	O
of	IN	O
the	DT	O
phosphite	JJ	O
linkages	NNS	O
.	.	O
The	DT	O
thiation	NN	O
reaction	NN	O
step	NN	O
time	NN	O
was	VBD	O
increased	VBN	O
to	TO	O
180	CD	O
sec	NN	O
and	CC	O
preceded	VBN	O
by	IN	O
the	DT	O
normal	JJ	O
capping	JJ	O
step	NN	O
.	.	O
After	IN	O
cleavage	NN	O
from	IN	O
the	DT	O
CPG	NNP	O
column	NN	O
and	CC	O
deblocking	NN	O
in	IN	O
concentrated	JJ	O
ammonium	NN	O
hydroxide	NN	O
at	IN	O
55°	CD	O
C.	NNP	O
(	(	O
12-16	JJ	O
hr	NN	O
)	)	O
,	,	O
the	DT	O
oligonucleotides	NNS	O
were	VBD	O
recovered	VBN	O
by	IN	O
precipitating	VBG	O
with	IN	O
>	JJ	O
3	CD	O
volumes	NNS	O
of	IN	O
ethanol	NN	O
from	IN	O
a	DT	O
1	CD	O
M	NNP	O
NH4OAc	NNP	O
solution	NN	O
.	.	O
Phosphinate	NNP	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,508,270	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Alkyl	NNP	O
phosphonate	NN	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
4,469,863	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
3′-Deoxy-3′-methylene	JJ	O
phosphonate	NN	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,610,289	CD	O
or	CC	O
5,625,050	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Phosphoramidite	NNP	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,256,775	CD	O
or	CC	O
5,366,878	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Alkylphosphonothioate	NNP	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	NN	O
in	IN	O
International	NNP	O
Patent	NNP	O
Application	NNP	O
Nos	NNP	O
.	.	O
PCT/US94/00902	NNP	O
and	CC	O
PCT/US93/06976	NNP	O
(	(	O
published	VBN	O
as	IN	O
International	NNP	O
Patent	NNP	O
Publication	NNP	O
Nos	NNP	O
.	.	O
WO	$	O
94/17093	CD	O
and	CC	O
WO	NNP	O
94/02499	CD	O
,	,	O
respectively	RB	O
)	)	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
3′-Deoxy-3′-amino	JJ	O
phosphoramidate	NN	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,476,925	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Phosphotriester	NNP	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,023,243	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Borano	NNP	O
phosphate	NN	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,130,302	CD	O
and	CC	O
5,177,198	CD	O
,	,	O
both	DT	O
herein	NNS	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Oligonucleosides	NNS	O
:	:	O
Methylenemethylimino	NN	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
also	RB	O
identified	VBN	O
as	IN	O
MMI	NNP	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
methylenedimethylhydrazo	NN	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
also	RB	O
identified	VBN	O
as	IN	O
MDH	NNP	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
and	CC	O
methylenecarbonylamino	NN	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
also	RB	O
identified	VBN	O
as	IN	O
amide-3	JJ	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
and	CC	O
methyleneaminocarbonyl	NN	O
linked	VBN	O
oligonucleosides	NNS	O
,	,	O
also	RB	O
identified	VBN	O
as	IN	O
amide-4	JJ	O
linked	VBD	O
oligonucleosides	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
mixed	JJ	O
backbone	NN	O
compounds	VBZ	O
having	VBG	O
,	,	O
for	IN	O
instance	NN	O
,	,	O
alternating	VBG	O
MMI	NNP	O
and	CC	O
P═O	NNP	O
or	CC	O
P═S	NNP	O
linkages	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,378,825	CD	O
,	,	O
5,386,023	CD	O
,	,	O
5,489,677	CD	O
,	,	O
5,602,240	CD	O
and	CC	O
5,610,289	CD	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
are	VBP	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Formacetal	NNP	O
and	CC	O
thioformacetal	JJ	O
linked	VBN	O
oligonucleosides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
5,264,562	CD	O
and	CC	O
5,264,564	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Ethylene	NNP	O
oxide	NN	O
linked	VBD	O
oligonucleosides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
described	VBN	O
in	IN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,223,618	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Example	RB	O
3	CD	O
RNA	NNP	O
Synthesis	NNP	O
In	IN	O
general	JJ	O
,	,	O
RNA	NNP	O
synthesis	NN	O
chemistry	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
the	DT	O
selective	JJ	O
incorporation	NN	O
of	IN	O
various	JJ	O
protecting	VBG	O
groups	NNS	O
at	IN	O
strategic	JJ	O
intermediary	JJ	O
reactions	NNS	O
.	.	O
Although	IN	O
one	CD	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
understand	VB	O
the	DT	O
use	NN	O
of	IN	O
protecting	VBG	O
groups	NNS	O
in	IN	O
organic	JJ	O
synthesis	NN	O
,	,	O
a	DT	O
useful	JJ	O
class	NN	O
of	IN	O
protecting	VBG	O
groups	NNS	O
includes	VBZ	O
silyl	JJ	O
ethers	NNS	O
.	.	O
In	IN	O
particular	JJ	O
bulky	NN	O
silyl	NN	O
ethers	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
protect	VB	O
the	DT	O
5′-hydroxyl	JJ	O
in	IN	O
combination	NN	O
with	IN	O
an	DT	O
acid-labile	JJ	O
orthoester	NN	O
protecting	VBG	O
group	NN	O
on	IN	O
the	DT	O
2′-hydroxyl	JJ	O
.	.	O
This	DT	O
set	NN	O
of	IN	O
protecting	VBG	O
groups	NNS	O
is	VBZ	O
then	RB	O
used	VBN	O
with	IN	O
standard	JJ	O
solid-phase	JJ	O
synthesis	NN	O
technology	NN	O
.	.	O
It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
lastly	RB	O
remove	VB	O
the	DT	O
acid	NN	O
labile	NN	O
orthoester	NN	O
protecting	VBG	O
group	NN	O
after	IN	O
all	DT	O
other	JJ	O
synthetic	JJ	O
steps	NNS	O
.	.	O
Moreover	RB	O
,	,	O
the	DT	O
early	JJ	O
use	NN	O
of	IN	O
the	DT	O
silyl	NN	O
protecting	VBG	O
groups	NNS	O
during	IN	O
synthesis	NN	O
ensures	NNS	O
facile	VBP	O
removal	NN	O
when	WRB	O
desired	VBN	O
,	,	O
without	IN	O
undesired	JJ	O
deprotection	NN	O
of	IN	O
2′	CD	O
hydroxyl	NN	O
.	.	O
Following	VBG	O
this	DT	O
procedure	NN	O
for	IN	O
the	DT	O
sequential	JJ	O
protection	NN	O
of	IN	O
the	DT	O
5′-hydroxyl	JJ	O
in	IN	O
combination	NN	O
with	IN	O
protection	NN	O
of	IN	O
the	DT	O
2′-hydroxyl	JJ	O
by	IN	O
protecting	VBG	O
groups	NNS	O
that	WDT	O
are	VBP	O
differentially	RB	O
removed	VBN	O
and	CC	O
are	VBP	O
differentially	RB	O
chemically	RB	O
labile	JJ	O
,	,	O
RNA	NNP	O
oligonucleotides	NNS	O
were	VBD	O
synthesized	VBN	O
.	.	O
RNA	NNP	O
oligonucleotides	NNS	O
are	VBP	O
synthesized	VBN	O
in	IN	O
a	DT	O
stepwise	NN	O
fashion	NN	O
.	.	O
Each	DT	O
nucleotide	NN	O
is	VBZ	O
added	VBN	O
sequentially	RB	O
(	(	O
3′-	JJ	O
to	TO	O
5′-direction	NN	O
)	)	O
to	TO	O
a	DT	O
solid	JJ	O
support-bound	JJ	O
oligonucleotide	NN	O
.	.	O
The	DT	O
first	JJ	O
nucleoside	NN	O
at	IN	O
the	DT	O
3′-end	CD	O
of	IN	O
the	DT	O
chain	NN	O
is	VBZ	O
covalently	RB	O
attached	VBN	O
to	TO	O
a	DT	O
solid	JJ	O
support	NN	O
.	.	O
The	DT	O
nucleotide	NN	O
precursor	NN	O
,	,	O
a	DT	O
ribonucleoside	NN	O
phosphoramidite	NN	O
,	,	O
and	CC	O
activator	NN	O
are	VBP	O
added	VBN	O
,	,	O
coupling	VBG	O
the	DT	O
second	JJ	O
base	NN	O
onto	IN	O
the	DT	O
5′-end	JJ	O
of	IN	O
the	DT	O
first	JJ	O
nucleoside	NN	O
.	.	O
The	DT	O
support	NN	O
is	VBZ	O
washed	VBN	O
and	CC	O
any	DT	O
unreacted	JJ	O
5′-hydroxyl	JJ	O
groups	NNS	O
are	VBP	O
capped	VBN	O
with	IN	O
acetic	JJ	O
anhydride	NN	O
to	TO	O
yield	VB	O
5′-acetyl	JJ	O
moieties	NNS	O
.	.	O
The	DT	O
linkage	NN	O
is	VBZ	O
then	RB	O
oxidized	VBN	O
to	TO	O
the	DT	O
more	RBR	O
stable	JJ	O
and	CC	O
ultimately	RB	O
desired	VBN	O
P	NNP	O
(	(	O
V	NNP	O
)	)	O
linkage	NN	O
.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
nucleotide	JJ	O
addition	NN	O
cycle	NN	O
,	,	O
the	DT	O
5′-silyl	JJ	O
group	NN	O
is	VBZ	O
cleaved	VBN	O
with	IN	O
fluoride	NN	O
.	.	O
The	DT	O
cycle	NN	O
is	VBZ	O
repeated	VBN	O
for	IN	O
each	DT	O
subsequent	JJ	O
nucleotide	NN	O
.	.	O
Following	VBG	O
synthesis	NN	O
,	,	O
the	DT	O
methyl	NN	O
protecting	VBG	O
groups	NNS	O
on	IN	O
the	DT	O
phosphates	NNS	O
are	VBP	O
cleaved	VBN	O
in	IN	O
30	CD	O
minutes	NNS	O
utilizing	VBG	O
1	CD	O
M	NNP	O
disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate	JJ	O
trihydrate	NN	O
(	(	O
S2Na2	NNP	O
)	)	O
in	IN	O
DMF	NNP	O
.	.	O
The	DT	O
deprotection	NN	O
solution	NN	O
is	VBZ	O
washed	VBN	O
from	IN	O
the	DT	O
solid	JJ	O
support-bound	NN	O
oligonucleotide	IN	O
using	VBG	O
water	NN	O
.	.	O
The	DT	O
support	NN	O
is	VBZ	O
then	RB	O
treated	VBN	O
with	IN	O
40	CD	O
%	NN	O
methylamine	NN	O
in	IN	O
water	NN	O
for	IN	O
10	CD	O
minutes	NNS	O
at	IN	O
55°	CD	O
C.	NNP	O
This	DT	O
releases	VBZ	O
the	DT	O
RNA	NNP	O
oligonucleotides	VBZ	O
into	IN	O
solution	NN	O
,	,	O
deprotects	VBZ	O
the	DT	O
exocyclic	JJ	O
amines	NNS	O
,	,	O
and	CC	O
modifies	VBZ	O
the	DT	O
2′-groups	JJ	O
.	.	O
The	DT	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
analyzed	VBN	O
by	IN	O
anion	NN	O
exchange	NN	O
HPLC	NNP	O
at	IN	O
this	DT	O
stage	NN	O
.	.	O
The	DT	O
2′-orthoester	JJ	O
groups	NNS	O
are	VBP	O
the	DT	O
last	JJ	O
protecting	NN	O
groups	NNS	O
to	TO	O
be	VB	O
removed	VBN	O
.	.	O
The	DT	O
ethylene	NN	O
glycol	NN	O
monoacetate	NN	O
orthoester	NN	O
protecting	VBG	O
group	NN	O
developed	VBN	O
by	IN	O
Dharmacon	NNP	O
Research	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
Lafayette	NNP	O
,	,	O
Colo.	NNP	O
)	)	O
,	,	O
is	VBZ	O
one	CD	O
example	NN	O
of	IN	O
a	DT	O
useful	JJ	O
orthoester	NN	O
protecting	VBG	O
group	NN	O
which	WDT	O
,	,	O
has	VBZ	O
the	DT	O
following	JJ	O
important	JJ	O
properties	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
stable	JJ	O
to	TO	O
the	DT	O
conditions	NNS	O
of	IN	O
nucleoside	JJ	O
phosphoramidite	JJ	O
synthesis	NN	O
and	CC	O
oligonucleotide	JJ	O
synthesis	NN	O
.	.	O
However	RB	O
,	,	O
after	IN	O
oligonucleotide	JJ	O
synthesis	NN	O
the	DT	O
oligonucleotide	NN	O
is	VBZ	O
treated	VBN	O
with	IN	O
methylamine	NN	O
which	WDT	O
not	RB	O
only	RB	O
cleaves	VBZ	O
the	DT	O
oligonucleotide	NN	O
from	IN	O
the	DT	O
solid	JJ	O
support	NN	O
but	CC	O
also	RB	O
removes	VBZ	O
the	DT	O
acetyl	NN	O
groups	NNS	O
from	IN	O
the	DT	O
orthoesters	NNS	O
.	.	O
The	DT	O
resulting	VBG	O
2-ethyl-hydroxyl	JJ	O
substituents	NNS	O
on	IN	O
the	DT	O
orthoester	NN	O
are	VBP	O
less	RBR	O
electron	IN	O
withdrawing	VBG	O
than	IN	O
the	DT	O
acetylated	JJ	O
precursor	NN	O
.	.	O
As	IN	O
a	DT	O
result	NN	O
,	,	O
the	DT	O
modified	JJ	O
orthoester	NN	O
becomes	VBZ	O
more	RBR	O
labile	JJ	O
to	TO	O
acid-catalyzed	JJ	O
hydrolysis	NN	O
.	.	O
Specifically	RB	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
cleavage	NN	O
is	VBZ	O
approximately	RB	O
10	CD	O
times	NNS	O
faster	RBR	O
after	IN	O
the	DT	O
acetyl	NN	O
groups	NNS	O
are	VBP	O
removed	VBN	O
.	.	O
Therefore	RB	O
,	,	O
this	DT	O
orthoester	NN	O
possesses	VBZ	O
sufficient	JJ	O
stability	NN	O
in	IN	O
order	NN	O
to	TO	O
be	VB	O
compatible	JJ	O
with	IN	O
oligonucleotide	JJ	O
synthesis	NN	O
and	CC	O
yet	RB	O
,	,	O
when	WRB	O
subsequently	RB	O
modified	VBN	O
,	,	O
permits	VBZ	O
deprotection	NN	O
to	TO	O
be	VB	O
carried	VBN	O
out	RP	O
under	IN	O
relatively	RB	O
mild	JJ	O
aqueous	JJ	O
conditions	NNS	O
compatible	JJ	O
with	IN	O
the	DT	O
final	JJ	O
RNA	NNP	O
oligonucleotide	NN	O
product	NN	O
.	.	O
Additionally	RB	O
,	,	O
methods	NNS	O
of	IN	O
RNA	NNP	O
synthesis	NN	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
(	(	O
Scaringe	NNP	B
,	,	I
S.	NNP	I
A.	NNP	I
Ph.D.	NNP	I
Thesis	NNP	I
,	,	I
University	NNP	I
of	IN	I
Colorado	NNP	I
,	,	I
1996	CD	I
;	:	O
Scaringe	NNP	B
,	,	I
S.	NNP	I
A.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
1998	CD	I
,	,	I
120	CD	I
,	,	I
11820-11821	CD	I
;	:	O
Matteucci	NNP	B
,	,	I
M.	NNP	I
D.	NNP	I
and	CC	I
Caruthers	NNP	I
,	,	I
M.	NNP	I
H.	NNP	I
J	NNP	I
.	.	I
Am	NNP	I
.	.	I
Chem	NNP	I
.	.	I
Soc.	NNP	I
,	,	I
1981	CD	I
,	,	I
103	CD	I
,	,	I
3185-3191	CD	I
;	:	O
Beaucage	NNP	B
,	,	I
S.	NNP	I
L.	NNP	I
and	CC	I
Caruthers	NNP	I
,	,	I
M.	NNP	I
H.	NNP	I
Tetrahedron	NNP	I
Lett.	NNP	I
,	,	I
1981	CD	I
,	,	I
22	CD	I
,	,	I
1859-1862	CD	I
;	:	O
Dahl	NNP	B
,	,	I
B.	NNP	I
J.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Acta	NNP	I
Chem	NNP	I
.	.	I
Scand.	NNP	I
,	,	I
1990	CD	I
,	,	I
44	CD	I
,	,	I
639-641	JJ	I
;	:	O
Reddy	NNP	B
,	,	I
M.	NNP	I
P.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Tetrahedron	NNP	I
Lett.	NNP	I
,	,	I
1994	CD	I
,	,	I
25	CD	I
,	,	I
4311-4314	JJ	I
;	:	O
Wincott	NNP	B
,	,	I
F.	NNP	I
et	FW	I
al.	NN	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Res.	NNP	I
,	,	I
1995	CD	I
,	,	I
23	CD	I
,	,	I
2677-2684	JJ	I
;	:	O
Griffin	NNP	B
,	,	I
B.	NNP	I
E.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Tetrahedron	NNP	I
,	,	I
1967	CD	I
,	,	I
23	CD	I
,	,	I
2301-2313	JJ	I
;	:	O
Griffin	NNP	B
,	,	I
B.	NNP	I
E.	NNP	I
,	,	I
et	FW	I
al.	NN	I
,	,	I
Tetrahedron	NNP	I
,	,	I
1967	CD	I
,	,	I
23	CD	I
,	,	I
2315-2331	JJ	I
)	)	O
.	.	O
RNA	NNP	O
antisense	NN	O
compounds	NNS	O
(	(	O
RNA	NNP	O
oligonucleotides	VBZ	O
)	)	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
can	MD	O
be	VB	O
synthesized	VBN	O
by	IN	O
the	DT	O
methods	NNS	O
herein	NN	O
or	CC	O
purchased	VBN	O
from	IN	O
Dharmacon	NNP	O
Research	NNP	O
,	,	O
Inc	NNP	O
(	(	O
Lafayette	NNP	O
,	,	O
Colo.	NNP	O
)	)	O
.	.	O
Once	RB	O
synthesized	VBN	O
,	,	O
complementary	JJ	O
RNA	NNP	O
antisense	NN	O
compounds	NNS	O
can	MD	O
then	RB	O
be	VB	O
annealed	VBN	O
by	IN	O
methods	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
to	TO	O
form	VB	O
double	RB	O
stranded	VBN	O
(	(	O
duplexed	VBN	O
)	)	O
antisense	NN	O
compounds	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
duplexes	NNS	O
can	MD	O
be	VB	O
formed	VBN	O
by	IN	O
combining	VBG	O
30	CD	O
μl	NN	O
of	IN	O
each	DT	O
of	IN	O
the	DT	O
complementary	JJ	O
strands	NNS	O
of	IN	O
RNA	NNP	O
oligonucleotides	NNS	O
(	(	O
50	CD	O
μM	NNP	O
RNA	NNP	O
oligonucleotide	IN	O
solution	NN	O
)	)	O
and	CC	O
15	CD	O
μl	NN	O
of	IN	O
5×	CD	O
annealing	VBG	O
buffer	NN	O
(	(	O
100	CD	O
mM	NN	O
potassium	NN	O
acetate	NN	O
,	,	O
30	CD	O
mM	JJ	O
HEPES-KOH	NNP	O
pH	NN	O
7.4	CD	O
,	,	O
2	CD	O
mM	NN	O
magnesium	NN	O
acetate	NN	O
)	)	O
followed	VBN	O
by	IN	O
heating	VBG	O
for	IN	O
1	CD	O
minute	NN	O
at	IN	O
90°	CD	O
C.	NNP	O
,	,	O
then	RB	O
1	CD	O
hour	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
The	DT	O
resulting	VBG	O
duplexed	JJ	O
antisense	NN	O
compounds	NNS	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
kits	NNS	O
,	,	O
assays	NNS	O
,	,	O
screens	NNS	O
,	,	O
or	CC	O
other	JJ	O
methods	NNS	O
to	TO	O
investigate	VB	O
the	DT	O
role	NN	O
of	IN	O
a	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
,	,	O
or	CC	O
for	IN	O
diagnostic	JJ	O
or	CC	O
therapeutic	JJ	O
purposes	NNS	O
.	.	O
Example	RB	O
4	CD	O
Synthesis	NN	O
of	IN	O
Chimeric	NNP	O
Compounds	NNP	O
Chimeric	NNP	O
oligonucleotides	NNS	O
,	,	O
oligonucleosides	NNS	O
or	CC	O
mixed	JJ	O
oligonucleotides/oligonucleosides	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
of	IN	O
several	JJ	O
different	JJ	O
types	NNS	O
.	.	O
These	DT	O
include	VBP	O
a	DT	O
first	JJ	O
type	NN	O
wherein	VBP	O
the	DT	O
“	NNP	O
gap	NN	O
”	NNP	O
segment	NN	O
of	IN	O
linked	VBN	O
nucleosides	NNS	O
is	VBZ	O
positioned	VBN	O
between	IN	O
5′	CD	O
and	CC	O
3′	CD	O
“	NNS	O
wing	VBG	O
”	JJ	O
segments	NNS	O
of	IN	O
linked	VBN	O
nucleosides	NNS	O
and	CC	O
a	DT	O
second	JJ	O
“	NN	O
open	JJ	O
end	NN	O
”	NN	O
type	NN	O
wherein	VBD	O
the	DT	O
“	NNP	O
gap	NN	O
”	NNP	O
segment	NN	O
is	VBZ	O
located	VBN	O
at	IN	O
either	CC	O
the	DT	O
3′	CD	O
or	CC	O
the	DT	O
5′	CD	O
terminus	NN	O
of	IN	O
the	DT	O
oligomeric	JJ	O
compound	NN	O
.	.	O
Oligonucleotides	NNS	O
of	IN	O
the	DT	O
first	JJ	O
type	NN	O
are	VBP	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
or	CC	O
gapped	VBD	O
oligonucleotides	NNS	O
.	.	O
Oligonucleotides	NNS	O
of	IN	O
the	DT	O
second	JJ	O
type	NN	O
are	VBP	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
as	IN	O
“	JJ	O
hemimers	NNS	O
”	VBP	O
or	CC	O
“	VBP	O
wingmers	NNS	O
”	VBP	O
.	.	O
[	JJ	O
2′-O-Me	JJ	O
]	NNP	O
-	:	O
[	JJ	O
2′-deoxy	JJ	O
]	NNP	O
-	:	O
[	JJ	O
2′-O-Me	JJ	O
]	NN	O
Chimeric	NNP	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
Chimeric	NNP	O
oligonucleotides	IN	O
having	VBG	O
2′-O-alkyl	JJ	O
phosphorothioate	NN	O
and	CC	O
2′-deoxy	JJ	O
phosphorothioate	NN	O
oligo-nucleotide	JJ	O
segments	NNS	O
are	VBP	O
synthesized	VBN	O
using	VBG	O
an	DT	O
Applied	NNP	O
Biosystems	NNP	O
automated	VBD	O
DNA	NNP	O
synthesizer	NN	O
Model	NNP	O
394	CD	O
,	,	O
as	IN	O
above	IN	O
.	.	O
Oligonucleotides	NNS	O
are	VBP	O
synthesized	VBN	O
using	VBG	O
the	DT	O
automated	JJ	O
synthesizer	NN	O
and	CC	O
2′-deoxy-5′-dimethoxytrityl-3′-O-phosphoramidite	JJ	O
for	IN	O
the	DT	O
DNA	NNP	O
portion	NN	O
and	CC	O
5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite	JJ	O
for	IN	O
5′	CD	O
and	CC	O
3′	CD	O
wings	NNS	O
.	.	O
The	DT	O
standard	JJ	O
synthesis	NN	O
cycle	NN	O
is	VBZ	O
modified	VBN	O
by	IN	O
incorporating	VBG	O
coupling	VBG	O
steps	NNS	O
with	IN	O
increased	VBN	O
reaction	NN	O
times	NNS	O
for	IN	O
the	DT	O
5′-dimethoxytrityl-2′-O-methyl-3′-O-phosphoramidite	JJ	O
.	.	O
The	DT	O
fully	RB	O
protected	VBN	O
oligonucleotide	NN	O
is	VBZ	O
cleaved	VBN	O
from	IN	O
the	DT	O
support	NN	O
and	CC	O
deprotected	VBN	O
in	IN	O
concentrated	JJ	O
ammonia	NN	O
(	(	O
NH4OH	NNP	O
)	)	O
for	IN	O
12-16	JJ	O
hr	NN	O
at	IN	O
55°	CD	O
C.	NNP	O
The	DT	O
deprotected	JJ	O
oligo	NN	O
is	VBZ	O
then	RB	O
recovered	VBN	O
by	IN	O
an	DT	O
appropriate	JJ	O
method	NN	O
(	(	O
precipitation	NN	O
,	,	O
column	NN	O
chromatography	NN	O
,	,	O
volume	NN	O
reduced	VBN	O
in	IN	O
vacuo	NN	O
and	CC	O
analyzed	VBD	O
spectrophotometrically	RB	O
for	IN	O
yield	NN	O
and	CC	O
for	IN	O
purity	NN	O
by	IN	O
capillary	JJ	O
electrophoresis	NN	O
and	CC	O
by	IN	O
mass	NN	O
spectrometry	NN	O
)	)	O
.	.	O
[	JJ	O
2′-O-	JJ	O
(	(	O
2-Methoxyethyl	JJ	O
)	)	O
]	SYM	O
-	:	O
[	JJ	O
2′-deoxy	JJ	O
]	NNP	O
-	:	O
[	JJ	O
2′-O-	JJ	O
(	(	O
Methoxyethyl	NNP	O
)	)	O
]	VBP	O
Chimeric	JJ	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
[	NNP	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
)	)	O
]	SYM	O
-	:	O
[	JJ	O
2′-deoxy	JJ	O
]	NNP	O
-	:	O
[	NN	O
-2′-O-	NN	O
(	(	O
methoxyethyl	NN	O
)	)	O
]	VBZ	O
chimeric	JJ	O
phosphorothioate	NN	O
oligonucleotides	NNS	O
were	VBD	O
prepared	VBN	O
as	IN	O
per	IN	O
the	DT	O
procedure	NN	O
above	IN	O
for	IN	O
the	DT	O
2′-O-methyl	JJ	O
chimeric	JJ	O
oligonucleotide	NN	O
,	,	O
with	IN	O
the	DT	O
substitution	NN	O
of	IN	O
2′-O-	JJ	O
(	(	O
methoxyethyl	NN	O
)	)	O
amidites	VBZ	O
for	IN	O
the	DT	O
2′-O-methyl	JJ	O
amidites	NNS	O
.	.	O
[	JJ	O
2′-O-	JJ	O
(	(	O
2-Methoxyethyl	JJ	O
)	)	O
Phosphodiester	NNP	O
]	NNP	O
-	:	O
[	JJ	O
2′-deoxy	JJ	O
Phosphorothioate	NNP	O
]	NNP	O
-	:	O
[	JJ	O
2′-O-	JJ	O
(	(	O
2-Methoxyethyl	JJ	O
)	)	O
Phosphodiester	NNP	O
]	NNP	O
Chimeric	NNP	O
Oligonucleotides	NNP	O
[	NNP	O
2′-O-	JJ	O
(	(	O
2-methoxyethyl	JJ	O
phosphodiester	NN	O
]	NNP	O
-	:	O
[	JJ	O
2′-deoxy	JJ	O
phosphorothioate	NN	O
]	NNP	O
-	:	O
[	JJ	O
2′-O-	JJ	O
(	(	O
methoxyethyl	NN	O
)	)	O
phosphodiester	NN	O
]	NNP	O
chimeric	NN	O
oligonucleotides	NNS	O
are	VBP	O
prepared	JJ	O
as	IN	O
per	IN	O
the	DT	O
above	JJ	O
procedure	NN	O
for	IN	O
the	DT	O
2′-O-methyl	JJ	O
chimeric	JJ	O
oligonucleotide	NN	O
with	IN	O
the	DT	O
substitution	NN	O
of	IN	O
2′-O-	JJ	O
(	(	O
methoxyethyl	NN	O
)	)	O
amidites	VBZ	O
for	IN	O
the	DT	O
2′-O-methyl	JJ	O
amidites	NNS	O
,	,	O
oxidation	NN	O
with	IN	O
iodine	NN	O
to	TO	O
generate	VB	O
the	DT	O
phosphodiester	NN	O
internucleotide	NN	O
linkages	VBZ	O
within	IN	O
the	DT	O
wing	JJ	O
portions	NNS	O
of	IN	O
the	DT	O
chimeric	JJ	O
structures	NNS	O
and	CC	O
sulfurization	NN	O
utilizing	VBG	O
3	CD	O
,	,	O
H-1,2	NNP	O
benzodithiole-3-one	NN	O
1,1	CD	O
dioxide	NN	O
(	(	O
Beaucage	NNP	O
Reagent	NNP	O
)	)	O
to	TO	O
generate	VB	O
the	DT	O
phosphorothioate	NN	O
internucleotide	NN	O
linkages	VBZ	O
for	IN	O
the	DT	O
center	NN	O
gap	NN	O
.	.	O
Other	JJ	O
chimeric	JJ	O
oligonucleotides	NNS	O
,	,	O
chimeric	JJ	O
oligonucleosides	NNS	O
and	CC	O
mixed	JJ	O
chimeric	NN	O
oligonucleotides/oligonucleosides	NNS	O
are	VBP	O
synthesized	VBN	O
according	VBG	O
to	TO	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,623,065	CD	O
,	,	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
Example	JJ	O
5	CD	O
Design	NNP	O
and	CC	O
Screening	NNP	O
of	IN	O
Duplexed	NNP	O
Antisense	NNP	O
Compounds	NNP	O
Targeting	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
duplexes	NNS	O
,	,	O
also	RB	O
known	VBN	O
as	IN	O
double-strand	NN	O
RNAs	NNP	O
(	(	O
dsRNAs	NN	O
)	)	O
or	CC	O
small	JJ	O
interfering	NN	O
RNAs	NNP	O
(	(	O
siRNAs	NN	O
)	)	O
,	,	O
comprising	VBG	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
and	CC	O
their	PRP$	O
complements	NNS	O
can	MD	O
be	VB	O
designed	VBN	O
to	TO	O
target	VB	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
.	.	O
The	DT	O
nucleobase	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
antisense	JJ	O
strand	NN	O
of	IN	O
the	DT	O
duplex	JJ	O
comprises	NNS	O
at	IN	O
least	JJS	O
an	DT	O
8-nucleobase	JJ	O
portion	NN	O
of	IN	O
an	DT	O
oligonucleotide	NN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O
The	DT	O
ends	NNS	O
of	IN	O
the	DT	O
strands	NNS	O
may	MD	O
be	VB	O
modified	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
natural	JJ	O
or	CC	O
modified	JJ	O
nucleobases	NNS	O
to	TO	O
form	VB	O
an	DT	O
overhang	NN	O
.	.	O
The	DT	O
sense	NN	O
strand	NN	O
of	IN	O
the	DT	O
dsRNA	NN	O
is	VBZ	O
then	RB	O
designed	VBN	O
and	CC	O
synthesized	VBN	O
as	IN	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
antisense	NN	O
strand	NN	O
and	CC	O
may	MD	O
also	RB	O
contain	VB	O
modifications	NNS	O
or	CC	O
additions	NNS	O
to	TO	O
either	DT	O
terminus	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
one	CD	O
embodiment	NN	O
,	,	O
both	DT	O
strands	NNS	O
of	IN	O
the	DT	O
dsRNA	NN	O
duplex	NN	O
would	MD	O
be	VB	O
complementary	JJ	O
over	IN	O
the	DT	O
central	JJ	O
nucleobases	NNS	O
,	,	O
each	DT	O
having	VBG	O
overhangs	NNS	O
at	IN	O
one	CD	O
or	CC	O
both	DT	O
termini	NNS	O
.	.	O
The	DT	O
antisense	NN	O
and	CC	O
sense	NN	O
strands	NNS	O
of	IN	O
the	DT	O
duplex	JJ	O
comprise	NN	O
from	IN	O
about	RB	O
17	CD	O
to	TO	O
25	CD	O
nucleotides	NNS	O
,	,	O
or	CC	O
from	IN	O
about	RB	O
19	CD	O
to	TO	O
23	CD	O
nucleotides	NNS	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
antisense	NN	O
and	CC	O
sense	NN	O
strands	NNS	O
comprise	VBP	O
20	CD	O
,	,	O
21	CD	O
or	CC	O
22	CD	O
nucleotides	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
duplex	JJ	O
comprising	VBG	O
an	DT	O
antisense	NN	O
strand	NN	O
having	VBG	O
the	DT	O
sequence	NN	O
CGAGAGGCGGACGGGACCG	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
489	CD	O
)	)	O
and	CC	O
having	VBG	O
a	DT	O
two-nucleobase	JJ	O
overhang	NN	O
of	IN	O
deoxythymidine	NN	O
(	(	O
dT	NN	O
)	)	O
has	VBZ	O
the	DT	O
following	JJ	O
structure	NN	O
(	(	O
Antisense	NNP	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
490	CD	O
and	CC	O
Complement	NNP	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
491	CD	O
)	)	O
:	:	O
Overhangs	NNS	O
can	MD	O
range	VB	O
from	IN	O
1	CD	O
to	TO	O
6	CD	O
nucleobases	NNS	O
and	CC	O
these	DT	O
nucleobases	NNS	O
may	MD	O
or	CC	O
may	MD	O
not	RB	O
be	VB	O
complementary	JJ	O
to	TO	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
One	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
understand	VB	O
that	IN	O
the	DT	O
overhang	NN	O
may	MD	O
be	VB	O
1	CD	O
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
or	CC	O
6	CD	O
nucleobases	NNS	O
in	IN	O
length	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
the	DT	O
duplexes	NNS	O
may	MD	O
have	VB	O
an	DT	O
overhang	NN	O
on	IN	O
only	RB	O
one	CD	O
terminus	NN	O
.	.	O
In	IN	O
another	DT	O
embodiment	NN	O
,	,	O
a	DT	O
duplex	JJ	O
comprising	VBG	O
an	DT	O
antisense	NN	O
strand	NN	O
having	VBG	O
the	DT	O
same	JJ	O
sequence	NN	O
CGAGAGGCGGACGGGACCG	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
489	CD	O
)	)	O
may	MD	O
be	VB	O
prepared	VBN	O
with	IN	O
blunt	NN	O
ends	NNS	O
(	(	O
no	DT	O
single	JJ	O
stranded	VBD	O
overhang	NN	O
)	)	O
as	IN	O
shown	VBN	O
(	(	O
Antisense	NNP	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
489	CD	O
and	CC	O
Complement	NNP	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
492	CD	O
)	)	O
:	:	O
The	DT	O
RNA	NNP	O
duplex	NN	O
can	MD	O
be	VB	O
unimolecular	JJ	O
or	CC	O
bimolecular	JJ	O
;	:	O
i.e.	NN	O
,	,	O
the	DT	O
two	CD	O
strands	NNS	O
can	MD	O
be	VB	O
part	NN	O
of	IN	O
a	DT	O
single	JJ	O
molecule	NN	O
or	CC	O
may	MD	O
be	VB	O
separate	JJ	O
molecules	NNS	O
.	.	O
RNA	NNP	O
strands	NNS	O
of	IN	O
the	DT	O
duplex	NN	O
can	MD	O
be	VB	O
synthesized	VBN	O
by	IN	O
methods	NNS	O
disclosed	VBN	O
herein	NN	O
or	CC	O
purchased	VBN	O
from	IN	O
Dharmacon	NNP	O
Research	NNP	O
Inc.	NNP	O
,	,	O
(	(	O
Lafayette	NNP	O
,	,	O
Colo.	NNP	O
)	)	O
.	.	O
Once	RB	O
synthesized	VBN	O
,	,	O
the	DT	O
complementary	JJ	O
strands	NNS	O
are	VBP	O
annealed	VBN	O
.	.	O
The	DT	O
single	JJ	O
strands	NNS	O
are	VBP	O
aliquoted	VBN	O
and	CC	O
diluted	VBN	O
to	TO	O
a	DT	O
concentration	NN	O
of	IN	O
50	CD	O
μM	NNS	O
.	.	O
Once	RB	O
diluted	VBN	O
,	,	O
30	CD	O
μL	NN	O
of	IN	O
each	DT	O
strand	NN	O
is	VBZ	O
combined	VBN	O
with	IN	O
15	CD	O
μL	NNS	O
of	IN	O
a	DT	O
5×	CD	O
solution	NN	O
of	IN	O
annealing	VBG	O
buffer	NN	O
.	.	O
The	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
said	VBD	O
buffer	NN	O
is	VBZ	O
100	CD	O
mM	NN	O
potassium	NN	O
acetate	NN	O
,	,	O
30	CD	O
mM	JJ	O
HEPES-KOH	NNP	O
pH	NN	O
7.4	CD	O
,	,	O
and	CC	O
2	CD	O
mM	NN	O
magnesium	NN	O
acetate	NN	O
.	.	O
The	DT	O
final	JJ	O
volume	NN	O
is	VBZ	O
75	CD	O
μL	NN	O
.	.	O
This	DT	O
solution	NN	O
is	VBZ	O
incubated	VBN	O
for	IN	O
1	CD	O
minute	NN	O
at	IN	O
90°	CD	O
C.	NNP	O
and	CC	O
then	RB	O
centrifuged	VBD	O
for	IN	O
15	CD	O
seconds	NNS	O
.	.	O
The	DT	O
tube	NN	O
is	VBZ	O
allowed	VBN	O
to	TO	O
sit	VB	O
for	IN	O
1	CD	O
hour	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
at	IN	O
which	WDT	O
time	NN	O
the	DT	O
dsRNA	NN	O
duplexes	NNS	O
are	VBP	O
used	VBN	O
in	IN	O
experimentation	NN	O
.	.	O
The	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
the	DT	O
dsRNA	NN	O
duplex	NN	O
is	VBZ	O
20	CD	O
μM	NN	O
.	.	O
This	DT	O
solution	NN	O
can	MD	O
be	VB	O
stored	VBN	O
frozen	JJ	O
(	(	O
−20°	NNP	O
C.	NNP	O
)	)	O
and	CC	O
freeze-thawed	JJ	O
up	NN	O
to	TO	O
5	CD	O
times	NNS	O
.	.	O
Once	RB	O
prepared	JJ	O
,	,	O
the	DT	O
duplexed	JJ	O
antisense	NN	O
compounds	NNS	O
are	VBP	O
evaluated	VBN	O
for	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
modulate	VB	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
.	.	O
When	WRB	O
cells	NNS	O
reached	VBD	O
80	CD	O
%	NN	O
confluency	NN	O
,	,	O
they	PRP	O
are	VBP	O
treated	VBN	O
with	IN	O
duplexed	JJ	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
For	IN	O
cells	NNS	O
grown	VBN	O
in	IN	O
96-well	CD	O
plates	NNS	O
,	,	O
wells	NNS	O
are	VBP	O
washed	VBN	O
once	RB	O
with	IN	O
200	CD	O
μL	JJ	O
OPTI-MEM-1	JJ	O
reduced-serum	JJ	O
medium	NN	O
(	(	O
Gibco	NNP	O
BRL	NNP	O
)	)	O
and	CC	O
then	RB	O
treated	VBD	O
with	IN	O
130	CD	O
μL	NNS	O
of	IN	O
OPTI-MEM-1	NNP	O
containing	VBG	O
12	CD	O
μg/mL	JJ	O
LIPOFECTIN™	NNP	O
reagent	NN	O
(	(	O
Gibco	NNP	O
BRL	NNP	O
)	)	O
and	CC	O
the	DT	O
desired	JJ	O
duplex	JJ	O
antisense	NN	O
compound	NN	O
at	IN	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
200	CD	O
nM	NNS	O
.	.	O
After	IN	O
5	CD	O
hours	NNS	O
of	IN	O
treatment	NN	O
,	,	O
the	DT	O
medium	NN	O
is	VBZ	O
replaced	VBN	O
with	IN	O
fresh	JJ	O
medium	NN	O
.	.	O
Cells	NNS	O
are	VBP	O
harvested	VBN	O
16	CD	O
hours	NNS	O
after	IN	O
treatment	NN	O
,	,	O
at	IN	O
which	WDT	O
time	NN	O
RNA	NNP	O
is	VBZ	O
isolated	VBN	O
and	CC	O
target	VB	O
reduction	NN	O
measured	VBN	O
by	IN	O
RT-PCR	NNP	O
.	.	O
Example	RB	O
6	CD	O
Oligonucleotide	NNP	O
Isolation	NNP	O
After	IN	O
cleavage	NN	O
from	IN	O
the	DT	O
controlled	VBN	O
pore	NN	O
glass	NN	O
solid	JJ	O
support	NN	O
and	CC	O
deblocking	NN	O
in	IN	O
concentrated	JJ	O
ammonium	NN	O
hydroxide	NN	O
at	IN	O
55°	CD	O
C.	NNP	O
for	IN	O
12-16	JJ	O
hours	NNS	O
,	,	O
the	DT	O
oligonucleotides	NNS	O
or	CC	O
oligonucleosides	NNS	O
are	VBP	O
recovered	VBN	O
by	IN	O
precipitation	NN	O
out	IN	O
of	IN	O
1	CD	O
M	NNP	O
NH4OAc	NNP	O
with	IN	O
>	NNP	O
3	CD	O
volumes	NNS	O
of	IN	O
ethanol	NN	O
.	.	O
Synthesized	VBN	O
oligonucleotides	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
electrospray	JJ	O
mass	NN	O
spectroscopy	NN	O
(	(	O
molecular	JJ	O
weight	NN	O
determination	NN	O
)	)	O
and	CC	O
by	IN	O
capillary	JJ	O
gel	NN	O
electrophoresis	NN	O
and	CC	O
judged	VBD	O
to	TO	O
be	VB	O
at	IN	O
least	JJS	O
70	CD	O
%	NN	O
full-length	JJ	O
material	NN	O
.	.	O
The	DT	O
relative	JJ	O
amounts	NNS	O
of	IN	O
phosphorothioate	NN	O
and	CC	O
phosphodiester	NN	O
linkages	NNS	O
obtained	VBN	O
in	IN	O
the	DT	O
synthesis	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
the	DT	O
ratio	NN	O
of	IN	O
correct	JJ	O
molecular	JJ	O
weight	NN	O
relative	NN	O
to	TO	O
the	DT	O
−16	NNP	O
amu	JJ	O
product	NN	O
(	(	O
+/−32+/−48	JJ	O
)	)	O
.	.	O
For	IN	O
some	DT	O
studies	NNS	O
oligonucleotides	NNS	O
were	VBD	O
purified	VBN	O
by	IN	O
HPLC	NNP	O
,	,	O
as	IN	O
described	VBN	O
by	IN	O
Chiang	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
1991	CD	I
,	,	I
266	CD	I
,	,	I
18162-18171	CD	I
.	.	O
Results	NNS	O
obtained	VBD	O
with	IN	O
HPLC-purified	NNP	O
material	NN	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
obtained	VBN	O
with	IN	O
non-HPLC	JJ	O
purified	JJ	O
material	NN	O
.	.	O
Example	RB	O
7	CD	O
Oligonucleotide	NNP	O
Synthesis—96	NNP	O
Well	NNP	O
Plate	NNP	O
Format	NNP	O
Oligonucleotides	NNP	O
were	VBD	O
synthesized	VBN	O
via	IN	O
solid	JJ	O
phase	NN	O
P	NNP	O
(	(	O
III	NNP	O
)	)	O
phosphoramidite	VBP	O
chemistry	NN	O
on	IN	O
an	DT	O
automated	JJ	O
synthesizer	NN	O
capable	JJ	O
of	IN	O
assembling	VBG	O
96	CD	O
sequences	NNS	O
simultaneously	RB	O
in	IN	O
a	DT	O
96-well	JJ	O
format	NN	O
.	.	O
Phosphodiester	NNP	O
internucleotide	NN	O
linkages	NNS	O
were	VBD	O
afforded	VBN	O
by	IN	O
oxidation	NN	O
with	IN	O
aqueous	JJ	O
iodine	NN	O
.	.	O
Phosphorothioate	NNP	O
internucleotide	NN	O
linkages	NNS	O
were	VBD	O
generated	VBN	O
by	IN	O
sulfurization	NN	O
utilizing	VBG	O
3	CD	O
,	,	O
H-1,2	NNP	O
benzodithiole-3-one	NN	O
1,1	CD	O
dioxide	NN	O
(	(	O
Beaucage	NNP	O
Reagent	NNP	O
)	)	O
in	IN	O
anhydrous	JJ	O
acetonitrile	NN	O
.	.	O
Standard	JJ	O
base-protected	JJ	O
beta-cyanoethyl-diiso-propyl	JJ	O
phosphoramidites	NNS	O
were	VBD	O
purchased	VBN	O
from	IN	O
commercial	JJ	O
vendors	NNS	O
(	(	O
e.g	NN	O
.	.	O
PE-Applied	JJ	O
Biosystems	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
,	,	O
or	CC	O
Pharmacia	NNP	O
,	,	O
Piscataway	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
.	.	O
Non-standard	NNP	O
nucleosides	NNS	O
are	VBP	O
synthesized	VBN	O
as	IN	O
per	JJ	O
standard	NN	O
or	CC	O
patented	VBN	O
methods	NNS	O
.	.	O
They	PRP	O
are	VBP	O
utilized	JJ	O
as	IN	O
base	NN	O
protected	VBD	O
beta-cyanoethyldiisopropyl	JJ	O
phosphoramidites	NNS	O
.	.	O
Oligonucleotides	NNS	O
were	VBD	O
cleaved	VBN	O
from	IN	O
support	NN	O
and	CC	O
deprotected	VBN	O
with	IN	O
concentrated	JJ	O
NH4OH	NNP	O
at	IN	O
elevated	JJ	O
temperature	NN	O
(	(	O
55-60°	JJ	O
C.	NNP	O
)	)	O
for	IN	O
12-16	JJ	O
hours	NNS	O
and	CC	O
the	DT	O
released	VBN	O
product	NN	O
then	RB	O
dried	VBD	O
in	IN	O
vacuo	NN	O
.	.	O
The	DT	O
dried	JJ	O
product	NN	O
was	VBD	O
then	RB	O
re-suspended	JJ	O
in	IN	O
sterile	JJ	O
water	NN	O
to	TO	O
afford	VB	O
a	DT	O
master	NN	O
plate	NN	O
from	IN	O
which	WDT	O
all	DT	O
analytical	JJ	O
and	CC	O
test	NN	O
plate	NN	O
samples	NNS	O
are	VBP	O
then	RB	O
diluted	VBN	O
utilizing	JJ	O
robotic	JJ	O
pipettors	NNS	O
.	.	O
Example	RB	O
8	CD	O
Oligonucleotide	NNP	O
Analysis—96-Well	NNP	O
Plate	NNP	O
Format	NNP	O
The	DT	O
concentration	NN	O
of	IN	O
oligonucleotide	NN	O
in	IN	O
each	DT	O
well	NN	O
was	VBD	O
assessed	VBN	O
by	IN	O
dilution	NN	O
of	IN	O
samples	NNS	O
and	CC	O
UV	NNP	O
absorption	NN	O
spectroscopy	NN	O
.	.	O
The	DT	O
full-length	JJ	O
integrity	NN	O
of	IN	O
the	DT	O
individual	JJ	O
products	NNS	O
was	VBD	O
evaluated	VBN	O
by	IN	O
capillary	JJ	O
electrophoresis	NN	O
(	(	O
CE	NNP	O
)	)	O
in	IN	O
either	CC	O
the	DT	O
96-well	JJ	O
format	NN	O
(	(	O
Beckman	NNP	O
P/ACE™	NNP	O
MDQ	NNP	O
apparatus	NN	O
)	)	O
or	CC	O
,	,	O
for	IN	O
individually	RB	O
prepared	JJ	O
samples	NNS	O
,	,	O
on	IN	O
a	DT	O
commercial	JJ	O
CE	NNP	O
apparatus	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Beckman	NNP	O
P/ACE™	NNP	O
5000	CD	O
,	,	O
ABI	NNP	O
270	CD	O
apparatus	NN	O
)	)	O
.	.	O
Base	NNP	O
and	CC	O
backbone	NN	O
composition	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
mass	NN	O
analysis	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
utilizing	JJ	O
electrospray-mass	JJ	O
spectroscopy	NN	O
.	.	O
All	DT	O
assay	VBP	O
test	NN	O
plates	NNS	O
were	VBD	O
diluted	VBN	O
from	IN	O
the	DT	O
master	NN	O
plate	NN	O
using	VBG	O
single	JJ	O
and	CC	O
multi-channel	JJ	O
robotic	JJ	O
pipettors	NNS	O
.	.	O
Plates	NNS	O
were	VBD	O
judged	VBN	O
to	TO	O
be	VB	O
acceptable	JJ	O
if	IN	O
at	IN	O
least	JJS	O
85	CD	O
%	NN	O
of	IN	O
the	DT	O
compounds	NNS	O
on	IN	O
the	DT	O
plate	NN	O
were	VBD	O
at	IN	O
least	JJS	O
85	CD	O
%	NN	O
full	JJ	O
length	NN	O
.	.	O
Example	RB	O
9	CD	O
Cell	NNP	O
Culture	NNP	O
and	CC	O
Oligonucleotide	NNP	O
Treatment	NNP	O
The	DT	O
effect	NN	O
of	IN	O
antisense	NN	O
compounds	NNS	O
on	IN	O
target	NN	O
nucleic	JJ	O
acid	JJ	O
expression	NN	O
can	MD	O
be	VB	O
tested	VBN	O
in	IN	O
any	DT	O
of	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
types	NNS	O
provided	VBD	O
that	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
present	JJ	O
at	IN	O
measurable	JJ	O
levels	NNS	O
.	.	O
This	DT	O
can	MD	O
be	VB	O
routinely	RB	O
determined	VBN	O
using	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
PCR	NNP	O
or	CC	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
.	.	O
The	DT	O
following	VBG	O
cell	NN	O
types	NNS	O
are	VBP	O
provided	VBN	O
for	IN	O
illustrative	JJ	O
purposes	NNS	O
,	,	O
but	CC	O
other	JJ	O
cell	NN	O
types	NNS	O
can	MD	O
be	VB	O
routinely	RB	O
used	VBN	O
,	,	O
provided	VBD	O
that	IN	O
the	DT	O
target	NN	O
is	VBZ	O
expressed	VBN	O
in	IN	O
the	DT	O
cell	NN	O
type	NN	O
chosen	NN	O
.	.	O
This	DT	O
can	MD	O
be	VB	O
readily	RB	O
determined	VBN	O
by	IN	O
methods	NNS	O
routine	JJ	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
for	IN	O
example	NN	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
,	,	O
ribonuclease	NN	O
protection	NN	O
assays	NNS	O
,	,	O
or	CC	O
real-time	JJ	O
PCR	NNP	O
.	.	O
T-24	JJ	O
Cells	NNS	O
:	:	O
The	DT	O
human	JJ	O
transitional	JJ	O
cell	NN	O
bladder	NN	O
carcinoma	NN	O
cell	NN	O
line	NN	O
T-24	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
ATCC	NNP	O
)	)	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
T-24	JJ	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
complete	JJ	O
McCoy	NNP	O
's	POS	O
5A	CD	O
basal	JJ	O
media	NNS	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
,	,	O
penicillin	$	O
100	CD	O
units	NNS	O
per	IN	O
mL	NN	O
,	,	O
and	CC	O
streptomycin	VBD	O
100	CD	O
micrograms	NNS	O
per	IN	O
mL	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
353872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
7000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
RT-PCR	JJ	O
analysis	NN	O
.	.	O
For	IN	O
Northern	NNP	O
blotting	NN	O
or	CC	O
other	JJ	O
analysis	NN	O
,	,	O
cells	NNS	O
may	MD	O
be	VB	O
seeded	VBN	O
onto	IN	O
100	CD	O
mm	NNS	O
or	CC	O
other	JJ	O
standard	JJ	O
tissue	NN	O
culture	NN	O
plates	NNS	O
and	CC	O
treated	VBD	O
similarly	RB	O
,	,	O
using	VBG	O
appropriate	JJ	O
volumes	NNS	O
of	IN	O
medium	NN	O
and	CC	O
oligonucleotide	NN	O
.	.	O
A549	NNP	O
Cells	NNP	O
:	:	O
The	DT	O
human	JJ	O
lung	NN	O
carcinoma	NN	O
cell	NN	O
line	NN	O
A549	NNP	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
ATCC	NNP	O
)	)	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
A549	NNP	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
DMEM	NNP	O
basal	NN	O
media	NNS	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
,	,	O
penicillin	$	O
100	CD	O
units	NNS	O
per	IN	O
mL	NN	O
,	,	O
and	CC	O
streptomycin	VBD	O
100	CD	O
micrograms	NNS	O
per	IN	O
mL	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
90	CD	O
%	NN	O
confluence	NN	O
.	.	O
NHDF	NNP	O
Cells	NNP	O
:	:	O
Human	NNP	O
neonatal	JJ	O
dermal	NN	O
fibroblast	NN	O
(	(	O
NHDF	NNP	O
)	)	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
Clonetics	NNPS	O
Corporation	NNP	O
(	(	O
Walkersville	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
.	.	O
NHDFs	NNP	O
were	VBD	O
routinely	RB	O
maintained	VBN	O
in	IN	O
Fibroblast	NNP	O
Growth	NNP	O
Medium	NNP	O
(	(	O
Clonetics	NNPS	O
Corporation	NNP	O
,	,	O
Walkersville	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
supplemented	VBN	O
as	IN	O
recommended	VBN	O
by	IN	O
the	DT	O
supplier	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
maintained	VBN	O
for	IN	O
up	RB	O
to	TO	O
10	CD	O
passages	NNS	O
as	IN	O
recommended	VBN	O
by	IN	O
the	DT	O
supplier	NN	O
.	.	O
HEK	NNP	O
Cells	NNP	O
:	:	O
Human	NNP	O
embryonic	VBZ	O
keratinocytes	NNS	O
(	(	O
HEK	NNP	O
)	)	O
were	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
Clonetics	NNPS	O
Corporation	NNP	O
(	(	O
Walkersville	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
.	.	O
HEKs	NNP	O
were	VBD	O
routinely	RB	O
maintained	VBN	O
in	IN	O
Keratinocyte	NNP	O
Growth	NNP	O
Medium	NNP	O
(	(	O
Clonetics	NNPS	O
Corporation	NNP	O
,	,	O
Walkersville	NNP	O
,	,	O
Md	NNP	O
.	.	O
)	)	O
formulated	VBN	O
as	IN	O
recommended	VBN	O
by	IN	O
the	DT	O
supplier	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
maintained	VBN	O
for	IN	O
up	RB	O
to	TO	O
10	CD	O
passages	NNS	O
as	IN	O
recommended	VBN	O
by	IN	O
the	DT	O
supplier	NN	O
.	.	O
3T3-L1	JJ	O
Cells	NNS	O
:	:	O
The	DT	O
mouse	NN	O
embryonic	JJ	O
adipocyte-like	JJ	O
cell	NN	O
line	NN	O
3T3-L1	CD	O
was	VBD	O
obtained	VBN	O
from	IN	O
the	DT	O
American	JJ	O
Type	NNP	O
Culture	NNP	O
Collection	NNP	O
(	(	O
Manassas	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
3T3-L1	JJ	O
cells	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
DMEM	NNP	O
,	,	O
high	JJ	O
glucose	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
routinely	RB	O
passaged	VBN	O
by	IN	O
trypsinization	NN	O
and	CC	O
dilution	NN	O
when	WRB	O
they	PRP	O
reached	VBD	O
80	CD	O
%	NN	O
confluence	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
4000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
RT-PCR	JJ	O
analysis	NN	O
.	.	O
For	IN	O
Northern	NNP	O
blotting	NN	O
or	CC	O
other	JJ	O
analyses	NNS	O
,	,	O
cells	NNS	O
may	MD	O
be	VB	O
seeded	VBN	O
onto	IN	O
100	CD	O
mm	NNS	O
or	CC	O
other	JJ	O
standard	JJ	O
tissue	NN	O
culture	NN	O
plates	NNS	O
and	CC	O
treated	VBD	O
similarly	RB	O
,	,	O
using	VBG	O
appropriate	JJ	O
volumes	NNS	O
of	IN	O
medium	NN	O
and	CC	O
oligonucleotide	NN	O
.	.	O
Primary	JJ	O
Mouse	NNP	O
Hepatocytes	VBZ	O
:	:	O
Primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
were	VBD	O
prepared	VBN	O
from	IN	O
CD-1	NNP	O
mice	NNS	O
purchased	VBD	O
from	IN	O
Charles	NNP	O
River	NNP	O
Labs	NNP	O
.	.	O
Primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
Hepatocyte	NNP	O
Attachment	NNP	O
Media	NNP	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
1	CD	O
%	NN	O
penicillin/streptomycin	NN	O
,	,	O
1	CD	O
%	NN	O
antibiotic-antimitotic	JJ	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
and	CC	O
10	CD	O
nM	JJ	O
bovine	NN	O
insulin	NN	O
(	(	O
Sigma-Aldrich	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
coated	VBN	O
with	IN	O
0.1	CD	O
mg/ml	NNS	O
collagen	NN	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
10,000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligomeric	JJ	O
compound	NN	O
transfection	NN	O
experiments	NNS	O
.	.	O
Treatment	NN	O
with	IN	O
Antisense	NNP	O
Compounds	NNS	O
:	:	O
When	WRB	O
cells	NNS	O
reached	VBD	O
65-75	CD	O
%	NN	O
confluency	NN	O
,	,	O
they	PRP	O
were	VBD	O
treated	VBN	O
with	IN	O
oligonucleotide	NN	O
.	.	O
For	IN	O
cells	NNS	O
grown	VBN	O
in	IN	O
96-well	CD	O
plates	NNS	O
,	,	O
wells	NNS	O
were	VBD	O
washed	VBN	O
once	RB	O
with	IN	O
100	CD	O
μL	JJ	O
OPTI-MEM™-1	JJ	O
reduced-serum	JJ	O
medium	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
and	CC	O
then	RB	O
treated	VBD	O
with	IN	O
130	CD	O
μL	NNS	O
of	IN	O
the	DT	O
OPTI-MEM™-1	NNP	O
medium	NN	O
containing	VBG	O
2.5	CD	O
or	CC	O
3	CD	O
μg/mL	JJ	O
LIPOFECTIN™	NNP	O
reagent	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
per	IN	O
100	CD	O
nM	NN	O
of	IN	O
oligonucleotide	NN	O
.	.	O
Cells	NNS	O
are	VBP	O
treated	VBN	O
and	CC	O
data	NNS	O
are	VBP	O
obtained	VBN	O
in	IN	O
triplicate	NN	O
.	.	O
After	IN	O
4-7	JJ	O
hours	NNS	O
of	IN	O
treatment	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
,	,	O
the	DT	O
medium	NN	O
was	VBD	O
replaced	VBN	O
with	IN	O
fresh	JJ	O
medium	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
harvested	VBN	O
16-24	JJ	O
hours	NNS	O
after	IN	O
oligonucleotide	JJ	O
treatment	NN	O
.	.	O
The	DT	O
concentration	NN	O
of	IN	O
oligonucleotide	NN	O
used	VBN	O
varies	NNS	O
from	IN	O
cell	NN	O
line	NN	O
to	TO	O
cell	VB	O
line	NN	O
.	.	O
To	TO	O
determine	VB	O
the	DT	O
optimal	JJ	O
oligonucleotide	JJ	O
concentration	NN	O
for	IN	O
a	DT	O
particular	JJ	O
cell	NN	O
line	NN	O
,	,	O
the	DT	O
cells	NNS	O
are	VBP	O
treated	VBN	O
with	IN	O
a	DT	O
positive	JJ	O
control	NN	O
oligonucleotide	NN	O
at	IN	O
a	DT	O
range	NN	O
of	IN	O
concentrations	NNS	O
.	.	O
For	IN	O
human	JJ	O
cells	NNS	O
the	DT	O
positive	JJ	O
control	NN	O
oligonucleotide	NN	O
is	VBZ	O
selected	VBN	O
from	IN	O
either	CC	O
ISIS	NNP	O
13920	CD	O
(	(	O
TCCGTCATCGCTCCTCAGGG	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
1	CD	O
)	)	O
which	WDT	O
is	VBZ	O
targeted	VBN	O
to	TO	O
human	JJ	O
H-ras	NNP	O
,	,	O
or	CC	O
ISIS	NNP	O
18078	CD	O
,	,	O
(	(	O
GTGCGCGCGAGCCCGAAATC	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
2	CD	O
)	)	O
which	WDT	O
is	VBZ	O
targeted	VBN	O
to	TO	O
human	JJ	O
Jun-N-terminal	JJ	O
kinase-2	NN	O
(	(	O
JNK2	NNP	O
)	)	O
.	.	O
Both	DT	O
controls	NNS	O
are	VBP	O
2′-O-methoxyethyl	JJ	O
gapmers	NNS	O
(	(	O
2′-O-methoxyethyls	JJ	O
shown	VBN	O
in	IN	O
bold	NN	O
)	)	O
with	IN	O
a	DT	O
phosphorothioate	NN	O
backbone	NN	O
.	.	O
For	IN	O
mouse	NN	O
or	CC	O
rat	NN	O
cells	NNS	O
the	DT	O
positive	JJ	O
control	NN	O
oligonucleotide	NN	O
is	VBZ	O
ISIS	NNP	O
15770	CD	O
,	,	O
ATGCATTCTGCCCCCAAGGA	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
3	CD	O
,	,	O
a	DT	O
2′-O-methoxyethyl	JJ	O
gapmer	NN	O
(	(	O
2′-O-methoxyethyls	JJ	O
shown	VBN	O
in	IN	O
bold	NN	O
)	)	O
with	IN	O
a	DT	O
phosphorothioate	NN	O
backbone	NN	O
which	WDT	O
is	VBZ	O
targeted	VBN	O
to	TO	O
both	DT	O
mouse	NN	O
and	CC	O
rat	VB	O
c-raf	NN	O
.	.	O
The	DT	O
concentration	NN	O
of	IN	O
positive	JJ	O
control	NN	O
oligonucleotide	IN	O
that	DT	O
results	NNS	O
in	IN	O
80	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
c-H-ras	NNS	O
(	(	O
for	IN	O
ISIS	NNP	O
13920	CD	O
)	)	O
,	,	O
JNK2	NNP	O
(	(	O
for	IN	O
ISIS	NNP	O
18078	CD	O
)	)	O
or	CC	O
c-raf	JJ	O
(	(	O
for	IN	O
ISIS	NNP	O
15770	CD	O
)	)	O
mRNA	NN	O
is	VBZ	O
then	RB	O
utilized	JJ	O
as	IN	O
the	DT	O
screening	NN	O
concentration	NN	O
for	IN	O
new	JJ	O
oligonucleotides	NNS	O
in	IN	O
subsequent	JJ	O
experiments	NNS	O
for	IN	O
that	DT	O
cell	NN	O
line	NN	O
.	.	O
If	IN	O
80	CD	O
%	NN	O
inhibition	NN	O
is	VBZ	O
not	RB	O
achieved	VBN	O
,	,	O
the	DT	O
lowest	JJS	O
concentration	NN	O
of	IN	O
positive	JJ	O
control	NN	O
oligonucleotide	IN	O
that	DT	O
results	NNS	O
in	IN	O
60	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
c-H-ras	NNS	O
,	,	O
JNK2	NNP	O
or	CC	O
c-raf	JJ	O
mRNA	NN	O
is	VBZ	O
then	RB	O
utilized	JJ	O
as	IN	O
the	DT	O
oligonucleotide	NN	O
screening	VBG	O
concentration	NN	O
in	IN	O
subsequent	JJ	O
experiments	NNS	O
for	IN	O
that	DT	O
cell	NN	O
line	NN	O
.	.	O
If	IN	O
60	CD	O
%	NN	O
inhibition	NN	O
is	VBZ	O
not	RB	O
achieved	VBN	O
,	,	O
that	IN	O
particular	JJ	O
cell	NN	O
line	NN	O
is	VBZ	O
deemed	VBN	O
as	IN	O
unsuitable	JJ	O
for	IN	O
oligonucleotide	JJ	O
transfection	NN	O
experiments	NNS	O
.	.	O
The	DT	O
concentrations	NNS	O
of	IN	O
antisense	NN	O
oligonucleotides	NNS	O
used	VBN	O
herein	NNS	O
are	VBP	O
from	IN	O
50	CD	O
nM	NNS	O
to	TO	O
300	CD	O
nM	NNS	O
.	.	O
Example	RB	O
10	CD	O
Analysis	NN	O
of	IN	O
Oligonucleotide	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
Expression	NNP	O
Antisense	NNP	O
modulation	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
can	MD	O
be	VB	O
assayed	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
ways	NNS	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
diacylglycerol	VB	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
can	MD	O
be	VB	O
quantitated	VBN	O
by	IN	O
,	,	O
e.g.	NN	O
,	,	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
,	,	O
competitive	JJ	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
,	,	O
or	CC	O
real-time	JJ	O
PCR	NNP	O
.	.	O
Quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
is	VBZ	O
presently	RB	O
preferred	VBN	O
.	.	O
RNA	JJ	O
analysis	NN	O
can	MD	O
be	VB	O
performed	VBN	O
on	IN	O
total	JJ	O
cellular	JJ	O
RNA	NNP	O
or	CC	O
poly	NN	O
(	(	O
A	DT	O
)	)	O
+	NN	O
mRNA	NN	O
.	.	O
The	DT	O
preferred	JJ	O
method	NN	O
of	IN	O
RNA	NNP	O
analysis	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
is	VBZ	O
the	DT	O
use	NN	O
of	IN	O
total	JJ	O
cellular	JJ	O
RNA	NNP	O
as	IN	O
described	VBN	O
in	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
.	.	O
Methods	NNS	O
of	IN	O
RNA	NNP	O
isolation	NN	O
are	VBP	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Northern	NNP	O
blot	NN	O
analysis	NN	O
is	VBZ	O
also	RB	O
routine	JJ	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Real-time	JJ	O
quantitative	NN	O
(	(	O
PCR	NNP	O
)	)	O
can	MD	O
be	VB	O
conveniently	RB	O
accomplished	VBN	O
using	VBG	O
the	DT	O
commercially	RB	O
available	JJ	O
ABI	NNP	O
PRISM™	NNP	O
7600	CD	O
,	,	O
7700	CD	O
,	,	O
or	CC	O
7900	CD	O
Sequence	NNP	O
Detection	NNP	O
System	NNP	O
,	,	O
available	JJ	O
from	IN	O
PE-Applied	NNP	O
Biosystems	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
and	CC	O
used	VBD	O
according	VBG	O
to	TO	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O
Protein	NNP	O
levels	NNS	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
can	MD	O
be	VB	O
quantitated	VBN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
ways	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
,	,	O
such	JJ	O
as	IN	O
immunoprecipitation	NN	O
,	,	O
Western	JJ	O
blot	NN	O
analysis	NN	O
(	(	O
immunoblotting	VBG	O
)	)	O
,	,	O
enzyme-linked	JJ	O
immunosorbent	NN	O
assay	NN	O
(	(	O
ELISA	NNP	O
)	)	O
or	CC	O
fluorescence-activated	JJ	O
cell	NN	O
sorting	VBG	O
(	(	O
FACS	NNP	O
)	)	O
.	.	O
Antibodies	NNS	O
directed	VBD	O
to	TO	O
diacylglycerol	VB	O
acyltransferase	JJ	O
2	CD	O
can	MD	O
be	VB	O
identified	VBN	O
and	CC	O
obtained	VBN	O
from	IN	O
a	DT	O
variety	NN	O
of	IN	O
sources	NNS	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
MSRS	NNP	O
catalog	NN	O
of	IN	O
antibodies	NNS	O
(	(	O
Aerie	NNP	O
Corporation	NNP	O
,	,	O
Birmingham	NNP	O
,	,	O
Mich.	NNP	O
)	)	O
,	,	O
or	CC	O
can	MD	O
be	VB	O
prepared	JJ	O
via	IN	O
conventional	JJ	O
monoclonal	JJ	O
or	CC	O
polyclonal	JJ	O
antibody	NN	O
generation	NN	O
methods	NNS	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Example	JJ	O
11	CD	O
Design	NNP	O
of	IN	O
Phenotypic	NNP	O
Assays	NNP	O
for	IN	O
the	DT	O
Use	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
Inhibitors	NNPS	O
Once	RB	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
inhibitors	NNS	O
have	VBP	O
been	VBN	O
identified	VBN	O
by	IN	O
the	DT	O
methods	NNS	O
disclosed	VBD	O
herein	NN	O
,	,	O
the	DT	O
compounds	NNS	O
are	VBP	O
further	RB	O
investigated	VBN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
phenotypic	NN	O
assays	NNS	O
,	,	O
each	DT	O
having	VBG	O
measurable	JJ	O
endpoints	NNS	O
predictive	NN	O
of	IN	O
efficacy	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
a	DT	O
particular	JJ	O
disease	NN	O
state	NN	O
or	CC	O
condition	NN	O
.	.	O
Phenotypic	NNP	O
assays	NNS	O
,	,	O
kits	NNS	O
and	CC	O
reagents	NNS	O
for	IN	O
their	PRP$	O
use	NN	O
are	VBP	O
well	RB	O
known	VBN	O
to	TO	O
those	DT	O
skilled	VBN	O
in	IN	O
the	DT	O
art	NN	O
and	CC	O
are	VBP	O
herein	NNS	O
used	VBN	O
to	TO	O
investigate	VB	O
the	DT	O
role	NN	O
and/or	NN	O
association	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
health	NN	O
and	CC	O
disease	NN	O
.	.	O
Representative	JJ	O
phenotypic	NN	O
assays	NNS	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
purchased	VBN	O
from	IN	O
any	DT	O
one	CD	O
of	IN	O
several	JJ	O
commercial	JJ	O
vendors	NNS	O
,	,	O
include	VBP	O
those	DT	O
for	IN	O
determining	VBG	O
cell	NN	O
viability	NN	O
,	,	O
cytotoxicity	NN	O
,	,	O
proliferation	NN	O
or	CC	O
cell	NN	O
survival	NN	O
(	(	O
Molecular	JJ	O
Probes	NNP	O
,	,	O
Eugene	NNP	O
,	,	O
Oreg	NNP	O
.	.	O
;	:	O
PerkinElmer	NNP	O
,	,	O
Boston	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
,	,	O
protein-based	JJ	O
assays	NNS	O
including	VBG	O
enzymatic	JJ	O
assays	NNS	O
(	(	O
Panvera	NNP	O
,	,	O
LLC	NNP	O
,	,	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
;	:	O
BD	NNP	O
Biosciences	NNPS	O
,	,	O
Franklin	NNP	O
Lakes	NNP	O
,	,	O
N.J.	NNP	O
;	:	O
Oncogene	NNP	O
Research	NNP	O
Products	NNPS	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
,	,	O
cell	NN	O
regulation	NN	O
,	,	O
signal	JJ	O
transduction	NN	O
,	,	O
inflammation	NN	O
,	,	O
oxidative	JJ	O
processes	NNS	O
and	CC	O
apoptosis	NN	O
(	(	O
Assay	NNP	O
Designs	NNP	O
Inc.	NNP	O
,	,	O
Ann	NNP	O
Arbor	NNP	O
,	,	O
Mich.	NNP	O
)	)	O
,	,	O
triglyceride	JJ	O
accumulation	NN	O
(	(	O
Sigma-Aldrich	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
,	,	O
angiogenesis	NN	O
assays	NNS	O
,	,	O
tube	NN	O
formation	NN	O
assays	NNS	O
,	,	O
cytokine	NN	O
and	CC	O
hormone	NN	O
assays	NNS	O
and	CC	O
metabolic	JJ	O
assays	NNS	O
(	(	O
Chemicon	NNP	O
International	NNP	O
Inc.	NNP	O
,	,	O
Temecula	NNP	O
,	,	O
Calif.	NNP	O
;	:	O
Amersham	NNP	O
Biosciences	NNPS	O
,	,	O
Piscataway	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
.	.	O
In	IN	O
one	CD	O
non-limiting	JJ	O
example	NN	O
,	,	O
cells	NNS	O
determined	VBD	O
to	TO	O
be	VB	O
appropriate	JJ	O
for	IN	O
a	DT	O
particular	JJ	O
phenotypic	NN	O
assay	NN	O
(	(	O
i.e.	JJ	O
,	,	O
MCF-7	NNP	O
cells	NNS	O
selected	VBN	O
for	IN	O
breast	NN	O
cancer	NN	O
studies	NNS	O
;	:	O
adipocytes	NNS	O
for	IN	O
obesity	NN	O
studies	NNS	O
)	)	O
are	VBP	O
treated	VBN	O
with	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
inhibitors	NNS	O
identified	VBN	O
from	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
studies	NNS	O
as	RB	O
well	RB	O
as	IN	O
control	NN	O
compounds	VBZ	O
at	IN	O
optimal	JJ	O
concentrations	NNS	O
which	WDT	O
are	VBP	O
determined	VBN	O
by	IN	O
the	DT	O
methods	NNS	O
described	VBN	O
above	IN	O
.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
treated	VBN	O
and	CC	O
untreated	JJ	O
cells	NNS	O
are	VBP	O
analyzed	VBN	O
by	IN	O
one	CD	O
or	CC	O
more	JJR	O
methods	NNS	O
specific	JJ	O
for	IN	O
the	DT	O
assay	NN	O
to	TO	O
determine	VB	O
phenotypic	NN	O
outcomes	NNS	O
and	CC	O
endpoints	NNS	O
.	.	O
Phenotypic	NNP	O
endpoints	NNS	O
include	VBP	O
changes	NNS	O
in	IN	O
cell	NN	O
morphology	NN	O
over	IN	O
time	NN	O
or	CC	O
treatment	NN	O
dose	NN	O
as	RB	O
well	RB	O
as	IN	O
changes	NNS	O
in	IN	O
levels	NNS	O
of	IN	O
cellular	JJ	O
components	NNS	O
such	JJ	O
as	IN	O
proteins	NNS	O
,	,	O
lipids	NNS	O
,	,	O
nucleic	JJ	O
acids	NNS	O
,	,	O
hormones	NNS	O
,	,	O
saccharides	NNS	O
or	CC	O
metals	NNS	O
.	.	O
Measurements	NNS	O
of	IN	O
cellular	JJ	O
status	NN	O
which	WDT	O
include	VBP	O
pH	NN	O
,	,	O
stage	NN	O
of	IN	O
the	DT	O
cell	NN	O
cycle	NN	O
,	,	O
intake	NN	O
or	CC	O
excretion	NN	O
of	IN	O
biological	JJ	O
indicators	NNS	O
by	IN	O
the	DT	O
cell	NN	O
,	,	O
are	VBP	O
also	RB	O
endpoints	NNS	O
of	IN	O
interest	NN	O
.	.	O
Analysis	NN	O
of	IN	O
the	DT	O
expression	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
genes	NNS	O
in	IN	O
the	DT	O
cell	NN	O
after	IN	O
treatment	NN	O
is	VBZ	O
also	RB	O
used	VBN	O
as	IN	O
an	DT	O
indicator	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
or	CC	O
potency	NN	O
of	IN	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
inhibitors	NNS	O
.	.	O
Hallmark	NNP	O
genes	NNS	O
,	,	O
or	CC	O
those	DT	O
genes	NNS	O
suspected	VBD	O
to	TO	O
be	VB	O
associated	VBN	O
with	IN	O
a	DT	O
specific	JJ	O
disease	NN	O
state	NN	O
,	,	O
condition	NN	O
,	,	O
or	CC	O
phenotype	NN	O
,	,	O
are	VBP	O
measured	VBN	O
in	IN	O
both	DT	O
treated	JJ	O
and	CC	O
untreated	JJ	O
cells	NNS	O
.	.	O
Example	RB	O
12	CD	O
RNA	NNP	O
Isolation	NNP	O
Poly	NNP	O
(	(	O
A	NNP	O
)	)	O
+	NN	O
mRNA	JJ	O
Isolation	NNP	O
Poly	NNP	O
(	(	O
A	NNP	O
)	)	O
+	NN	O
mRNA	NN	O
was	VBD	O
isolated	VBN	O
according	VBG	O
to	TO	O
Miura	NNP	B
et	FW	I
al.	NN	I
,	,	I
(	(	I
Clin	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
1996	CD	I
,	,	I
42	CD	I
,	,	I
1758-1764	JJ	I
)	)	I
.	.	O
Other	JJ	O
methods	NNS	O
for	IN	O
poly	NN	O
(	(	O
A	DT	O
)	)	O
+	NN	O
mRNA	JJ	O
isolation	NN	O
are	VBP	O
routine	JJ	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Briefly	NNP	O
,	,	O
for	IN	O
cells	NNS	O
grown	VBN	O
on	IN	O
96-well	CD	O
plates	NNS	O
,	,	O
growth	NN	O
medium	NN	O
was	VBD	O
removed	VBN	O
from	IN	O
the	DT	O
cells	NNS	O
and	CC	O
each	DT	O
well	NN	O
was	VBD	O
washed	VBN	O
with	IN	O
200	CD	O
μL	NNS	O
cold	JJ	O
PBS	NNP	O
.	.	O
60	CD	O
μL	JJ	O
lysis	NN	O
buffer	NN	O
(	(	O
10	CD	O
mM	RB	O
Tris-HCl	NNP	O
,	,	O
pH	NN	O
7.6	CD	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
0.5	CD	O
M	NNP	O
NaCl	NNP	O
,	,	O
0.5	CD	O
%	NN	O
NP-40	NNP	O
,	,	O
20	CD	O
mM	JJ	O
vanadyl-ribonucleoside	JJ	O
complex	NN	O
)	)	O
was	VBD	O
added	VBN	O
to	TO	O
each	DT	O
well	NN	O
,	,	O
the	DT	O
plate	NN	O
was	VBD	O
gently	RB	O
agitated	VBN	O
and	CC	O
then	RB	O
incubated	VBD	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
five	CD	O
minutes	NNS	O
.	.	O
55	CD	O
μL	NN	O
of	IN	O
lysate	NN	O
was	VBD	O
transferred	VBN	O
to	TO	O
Oligo	NNP	O
d	NN	O
(	(	O
T	NNP	O
)	)	O
coated	VBD	O
96-well	CD	O
plates	NNS	O
(	(	O
AGCT	NNP	O
Inc.	NNP	O
,	,	O
Irvine	NNP	O
Calif.	NNP	O
)	)	O
.	.	O
Plates	NNS	O
were	VBD	O
incubated	VBN	O
for	IN	O
60	CD	O
minutes	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
,	,	O
washed	VBD	O
3	CD	O
times	NNS	O
with	IN	O
200	CD	O
μL	NNS	O
of	IN	O
wash	NN	O
buffer	NN	O
(	(	O
10	CD	O
mM	RB	O
Tris-HCl	NNP	O
pH	NN	O
7.6	CD	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
0.3	CD	O
M	NNP	O
NaCl	NNP	O
)	)	O
.	.	O
After	IN	O
the	DT	O
final	JJ	O
wash	NN	O
,	,	O
the	DT	O
plate	NN	O
was	VBD	O
blotted	VBN	O
on	IN	O
paper	NN	O
towels	NNS	O
to	TO	O
remove	VB	O
excess	JJ	O
wash	NN	O
buffer	NN	O
and	CC	O
then	RB	O
air-dried	JJ	O
for	IN	O
5	CD	O
minutes	NNS	O
.	.	O
60	CD	O
μL	NN	O
of	IN	O
elution	NN	O
buffer	NN	O
(	(	O
5	CD	O
mM	RB	O
Tris-HCl	NNP	O
pH	NN	O
7.6	CD	O
)	)	O
,	,	O
preheated	VBD	O
to	TO	O
70°	CD	O
C.	NNP	O
,	,	O
was	VBD	O
added	VBN	O
to	TO	O
each	DT	O
well	NN	O
,	,	O
the	DT	O
plate	NN	O
was	VBD	O
incubated	VBN	O
on	IN	O
a	DT	O
90°	CD	O
C.	NNP	O
hot	JJ	O
plate	NN	O
for	IN	O
5	CD	O
minutes	NNS	O
,	,	O
and	CC	O
the	DT	O
eluate	NN	O
was	VBD	O
then	RB	O
transferred	VBN	O
to	TO	O
a	DT	O
fresh	JJ	O
96-well	CD	O
plate	NN	O
.	.	O
Cells	NNP	O
grown	VBN	O
on	IN	O
100	CD	O
mm	NN	O
or	CC	O
other	JJ	O
standard	JJ	O
plates	NNS	O
may	MD	O
be	VB	O
treated	VBN	O
similarly	RB	O
,	,	O
using	VBG	O
appropriate	JJ	O
volumes	NNS	O
of	IN	O
all	DT	O
solutions	NNS	O
.	.	O
Total	JJ	O
RNA	NNP	O
Isolation	NNP	O
Total	NNP	O
RNA	NNP	O
was	VBD	O
isolated	VBN	O
using	VBG	O
an	DT	O
RNEASY™	NNP	O
96	CD	O
kit	NN	O
and	CC	O
buffers	NNS	O
purchased	VBN	O
from	IN	O
Qiagen	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
Valencia	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
following	VBG	O
the	DT	O
manufacturer	NN	O
's	POS	O
recommended	JJ	O
procedures	NNS	O
.	.	O
Briefly	NNP	O
,	,	O
for	IN	O
cells	NNS	O
grown	VBN	O
on	IN	O
96-well	CD	O
plates	NNS	O
,	,	O
growth	NN	O
medium	NN	O
was	VBD	O
removed	VBN	O
from	IN	O
the	DT	O
cells	NNS	O
and	CC	O
each	DT	O
well	NN	O
was	VBD	O
washed	VBN	O
with	IN	O
200	CD	O
μL	NNS	O
cold	JJ	O
PBS	NNP	O
.	.	O
150	CD	O
μL	JJ	O
Buffer	NNP	O
RLT	NNP	O
was	VBD	O
added	VBN	O
to	TO	O
each	DT	O
well	NN	O
and	CC	O
the	DT	O
plate	NN	O
vigorously	RB	O
agitated	VBD	O
for	IN	O
20	CD	O
seconds	NNS	O
.	.	O
150	CD	O
μL	NN	O
of	IN	O
70	CD	O
%	NN	O
ethanol	NN	O
was	VBD	O
then	RB	O
added	VBN	O
to	TO	O
each	DT	O
well	NN	O
and	CC	O
the	DT	O
contents	NNS	O
mixed	VBN	O
by	IN	O
pipetting	VBG	O
three	CD	O
times	NNS	O
up	RB	O
and	CC	O
down	RB	O
.	.	O
The	DT	O
samples	NNS	O
were	VBD	O
then	RB	O
transferred	VBN	O
to	TO	O
the	DT	O
RNEASY™	NNP	O
96	CD	O
well	RB	O
plate	VB	O
attached	VBN	O
to	TO	O
a	DT	O
QIAVAC™	NNP	O
manifold	NN	O
fitted	VBN	O
with	IN	O
a	DT	O
waste	NN	O
collection	NN	O
tray	NN	O
and	CC	O
attached	VBN	O
to	TO	O
a	DT	O
vacuum	NN	O
source	NN	O
.	.	O
Vacuum	NNP	O
was	VBD	O
applied	VBN	O
for	IN	O
1	CD	O
minute	NN	O
.	.	O
500	CD	O
μL	NN	O
of	IN	O
Buffer	NNP	O
RW1	NNP	O
was	VBD	O
added	VBN	O
to	TO	O
each	DT	O
well	NN	O
of	IN	O
the	DT	O
RNEASY™	NNP	O
96	CD	O
plate	NN	O
and	CC	O
incubated	VBN	O
for	IN	O
15	CD	O
minutes	NNS	O
and	CC	O
the	DT	O
vacuum	NN	O
was	VBD	O
again	RB	O
applied	VBN	O
for	IN	O
1	CD	O
minute	NN	O
.	.	O
An	DT	O
additional	JJ	O
500	CD	O
μL	NN	O
of	IN	O
Buffer	NNP	O
RW1	NNP	O
was	VBD	O
added	VBN	O
to	TO	O
each	DT	O
well	NN	O
of	IN	O
the	DT	O
RNEASY™	NNP	O
96	CD	O
plate	NN	O
and	CC	O
the	DT	O
vacuum	NN	O
was	VBD	O
applied	VBN	O
for	IN	O
2	CD	O
minutes	NNS	O
.	.	O
1	CD	O
mL	NN	O
of	IN	O
Buffer	NNP	O
RPE	NNP	O
was	VBD	O
then	RB	O
added	VBN	O
to	TO	O
each	DT	O
well	NN	O
of	IN	O
the	DT	O
RNEASY™	NNP	O
96	CD	O
plate	NN	O
and	CC	O
the	DT	O
vacuum	NN	O
applied	VBD	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
90	CD	O
seconds	NNS	O
.	.	O
The	DT	O
Buffer	NNP	O
RPE	NNP	O
wash	NN	O
was	VBD	O
then	RB	O
repeated	VBN	O
and	CC	O
the	DT	O
vacuum	NN	O
was	VBD	O
applied	VBN	O
for	IN	O
an	DT	O
additional	JJ	O
3	CD	O
minutes	NNS	O
.	.	O
The	DT	O
plate	NN	O
was	VBD	O
then	RB	O
removed	VBN	O
from	IN	O
the	DT	O
QIAVAC™	NNP	O
manifold	NN	O
and	CC	O
blotted	VBD	O
dry	NNS	O
on	IN	O
paper	NN	O
towels	NNS	O
.	.	O
The	DT	O
plate	NN	O
was	VBD	O
then	RB	O
re-attached	JJ	O
to	TO	O
the	DT	O
QIAVAC™	NNP	O
manifold	NN	O
fitted	VBN	O
with	IN	O
a	DT	O
collection	NN	O
tube	NN	O
rack	NN	O
containing	VBG	O
1.2	CD	O
mL	JJ	O
collection	NN	O
tubes	NNS	O
.	.	O
RNA	NNP	O
was	VBD	O
then	RB	O
eluted	VBN	O
by	IN	O
pipetting	VBG	O
140	CD	O
μL	NN	O
of	IN	O
RNase	NNP	O
free	JJ	O
water	NN	O
into	IN	O
each	DT	O
well	NN	O
,	,	O
incubating	VBG	O
1	CD	O
minute	NN	O
,	,	O
and	CC	O
then	RB	O
applying	VBG	O
the	DT	O
vacuum	NN	O
for	IN	O
3	CD	O
minutes	NNS	O
.	.	O
The	DT	O
repetitive	JJ	O
pipetting	NN	O
and	CC	O
elution	NN	O
steps	NNS	O
may	MD	O
be	VB	O
automated	VBN	O
using	VBG	O
a	DT	O
QIAGEN®	NNP	O
Bio-Robot™	NNP	O
9604	CD	O
instrument	NN	O
(	(	O
Qiagen	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Valencia	NNP	O
Calif.	NNP	O
)	)	O
.	.	O
Essentially	RB	O
,	,	O
after	IN	O
lysing	VBG	O
of	IN	O
the	DT	O
cells	NNS	O
on	IN	O
the	DT	O
culture	NN	O
plate	NN	O
,	,	O
the	DT	O
plate	NN	O
is	VBZ	O
transferred	VBN	O
to	TO	O
the	DT	O
robot	NN	O
deck	NN	O
where	WRB	O
the	DT	O
pipetting	NN	O
,	,	O
DNase	NNP	O
treatment	NN	O
and	CC	O
elution	NN	O
steps	NNS	O
are	VBP	O
carried	VBN	O
out	RP	O
.	.	O
Example	JJ	O
13	CD	O
Real-Time	JJ	O
Quantitative	NNP	O
PCR	NNP	O
Analysis	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
mRNA	NN	O
Levels	NNP	O
Quantitation	NNP	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
was	VBD	O
accomplished	VBN	O
by	IN	O
real-time	JJ	O
quantitative	JJ	O
PCR	NNP	O
using	VBG	O
the	DT	O
ABI	NNP	O
PRISM™	NNP	O
7600	CD	O
,	,	O
7700	CD	O
,	,	O
or	CC	O
7900	CD	O
Sequence	NNP	O
Detection	NNP	O
System	NNP	O
(	(	O
PE-Applied	JJ	O
Biosystems	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
according	VBG	O
to	TO	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O
This	DT	O
is	VBZ	O
a	DT	O
closed-tube	JJ	O
,	,	O
non-gel-based	JJ	O
,	,	O
fluorescence	NN	O
detection	NN	O
system	NN	O
which	WDT	O
allows	VBZ	O
high-throughput	NN	O
quantitation	NN	O
of	IN	O
polymerase	NN	O
chain	NN	O
reaction	NN	O
(	(	O
PCR	NNP	O
)	)	O
products	NNS	O
in	IN	O
real-time	NN	O
.	.	O
As	IN	O
opposed	VBN	O
to	TO	O
standard	VB	O
PCR	NNP	O
in	IN	O
which	WDT	O
amplification	NN	O
products	NNS	O
are	VBP	O
quantitated	VBN	O
after	IN	O
the	DT	O
PCR	NNP	O
is	VBZ	O
completed	VBN	O
,	,	O
products	NNS	O
in	IN	O
real-time	JJ	O
quantitative	JJ	O
PCR	NNP	O
are	VBP	O
quantitated	VBN	O
as	IN	O
they	PRP	O
accumulate	VBP	O
.	.	O
This	DT	O
is	VBZ	O
accomplished	VBN	O
by	IN	O
including	VBG	O
in	IN	O
the	DT	O
PCR	NNP	O
reaction	NN	O
an	DT	O
oligonucleotide	JJ	O
probe	NN	O
that	IN	O
anneals	VBZ	O
specifically	RB	O
between	IN	O
the	DT	O
forward	NN	O
and	CC	O
reverse	NN	O
PCR	NNP	O
primers	NNS	O
,	,	O
and	CC	O
contains	VBZ	O
two	CD	O
fluorescent	JJ	O
dyes	NNS	O
.	.	O
A	DT	O
reporter	NN	O
dye	NN	O
(	(	O
e.g.	JJ	O
,	,	O
FAM	NNP	O
or	CC	O
JOE	NNP	O
,	,	O
obtained	VBN	O
from	IN	O
either	DT	O
PE-Applied	JJ	O
Biosystems	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
,	,	O
Operon	NNP	O
Technologies	NNPS	O
Inc.	NNP	O
,	,	O
Alameda	NNP	O
,	,	O
Calif.	NNP	O
or	CC	O
Integrated	VBN	O
DNA	NNP	O
Technologies	NNPS	O
Inc.	NNP	O
,	,	O
Coralville	NNP	O
,	,	O
Iowa	NNP	O
)	)	O
is	VBZ	O
attached	VBN	O
to	TO	O
the	DT	O
5′	CD	O
end	NN	O
of	IN	O
the	DT	O
probe	NN	O
and	CC	O
a	DT	O
quencher	NN	O
dye	NN	O
(	(	O
e.g.	JJ	O
,	,	O
TAMRA	NNP	O
,	,	O
obtained	VBN	O
from	IN	O
either	DT	O
PE-Applied	JJ	O
Biosystems	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
,	,	O
Operon	NNP	O
Technologies	NNPS	O
Inc.	NNP	O
,	,	O
Alameda	NNP	O
,	,	O
Calif.	NNP	O
or	CC	O
Integrated	VBN	O
DNA	NNP	O
Technologies	NNPS	O
Inc.	NNP	O
,	,	O
Coralville	NNP	O
,	,	O
Iowa	NNP	O
)	)	O
is	VBZ	O
attached	VBN	O
to	TO	O
the	DT	O
3′	CD	O
end	NN	O
of	IN	O
the	DT	O
probe	NN	O
.	.	O
When	WRB	O
the	DT	O
probe	NN	O
and	CC	O
dyes	NNS	O
are	VBP	O
intact	JJ	O
,	,	O
reporter	JJ	O
dye	NN	O
emission	NN	O
is	VBZ	O
quenched	VBN	O
by	IN	O
the	DT	O
proximity	NN	O
of	IN	O
the	DT	O
3′	CD	O
quencher	NN	O
dye	NN	O
.	.	O
During	IN	O
amplification	NN	O
,	,	O
annealing	VBG	O
of	IN	O
the	DT	O
probe	NN	O
to	TO	O
the	DT	O
target	NN	O
sequence	NN	O
creates	VBZ	O
a	DT	O
substrate	NN	O
that	WDT	O
can	MD	O
be	VB	O
cleaved	VBN	O
by	IN	O
the	DT	O
5′-exonuclease	JJ	O
activity	NN	O
of	IN	O
Taq	NNP	O
polymerase	NN	O
.	.	O
During	IN	O
the	DT	O
extension	NN	O
phase	NN	O
of	IN	O
the	DT	O
PCR	NNP	O
amplification	NN	O
cycle	NN	O
,	,	O
cleavage	NN	O
of	IN	O
the	DT	O
probe	NN	O
by	IN	O
Taq	NNP	O
polymerase	NN	O
releases	VBZ	O
the	DT	O
reporter	NN	O
dye	NN	O
from	IN	O
the	DT	O
remainder	NN	O
of	IN	O
the	DT	O
probe	NN	O
(	(	O
and	CC	O
hence	RB	O
from	IN	O
the	DT	O
quencher	JJR	O
moiety	NN	O
)	)	O
and	CC	O
a	DT	O
sequence-specific	JJ	O
fluorescent	JJ	O
signal	NN	O
is	VBZ	O
generated	VBN	O
.	.	O
With	IN	O
each	DT	O
cycle	NN	O
,	,	O
additional	JJ	O
reporter	NN	O
dye	NN	O
molecules	NNS	O
are	VBP	O
cleaved	VBN	O
from	IN	O
their	PRP$	O
respective	JJ	O
probes	NNS	O
,	,	O
and	CC	O
the	DT	O
fluorescence	NN	O
intensity	NN	O
is	VBZ	O
monitored	VBN	O
at	IN	O
regular	JJ	O
intervals	NNS	O
by	IN	O
laser	NN	O
optics	NNS	O
built	VBN	O
into	IN	O
the	DT	O
ABI	NNP	O
PRISM™	NNP	O
Sequence	NNP	O
Detection	NNP	O
System	NNP	O
.	.	O
In	IN	O
each	DT	O
assay	NN	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
parallel	JJ	O
reactions	NNS	O
containing	VBG	O
serial	JJ	O
dilutions	NNS	O
of	IN	O
mRNA	NN	O
from	IN	O
untreated	JJ	O
control	NN	O
samples	VBZ	O
generates	VBZ	O
a	DT	O
standard	JJ	O
curve	NN	O
that	WDT	O
is	VBZ	O
used	VBN	O
to	TO	O
quantitate	VB	O
the	DT	O
percent	NN	O
inhibition	NN	O
after	IN	O
antisense	JJ	O
oligonucleotide	JJ	O
treatment	NN	O
of	IN	O
test	NN	O
samples	NNS	O
.	.	O
Prior	RB	O
to	TO	O
quantitative	VB	O
PCR	NNP	O
analysis	NN	O
,	,	O
primer-probe	JJ	O
sets	NNS	O
specific	JJ	O
to	TO	O
the	DT	O
target	NN	O
gene	NN	O
being	VBG	O
measured	VBN	O
are	VBP	O
evaluated	VBN	O
for	IN	O
their	PRP$	O
ability	NN	O
to	TO	O
be	VB	O
“	JJ	O
multiplexed	JJ	O
”	NN	O
with	IN	O
a	DT	O
GAPDH	NNP	O
amplification	NN	O
reaction	NN	O
.	.	O
In	IN	O
multiplexing	NN	O
,	,	O
both	CC	O
the	DT	O
target	NN	O
gene	NN	O
and	CC	O
the	DT	O
internal	JJ	O
standard	NN	O
gene	NN	O
GAPDH	NNP	O
are	VBP	O
amplified	VBN	O
concurrently	RB	O
in	IN	O
a	DT	O
single	JJ	O
sample	NN	O
.	.	O
In	IN	O
this	DT	O
analysis	NN	O
,	,	O
mRNA	RB	O
isolated	VBN	O
from	IN	O
untreated	JJ	O
cells	NNS	O
is	VBZ	O
serially	RB	O
diluted	VBN	O
.	.	O
Each	DT	O
dilution	NN	O
is	VBZ	O
amplified	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
primer-probe	JJ	O
sets	NNS	O
specific	JJ	O
for	IN	O
GAPDH	NNP	O
only	RB	O
,	,	O
target	VB	O
gene	NN	O
only	RB	O
(	(	O
“	JJ	O
single-plexing	JJ	O
”	NN	O
)	)	O
,	,	O
or	CC	O
both	DT	O
(	(	O
multiplexing	VBG	O
)	)	O
.	.	O
Following	VBG	O
PCR	NNP	O
amplification	NN	O
,	,	O
standard	JJ	O
curves	NNS	O
of	IN	O
GAPDH	NNP	O
and	CC	O
target	VB	O
mRNA	JJ	O
signal	NN	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
dilution	NN	O
are	VBP	O
generated	VBN	O
from	IN	O
both	DT	O
the	DT	O
single-plexed	JJ	O
and	CC	O
multiplexed	JJ	O
samples	NNS	O
.	.	O
If	IN	O
both	DT	O
the	DT	O
slope	NN	O
and	CC	O
correlation	NN	O
coefficient	NN	O
of	IN	O
the	DT	O
GAPDH	NNP	O
and	CC	O
target	NN	O
signals	NNS	O
generated	VBD	O
from	IN	O
the	DT	O
multiplexed	JJ	O
samples	NNS	O
fall	VBP	O
within	IN	O
10	CD	O
%	NN	O
of	IN	O
their	PRP$	O
corresponding	NN	O
values	NNS	O
generated	VBD	O
from	IN	O
the	DT	O
single-plexed	JJ	O
samples	NNS	O
,	,	O
the	DT	O
primer-probe	NN	O
set	NN	O
specific	NN	O
for	IN	O
that	DT	O
target	NN	O
is	VBZ	O
deemed	VBN	O
multiplexable	JJ	O
.	.	O
Other	JJ	O
methods	NNS	O
of	IN	O
PCR	NNP	O
are	VBP	O
also	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Gene	NNP	O
target	NN	O
quantities	NNS	O
are	VBP	O
obtained	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
.	.	O
Prior	RB	O
to	TO	O
the	DT	O
real-time	JJ	O
PCR	NNP	O
,	,	O
isolated	JJ	O
RNA	NNP	O
is	VBZ	O
subjected	VBN	O
to	TO	O
a	DT	O
reverse	NN	O
transcriptase	NN	O
(	(	O
RT	NNP	O
)	)	O
reaction	NN	O
,	,	O
for	IN	O
the	DT	O
purpose	NN	O
of	IN	O
generating	VBG	O
complementary	JJ	O
DNA	NNP	O
(	(	O
cDNA	NN	O
)	)	O
.	.	O
The	DT	O
real-time	JJ	O
PCR	NNP	O
is	VBZ	O
then	RB	O
performed	VBN	O
on	IN	O
the	DT	O
resulting	VBG	O
cDNA	NN	O
.	.	O
Reverse	JJ	O
transcriptase	NN	O
and	CC	O
PCR	NNP	O
reagents	NNS	O
were	VBD	O
obtained	VBN	O
from	IN	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
(	(	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
RT	NNP	O
,	,	O
real-time	JJ	O
PCR	NNP	O
reactions	NNS	O
were	VBD	O
carried	VBN	O
out	RP	O
by	IN	O
adding	VBG	O
20	CD	O
μL	JJ	O
PCR	NNP	O
cocktail	NN	O
(	(	O
2.5×PCR	CD	O
buffer	NN	O
minus	NN	O
MgCl2	NNP	O
,	,	O
6.6	CD	O
mM	NN	O
MgCl2	NNP	O
,	,	O
375	CD	O
μM	JJ	O
each	DT	O
of	IN	O
dATP	NN	O
,	,	O
dCTP	NN	O
,	,	O
dCTP	NN	O
and	CC	O
dGTP	NN	O
,	,	O
375	CD	O
nM	JJ	O
each	DT	O
of	IN	O
forward	RB	O
primer	NN	O
and	CC	O
reverse	VB	O
primer	NN	O
,	,	O
125	CD	O
nM	NN	O
of	IN	O
probe	NN	O
,	,	O
4	CD	O
Units	NNS	O
RNase	NNP	O
inhibitor	NN	O
,	,	O
1.25	CD	O
Units	NNS	O
PLATINUM®	NNP	O
Taq	NNP	O
polymerase	NN	O
,	,	O
5	CD	O
Units	NNS	O
MuLV	NNP	O
reverse	NN	O
transcriptase	NN	O
,	,	O
and	CC	O
2.5×ROX	CD	O
dye	NN	O
)	)	O
to	TO	O
96-well	CD	O
plates	NNS	O
containing	VBG	O
30	CD	O
μL	JJ	O
total	JJ	O
RNA	NNP	O
solution	NN	O
(	(	O
20-200	JJ	O
ng	NN	O
)	)	O
.	.	O
The	DT	O
RT	NNP	O
reaction	NN	O
was	VBD	O
carried	VBN	O
out	RP	O
by	IN	O
incubation	NN	O
for	IN	O
30	CD	O
minutes	NNS	O
at	IN	O
48°	CD	O
C.	NNP	O
Following	VBG	O
a	DT	O
10	CD	O
minute	NN	O
incubation	NN	O
at	IN	O
95°	CD	O
C.	NNP	O
to	TO	O
activate	VB	O
the	DT	O
PLATINUM®	NNP	O
Taq	NNP	O
polymerase	NN	O
,	,	O
40	CD	O
cycles	NNS	O
of	IN	O
a	DT	O
two-step	JJ	O
PCR	NNP	O
protocol	NN	O
were	VBD	O
carried	VBN	O
out	IN	O
:	:	O
95°	CD	O
C.	NNP	O
for	IN	O
15	CD	O
seconds	NNS	O
(	(	O
denaturation	NN	O
)	)	O
followed	VBN	O
by	IN	O
60°	CD	O
C.	NNP	O
for	IN	O
1.5	CD	O
minutes	NNS	O
(	(	O
annealing/extension	NN	O
)	)	O
.	.	O
The	DT	O
method	NN	O
of	IN	O
obtaining	VBG	O
gene	NN	O
target	NN	O
quantities	NNS	O
by	IN	O
RT	NNP	O
,	,	O
real-time	JJ	O
PCR	NNP	O
is	VBZ	O
often	RB	O
referred	VBN	O
to	TO	O
as	IN	O
simply	RB	O
real-time	JJ	O
PCR	NNP	O
.	.	O
Gene	NNP	O
target	NN	O
quantities	NNS	O
obtained	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
are	VBP	O
normalized	VBN	O
using	VBG	O
either	CC	O
the	DT	O
expression	NN	O
level	NN	O
of	IN	O
GAPDH	NNP	O
,	,	O
a	DT	O
gene	NN	O
whose	WP$	O
expression	NN	O
is	VBZ	O
constant	JJ	O
,	,	O
or	CC	O
by	IN	O
quantifying	VBG	O
total	JJ	O
RNA	NNP	O
using	VBG	O
the	DT	O
RIBOGREEN™	NNP	O
reagent	NN	O
(	(	O
Molecular	JJ	O
Probes	NNP	O
,	,	O
Inc.	NNP	O
Eugene	NNP	O
,	,	O
Oreg	NNP	O
.	.	O
)	)	O
.	.	O
GAPDH	NNP	O
expression	NN	O
is	VBZ	O
quantified	VBN	O
by	IN	O
real	JJ	O
time	NN	O
real-time	JJ	O
PCR	NNP	O
,	,	O
by	IN	O
being	VBG	O
run	VBN	O
simultaneously	RB	O
with	IN	O
the	DT	O
target	NN	O
,	,	O
multiplexing	NN	O
,	,	O
or	CC	O
separately	RB	O
.	.	O
Total	JJ	O
RNA	NNP	O
is	VBZ	O
quantified	VBN	O
using	VBG	O
RIBOGREEN™	NNP	O
RNA	NNP	O
quantification	NN	O
reagent	NN	O
(	(	O
Molecular	JJ	O
Probes	NNP	O
,	,	O
Inc.	NNP	O
Eugene	NNP	O
,	,	O
Oreg	NNP	O
.	.	O
)	)	O
.	.	O
Methods	NNS	O
of	IN	O
RNA	NNP	O
quantification	NN	O
by	IN	O
the	DT	O
RIBOGREEN™	NNP	O
reagent	NN	O
are	VBP	O
taught	VBN	O
in	IN	O
Jones	NNP	B
,	,	I
L.	NNP	I
J.	NNP	I
,	,	I
et	FW	I
al	NN	I
,	,	I
(	(	I
Analytical	JJ	I
Biochemistry	NNP	I
,	,	I
1998	CD	I
,	,	I
265	CD	I
,	,	I
368-374	JJ	I
)	)	I
.	.	O
In	IN	O
this	DT	O
assay	NN	O
,	,	O
170	CD	O
μL	NN	O
of	IN	O
RiboGreen™	NNP	O
working	VBG	O
reagent	NN	O
(	(	O
the	DT	O
RIBOGREEN™	NNP	O
reagent	NN	O
diluted	VBD	O
1:350	CD	O
in	IN	O
10	CD	O
mM	JJ	O
Tris-HCl	NNP	O
,	,	O
1	CD	O
mM	NN	O
EDTA	NNP	O
,	,	O
pH	RB	O
7.5	CD	O
)	)	O
was	VBD	O
pipetted	VBN	O
into	IN	O
a	DT	O
96-well	JJ	O
plate	NN	O
containing	VBG	O
30	CD	O
μL	JJ	O
purified	VBN	O
,	,	O
cellular	JJ	O
RNA	NNP	O
.	.	O
The	DT	O
plate	NN	O
was	VBD	O
read	VBN	O
in	IN	O
a	DT	O
CytoFluor	NNP	O
4000	CD	O
apparatus	NN	O
(	(	O
PE	NNP	O
Applied	NNP	O
Biosystems	NNP	O
)	)	O
with	IN	O
excitation	NN	O
at	IN	O
485	CD	O
nm	NNS	O
and	CC	O
emission	NN	O
at	IN	O
530	CD	O
nm	NNS	O
.	.	O
Probes	NNS	O
and	CC	O
primers	NNS	O
to	TO	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
were	VBD	O
designed	VBN	O
to	TO	O
hybridize	VB	O
to	TO	O
a	DT	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
sequence	NN	O
,	,	O
using	VBG	O
published	VBN	O
sequence	NN	O
information	NN	O
(	(	O
GENBANK®	NNP	O
accession	NN	O
number	NN	O
NM—032564.2	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
)	)	O
.	.	O
For	IN	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
the	DT	O
PCR	NNP	O
primers	NNS	O
were	VBD	O
:	:	O
forward	JJ	O
primer	NN	O
:	:	O
CATACGGCCTTACCTGGCTACA	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
5	CD	O
)	)	O
reverse	NN	O
primer	NN	O
:	:	O
CAGACATCAGGTACTCCCTCAACA	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
6	CD	O
)	)	O
and	CC	O
the	DT	O
PCR	NNP	O
probe	NN	O
was	VBD	O
:	:	O
FAM-TGGCAGGCAACTTCCGAATGCC-TAMRA	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
7	CD	O
)	)	O
where	WRB	O
FAM	NNP	O
is	VBZ	O
the	DT	O
fluorescent	JJ	O
dye	NN	O
and	CC	O
TAMRA	NNP	O
is	VBZ	O
the	DT	O
quencher	NN	O
dye	NN	O
.	.	O
For	IN	O
human	JJ	O
GAPDH	NNP	O
the	DT	O
PCR	NNP	O
primers	NNS	O
were	VBD	O
:	:	O
forward	JJ	O
primer	NN	O
:	:	O
GAAGGTGAAGGTCGGAGTC	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:8	NNP	O
)	)	O
reverse	VBZ	O
primer	NN	O
:	:	O
GAAGATGGTGATGGGATTTC	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:9	NNP	O
)	)	O
and	CC	O
the	DT	O
PCR	NNP	O
probe	NN	O
was	VBD	O
:	:	O
5′	CD	O
JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA	JJ	O
3′	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
10	CD	O
)	)	O
where	WRB	O
JOE	NNP	O
is	VBZ	O
the	DT	O
fluorescent	JJ	O
reporter	NN	O
dye	NN	O
and	CC	O
TAMRA	NNP	O
is	VBZ	O
the	DT	O
quencher	NN	O
dye	NN	O
.	.	O
Probes	NNS	O
and	CC	O
primers	NNS	O
to	TO	O
mouse	VB	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
were	VBD	O
designed	VBN	O
to	TO	O
hybridize	VB	O
to	TO	O
a	DT	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
sequence	NN	O
,	,	O
using	VBG	O
published	VBN	O
sequence	NN	O
information	NN	O
(	(	O
GENBANK®	NNP	O
accession	NN	O
number	NN	O
AK002443.1	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:11	NNP	O
)	)	O
.	.	O
For	IN	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
the	DT	O
PCR	NNP	O
primers	NNS	O
were	VBD	O
:	:	O
forward	JJ	O
primer	NN	O
:	:	O
ACTCTGGAGGTTGGCACCAT	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:12	NNP	O
)	)	O
reverse	VBZ	O
primer	NN	O
:	:	O
GGGTGTGGCTCAGGAGGAT	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
13	CD	O
)	)	O
and	CC	O
the	DT	O
PCR	NNP	O
probe	NN	O
was	VBD	O
:	:	O
FAM-CAGCGTTGCTCTGGCGCA-TAMRA	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
14	CD	O
)	)	O
where	WRB	O
FAM	NNP	O
is	VBZ	O
the	DT	O
fluorescent	JJ	O
reporter	NN	O
dye	NN	O
and	CC	O
TAMRA	NNP	O
is	VBZ	O
the	DT	O
quencher	NN	O
dye	NN	O
.	.	O
For	IN	O
mouse	NN	O
GAPDH	NNP	O
the	DT	O
PCR	NNP	O
primers	NNS	O
were	VBD	O
:	:	O
forward	JJ	O
primer	NN	O
:	:	O
GGCAAATTCAACGGCACAGT	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:15	NNP	O
)	)	O
reverse	VBZ	O
primer	NN	O
:	:	O
GGGTCTCGCTCCTGGAAGAT	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO:16	NNP	O
)	)	O
and	CC	O
the	DT	O
PCR	NNP	O
probe	NN	O
was	VBD	O
:	:	O
5′	CD	O
JOE-AAGGCCGAGAATGGGAAGCTTGTCATC-TAMRA	JJ	O
3′	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
17	CD	O
)	)	O
where	WRB	O
JOE	NNP	O
is	VBZ	O
the	DT	O
fluorescent	JJ	O
reporter	NN	O
dye	NN	O
and	CC	O
TAMRA	NNP	O
is	VBZ	O
the	DT	O
quencher	NN	O
dye	NN	O
.	.	O
Example	RB	O
14	CD	O
Northern	NNP	O
Blot	NNP	O
Analysis	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
mRNA	NN	O
Levels	NNP	O
Eighteen	NNP	O
hours	NNS	O
after	IN	O
antisense	JJ	O
treatment	NN	O
,	,	O
cell	NN	O
monolayers	NNS	O
were	VBD	O
washed	VBN	O
twice	RB	O
with	IN	O
cold	JJ	O
PBS	NNP	O
and	CC	O
lysed	VBN	O
in	IN	O
1	CD	O
mL	NNS	O
RNAZOL™	NNP	O
reagent	NN	O
(	(	O
TEL-TEST	NNP	O
“	NNP	O
B	NNP	O
”	NNP	O
Inc.	NNP	O
,	,	O
Friendswood	NNP	O
,	,	O
Tex	NNP	O
.	.	O
)	)	O
.	.	O
Total	JJ	O
RNA	NNP	O
was	VBD	O
prepared	VBN	O
following	VBG	O
manufacturer	NN	O
's	POS	O
recommended	JJ	O
protocols	NNS	O
.	.	O
Twenty	NNP	O
micrograms	NNS	O
of	IN	O
total	JJ	O
RNA	NNP	O
was	VBD	O
fractionated	VBN	O
by	IN	O
electrophoresis	NN	O
through	IN	O
1.2	CD	O
%	NN	O
agarose	JJ	O
gels	NNS	O
containing	VBG	O
1.1	CD	O
%	NN	O
formaldehyde	NN	O
using	VBG	O
a	DT	O
MOPS	NNP	O
buffer	NN	O
system	NN	O
(	(	O
AMRESCO	NNP	O
,	,	O
Inc.	NNP	O
Solon	NNP	O
,	,	O
Ohio	NNP	O
)	)	O
.	.	O
RNA	NNP	O
was	VBD	O
transferred	VBN	O
from	IN	O
the	DT	O
gel	NN	O
to	TO	O
HYBOND™-N+	NNP	O
nylon	NN	O
membranes	NNS	O
(	(	O
Amersham	NNP	O
Pharmacia	NNP	O
Biotech	NNP	O
,	,	O
Piscataway	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
by	IN	O
overnight	JJ	O
capillary	JJ	O
transfer	NN	O
using	VBG	O
a	DT	O
Northern/Southern	NNP	O
Transfer	NNP	O
buffer	NN	O
system	NN	O
(	(	O
TEL-TEST	JJ	O
“	NN	O
B	NNP	O
”	NNP	O
Inc.	NNP	O
,	,	O
Friendswood	NNP	O
,	,	O
Tex	NNP	O
.	.	O
)	)	O
.	.	O
RNA	NNP	O
transfer	NN	O
was	VBD	O
confirmed	VBN	O
by	IN	O
UV	NNP	O
visualization	NN	O
.	.	O
Membranes	NNS	O
were	VBD	O
fixed	VBN	O
by	IN	O
UV	NNP	O
cross-linking	NN	O
using	VBG	O
a	DT	O
STRATALINKER™	NNP	O
UV	NNP	O
Crosslinker	NNP	O
2400	CD	O
instrument	NN	O
(	(	O
Stratagene	NNP	O
,	,	O
Inc	NNP	O
,	,	O
La	NNP	O
Jolla	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
and	CC	O
then	RB	O
probed	VBD	O
using	VBG	O
QUICKHYB™	NNP	O
hybridization	NN	O
solution	NN	O
(	(	O
Stratagene	NNP	B
,	,	I
La	NNP	I
Jolla	NNP	I
,	,	I
Calif.	NNP	I
)	)	O
using	VBG	O
manufacturer	NN	O
's	POS	O
recommendations	NNS	O
for	IN	O
stringent	JJ	O
conditions	NNS	O
.	.	O
To	TO	O
detect	VB	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
a	DT	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
specific	JJ	O
probe	NN	O
was	VBD	O
prepared	VBN	O
by	IN	O
PCR	NNP	O
using	VBG	O
the	DT	O
forward	NN	O
primer	NN	O
CATACGGCCTTACCTGGCTACA	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
5	CD	O
)	)	O
and	CC	O
the	DT	O
reverse	NN	O
primer	NN	O
CAGACATCAGGTACTCCCTCAACA	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
6	CD	O
)	)	O
.	.	O
To	TO	O
normalize	VB	O
for	IN	O
variations	NNS	O
in	IN	O
loading	NN	O
and	CC	O
transfer	VB	O
efficiency	NN	O
membranes	NNS	O
were	VBD	O
stripped	VBN	O
and	CC	O
probed	VBN	O
for	IN	O
human	JJ	O
glyceraldehyde-3-phosphate	JJ	O
dehydrogenase	NN	O
(	(	O
GAPDH	NNP	O
)	)	O
RNA	NNP	O
(	(	O
Clontech	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
To	TO	O
detect	VB	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
a	DT	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
specific	JJ	O
probe	NN	O
was	VBD	O
prepared	VBN	O
by	IN	O
PCR	NNP	O
using	VBG	O
the	DT	O
forward	NN	O
primer	NN	O
ACTCTGGAGGTTGGCACCAT	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
12	CD	O
)	)	O
and	CC	O
the	DT	O
reverse	NN	O
primer	NN	O
GGGTGTGGCTCAGGAGGAT	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
13	CD	O
)	)	O
.	.	O
To	TO	O
normalize	VB	O
for	IN	O
variations	NNS	O
in	IN	O
loading	NN	O
and	CC	O
transfer	VB	O
efficiency	NN	O
membranes	NNS	O
were	VBD	O
stripped	VBN	O
and	CC	O
probed	VBN	O
for	IN	O
mouse	NN	O
glyceraldehyde-3-phosphate	JJ	O
dehydrogenase	NN	O
(	(	O
GAPDH	NNP	O
)	)	O
RNA	NNP	O
(	(	O
Clontech	NNP	O
,	,	O
Palo	NNP	O
Alto	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Hybridized	VBN	O
membranes	NNS	O
were	VBD	O
visualized	VBN	O
and	CC	O
quantitated	VBN	O
using	VBG	O
PHOSPHORIMAGER™	NNP	O
and	CC	O
IMAGEQUANT™	NNP	O
Software	NNP	O
V3.3	NNP	O
(	(	O
Molecular	NNP	O
Dynamics	NNP	O
,	,	O
Sunnyvale	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Data	NNP	O
was	VBD	O
normalized	VBN	O
to	TO	O
GAPDH	NNP	O
levels	NNS	O
in	IN	O
untreated	JJ	O
controls	NNS	O
.	.	O
Example	RB	O
15	CD	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Human	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
Expression	NNP	O
by	IN	O
Chimeric	NNP	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
Having	NNP	O
2′-MOE	JJ	O
Wings	NNP	O
and	CC	O
a	DT	O
Deoxy	NNP	O
Gap	NNP	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
was	VBD	O
designed	VBN	O
to	TO	O
target	VB	O
different	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
RNA	NNP	O
,	,	O
using	VBG	O
published	VBN	O
sequences	NNS	O
(	(	O
GENBANK®	NNP	O
accession	NN	O
number	NN	O
NM—032564.2	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
,	,	O
nucleotides	NNS	O
5669186	CD	O
to	TO	O
5712008	CD	O
of	IN	O
the	DT	O
nucleotide	JJ	O
sequence	NN	O
with	IN	O
the	DT	O
GenBank	NNP	O
accession	NN	O
number	NN	O
NT—033927.5	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
18	CD	O
)	)	O
.	.	O
The	DT	O
compounds	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O
“	NN	O
Target	NNP	O
site	NN	O
”	NN	O
indicates	VBZ	O
the	DT	O
first	JJ	O
(	(	O
5′-most	JJ	O
)	)	O
nucleotide	IN	O
number	NN	O
on	IN	O
the	DT	O
particular	JJ	O
target	NN	O
sequence	NN	O
to	TO	O
which	WDT	O
the	DT	O
compound	NN	O
binds	VBZ	O
.	.	O
All	DT	O
compounds	NNS	O
in	IN	O
Table	JJ	O
1	CD	O
are	VBP	O
chimeric	JJ	O
oligonucleotides	NNS	O
(	(	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
ten	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
The	DT	O
compounds	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
by	IN	O
quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	VBN	O
in	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
.	.	O
Data	NNS	O
are	VBP	O
averages	NNS	O
from	IN	O
three	CD	O
experiments	NNS	O
in	IN	O
which	WDT	O
A549	NNP	O
cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
125	CD	O
nM	NNS	O
of	IN	O
the	DT	O
antisense	JJ	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
If	IN	O
present	JJ	O
,	,	O
“	JJ	O
N.D.	NNP	O
”	NNP	O
indicates	VBZ	O
“	VBP	O
no	DT	O
data	NN	O
”	NN	O
.	.	O
ISIS	NNP	O
18078	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
2	CD	O
)	)	O
was	VBD	O
used	VBN	O
in	IN	O
this	DT	O
assay	NN	O
as	IN	O
a	DT	O
negative	JJ	O
control	NN	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
,	,	O
SEQ	NNP	O
ID	NNP	O
Nos	NNP	O
:	:	O
20	CD	O
,	,	O
21	CD	O
,	,	O
23	CD	O
,	,	O
24	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
27	CD	O
,	,	O
28	CD	O
,	,	O
29	CD	O
,	,	O
30	CD	O
,	,	O
31	CD	O
,	,	O
32	CD	O
,	,	O
33	CD	O
,	,	O
34	CD	O
,	,	O
35	CD	O
,	,	O
36	CD	O
,	,	O
37	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
40	CD	O
,	,	O
41	CD	O
,	,	O
42	CD	O
,	,	O
43	CD	O
,	,	O
44	CD	O
,	,	O
45	CD	O
,	,	O
46	CD	O
,	,	O
47	CD	O
,	,	O
48	CD	O
,	,	O
49	CD	O
,	,	O
50	CD	O
,	,	O
51	CD	O
,	,	O
52	CD	O
,	,	O
53	CD	O
,	,	O
54	CD	O
,	,	O
56	CD	O
,	,	O
57	CD	O
,	,	O
58	CD	O
,	,	O
60	CD	O
,	,	O
61	CD	O
,	,	O
62	CD	O
,	,	O
63	CD	O
,	,	O
64	CD	O
,	,	O
65	CD	O
,	,	O
66	CD	O
,	,	O
68	CD	O
,	,	O
69	CD	O
,	,	O
70	CD	O
,	,	O
71	CD	O
,	,	O
72	CD	O
,	,	O
73	CD	O
,	,	O
75	CD	O
,	,	O
76	CD	O
,	,	O
77	CD	O
,	,	O
78	CD	O
,	,	O
80	CD	O
,	,	O
81	CD	O
,	,	O
82	CD	O
,	,	O
83	CD	O
,	,	O
84	CD	O
,	,	O
85	CD	O
,	,	O
86	CD	O
,	,	O
87	CD	O
,	,	O
88	CD	O
,	,	O
89	CD	O
,	,	O
90	CD	O
,	,	O
91	CD	O
,	,	O
92	CD	O
,	,	O
94	CD	O
,	,	O
95	CD	O
,	,	O
96	CD	O
and	CC	O
97	CD	O
demonstrated	VBN	O
at	IN	O
least	JJS	O
40	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
in	IN	O
this	DT	O
assay	NN	O
and	CC	O
are	VBP	O
therefore	RB	O
preferred	JJ	O
.	.	O
More	RBR	O
preferred	JJ	O
are	VBP	O
SEQ	NNP	O
ID	NNP	O
Nos	NNP	O
:	:	O
65	CD	O
,	,	O
26	CD	O
,	,	O
29	CD	O
and	CC	O
35	CD	O
.	.	O
The	DT	O
target	NN	O
regions	NNS	O
to	TO	O
which	WDT	O
these	DT	O
preferred	JJ	O
sequences	NNS	O
are	VBP	O
complementary	JJ	O
are	VBP	O
herein	RB	O
referred	VBN	O
to	TO	O
as	IN	O
“	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
”	JJ	O
and	CC	O
are	VBP	O
therefore	RB	O
preferred	JJ	O
for	IN	O
targeting	VBG	O
by	IN	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
These	DT	O
preferred	JJ	O
target	NN	O
segments	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
.	.	O
These	DT	O
sequences	NNS	O
are	VBP	O
shown	VBN	O
to	TO	O
contain	VB	O
thymine	NN	O
(	(	O
T	NNP	O
)	)	O
but	CC	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	DT	O
thymine	NN	O
(	(	O
T	NNP	O
)	)	O
is	VBZ	O
generally	RB	O
replaced	VBN	O
by	IN	O
uracil	NN	O
(	(	O
U	NNP	O
)	)	O
in	IN	O
RNA	NNP	O
sequences	NNS	O
.	.	O
The	DT	O
sequences	NNS	O
represent	VBP	O
the	DT	O
reverse	NN	O
complement	NN	O
of	IN	O
the	DT	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O
“	NN	O
Target	NNP	O
site	NN	O
”	NN	O
indicates	VBZ	O
the	DT	O
first	JJ	O
(	(	O
5′-most	JJ	O
)	)	O
nucleotide	IN	O
number	NN	O
on	IN	O
the	DT	O
particular	JJ	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
which	WDT	O
the	DT	O
oligonucleotide	NN	O
binds	VBZ	O
.	.	O
Also	RB	O
shown	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
is	VBZ	O
the	DT	O
species	NNS	O
in	IN	O
which	WDT	O
each	DT	O
of	IN	O
the	DT	O
preferred	JJ	O
target	NN	O
segments	NNS	O
was	VBD	O
found	VBN	O
.	.	O
Example	RB	O
16	CD	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Mouse	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
Expression	NNP	O
by	IN	O
Chimeric	NNP	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
Having	NNP	O
2′-MOE	JJ	O
Wings	NNP	O
and	CC	O
a	DT	O
Deoxy	NNP	O
Gap	NNP	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
was	VBD	O
designed	VBN	O
to	TO	O
target	VB	O
different	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
RNA	NNP	O
,	,	O
using	VBG	O
published	VBN	O
sequences	NNS	O
(	(	O
GENBANK®	NNP	O
accession	NN	O
number	NN	O
AK002443.1	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
11	CD	O
)	)	O
.	.	O
The	DT	O
compounds	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
.	.	O
“	NN	O
Target	NNP	O
site	NN	O
”	NN	O
indicates	VBZ	O
the	DT	O
first	JJ	O
(	(	O
5′-most	JJ	O
)	)	O
nucleotide	IN	O
number	NN	O
on	IN	O
the	DT	O
particular	JJ	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
which	WDT	O
the	DT	O
compound	NN	O
binds	VBZ	O
.	.	O
All	DT	O
compounds	NNS	O
in	IN	O
Table	JJ	O
2	CD	O
are	VBP	O
chimeric	JJ	O
oligonucleotides	NNS	O
(	(	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
ten	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-β-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
The	DT	O
compounds	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
by	IN	O
quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	VBN	O
in	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
.	.	O
Data	NNS	O
are	VBP	O
averages	NNS	O
from	IN	O
three	CD	O
experiments	NNS	O
in	IN	O
which	WDT	O
3T3-L1	JJ	O
cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
150	CD	O
nM	NNS	O
of	IN	O
the	DT	O
antisense	JJ	O
oligonucleotides	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
If	IN	O
present	JJ	O
,	,	O
“	JJ	O
N.D.	NNP	O
”	NNP	O
indicates	VBZ	O
“	VBP	O
no	DT	O
data	NN	O
”	NN	O
.	.	O
ISIS	NNP	O
18078	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
2	CD	O
)	)	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
negative	JJ	O
control	NN	O
in	IN	O
this	DT	O
assay	NN	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
,	,	O
SEQ	NNP	O
ID	NNP	O
Nos	NNP	O
:	:	O
21	CD	O
,	,	O
25	CD	O
,	,	O
26	CD	O
,	,	O
38	CD	O
,	,	O
39	CD	O
,	,	O
47	CD	O
,	,	O
101	CD	O
,	,	O
109	CD	O
,	,	O
114	CD	O
,	,	O
115	CD	O
,	,	O
120	CD	O
,	,	O
121	CD	O
,	,	O
122	CD	O
,	,	O
123	CD	O
,	,	O
124	CD	O
,	,	O
127	CD	O
,	,	O
128	CD	O
,	,	O
130	CD	O
,	,	O
133	CD	O
,	,	O
136	CD	O
and	CC	O
142	CD	O
demonstrated	VBN	O
at	IN	O
least	JJS	O
35	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
in	IN	O
this	DT	O
experiment	NN	O
and	CC	O
are	VBP	O
therefore	RB	O
preferred	JJ	O
.	.	O
More	RBR	O
preferred	JJ	O
are	VBP	O
SEQ	NNP	O
ID	NNP	O
Nos	NNP	O
:	:	O
142	CD	O
,	,	O
109	CD	O
and	CC	O
121	CD	O
.	.	O
The	DT	O
target	NN	O
regions	NNS	O
to	TO	O
which	WDT	O
these	DT	O
preferred	JJ	O
sequences	NNS	O
are	VBP	O
complementary	JJ	O
are	VBP	O
herein	RB	O
referred	VBN	O
to	TO	O
as	IN	O
“	JJ	O
preferred	JJ	O
target	NN	O
segments	NNS	O
”	JJ	O
and	CC	O
are	VBP	O
therefore	RB	O
preferred	JJ	O
for	IN	O
targeting	VBG	O
by	IN	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
.	.	O
These	DT	O
preferred	JJ	O
target	NN	O
segments	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
.	.	O
These	DT	O
sequences	NNS	O
are	VBP	O
shown	VBN	O
to	TO	O
contain	VB	O
thymine	NN	O
(	(	O
T	NNP	O
)	)	O
but	CC	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	DT	O
thymine	NN	O
(	(	O
T	NNP	O
)	)	O
is	VBZ	O
generally	RB	O
replaced	VBN	O
by	IN	O
uracil	NN	O
(	(	O
U	NNP	O
)	)	O
in	IN	O
RNA	NNP	O
sequences	NNS	O
.	.	O
The	DT	O
sequences	NNS	O
represent	VBP	O
the	DT	O
reverse	NN	O
complement	NN	O
of	IN	O
the	DT	O
preferred	JJ	O
antisense	NN	O
compounds	NNS	O
shown	VBN	O
in	IN	O
Tables	NNP	O
1	CD	O
and	CC	O
2	CD	O
.	.	O
“	NN	O
Target	NNP	O
site	NN	O
”	NN	O
indicates	VBZ	O
the	DT	O
first	JJ	O
(	(	O
5′-most	JJ	O
)	)	O
nucleotide	IN	O
number	NN	O
on	IN	O
the	DT	O
particular	JJ	O
target	NN	O
nucleic	JJ	O
acid	NN	O
to	TO	O
which	WDT	O
the	DT	O
oligonucleotide	NN	O
binds	VBZ	O
.	.	O
Also	RB	O
shown	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
is	VBZ	O
the	DT	O
species	NNS	O
in	IN	O
which	WDT	O
each	DT	O
of	IN	O
the	DT	O
preferred	JJ	O
target	NN	O
segments	NNS	O
was	VBD	O
found	VBN	O
.	.	O
As	IN	O
these	DT	O
“	NNS	O
preferred	VBD	O
target	NN	O
segments	NNS	O
”	WDT	O
have	VBP	O
been	VBN	O
found	VBN	O
by	IN	O
experimentation	NN	O
to	TO	O
be	VB	O
open	JJ	O
to	TO	O
,	,	O
and	CC	O
accessible	JJ	O
for	IN	O
,	,	O
hybridization	NN	O
with	IN	O
the	DT	O
antisense	JJ	O
compounds	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
recognize	VB	O
or	CC	O
be	VB	O
able	JJ	O
to	TO	O
ascertain	VB	O
,	,	O
using	VBG	O
no	DT	O
more	JJR	O
than	IN	O
routine	JJ	O
experimentation	NN	O
,	,	O
further	JJ	O
embodiments	NNS	O
of	IN	O
the	DT	O
invention	NN	O
that	IN	O
encompass	VBZ	O
other	JJ	O
compounds	NNS	O
that	WDT	O
specifically	RB	O
hybridize	VBP	O
to	TO	O
these	DT	O
preferred	VBN	O
target	NN	O
segments	NNS	O
and	CC	O
consequently	RB	O
inhibit	VB	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
According	VBG	O
to	TO	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
antisense	JJ	O
compounds	NNS	O
include	VBP	O
antisense	JJ	O
oligomeric	JJ	O
compounds	NNS	O
,	,	O
antisense	NN	O
oligonucleotides	NNS	O
,	,	O
siRNAs	NN	O
,	,	O
external	JJ	O
guide	NN	O
sequence	NN	O
(	(	O
EGS	NNP	O
)	)	O
oligonucleotides	VBZ	O
,	,	O
alternate	JJ	O
splicers	NNS	O
,	,	O
and	CC	O
other	JJ	O
short	JJ	O
oligomeric	NN	O
compounds	NNS	O
which	WDT	O
hybridize	VBP	O
to	TO	O
at	IN	O
least	JJS	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
target	NN	O
nucleic	JJ	O
acid	NN	O
.	.	O
Example	RB	O
17	CD	O
Western	JJ	O
Blot	NNP	O
Analysis	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
Protein	NNP	O
Levels	NNP	O
Western	NNP	O
blot	NN	O
analysis	NN	O
(	(	O
immunoblot	JJ	O
analysis	NN	O
)	)	O
is	VBZ	O
carried	VBN	O
out	IN	O
using	VBG	O
standard	JJ	O
methods	NNS	O
.	.	O
Cells	NNS	O
are	VBP	O
harvested	VBN	O
16-20	JJ	O
h	NN	O
after	IN	O
oligonucleotide	JJ	O
treatment	NN	O
,	,	O
washed	VBD	O
once	RB	O
with	IN	O
PBS	NNP	O
,	,	O
suspended	VBN	O
in	IN	O
Laemmli	NNP	O
buffer	NN	O
(	(	O
100	CD	O
ul/well	NN	O
)	)	O
,	,	O
boiled	VBD	O
for	IN	O
5	CD	O
minutes	NNS	O
and	CC	O
loaded	VBN	O
on	IN	O
a	DT	O
16	CD	O
%	NN	O
SDS-PAGE	JJ	O
gel	NN	O
.	.	O
Gels	NNS	O
are	VBP	O
run	VBN	O
for	IN	O
1.5	CD	O
hours	NNS	O
at	IN	O
150	CD	O
V	NNP	O
,	,	O
and	CC	O
transferred	VBD	O
to	TO	O
membrane	VB	O
for	IN	O
western	JJ	O
blotting	NN	O
.	.	O
Appropriate	NNP	O
primary	JJ	O
antibody	NN	O
directed	VBD	O
to	TO	O
diacylglycerol	VB	O
acyltransferase	JJ	O
2	CD	O
is	VBZ	O
used	VBN	O
,	,	O
with	IN	O
a	DT	O
radiolabeled	JJ	O
or	CC	O
fluorescently	RB	O
labeled	VBN	O
secondary	JJ	O
antibody	NN	O
directed	VBN	O
against	IN	O
the	DT	O
primary	JJ	O
antibody	NN	O
species	NNS	O
.	.	O
Bands	NNS	O
are	VBP	O
visualized	VBN	O
using	VBG	O
a	DT	O
PHOSPHORIMAGER™	NNP	O
instrument	NN	O
(	(	O
Molecular	JJ	O
Dynamics	NNS	O
,	,	O
Sunnyvale	NNP	O
Calif.	NNP	O
)	)	O
.	.	O
Example	JJ	O
18	CD	O
Effects	NNS	O
of	IN	O
Antisense	NNP	O
Inhibition	NNP	O
on	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
Levels	NNS	O
:	:	O
In	IN	O
Vivo	NNP	O
Studies	NNPS	O
in	IN	O
a	DT	O
Diet-Induced	JJ	O
Model	NNP	O
of	IN	O
Obesity	NNP	O
The	DT	O
C57BL/6	NNP	O
mouse	NN	O
strain	NN	O
is	VBZ	O
reported	VBN	O
to	TO	O
be	VB	O
susceptible	JJ	O
to	TO	O
hyperlipidemia-induced	JJ	O
atherosclerotic	JJ	O
plaque	NN	O
formation	NN	O
.	.	O
Accordingly	RB	O
,	,	O
these	DT	O
mice	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
high-fat	JJ	O
diet	NN	O
and	CC	O
used	VBN	O
in	IN	O
the	DT	O
following	JJ	O
studies	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
effects	NNS	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
antisense	NN	O
oligonucleotides	NNS	O
on	IN	O
mRNA	JJ	O
expression	NN	O
in	IN	O
a	DT	O
model	NN	O
of	IN	O
diet-induced	JJ	O
obesity	NN	O
.	.	O
Male	JJ	O
C57BL/6	NNP	O
mice	NN	O
at	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
were	VBD	O
purchased	VBN	O
from	IN	O
Jackson	NNP	O
Laboratories	NNPS	O
(	(	O
Ben	NNP	O
Harbor	NNP	O
,	,	O
Me	NNP	O
.	.	O
)	)	O
.	.	O
Mice	NNP	O
were	VBD	O
fed	VBN	O
regular	JJ	O
rodent	NN	O
chow	NN	O
(	(	O
#	#	O
8604	CD	O
,	,	O
Harlan-Teklad	NNP	O
,	,	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
for	IN	O
5	CD	O
days	NNS	O
and	CC	O
were	VBD	O
subsequently	RB	O
placed	VBN	O
on	IN	O
a	DT	O
high-fat	JJ	O
diet	JJ	O
containing	VBG	O
60	CD	O
%	NN	O
calories	NNS	O
from	IN	O
fat	NN	O
(	(	O
Research	NNP	O
Diet	NNP	O
D12492	NNP	O
,	,	O
Research	NNP	O
Diets	NNP	O
Inc.	NNP	O
,	,	O
New	NNP	O
Brunswick	NNP	O
,	,	O
N.J.	NNP	O
)	)	O
.	.	O
After	IN	O
8	CD	O
weeks	NNS	O
on	IN	O
the	DT	O
high-fat	JJ	O
diet	NN	O
,	,	O
mice	NN	O
were	VBD	O
divided	VBN	O
into	IN	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
groups	NNS	O
of	IN	O
eight	CD	O
animals	NNS	O
each	DT	O
,	,	O
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
.	.	O
One	CD	O
group	NN	O
received	VBD	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
ISIS	NNP	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
No	NNP	O
:	:	O
142	CD	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
25	CD	O
mg/kg	JJ	O
twice	RB	O
per	IN	O
week	NN	O
for	IN	O
7	CD	O
weeks	NNS	O
.	.	O
The	DT	O
second	JJ	O
group	NN	O
received	VBD	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
control	NN	O
oligonucleotide	IN	O
ISIS	NNP	O
141923	CD	O
(	(	O
CCTTCCCTGAAGGTTCCTCC	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
229	CD	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
25	CD	O
mg/kg	JJ	O
twice	RB	O
per	IN	O
week	NN	O
for	IN	O
7	CD	O
weeks	NNS	O
.	.	O
Oligonucleotides	NNS	O
were	VBD	O
dissolved	VBN	O
in	IN	O
0.9	CD	O
%	NN	O
saline	NN	O
for	IN	O
injection	NN	O
.	.	O
The	DT	O
third	JJ	O
group	NN	O
received	VBD	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
saline	JJ	O
twice	JJ	O
weekly	NN	O
for	IN	O
7	CD	O
weeks	NNS	O
.	.	O
This	DT	O
saline-injected	JJ	O
group	NN	O
served	VBD	O
as	IN	O
the	DT	O
control	NN	O
group	NN	O
to	TO	O
which	WDT	O
the	DT	O
oligonucleotide-treated	JJ	O
groups	NNS	O
were	VBD	O
compared	VBN	O
.	.	O
A	DT	O
group	NN	O
of	IN	O
8	CD	O
C57B1/6	NNP	O
mice	NN	O
,	,	O
fed	VBD	O
regular	JJ	O
rodent	NN	O
chow	NN	O
and	CC	O
treated	VBN	O
with	IN	O
saline	NN	O
,	,	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
normal	JJ	O
,	,	O
lean	JJ	O
group	NN	O
.	.	O
ISIS	NNP	O
141923	CD	O
,	,	O
which	WDT	O
is	VBZ	O
not	RB	O
complementary	JJ	O
to	TO	O
any	DT	O
known	VBN	O
gene	NN	O
,	,	O
is	VBZ	O
a	DT	O
chimeric	JJ	O
oligonucleotide	NN	O
(	(	O
“	JJ	O
gapmer	NN	O
”	NN	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
ten	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
After	IN	O
the	DT	O
7	CD	O
week	NN	O
treatment	NN	O
period	NN	O
,	,	O
the	DT	O
mice	NN	O
were	VBD	O
sacrificed	VBN	O
and	CC	O
diacylglycerol	VB	O
acyltransferase	NN	O
2	CD	O
(	(	O
DGAT2	NNP	O
)	)	O
mRNA	NN	O
levels	NNS	O
were	VBD	O
evaluated	VBN	O
in	IN	O
liver	NN	O
,	,	O
brown	IN	O
adipose	JJ	O
tissue	NN	O
(	(	O
BAT	NNP	O
)	)	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
(	(	O
WAT	NNP	O
)	)	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
diacylglycerol	NN	O
acyltransferase	NN	O
1	CD	O
(	(	O
DGAT1	NNP	O
)	)	O
mRNA	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
in	IN	O
these	DT	O
tissues	NNS	O
.	.	O
mRNA	JJ	O
expression	NN	O
levels	NNS	O
were	VBD	O
quantitated	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	VBN	O
in	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
.	.	O
The	DT	O
results	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
4	CD	O
and	CC	O
are	VBP	O
expressed	VBN	O
as	IN	O
percent	NN	O
inhibition	NN	O
relative	JJ	O
to	TO	O
saline-treated	JJ	O
mice	NN	O
receiving	VBG	O
a	DT	O
high	JJ	O
fat	NN	O
diet	NN	O
.	.	O
A	DT	O
“	JJ	O
+	NN	O
”	NN	O
preceding	VBG	O
the	DT	O
number	NN	O
indicates	VBZ	O
that	IN	O
gene	NN	O
expression	NN	O
was	VBD	O
increased	VBN	O
,	,	O
rather	RB	O
than	IN	O
inhibited	VBN	O
.	.	O
The	DT	O
data	NN	O
demonstrate	NN	O
that	WDT	O
diacylglycerol	VBZ	O
acyltransferase	VBZ	O
2	CD	O
antisense	JJ	O
oligonucleotide	RB	O
treatment	NN	O
can	MD	O
effectively	RB	O
inhibit	VB	O
target	NN	O
mRNA	JJ	O
expression	NN	O
in	IN	O
liver	NN	O
,	,	O
brown	VBN	O
adipose	JJ	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
.	.	O
Diacylglycerol	NNP	O
acyltransferase	VBD	O
1	CD	O
expression	NN	O
levels	NNS	O
were	VBD	O
lowered	VBN	O
in	IN	O
liver	NN	O
and	CC	O
brown	JJ	O
adipose	JJ	O
tissue	NN	O
.	.	O
Body	NN	O
weight	NN	O
and	CC	O
food	NN	O
intake	NN	O
were	VBD	O
monitored	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O
Metabolic	JJ	O
rate	NN	O
was	VBD	O
measured	VBN	O
using	VBG	O
indirect	JJ	O
calorimetry	NN	O
in	IN	O
a	DT	O
metabolic	JJ	O
chamber	NN	O
(	(	O
Oxymax	NNP	O
System	NNP	O
,	,	O
Columbus	NNP	O
Instruments	NNP	O
,	,	O
Columbus	NNP	O
,	,	O
Ohio	NNP	O
)	)	O
.	.	O
Adipose	NNP	O
tissue	NN	O
weight	NN	O
was	VBD	O
also	RB	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O
Body	NN	O
weight	NN	O
,	,	O
adipose	JJ	O
tissue	NN	O
weight	NN	O
,	,	O
food	NN	O
intake	NN	O
and	CC	O
metabolic	JJ	O
rate	NN	O
were	VBD	O
not	RB	O
changed	VBN	O
in	IN	O
diet-induced	JJ	O
obese	JJ	O
mice	NNS	O
treated	VBN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
.	.	O
In	IN	O
a	DT	O
similar	JJ	O
study	NN	O
,	,	O
animals	NNS	O
received	VBD	O
twice	RB	O
weekly	RB	O
,	,	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
saline	NN	O
,	,	O
25	CD	O
mg/kg	NN	O
ISIS	NNP	O
217376	CD	O
or	CC	O
25	CD	O
mg/kg	JJ	O
ISIS	NNP	O
141923	CD	O
,	,	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
5	CD	O
weeks	NNS	O
.	.	O
In	IN	O
these	DT	O
mice	NNS	O
,	,	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
approximately	RB	O
90	CD	O
%	NN	O
in	IN	O
liver	NN	O
and	CC	O
white	JJ	O
adipose	JJ	O
fat	NN	O
tissues	NNS	O
.	.	O
Example	JJ	O
19	CD	O
Effects	NNS	O
of	IN	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
on	IN	O
Markers	NNS	O
of	IN	O
Lipid	NNP	O
and	CC	O
Glucose	NNP	O
Metabolism	NNP	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
ISIS	NNP	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
was	VBD	O
tested	VBN	O
for	IN	O
its	PRP$	O
ability	NN	O
to	TO	O
affect	VB	O
lipid	JJ	O
and	CC	O
glucose	JJ	O
metabolism	NN	O
in	IN	O
the	DT	O
diet-induced	JJ	O
obese	JJ	O
mice	NN	O
that	WDT	O
received	VBD	O
antisense	JJ	O
oligonucleotide	RB	O
treatment	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
18	CD	O
.	.	O
These	DT	O
mice	NNS	O
were	VBD	O
further	RB	O
evaluated	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
7	CD	O
week	NN	O
treatment	NN	O
period	NN	O
for	IN	O
levels	NNS	O
of	IN	O
serum	NN	O
free	JJ	O
fatty	JJ	O
acids	NNS	O
,	,	O
which	WDT	O
were	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
NEFA	NNP	O
C	NNP	O
assay	VBP	O
kit	NN	O
(	(	O
part	NN	O
#	#	O
994-75409	CD	O
,	,	O
Wako	NNP	O
Chemicals	NNP	O
,	,	O
GmbH	NNP	O
,	,	O
Germany	NNP	O
)	)	O
.	.	O
Also	RB	O
measured	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
7	CD	O
week	NN	O
treatment	NN	O
period	NN	O
were	VBD	O
triglycerides	NNS	O
(	(	O
TRIG	NNP	O
)	)	O
,	,	O
cholesterol	NN	O
,	,	O
including	VBG	O
total	JJ	O
cholesterol	NN	O
(	(	O
CHOL	NNP	O
)	)	O
and	CC	O
high	JJ	O
(	(	O
HDL	NNP	O
)	)	O
and	CC	O
low	JJ	O
(	(	O
LDL	NNP	O
)	)	O
density	NN	O
lipoprotein	NN	O
cholesterol	NN	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
were	VBD	O
measured	VBN	O
using	VBG	O
the	DT	O
Hitachi	NNP	O
717®	CD	O
analyzer	NN	O
instrument	NN	O
(	(	O
Roche	NNP	O
Diagnostics	NNP	O
,	,	O
Indianapolis	NNP	O
,	,	O
Ind	NNP	O
.	.	O
)	)	O
.	.	O
The	DT	O
data	NN	O
,	,	O
expressed	VBN	O
as	IN	O
percent	NN	O
reduction	NN	O
relative	NN	O
to	TO	O
the	DT	O
saline	NN	O
control	NN	O
,	,	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
5	CD	O
.	.	O
The	DT	O
results	NNS	O
demonstrate	VBP	O
that	IN	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
,	,	O
which	WDT	O
was	VBD	O
presented	VBN	O
in	IN	O
Example	NNP	O
18	CD	O
,	,	O
leads	VBZ	O
to	TO	O
significant	JJ	O
reductions	NNS	O
in	IN	O
of	IN	O
335	CD	O
,	,	O
41	CD	O
%	NN	O
and	CC	O
31	CD	O
%	NN	O
in	IN	O
serum	JJ	O
free	JJ	O
fatty	NN	O
acids	NNS	O
,	,	O
serum	NN	O
triglycerides	NNS	O
and	CC	O
total	JJ	O
cholesterol	NN	O
,	,	O
respectively	RB	O
.	.	O
Furthermore	RB	O
,	,	O
HDL	NNP	O
cholesterol	NN	O
was	VBD	O
reduced	VBN	O
.	.	O
No	DT	O
significant	JJ	O
change	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
LDL	NNP	O
cholesterol	NN	O
levels	NNS	O
.	.	O
Plasma	NNP	O
glucose	JJ	O
concentrations	NNS	O
(	(	O
n=8	JJ	O
mice	NN	O
)	)	O
were	VBD	O
measured	VBN	O
at	IN	O
0	CD	O
(	(	O
beginning	VBG	O
of	IN	O
study	NN	O
)	)	O
,	,	O
3	CD	O
and	CC	O
7	CD	O
(	(	O
end	NN	O
of	IN	O
study	NN	O
)	)	O
weeks	NNS	O
of	IN	O
treatment	NN	O
by	IN	O
routine	JJ	O
clinical	JJ	O
analysis	NN	O
using	VBG	O
a	DT	O
YSI2700	NNP	O
Select™	NNP	O
Biochemistry	NNP	O
Analyzer	NNP	O
(	(	O
YSI	NNP	O
Inc.	NNP	O
,	,	O
Yellow	NNP	O
Spring	NNP	O
,	,	O
Ohio	NNP	O
)	)	O
.	.	O
Plasma	NNP	O
insulin	NN	O
levels	NNS	O
(	(	O
n=6	NN	O
to	TO	O
8	CD	O
mice	NNS	O
)	)	O
were	VBD	O
measured	VBN	O
in	IN	O
the	DT	O
fed	NN	O
state	NN	O
at	IN	O
0	CD	O
,	,	O
3	CD	O
and	CC	O
7	CD	O
weeks	NNS	O
and	CC	O
following	VBG	O
a	DT	O
4-hour	JJ	O
fast	NN	O
at	IN	O
4	CD	O
weeks	NNS	O
,	,	O
using	VBG	O
an	DT	O
insulin	NN	O
ELISA	NNP	O
kit	NNP	O
(	(	O
#	#	O
10-1137-10	CD	O
,	,	O
ALPCO	NNP	O
Diagnostics	NNP	O
,	,	O
Windham	NNP	O
,	,	O
N.	NNP	O
H.	NNP	O
)	)	O
according	VBG	O
to	TO	O
the	DT	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O
After	IN	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
an	DT	O
insulin	NN	O
tolerance	NN	O
test	NN	O
(	(	O
n=8	JJ	O
mice	NN	O
)	)	O
was	VBD	O
performed	VBN	O
after	IN	O
a	DT	O
3-hour	JJ	O
fast	NN	O
.	.	O
After	IN	O
5	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
a	DT	O
glucose	JJ	O
tolerance	NN	O
test	NN	O
(	(	O
n=8	JJ	O
mice	NN	O
)	)	O
was	VBD	O
performed	VBN	O
after	IN	O
an	DT	O
overnight	JJ	O
fast	NN	O
.	.	O
For	IN	O
the	DT	O
tolerance	NN	O
tests	NNS	O
,	,	O
a	DT	O
baseline	NN	O
tail	NN	O
blood	NN	O
glucose	JJ	O
measurement	NN	O
was	VBD	O
obtained	VBN	O
,	,	O
after	IN	O
which	WDT	O
1.0	CD	O
g/kg	NN	O
glucose	NN	O
or	CC	O
0.5	CD	O
units/kg	JJ	O
insulin	NN	O
was	VBD	O
administered	VBN	O
intraperitoneally	RB	O
.	.	O
Tail	NNP	O
blood	NN	O
glucose	NN	O
levels	NNS	O
were	VBD	O
measured	VBN	O
at	IN	O
15	CD	O
,	,	O
30	CD	O
,	,	O
60	CD	O
,	,	O
90	CD	O
and	CC	O
120	CD	O
minutes	NNS	O
following	VBG	O
the	DT	O
challenge	NN	O
with	IN	O
glucose	NN	O
or	CC	O
insulin	NN	O
,	,	O
using	VBG	O
a	DT	O
Glucometer®	NNP	O
instrument	NN	O
(	(	O
Abbott	NNP	O
Laboratories	NNPS	O
,	,	O
Bedford	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
.	.	O
Treatment	NN	O
with	IN	O
an	DT	O
antisense	JJ	O
oligonucleotide	NN	O
targeted	VBD	O
to	TO	O
diacylglycerol	VB	O
acyltransferase	NN	O
2	CD	O
reduced	VBD	O
plasma	JJ	O
insulin	NN	O
levels	NNS	O
by	IN	O
50	CD	O
%	NN	O
in	IN	O
the	DT	O
fasted	JJ	O
state	NN	O
at	IN	O
4	CD	O
weeks	NNS	O
and	CC	O
by	IN	O
69	CD	O
%	NN	O
in	IN	O
the	DT	O
fed	NN	O
state	NN	O
at	IN	O
the	DT	O
7	CD	O
weeks	NNS	O
.	.	O
Plasma	NNP	O
glucose	NN	O
levels	NNS	O
were	VBD	O
unchanged	JJ	O
by	IN	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
in	IN	O
diet-induced	JJ	O
obese	JJ	O
mice	NN	O
.	.	O
Neither	DT	O
insulin	NN	O
sensitivity	NN	O
nor	CC	O
glucose	JJ	O
tolerance	NN	O
was	VBD	O
improved	VBN	O
by	IN	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
.	.	O
Example	JJ	O
20	CD	O
Effects	NNS	O
of	IN	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
on	IN	O
Hepatic	NNP	O
Triglycerides	NNP	O
and	CC	O
Steatosis	NNP	O
in	IN	O
Diet-Induced	NNP	O
Obese	NNP	O
Mice	NNP	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
ISIS	NNP	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
was	VBD	O
tested	VBN	O
for	IN	O
its	PRP$	O
ability	NN	O
to	TO	O
affect	VB	O
triglyceride	NN	O
and	CC	O
glycogen	NN	O
content	NN	O
in	IN	O
the	DT	O
livers	NNS	O
of	IN	O
diet-induced	JJ	O
obese	JJ	O
mice	NN	O
.	.	O
The	DT	O
diet-induced	JJ	O
obese	JJ	O
mice	NN	O
that	WDT	O
received	VBD	O
antisense	JJ	O
oligonucleotide	RB	O
treatment	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
18	CD	O
,	,	O
were	VBD	O
further	RB	O
evaluated	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
7	CD	O
week	NN	O
treatment	NN	O
period	NN	O
for	IN	O
hepatic	JJ	O
triglycerides	NNS	O
and	CC	O
glycogen	NN	O
content	NN	O
.	.	O
Hepatic	JJ	O
triglyceride	NN	O
content	NN	O
,	,	O
which	WDT	O
is	VBZ	O
evaluated	VBN	O
by	IN	O
biochemical	JJ	O
analysis	NN	O
of	IN	O
liver	NN	O
triglyceride	NN	O
concentration	NN	O
and	CC	O
histological	JJ	O
examination	NN	O
of	IN	O
liver	JJ	O
tissue	NN	O
,	,	O
was	VBD	O
used	VBN	O
to	TO	O
assess	VB	O
hepatic	JJ	O
steatosis	NN	O
,	,	O
or	CC	O
accumulation	NN	O
of	IN	O
lipids	NNS	O
in	IN	O
the	DT	O
liver	NN	O
.	.	O
To	TO	O
measure	VB	O
liver	JJ	O
tissue	NN	O
triglyceride	IN	O
concentration	NN	O
,	,	O
triglycerides	NNS	O
were	VBD	O
extracted	VBN	O
from	IN	O
liver	JJ	O
tissue	NN	O
in	IN	O
HPLC-grade	NNP	O
acetone	NN	O
,	,	O
using	VBG	O
a	DT	O
weight	NN	O
:	:	O
volume	NN	O
ratio	NN	O
of	IN	O
1:20	CD	O
.	.	O
Triglycerides	NNS	O
were	VBD	O
measured	VBN	O
using	VBG	O
an	DT	O
Infinity	NNP	O
Triglycerides	NNP	O
Reagent	NNP	O
Kit	NNP	O
(	(	O
Sigma-Aldrich	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
.	.	O
Liver	NNP	O
and	CC	O
muscle	NN	O
glycogen	NN	O
concentrations	NNS	O
were	VBD	O
measured	VBN	O
as	IN	O
described	VBN	O
by	IN	O
Desai	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
Diabetes	NNPS	I
,	,	I
2001	CD	I
,	,	I
50	CD	I
,	,	I
2287-2295	JJ	I
)	)	I
.	.	O
To	TO	O
measure	VB	O
glycogen	NN	O
concentrations	NNS	O
,	,	O
liver	NN	O
and	CC	O
muscle	NN	O
tissue	NN	O
were	VBD	O
homogenized	VBN	O
in	IN	O
0.03	CD	O
N	NNP	O
HCl	NNP	O
(	(	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
0.5	CD	O
mg/mL	NN	O
)	)	O
.	.	O
100	CD	O
μL	NN	O
of	IN	O
homogenate	NN	O
was	VBD	O
mixed	JJ	O
with	IN	O
400	CD	O
μL	NNS	O
of	IN	O
1.25	CD	O
N	NNP	O
HCl	NNP	O
and	CC	O
heated	VBN	O
for	IN	O
1	CD	O
hour	NN	O
at	IN	O
100°	CD	O
C.	NNP	O
Following	NNP	O
centrifugation	NN	O
of	IN	O
the	DT	O
samples	NNS	O
at	IN	O
14,000	CD	O
rpm	NN	O
,	,	O
10	CD	O
μL	NN	O
of	IN	O
the	DT	O
supernatant	NN	O
was	VBD	O
mixed	JJ	O
with	IN	O
1	CD	O
mL	NNS	O
of	IN	O
glucose	JJ	O
oxidase	JJ	O
reagent	NN	O
(	(	O
Sigma-Aldrich	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
.	.	O
After	IN	O
a	DT	O
10	CD	O
minute	NN	O
incubation	NN	O
at	IN	O
37°	CD	O
C.	NNP	O
,	,	O
the	DT	O
absorbance	NN	O
was	VBD	O
read	VBN	O
at	IN	O
505	CD	O
nm	NNS	O
.	.	O
A	DT	O
standard	JJ	O
curve	NN	O
was	VBD	O
generated	VBN	O
using	VBG	O
glycogen	NN	O
type	NN	O
II	NNP	O
from	IN	O
rabbit	NN	O
liver	NN	O
and	CC	O
used	VBD	O
to	TO	O
determine	VB	O
the	DT	O
glycogen	NN	O
concentrations	NNS	O
.	.	O
The	DT	O
data	NN	O
for	IN	O
hepatic	JJ	O
lipid	NN	O
and	CC	O
glycogen	NN	O
content	NN	O
(	(	O
n=8	JJ	O
mice	NN	O
)	)	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
6	CD	O
and	CC	O
are	VBP	O
expressed	VBN	O
as	IN	O
percent	NN	O
reduction	NN	O
relative	JJ	O
to	TO	O
saline-treated	JJ	O
,	,	O
high-fat	JJ	O
diet	JJ	O
mice	NN	O
.	.	O
The	DT	O
results	NNS	O
in	IN	O
Table	JJ	O
6	CD	O
demonstrate	NN	O
that	IN	O
7	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
antisense	JJ	O
oligonucleotide	RB	O
targeted	VBN	O
to	TO	O
diacylglycerol	VB	O
acyltransferase	JJ	O
2	CD	O
yields	NNS	O
a	DT	O
marked	JJ	O
reduction	NN	O
of	IN	O
56	CD	O
%	NN	O
in	IN	O
hepatic	JJ	O
triglyceride	NN	O
content	NN	O
compared	VBN	O
to	TO	O
saline-	JJ	O
and	CC	O
control	VB	O
oligonucleotide-treated	JJ	O
mice	NN	O
,	,	O
indicating	VBG	O
an	DT	O
improvement	NN	O
in	IN	O
hepatic	JJ	O
steatosis	NN	O
.	.	O
Hepatic	JJ	O
glycogen	NN	O
content	NN	O
at	IN	O
7	CD	O
weeks	NNS	O
,	,	O
shown	VBN	O
in	IN	O
Table	JJ	O
6	CD	O
,	,	O
was	VBD	O
unchanged	JJ	O
by	IN	O
ISIS	NNP	O
217376	CD	O
treatment	NN	O
.	.	O
In	IN	O
the	DT	O
5-week	JJ	O
study	NN	O
,	,	O
hepatic	JJ	O
triglyceride	NN	O
content	NN	O
was	VBD	O
lowered	VBN	O
by	IN	O
62	CD	O
%	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O
Muscle	NNP	O
glycogen	NN	O
content	NN	O
after	IN	O
5	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
was	VBD	O
unchanged	JJ	O
by	IN	O
ISIS	NNP	O
217376	CD	O
treatment	NN	O
.	.	O
The	DT	O
reduction	NN	O
in	IN	O
hepatic	JJ	O
triglycerides	NNS	O
was	VBD	O
also	RB	O
evaluated	VBN	O
by	IN	O
histological	JJ	O
examination	NN	O
of	IN	O
liver	JJ	O
tissue	NN	O
(	(	O
n=4	JJ	O
mice	NN	O
)	)	O
.	.	O
Liver	NNP	O
tissue	NN	O
was	VBD	O
fixed	VBN	O
in	IN	O
10	CD	O
%	NN	O
neutral	JJ	O
buffered	VBN	O
formalin	NN	O
and	CC	O
embedded	VBN	O
in	IN	O
paraffin	NN	O
wax	NN	O
.	.	O
Multiple	JJ	O
adjacent	JJ	O
4-um	JJ	O
sections	NNS	O
were	VBD	O
cut	VBN	O
and	CC	O
mounted	VBN	O
on	IN	O
glass	NN	O
slides	NNS	O
.	.	O
After	IN	O
dehydration	NN	O
,	,	O
the	DT	O
sections	NNS	O
were	VBD	O
stained	VBN	O
with	IN	O
hematoxylin	NN	O
and	CC	O
eosin	NN	O
,	,	O
which	WDT	O
stain	VBP	O
nuclei	NNS	O
and	CC	O
cytoplasm	NN	O
,	,	O
respectively	RB	O
.	.	O
This	DT	O
histological	JJ	O
analysis	NN	O
revealed	VBD	O
a	DT	O
marked	JJ	O
improvement	NN	O
in	IN	O
hepatic	JJ	O
steatosis	NN	O
following	VBG	O
7	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
saline-treated	JJ	O
or	CC	O
ISIS	JJ	O
141923-treated	JJ	O
mice	NN	O
.	.	O
Thus	RB	O
,	,	O
an	DT	O
improvement	NN	O
in	IN	O
hepatic	JJ	O
steatosis	NN	O
was	VBD	O
demonstrated	VBN	O
by	IN	O
both	DT	O
histological	JJ	O
and	CC	O
biochemical	JJ	O
methods	NNS	O
.	.	O
Example	JJ	O
21	CD	O
Effects	NNS	O
of	IN	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
on	IN	O
Hepatic	NNP	O
Lipogenic	NNP	O
and	CC	O
Gluconeogenic	NNP	O
Genes	NNP	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
ISIS	NNP	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
was	VBD	O
tested	VBN	O
for	IN	O
its	PRP$	O
ability	NN	O
to	TO	O
affect	VB	O
the	DT	O
expression	NN	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
and	CC	O
glucose	JJ	O
metabolism	NN	O
.	.	O
The	DT	O
diet-induced	JJ	O
obese	JJ	O
mice	NN	O
that	WDT	O
received	VBD	O
antisense	JJ	O
oligonucleotide	RB	O
treatment	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
18	CD	O
,	,	O
were	VBD	O
further	RB	O
evaluated	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
7	CD	O
week	NN	O
treatment	NN	O
period	NN	O
for	IN	O
expression	NN	O
levels	NNS	O
of	IN	O
genes	NNS	O
that	WDT	O
participate	VBP	O
in	IN	O
lipid	JJ	O
metabolism	NN	O
,	,	O
gluconeogenesis	NN	O
and	CC	O
glucose	JJ	O
metabolism	NN	O
.	.	O
mRNA	NN	O
levels	NNS	O
in	IN	O
liver	NN	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
were	VBD	O
quantitated	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	VBN	O
in	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
,	,	O
using	VBG	O
primer-probe	JJ	O
sets	NNS	O
that	WDT	O
were	VBD	O
generated	VBN	O
using	VBG	O
the	DT	O
GenBank®	NNP	O
accession	NN	O
numbers	NNS	O
provided	VBN	O
in	IN	O
Table	JJ	O
7	CD	O
.	.	O
The	DT	O
results	NNS	O
are	VBP	O
presented	VBN	O
as	IN	O
percent	NN	O
change	NN	O
relative	JJ	O
to	TO	O
saline-treated	JJ	O
,	,	O
high-fat	JJ	O
diet	JJ	O
control	NN	O
mice	NN	O
and	CC	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
7	CD	O
(	(	O
n=6	NN	O
to	TO	O
8	CD	O
mice	NN	O
)	)	O
.	.	O
These	DT	O
data	NNS	O
demonstrate	VBP	O
that	IN	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
,	,	O
in	IN	O
addition	NN	O
to	TO	O
reducing	VBG	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
in	IN	O
diet-induced	JJ	O
obese	JJ	O
mice	NN	O
,	,	O
caused	VBD	O
concordant	JJ	O
reductions	NNS	O
in	IN	O
the	DT	O
expression	NN	O
of	IN	O
additional	JJ	O
genes	NNS	O
that	WDT	O
participate	VBP	O
in	IN	O
lipid	JJ	O
metabolism	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
in	IN	O
liver	NN	O
,	,	O
decreases	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
expression	NN	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
triglyceride	JJ	O
synthesis	NN	O
(	(	O
e.g.	NN	O
,	,	O
glycerol	VB	O
kinase	NN	O
)	)	O
,	,	O
de	FW	O
novo	FW	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
(	(	O
e.g.	JJ	O
,	,	O
ATP-citrate	JJ	O
lyase	NN	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
1	CD	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
2	CD	O
and	CC	O
fatty	JJ	O
acid	JJ	O
synthase	NN	O
)	)	O
fatty	VBZ	O
acid	JJ	O
oxidation	NN	O
(	(	O
e.g.	JJ	O
,	,	O
carnitine	JJ	O
palmitoyltransferase	NN	O
I	PRP	O
)	)	O
,	,	O
fatty	JJ	O
acid	JJ	O
desaturation	NN	O
(	(	O
e.g.	JJ	O
,	,	O
stearoyl-CoA	JJ	O
desaturase	NN	O
1	CD	O
)	)	O
and	CC	O
cholesterol	NN	O
synthesis	NN	O
(	(	O
e.g.	JJ	O
,	,	O
HMG-CoA	NNP	O
reductase	NN	O
)	)	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
expression	NN	O
of	IN	O
glycogen	NN	O
phosphorylase	NN	O
,	,	O
which	WDT	O
participates	VBZ	O
in	IN	O
glycogen	NN	O
metabolism	NN	O
,	,	O
was	VBD	O
reduced	VBN	O
following	VBG	O
ISIS	NNP	O
217376	CD	O
treatment	NN	O
of	IN	O
diet-induced	JJ	O
obese	JJ	O
mice	NN	O
.	.	O
Lipoprotein	NNP	O
lipase	NN	O
,	,	O
which	WDT	O
participates	VBZ	O
in	IN	O
fatty	JJ	O
acid	JJ	O
storage	NN	O
in	IN	O
adipose	JJ	O
tissue	NN	O
,	,	O
exhibited	VBD	O
reduced	JJ	O
expression	NN	O
as	RB	O
well	RB	O
.	.	O
The	DT	O
expression	NN	O
of	IN	O
sterol	NN	O
regulatory	JJ	O
binding	NN	O
element	NN	O
protein	NN	O
1	CD	O
,	,	O
which	WDT	O
functions	VBZ	O
as	IN	O
a	DT	O
hepatic	JJ	O
transcription	NN	O
factor	NN	O
in	IN	O
the	DT	O
context	NN	O
of	IN	O
lipid	JJ	O
metabolism	NN	O
,	,	O
was	VBD	O
lowered	VBN	O
in	IN	O
diet-induced	JJ	O
mice	NN	O
treated	VBN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
,	,	O
as	IN	O
compared	VBN	O
to	TO	O
control	VB	O
groups	NNS	O
.	.	O
The	DT	O
expression	NN	O
levels	NNS	O
of	IN	O
genes	NNS	O
related	VBN	O
to	TO	O
gluconeogenesis	NN	O
(	(	O
e.g.	JJ	O
,	,	O
glucose-6-phosphatase	JJ	O
and	CC	O
phosphoenolpyruvate	JJ	O
carboxykinase	NN	O
1	CD	O
)	)	O
,	,	O
glucose	JJ	O
uptake	NN	O
in	IN	O
both	DT	O
liver	NN	O
and	CC	O
fat	NN	O
(	(	O
e.g.	NN	O
,	,	O
glucose	JJ	O
transporter	NN	O
type	NN	O
2	CD	O
and	CC	O
glucose	VB	O
transporter	JJR	O
type	NN	O
4	CD	O
)	)	O
and	CC	O
lipid	JJ	O
homeostasis	NN	O
in	IN	O
fat	NN	O
(	(	O
e.g.	NN	O
,	,	O
hormone	NN	O
sensitive	JJ	O
lipase	NN	O
and	CC	O
lipoprotein	JJ	O
lipase	NN	O
)	)	O
were	VBD	O
not	RB	O
significantly	RB	O
lowered	VBN	O
.	.	O
These	DT	O
data	NNS	O
demonstrate	NN	O
that	IN	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
results	NNS	O
in	IN	O
the	DT	O
down-regulation	NN	O
of	IN	O
genes	NNS	O
in	IN	O
the	DT	O
lipogenic	JJ	O
pathway	NN	O
.	.	O
Example	JJ	O
22	CD	O
Effects	NNS	O
of	IN	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
in	IN	O
the	DT	O
Ob/Ob	NNP	O
Mouse	NNP	O
Model	NNP	O
of	IN	O
Obesity	NNP	O
Leptin	NNP	O
is	VBZ	O
a	DT	O
hormone	NN	O
produced	VBN	O
by	IN	O
fat	NN	O
that	WDT	O
regulates	VBZ	O
appetite	RB	O
.	.	O
Deficiencies	NNS	O
in	IN	O
this	DT	O
hormone	NN	O
in	IN	O
both	DT	O
humans	NNS	O
and	CC	O
non-human	JJ	O
animals	NNS	O
leads	VBZ	O
to	TO	O
obesity	NN	O
.	.	O
ob/ob	JJ	O
mice	NNS	O
have	VBP	O
a	DT	O
mutation	NN	O
in	IN	O
the	DT	O
leptin	NN	O
gene	NN	O
which	WDT	O
results	NNS	O
in	IN	O
obesity	NN	O
and	CC	O
hyperglycemia	NN	O
.	.	O
As	IN	O
such	JJ	O
,	,	O
these	DT	O
mice	NNS	O
are	VBP	O
a	DT	O
useful	JJ	O
model	NN	O
for	IN	O
the	DT	O
investigation	NN	O
of	IN	O
obesity	NN	O
and	CC	O
treatments	NNS	O
designed	VBN	O
to	TO	O
reduce	VB	O
obesity	NN	O
.	.	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
were	VBD	O
investigated	VBN	O
in	IN	O
the	DT	O
ob/ob	NN	O
mouse	NN	O
model	NN	O
of	IN	O
obesity	NN	O
.	.	O
Male	JJ	O
ob/ob	NN	O
(	(	O
C57B1/6J-Lepob/Lepob	NNP	O
)	)	O
mice	NN	O
at	IN	O
6-7	JJ	O
weeks	NNS	O
of	IN	O
age	NN	O
were	VBD	O
purchased	VBN	O
from	IN	O
Jackson	NNP	O
Laboratories	NNPS	O
(	(	O
Bar	NNP	O
Harbor	NNP	O
,	,	O
Me	NNP	O
.	.	O
)	)	O
.	.	O
During	IN	O
a	DT	O
1	CD	O
week	NN	O
acclimation	NN	O
period	NN	O
and	CC	O
throughout	IN	O
the	DT	O
study	NN	O
,	,	O
mice	NNS	O
were	VBD	O
fed	VBN	O
a	DT	O
diet	NN	O
with	IN	O
a	DT	O
fat	JJ	O
content	NN	O
of	IN	O
10-15	JJ	O
%	NN	O
(	(	O
Labdiets	NNP	O
#	#	O
5015	CD	O
,	,	O
Purina	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
.	.	O
After	IN	O
the	DT	O
1	CD	O
week	NN	O
acclimation	NN	O
period	NN	O
,	,	O
mice	NN	O
were	VBD	O
placed	VBN	O
into	IN	O
treatment	NN	O
groups	NNS	O
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
tail	NN	O
blood	NN	O
glucose	NN	O
,	,	O
which	WDT	O
was	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
Glucometer®	NNP	O
instrument	NN	O
(	(	O
Abbott	NNP	O
Laboratories	NNPS	O
,	,	O
Bedford	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
as	IN	O
described	VBN	O
herein	NN	O
.	.	O
For	IN	O
a	DT	O
period	NN	O
of	IN	O
4	CD	O
weeks	NNS	O
,	,	O
mice	NNS	O
received	VBD	O
subcutaneous	JJ	O
,	,	O
twice-weekly	JJ	O
injections	NNS	O
of	IN	O
ISIS	NNP	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
or	CC	O
ISIS	$	O
116847	CD	O
(	(	O
CTGCTAGCCTCTGGATTTGA	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
230	CD	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
25	CD	O
mg/kg	NN	O
.	.	O
ISIS	$	O
116847	CD	O
does	VBZ	O
not	RB	O
target	VB	O
the	DT	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
gene	NN	O
and	CC	O
was	VBD	O
used	VBN	O
as	IN	O
a	DT	O
control	NN	O
.	.	O
A	DT	O
group	NN	O
of	IN	O
saline-injected	JJ	O
mice	NN	O
served	VBD	O
as	IN	O
the	DT	O
control	NN	O
group	NN	O
to	TO	O
which	WDT	O
the	DT	O
oligonucleotide-treated	JJ	O
animals	NNS	O
were	VBD	O
compared	VBN	O
.	.	O
Each	DT	O
group	NN	O
contained	VBD	O
10	CD	O
animals	NNS	O
.	.	O
ISIS	NNP	O
116847	CD	O
is	VBZ	O
a	DT	O
chimeric	JJ	O
oligonucleotide	NN	O
(	(	O
“	JJ	O
gapmer	NN	O
”	NN	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
ten	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
A	DT	O
group	NN	O
of	IN	O
saline-injected	JJ	O
mice	NN	O
served	VBD	O
as	IN	O
an	DT	O
untreated	JJ	O
control	NN	O
.	.	O
Each	DT	O
treatment	NN	O
group	NN	O
consisted	VBD	O
of	IN	O
8	CD	O
mice	NNS	O
.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
four	CD	O
week	NN	O
treatment	NN	O
period	NN	O
,	,	O
the	DT	O
mice	NN	O
were	VBD	O
sacrificed	VBN	O
and	CC	O
target	VB	O
expression	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
1	CD	O
expression	NN	O
,	,	O
was	VBD	O
measured	VBN	O
in	IN	O
liver	NN	O
and	CC	O
fat	JJ	O
tissue	NN	O
.	.	O
mRNA	JJ	O
expression	NN	O
was	VBD	O
quantitated	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	VBN	O
in	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
.	.	O
These	DT	O
organs	NNS	O
were	VBD	O
also	RB	O
weighed	VBN	O
.	.	O
The	DT	O
data	NNS	O
are	VBP	O
expressed	VBN	O
as	IN	O
percent	NN	O
inhibition	NN	O
relative	NN	O
to	TO	O
saline	VB	O
control	NN	O
and	CC	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
8	CD	O
.	.	O
A	DT	O
“	JJ	O
+	NN	O
”	NN	O
preceding	VBG	O
the	DT	O
number	NN	O
indicates	VBZ	O
that	IN	O
gene	NN	O
expression	NN	O
was	VBD	O
increased	VBN	O
,	,	O
rather	RB	O
than	IN	O
inhibited	VBN	O
.	.	O
The	DT	O
results	NNS	O
shown	VBN	O
in	IN	O
Table	JJ	O
8	CD	O
illustrate	NN	O
that	WDT	O
treatment	NN	O
of	IN	O
ob/ob	JJ	O
mice	NN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
effectively	RB	O
inhibited	VBN	O
,	,	O
by	IN	O
83	CD	O
%	NN	O
and	CC	O
90	CD	O
%	NN	O
,	,	O
the	DT	O
expression	NN	O
of	IN	O
target	NN	O
mRNA	NN	O
in	IN	O
both	DT	O
liver	NN	O
and	CC	O
fat	JJ	O
tissues	NNS	O
,	,	O
respectively	RB	O
.	.	O
Liver	NNP	O
weight	NN	O
was	VBD	O
reduced	VBN	O
by	IN	O
21	CD	O
%	NN	O
in	IN	O
ob/ob	JJ	O
mice	NN	O
treated	VBN	O
with	IN	O
the	DT	O
antisense	JJ	O
oligonucleotide	NN	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
but	CC	O
fat	JJ	O
tissue	NN	O
weight	NN	O
was	VBD	O
not	RB	O
significantly	RB	O
changed	VBN	O
.	.	O
No	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
1	CD	O
mRNA	NN	O
expression	NN	O
was	VBD	O
observed	VBN	O
.	.	O
Throughout	IN	O
the	DT	O
study	NN	O
period	NN	O
,	,	O
body	NN	O
weight	NN	O
and	CC	O
food	NN	O
intake	NN	O
were	VBD	O
monitored	VBN	O
,	,	O
however	RB	O
,	,	O
no	DT	O
changes	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
ISIS	NNP	O
217376-treated	JJ	O
mice	NN	O
relative	NN	O
to	TO	O
saline-treated	JJ	O
mice	NN	O
.	.	O
Similarly	RB	O
,	,	O
no	DT	O
change	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
adipose	JJ	O
tissue	NN	O
weight	NN	O
.	.	O
Metabolic	JJ	O
rate	NN	O
,	,	O
measured	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
,	,	O
was	VBD	O
also	RB	O
unchanged	JJ	O
following	VBG	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
.	.	O
The	DT	O
expression	NN	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
lipogenesis	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
fatty	JJ	O
acid	JJ	O
synthase	NN	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
1	CD	O
and	CC	O
acetyl-CoA	JJ	O
carboxylase	NN	O
2	CD	O
,	,	O
were	VBD	O
decreased	VBN	O
following	VBG	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217386	CD	O
.	.	O
Example	JJ	O
23	CD	O
Effects	NNS	O
of	IN	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
in	IN	O
Ob/Ob	NNP	O
Mice	NNP	O
on	IN	O
Serum	NNP	O
and	CC	O
Liver	NNP	O
Lipid	NNP	O
Content	NNP	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
ISIS	NNP	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
was	VBD	O
tested	VBN	O
for	IN	O
its	PRP$	O
effect	NN	O
on	IN	O
serum	NN	O
lipids	NNS	O
and	CC	O
free	JJ	O
fatty	NN	O
acids	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
tissue	NN	O
triglyceride	NN	O
levels	NNS	O
,	,	O
in	IN	O
ob/ob	JJ	O
mice	NN	O
.	.	O
The	DT	O
ob/ob	JJ	O
mice	NN	O
that	WDT	O
received	VBD	O
antisense	JJ	O
oligonucleotide	RB	O
treatment	NN	O
,	,	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
22	CD	O
,	,	O
were	VBD	O
further	RB	O
evaluated	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
4	CD	O
week	NN	O
treatment	NN	O
period	NN	O
for	IN	O
serum	JJ	O
free	JJ	O
fatty	NN	O
acids	NNS	O
,	,	O
serum	NN	O
cholesterol	NN	O
(	(	O
CHOL	NNP	O
)	)	O
,	,	O
and	CC	O
serum	NN	O
,	,	O
liver	RB	O
tissue	NN	O
and	CC	O
fat	JJ	O
tissue	NN	O
triglycerides	NNS	O
(	(	O
TRIG	NNP	O
)	)	O
,	,	O
all	DT	O
of	IN	O
which	WDT	O
were	VBD	O
measured	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
Hepatic	JJ	O
steatosis	NN	O
,	,	O
or	CC	O
accumulation	NN	O
of	IN	O
lipids	NNS	O
in	IN	O
the	DT	O
liver	NN	O
,	,	O
was	VBD	O
assessed	VBN	O
biochemically	RB	O
and	CC	O
histologically	RB	O
,	,	O
as	IN	O
described	VBN	O
herein	NN	O
.	.	O
The	DT	O
data	NN	O
describing	NN	O
serum	NN	O
and	CC	O
tissue	NN	O
lipid	NN	O
levels	NNS	O
,	,	O
shown	VBN	O
in	IN	O
Table	JJ	O
9	CD	O
,	,	O
are	VBP	O
expressed	VBN	O
as	IN	O
percent	NN	O
reduction	NN	O
relative	JJ	O
to	TO	O
saline-treated	JJ	O
control	NN	O
ob/ob	JJ	O
mice	NN	O
.	.	O
As	IN	O
in	IN	O
Example	NNP	O
22	CD	O
,	,	O
the	DT	O
results	NNS	O
are	VBP	O
the	DT	O
average	NN	O
of	IN	O
measurements	NNS	O
from	IN	O
8	CD	O
mice	NNS	O
.	.	O
The	DT	O
data	NN	O
illustrate	NN	O
that	WDT	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
ob/ob	JJ	O
mice	NN	O
causes	VBZ	O
a	DT	O
reduction	NN	O
of	IN	O
21	CD	O
%	NN	O
in	IN	O
triglyceride	NN	O
levels	NNS	O
in	IN	O
liver	NN	O
tissue	NN	O
and	CC	O
a	DT	O
reduction	NN	O
of	IN	O
22	CD	O
%	NN	O
in	IN	O
serum	JJ	O
free	JJ	O
fatty	JJ	O
acids	NNS	O
.	.	O
The	DT	O
decrease	NN	O
in	IN	O
liver	JJ	O
tissue	NN	O
triglyceride	NN	O
content	NN	O
indicates	VBZ	O
an	DT	O
improvement	NN	O
in	IN	O
hepatic	JJ	O
steatosis	NN	O
.	.	O
Furthermore	RB	O
,	,	O
histological	JJ	O
evaluation	NN	O
of	IN	O
liver	JJ	O
tissue	NN	O
indicated	VBD	O
a	DT	O
marked	JJ	O
improvement	NN	O
in	IN	O
hepatic	JJ	O
steatosis	NN	O
.	.	O
No	DT	O
significant	JJ	O
change	NN	O
in	IN	O
serum	NN	O
triglyceride	NN	O
,	,	O
fat	JJ	O
tissue	NN	O
triglyceride	NN	O
or	CC	O
cholesterol	NN	O
was	VBD	O
observed	VBN	O
.	.	O
Example	RB	O
24	CD	O
Plasma	NNP	O
Insulin	NNP	O
and	CC	O
Glucose	NNP	O
Levels	NNP	O
Following	NNP	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerolacyltransferase	NNP	O
2	CD	O
in	IN	O
Ob/Ob	NNP	O
Mice	NNP	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
the	DT	O
ob/ob	JJ	O
mice	NN	O
treated	VBD	O
as	IN	O
described	VBN	O
in	IN	O
Example	JJ	O
22	CD	O
were	VBD	O
further	RB	O
evaluated	VBN	O
for	IN	O
insulin	NN	O
and	CC	O
glucose	JJ	O
levels	NNS	O
.	.	O
Plasma	NNP	O
glucose	NN	O
was	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
antisense	JJ	O
oligonucleotide	NN	O
treatment	NN	O
and	CC	O
after	IN	O
2	CD	O
weeks	NNS	O
and	CC	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O
Plasma	NNP	O
insulin	NN	O
was	VBD	O
measured	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
following	VBG	O
2	CD	O
weeks	NNS	O
and	CC	O
4	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O
After	IN	O
3	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
glucose	NN	O
and	CC	O
insulin	JJ	O
tolerance	NN	O
tests	NNS	O
were	VBD	O
also	RB	O
performed	VBN	O
(	(	O
as	IN	O
described	VBN	O
herein	NN	O
)	)	O
in	IN	O
mice	NN	O
fasting	NN	O
for	IN	O
16	CD	O
and	CC	O
4	CD	O
hours	NNS	O
,	,	O
respectively	RB	O
.	.	O
Relative	JJ	O
to	TO	O
saline-treated	JJ	O
control	NN	O
ob/ob	JJ	O
mice	NN	O
,	,	O
plasma	JJ	O
insulin	NN	O
in	IN	O
ob/ob	JJ	O
mice	NN	O
receiving	VBG	O
ISIS	NNP	O
217376	CD	O
was	VBD	O
reduced	VBN	O
by	IN	O
43	CD	O
%	NN	O
at	IN	O
both	DT	O
2	CD	O
weeks	NNS	O
and	CC	O
4	CD	O
weeks	NNS	O
of	IN	O
antisense	JJ	O
oligonucleotide	JJ	O
treatment	NN	O
.	.	O
No	DT	O
significant	JJ	O
change	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
plasma	NN	O
glucose	NN	O
levels	NNS	O
,	,	O
and	CC	O
no	DT	O
improvements	NNS	O
in	IN	O
glucose	JJ	O
tolerance	NN	O
or	CC	O
insulin	NN	O
sensitivity	NN	O
were	VBD	O
observed	VBN	O
.	.	O
Example	JJ	O
25	CD	O
Effects	NNS	O
of	IN	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
in	IN	O
the	DT	O
db/db	NN	O
Mouse	NNP	O
Model	NNP	O
of	IN	O
Obesity	NNP	O
A	NNP	O
deficiency	NN	O
in	IN	O
the	DT	O
leptin	NN	O
hormone	NN	O
receptor	NN	O
mice	NN	O
also	RB	O
results	NNS	O
in	IN	O
obesity	NN	O
and	CC	O
hyperglycemia	NN	O
.	.	O
These	DT	O
mice	NNS	O
are	VBP	O
referred	VBN	O
to	TO	O
as	IN	O
db/db	JJ	O
mice	NN	O
and	CC	O
,	,	O
like	IN	O
the	DT	O
ob/ob	JJ	O
mice	NN	O
,	,	O
are	VBP	O
used	VBN	O
as	IN	O
a	DT	O
mouse	NN	O
model	NN	O
of	IN	O
obesity	NN	O
.	.	O
In	IN	O
accordance	NN	O
with	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
with	IN	O
ISIS	NNP	O
217276	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
was	VBD	O
investigated	VBN	O
for	IN	O
its	PRP$	O
effects	NNS	O
in	IN	O
db/db	JJ	O
mice	NN	O
.	.	O
Six-week	JJ	O
old	JJ	O
male	NN	O
db/db	NN	O
(	(	O
C57B1/6J-Leprdb/Leprdb	NNP	O
)	)	O
mice	NN	O
were	VBD	O
fed	VBN	O
a	DT	O
15-20	JJ	O
%	NN	O
fat	JJ	O
diet	NN	O
(	(	O
Labdiets	NNP	O
#	#	O
5008	CD	O
,	,	O
Purina	NNP	O
,	,	O
St.	NNP	O
Louis	NNP	O
,	,	O
Mo	NNP	O
.	.	O
)	)	O
for	IN	O
a	DT	O
7-day	JJ	O
acclimation	NN	O
period	NN	O
and	CC	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O
Following	VBG	O
the	DT	O
acclimation	NN	O
period	NN	O
,	,	O
the	DT	O
mice	NN	O
were	VBD	O
placed	VBN	O
into	IN	O
treatment	NN	O
groups	NNS	O
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
tail	NN	O
blood	NN	O
glucose	NN	O
,	,	O
which	WDT	O
was	VBD	O
measured	VBN	O
using	VBG	O
a	DT	O
Glucometer®	NNP	O
instrument	NN	O
(	(	O
Abbott	NNP	O
Laboratories	NNPS	O
,	,	O
Bedford	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
as	IN	O
described	VBN	O
herein	NN	O
.	.	O
Mice	NNP	O
received	VBD	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
ISIS	NNP	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
or	CC	O
the	DT	O
control	NN	O
oligonucleotide	IN	O
ISIS	NNP	O
116847	CD	O
(	(	O
CTGCTAGCCTCTGGATTTGA	NNP	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
230	CD	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
25	CD	O
mg/kg	JJ	O
twice	RB	O
per	IN	O
week	NN	O
for	IN	O
5	CD	O
weeks	NNS	O
.	.	O
A	DT	O
group	NN	O
of	IN	O
saline-injected	JJ	O
mice	NN	O
served	VBD	O
as	IN	O
untreated	JJ	O
controls	NNS	O
.	.	O
Each	DT	O
treatment	NN	O
group	NN	O
contained	VBD	O
10	CD	O
mice	NN	O
.	.	O
After	IN	O
the	DT	O
5	CD	O
week	NN	O
treatment	NN	O
period	NN	O
,	,	O
mice	NN	O
were	VBD	O
sacrificed	VBN	O
and	CC	O
diacylglycerol	VB	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
(	(	O
n=4	JJ	O
mice	NN	O
)	)	O
were	VBD	O
evaluated	VBN	O
in	IN	O
liver	NN	O
,	,	O
brown	IN	O
adipose	JJ	O
tissue	NN	O
(	(	O
BAT	NNP	O
)	)	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
(	(	O
WAT	NNP	O
)	)	O
.	.	O
Diacylglycerol	NNP	O
acyltransferase	VBD	O
1	CD	O
mRNA	NN	O
levels	NNS	O
were	VBD	O
also	RB	O
measured	VBN	O
in	IN	O
these	DT	O
tissues	NNS	O
.	.	O
mRNA	JJ	O
expression	NN	O
levels	NNS	O
were	VBD	O
quantitated	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	VBN	O
in	IN	O
other	JJ	O
examples	NNS	O
herein	NNS	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
liver	NN	O
triglycerides	NNS	O
(	(	O
n=6	JJ	O
mice	NN	O
)	)	O
and	CC	O
plasma	$	O
glucose	NN	O
(	(	O
n=8	JJ	O
mice	NN	O
)	)	O
were	VBD	O
measured	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
The	DT	O
results	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
10	CD	O
and	CC	O
are	VBP	O
expressed	VBN	O
as	IN	O
percent	NN	O
inhibition	NN	O
(	(	O
for	IN	O
mRNA	NN	O
expression	NN	O
)	)	O
or	CC	O
reduction	NN	O
(	(	O
for	IN	O
glucose	NN	O
and	CC	O
triglycerides	NNS	O
)	)	O
relative	VBP	O
to	TO	O
saline	VB	O
treated	JJ	O
mice	NN	O
.	.	O
An	DT	O
increase	NN	O
in	IN	O
gene	NN	O
expression	NN	O
or	CC	O
liver	NN	O
triglycerides	NNS	O
is	VBZ	O
indicated	VBN	O
by	IN	O
a	DT	O
“	JJ	O
+	NN	O
”	NN	O
preceding	VBG	O
the	DT	O
number	NN	O
.	.	O
Liver	NNP	O
tissue	NN	O
samples	NNS	O
were	VBD	O
processed	VBN	O
for	IN	O
histological	JJ	O
examination	NN	O
,	,	O
as	IN	O
described	VBN	O
herein	NN	O
,	,	O
for	IN	O
the	DT	O
evaluation	NN	O
of	IN	O
hepatic	JJ	O
steatosis	NN	O
,	,	O
or	CC	O
accumulation	NN	O
of	IN	O
lipids	NNS	O
in	IN	O
the	DT	O
liver	NN	O
.	.	O
Liver	JJ	O
sections	NNS	O
were	VBD	O
stained	VBN	O
with	IN	O
oil	NN	O
red	JJ	O
0	CD	O
stain	NN	O
,	,	O
which	WDT	O
is	VBZ	O
commonly	RB	O
used	VBN	O
to	TO	O
visualize	VB	O
lipid	JJ	O
deposits	NNS	O
,	,	O
and	CC	O
counterstained	VBD	O
with	IN	O
hematoxylin	NN	O
and	CC	O
eosin	NN	O
,	,	O
to	TO	O
visualize	VB	O
nuclei	NNS	O
and	CC	O
cytoplasm	NN	O
,	,	O
respectively	RB	O
.	.	O
These	DT	O
data	NNS	O
illustrate	VBP	O
that	IN	O
target	NN	O
mRNA	JJ	O
expression	NN	O
was	VBD	O
effectively	RB	O
inhibited	VBN	O
by	IN	O
95	CD	O
%	NN	O
,	,	O
80	CD	O
%	NN	O
and	CC	O
87	CD	O
%	NN	O
in	IN	O
liver	NN	O
,	,	O
white	JJ	O
adipose	NN	O
and	CC	O
brown	JJ	O
adipose	JJ	O
tissues	NNS	O
,	,	O
respectively	RB	O
,	,	O
of	IN	O
db/db	JJ	O
mice	NNS	O
treated	VBN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
.	.	O
Furthermore	RB	O
,	,	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
in	IN	O
db/db	JJ	O
mice	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
41	CD	O
%	NN	O
reduction	NN	O
in	IN	O
hepatic	JJ	O
triglyceride	NN	O
content	NN	O
as	IN	O
measured	VBN	O
biochemically	RB	O
and	CC	O
marked	VBD	O
reductions	NNS	O
in	IN	O
lipid	JJ	O
accumulation	NN	O
as	IN	O
measured	VBN	O
histologically	RB	O
,	,	O
demonstrating	VBG	O
an	DT	O
improvement	NN	O
in	IN	O
hepatic	JJ	O
steatosis	NN	O
.	.	O
No	DT	O
significant	JJ	O
change	NN	O
in	IN	O
plasma	NN	O
glucose	NN	O
was	VBD	O
observed	VBN	O
.	.	O
The	DT	O
expression	NN	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
lipogenesis	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
fatty	JJ	O
acid	JJ	O
synthase	NN	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
1	CD	O
and	CC	O
acetyl-CoA	JJ	O
carboxylase	NN	O
2	CD	O
were	VBD	O
decreased	VBN	O
following	VBG	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217386	CD	O
.	.	O
Together	RB	O
with	IN	O
the	DT	O
data	NNS	O
described	VBD	O
herein	NN	O
,	,	O
these	DT	O
data	NNS	O
illustrate	VBP	O
that	IN	O
the	DT	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
mouse	NN	O
models	NNS	O
of	IN	O
diet-induced	JJ	O
obesity	NN	O
,	,	O
leptin	JJ	O
deficiency	NN	O
and	CC	O
defects	NNS	O
in	IN	O
leptin	NN	O
signaling	NN	O
reduced	VBN	O
hepatic	JJ	O
steatosis	NN	O
and	CC	O
hepatic	JJ	O
lipogenesis	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
hyperlipidimia	NN	O
.	.	O
Example	JJ	O
26	CD	O
Design	NNP	O
and	CC	O
Screening	NNP	O
of	IN	O
siRNAs	NN	O
Targeting	NNP	O
Human	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
nucleic	JJ	O
acid	NN	O
duplexes	NNS	O
(	(	O
siRNAs	NN	O
)	)	O
was	VBD	O
designed	VBN	O
to	TO	O
target	VB	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
)	)	O
and	CC	O
is	VBZ	O
shown	VBN	O
in	IN	O
Table	JJ	O
11	CD	O
.	.	O
All	DT	O
compounds	NNS	O
in	IN	O
Table	JJ	O
11	CD	O
are	VBP	O
oligoribonucleotides	JJ	O
19	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
with	IN	O
phosphodiester	NN	O
internucleoside	NN	O
linkages	NNS	O
(	(	O
backbones	NNS	O
)	)	O
throughout	IN	O
the	DT	O
compound	NN	O
.	.	O
The	DT	O
compounds	NNS	O
were	VBD	O
prepared	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
with	IN	O
blunt	NN	O
ends	NNS	O
.	.	O
Table	JJ	O
11	CD	O
shows	VBZ	O
the	DT	O
antisense	JJ	O
strand	NN	O
of	IN	O
the	DT	O
siRNA	NN	O
,	,	O
and	CC	O
the	DT	O
sense	NN	O
strand	NN	O
is	VBZ	O
synthesized	VBN	O
as	IN	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
antisense	NN	O
strand	NN	O
.	.	O
These	DT	O
sequences	NNS	O
are	VBP	O
shown	VBN	O
to	TO	O
contain	VB	O
uracil	JJ	O
(	(	O
U	NNP	O
)	)	O
but	CC	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
will	MD	O
appreciate	VB	O
that	IN	O
uracil	NN	O
(	(	O
U	NNP	O
)	)	O
is	VBZ	O
generally	RB	O
replaced	VBN	O
by	IN	O
thymine	NN	O
(	(	O
T	NNP	O
)	)	O
in	IN	O
DNA	NN	O
sequences	NNS	O
.	.	O
“	NN	O
Target	NNP	O
site	NN	O
”	NN	O
indicates	VBZ	O
the	DT	O
first	JJ	O
(	(	O
5′-most	JJ	O
)	)	O
nucleotide	IN	O
number	NN	O
on	IN	O
the	DT	O
particular	JJ	O
target	NN	O
sequence	NN	O
to	TO	O
which	WDT	O
the	DT	O
compound	NN	O
binds	VBZ	O
.	.	O
The	DT	O
compounds	NNS	O
in	IN	O
Table	JJ	O
11	CD	O
were	VBD	O
tested	VBN	O
for	IN	O
their	PRP$	O
effects	NNS	O
on	IN	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
in	IN	O
A549	NNP	O
cells	NNS	O
.	.	O
siRNA	NN	O
controls	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
target	VB	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
included	VBD	O
the	DT	O
duplex	NN	O
of	IN	O
ISIS	NNP	O
335449	CD	O
(	(	O
TTTGTCTCTGGTCCTTACTT	NNP	O
;	:	O
incorporated	VBN	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
231	CD	O
)	)	O
and	CC	O
its	PRP$	O
complement	NN	O
,	,	O
and	CC	O
the	DT	O
duplex	NN	O
of	IN	O
ISIS	NNP	O
359661	CD	O
(	(	O
TTATCGCTTCTCGTTGCTT	NNP	O
;	:	O
incorporated	VBN	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
232	CD	O
)	)	O
and	CC	O
its	PRP$	O
complement	NN	O
.	.	O
ISIS	NNP	O
335449	CD	O
is	VBZ	O
an	DT	O
oligoribonucleotide	JJ	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
with	IN	O
phosphodiester	NN	O
internucleoside	NN	O
linkages	NNS	O
(	(	O
backbones	NNS	O
)	)	O
throughout	IN	O
the	DT	O
compound	NN	O
.	.	O
ISIS	NNP	O
359661	CD	O
is	VBZ	O
an	DT	O
oligoribonucleotide	JJ	O
19	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
with	IN	O
phosphodiester	NN	O
internucleoside	NN	O
linkages	NNS	O
(	(	O
backbones	NNS	O
)	)	O
throughout	IN	O
the	DT	O
compound	NN	O
.	.	O
Both	DT	O
ISIS	NNP	O
335449	CD	O
and	CC	O
ISIS	NNP	O
359661	CD	O
and	CC	O
their	PRP$	O
complements	NNS	O
were	VBD	O
prepared	VBN	O
with	IN	O
blunt	NN	O
ends	NNS	O
.	.	O
Control	NNP	O
RNase	NNP	O
H	NNP	O
oligonucleotides	NNS	O
were	VBD	O
the	DT	O
gapmers	NNS	O
ISIS	NNP	O
141923	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
229	CD	O
)	)	O
and	CC	O
ISIS	$	O
129700	CD	O
(	(	O
TAGTGCGGACCTACCCACGA	NNP	O
;	:	O
incorporated	VBN	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
233	CD	O
)	)	O
,	,	O
neither	DT	O
of	IN	O
which	WDT	O
targets	NNS	O
human	VBP	O
diacylglycerol	VB	O
acyltransferase	NN	O
2	CD	O
.	.	O
ISIS	NNP	O
129700	CD	O
is	VBZ	O
a	DT	O
chimeric	JJ	O
oligonucleotide	NN	O
(	(	O
“	JJ	O
gapmer	NN	O
”	NN	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
9	CD	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
the	DT	O
5′	CD	O
and	CC	O
3′	CD	O
ends	NNS	O
by	IN	O
a	DT	O
five-nucleotide	JJ	O
“	NN	O
wing	VBG	O
”	NNP	O
and	CC	O
a	DT	O
six-nucleotide	JJ	O
“	NN	O
wing	VBG	O
”	NNP	O
,	,	O
respectively	RB	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidines	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
A549	NNP	O
cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
150	CD	O
nM	NNS	O
of	IN	O
siRNA	JJ	O
compounds	NNS	O
mixed	JJ	O
with	IN	O
15	CD	O
μg/mL	NNS	O
LIPOFECTIN™	NNP	O
reagent	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
or	CC	O
with	IN	O
150	CD	O
nM	NNS	O
of	IN	O
single-strand	NN	O
oligonucleotides	NNS	O
mixed	JJ	O
with	IN	O
15	CD	O
μg/mL	NNS	O
LIPOFECTIN™	NNP	O
reagent	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
4	CD	O
hours	NNS	O
,	,	O
followed	VBN	O
by	IN	O
20	CD	O
hours	NNS	O
of	IN	O
culture	NN	O
in	IN	O
normal	JJ	O
growth	NN	O
medium	NN	O
.	.	O
Human	NNP	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
expression	NN	O
was	VBD	O
measured	VBN	O
by	IN	O
quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
Results	NNS	O
were	VBD	O
normalized	VBN	O
to	TO	O
untreated	JJ	O
control	NN	O
cells	NNS	O
,	,	O
which	WDT	O
were	VBD	O
not	RB	O
treated	VBN	O
with	IN	O
dsRNA	JJ	O
compounds	NNS	O
or	CC	O
RNase	NNP	O
H	NNP	O
oligonucleotides	NNS	O
.	.	O
Data	NNS	O
are	VBP	O
the	DT	O
average	NN	O
of	IN	O
2	CD	O
experiments	NNS	O
and	CC	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
11	CD	O
.	.	O
Where	WRB	O
present	JJ	O
,	,	O
“	JJ	O
N.D.	NNP	O
”	NNP	O
indicates	VBZ	O
“	MD	O
not	RB	O
determined	VB	O
”	NN	O
.	.	O
These	DT	O
data	NNS	O
demonstrated	VBD	O
that	IN	O
siRNAs	NN	O
targeted	VBN	O
to	TO	O
diacylglycerol	VB	O
acyltransferase	NN	O
2	CD	O
,	,	O
for	IN	O
example	NN	O
,	,	O
duplexes	NNS	O
of	IN	O
ISIS	NNP	O
361888	CD	O
,	,	O
ISIS	NNP	O
361892	CD	O
,	,	O
ISIS	NNP	O
361893	CD	O
,	,	O
ISIS	NNP	O
361901	CD	O
and	CC	O
ISIS	NNP	O
361902	CD	O
,	,	O
and	CC	O
their	PRP$	O
respective	JJ	O
complements	NNS	O
,	,	O
inhibited	JJ	O
expression	NN	O
of	IN	O
the	DT	O
target	NN	O
mRNA	NN	O
.	.	O
Example	RB	O
27	CD	O
Inhibition	NNP	O
of	IN	O
Mouse	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
mRNA	NN	O
Expression	NN	O
in	IN	O
Mouse	NNP	O
Primary	NNP	O
Hepatocytes	NNP	O
Dose	NNP	O
Response	NNP	O
Studies	NNPS	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
four	CD	O
oligonucleotides	NNS	O
targeted	VBN	O
to	TO	O
mouse	VB	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
were	VBD	O
selected	VBN	O
for	IN	O
additional	JJ	O
dose-response	JJ	O
studies	NNS	O
.	.	O
These	DT	O
compounds	NNS	O
were	VBD	O
ISIS	NNP	O
217312	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
21	CD	O
)	)	O
,	,	O
ISIS	NNP	O
217311	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
109	CD	O
)	)	O
,	,	O
ISIS	NNP	O
217352	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
121	CD	O
)	)	O
,	,	O
and	CC	O
ISIS	NNP	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
.	.	O
ISIS	NNP	O
129690	CD	O
(	(	O
TTAGAATACGTCGCGTTATG	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
271	CD	O
)	)	O
,	,	O
and	CC	O
ISIS	NNP	O
129696	CD	O
(	(	O
ATTCGCCAGACAACACTGAC	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
272	CD	O
)	)	O
which	WDT	O
are	VBP	O
not	RB	O
targeted	VBN	O
to	TO	O
diacylglycerol	VB	O
acyltransferase	NN	O
2	CD	O
,	,	O
served	VBD	O
as	IN	O
controls	NNS	O
.	.	O
ISIS	NNP	O
129690	CD	O
and	CC	O
ISIS	NNP	O
129696	CD	O
are	VBP	O
chimeric	JJ	O
oligonucleotides	NNS	O
(	(	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
ten	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
Primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
were	VBD	O
prepared	VBN	O
from	IN	O
CD-1	NNP	O
mice	NNS	O
purchased	VBD	O
from	IN	O
Charles	NNP	O
River	NNP	O
Labs	NNP	O
(	(	O
Wilmington	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
.	.	O
Primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
were	VBD	O
routinely	RB	O
cultured	VBN	O
in	IN	O
William	NNP	O
's	POS	O
Medium	NNP	O
E	NNP	O
,	,	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
1	CD	O
%	NN	O
penicillin/streptomycin	NN	O
,	,	O
2	CD	O
mM	NN	O
L-glutamine	NNP	O
,	,	O
and	CC	O
0.01	CD	O
M	NNP	O
HEPES	NNP	O
(	(	O
medium	NN	O
and	CC	O
supplements	NNS	O
from	IN	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
,	,	O
BD	NNP	O
Biosciences	NNPS	O
)	)	O
coated	VBD	O
with	IN	O
0.1	CD	O
mg/ml	NNS	O
collagen	NN	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
10,000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligonucleotide	JJ	O
transfection	NN	O
experiments	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
transfected	VBN	O
using	VBG	O
OPTI-MEM™	NNP	O
medium	NN	O
containing	VBG	O
2.5	CD	O
μl	JJ	O
per	IN	O
100	CD	O
nM	NN	O
of	IN	O
oligonucleotide	NN	O
.	.	O
Diacylglycerol	NNP	O
acyltransferase	VBD	O
2	CD	O
mRNA	JJ	O
expression	NN	O
was	VBD	O
quantitated	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
Results	NNS	O
of	IN	O
these	DT	O
studies	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
12	CD	O
.	.	O
Data	NNS	O
are	VBP	O
averages	NNS	O
from	IN	O
three	CD	O
experiments	NNS	O
and	CC	O
are	VBP	O
expressed	VBN	O
as	IN	O
percent	NN	O
inhibition	NN	O
of	IN	O
untreated	JJ	O
control	NN	O
.	.	O
Also	RB	O
shown	VBN	O
is	VBZ	O
the	DT	O
IC50	NNP	O
for	IN	O
each	DT	O
oligonucleotide	NN	O
,	,	O
which	WDT	O
represents	VBZ	O
the	DT	O
concentration	NN	O
required	VBN	O
for	IN	O
50	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
target	NN	O
expression	NN	O
.	.	O
Where	WRB	O
present	JJ	O
,	,	O
“	JJ	O
N.D.	NNP	O
”	NNP	O
indicates	VBZ	O
not	RB	O
determined	VBN	O
.	.	O
As	IN	O
demonstrated	VBN	O
in	IN	O
Table	JJ	O
12	CD	O
,	,	O
ISIS	NNP	O
217311	CD	O
,	,	O
ISIS	NNP	O
217312	CD	O
,	,	O
ISIS	NNP	O
217352	CD	O
and	CC	O
ISIS	NNP	O
217376	CD	O
inhibited	VBD	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
expression	NN	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
manner	NN	O
.	.	O
Example	RB	O
28	CD	O
Inhibition	NNP	O
of	IN	O
Mouse	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
in	IN	O
Primary	NNP	O
Mouse	NNP	O
Hepatocytes	VBZ	O
:	:	O
Additional	NNP	O
Dose	NNP	O
Response	NNP	O
Studies	NNPS	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
an	DT	O
additional	JJ	O
antisense	NN	O
compound	NN	O
was	VBD	O
designed	VBN	O
to	TO	O
target	VB	O
mouse	VB	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
RNA	NNP	O
,	,	O
using	VBG	O
published	VBN	O
sequence	NN	O
data	NNS	O
(	(	O
GenBank	NNP	O
accession	NN	O
number	NN	O
AF384160.1	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
273	CD	O
)	)	O
.	.	O
The	DT	O
compound	NN	O
was	VBD	O
designated	VBN	O
ISIS	NNP	O
287498	CD	O
(	(	O
ATGCACTCGAGAACTCGGTA	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
274	CD	O
)	)	O
,	,	O
and	CC	O
the	DT	O
target	NN	O
site	NN	O
is	VBZ	O
nucleotide	JJ	O
1277	CD	O
of	IN	O
the	DT	O
3′	CD	O
UTR	NNP	O
region	NN	O
of	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
.	.	O
ISIS	NNP	O
287498	CD	O
and	CC	O
ISIS	NNP	O
217352	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
121	CD	O
)	)	O
were	VBD	O
analyzed	VBN	O
for	IN	O
their	PRP$	O
effects	NNS	O
on	IN	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
.	.	O
Control	NNP	O
oligonucleotides	NNS	O
were	VBD	O
ISIS	NNP	O
129686	CD	O
(	(	O
CGTTATTAACCTCCGTTGAA	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
275	CD	O
)	)	O
and	CC	O
129690	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
271	CD	O
)	)	O
.	.	O
ISIS	NNP	O
129686	CD	O
and	CC	O
ISIS	NNP	O
129690	CD	O
are	VBP	O
not	RB	O
targeted	VBN	O
to	TO	O
diacylglycerol	VB	O
acyltransferase	JJ	O
2	CD	O
.	.	O
ISIS	NNP	O
129686	CD	O
and	CC	O
ISIS	NNP	O
287498	CD	O
are	VBP	O
chimeric	JJ	O
oligonucleotides	NNS	O
(	(	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
ten	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
Primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
,	,	O
isolated	VBN	O
and	CC	O
cultured	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
27	CD	O
,	,	O
were	VBD	O
treated	VBN	O
with	IN	O
50	CD	O
,	,	O
100	CD	O
,	,	O
200	CD	O
,	,	O
and	CC	O
400	CD	O
nM	NN	O
of	IN	O
ISIS	NNP	O
287498	CD	O
,	,	O
ISIS	NNP	O
217352	CD	O
,	,	O
ISIS	NNP	O
129686	CD	O
and	CC	O
ISIS	NNP	O
129690	CD	O
.	.	O
Diacylglycerol	NNP	O
acyltransferase	VBD	O
2	CD	O
mRNA	NN	O
levels	NNS	O
were	VBD	O
quantitated	VBN	O
by	IN	O
real-time	JJ	O
PCR	NNP	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
Results	NNS	O
of	IN	O
these	DT	O
studies	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
13	CD	O
.	.	O
Data	NNS	O
are	VBP	O
averages	NNS	O
from	IN	O
three	CD	O
experiments	NNS	O
and	CC	O
are	VBP	O
expressed	VBN	O
as	IN	O
percent	NN	O
inhibition	NN	O
normalized	VBN	O
to	TO	O
expression	VB	O
in	IN	O
untreated	JJ	O
control	NN	O
cells	NNS	O
.	.	O
As	IN	O
demonstrated	VBN	O
in	IN	O
Table	JJ	O
13	CD	O
,	,	O
ISIS	NNP	O
217352	CD	O
and	CC	O
ISIS	NNP	O
287498	CD	O
inhibited	VBD	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
expression	NN	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
manner	NN	O
.	.	O
Example	RB	O
29	CD	O
Chimeric	NNP	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
Having	NNP	O
2′-MOE	JJ	O
Wings	NNP	O
and	CC	O
a	DT	O
Deoxy	NNP	O
Gap	NNP	O
Targeting	NNP	O
Human	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
an	DT	O
additional	JJ	O
series	NN	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
was	VBD	O
designed	VBN	O
to	TO	O
target	VB	O
different	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
human	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
RNA	NNP	O
,	,	O
using	VBG	O
published	VBN	O
sequence	NN	O
data	NNS	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
4	CD	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
18	CD	O
)	)	O
.	.	O
The	DT	O
compounds	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Tables	NNP	O
14	CD	O
and	CC	O
15	CD	O
.	.	O
“	NN	O
Target	NNP	O
site	NN	O
”	NN	O
indicates	VBZ	O
the	DT	O
first	JJ	O
(	(	O
5′-most	JJ	O
)	)	O
nucleotide	IN	O
number	NN	O
on	IN	O
the	DT	O
particular	JJ	O
target	NN	O
sequence	NN	O
to	TO	O
which	WDT	O
the	DT	O
compound	NN	O
binds	VBZ	O
.	.	O
All	DT	O
compounds	NNS	O
in	IN	O
Tables	NNP	O
14	CD	O
and	CC	O
15	CD	O
are	VBP	O
chimeric	JJ	O
oligonucleotides	NNS	O
(	(	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
The	DT	O
compounds	NNS	O
in	IN	O
Table	JJ	O
14	CD	O
are	VBP	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
ten	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
compounds	NNS	O
in	IN	O
Table	JJ	O
15	CD	O
are	VBP	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
sixteen	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
two-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
In	IN	O
all	DT	O
compounds	VBZ	O
the	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotides	NNS	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
Example	RB	O
30	CD	O
Chimeric	NNP	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
Having	NNP	O
2′-MOE	JJ	O
Wings	NNP	O
and	CC	O
a	DT	O
Deoxy	NNP	O
Gap	NNP	O
and	CC	O
Targeting	NNP	O
Rat	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
a	DT	O
series	NN	O
of	IN	O
antisense	JJ	O
compounds	NNS	O
was	VBD	O
designed	VBN	O
to	TO	O
target	VB	O
different	JJ	O
regions	NNS	O
of	IN	O
the	DT	O
rat	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
RNA	NNP	O
,	,	O
using	VBG	O
published	VBN	O
sequence	NN	O
data	NNS	O
(	(	O
GenBank	NNP	O
accession	NN	O
number	NN	O
XM—341887.1	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
412	CD	O
,	,	O
GenBank	NNP	O
accession	NN	O
number	NN	O
AA956461.1	NNP	O
,	,	O
the	DT	O
complement	NN	O
of	IN	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	RB	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
413	CD	O
)	)	O
.	.	O
The	DT	O
compounds	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
16	CD	O
.	.	O
“	NN	O
Target	NNP	O
site	NN	O
”	NN	O
indicates	VBZ	O
the	DT	O
first	JJ	O
(	(	O
5′-most	JJ	O
)	)	O
nucleotide	IN	O
number	NN	O
on	IN	O
the	DT	O
particular	JJ	O
target	NN	O
sequence	NN	O
to	TO	O
which	WDT	O
the	DT	O
compound	NN	O
binds	VBZ	O
.	.	O
All	DT	O
compounds	NNS	O
in	IN	O
Table	JJ	O
16	CD	O
are	VBP	O
chimeric	JJ	O
oligonucleotides	NNS	O
(	(	O
“	JJ	O
gapmers	NNS	O
”	VBP	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
ten	JJ	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
five-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotides	NNS	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
Example	JJ	O
31	CD	O
Design	NNP	O
of	IN	O
an	DT	O
Antisense	NNP	O
Chimeric	NNP	O
Phosphorothioate	NNP	O
Oligonucleotides	NNP	O
Having	NNP	O
2′-MOE	JJ	O
Wings	NNP	O
and	CC	O
a	DT	O
Deoxy	NNP	O
Gap	NNP	O
and	CC	O
Targeting	NNP	O
Mouse	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
Expression	NNP	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
an	DT	O
antisense	NN	O
compound	NN	O
ISIS	NNP	O
337205	CD	O
(	(	O
ATGCACTCAAGAACTCGGTA	NNP	O
,	,	O
incorporated	JJ	O
herein	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
485	CD	O
)	)	O
was	VBD	O
designed	VBN	O
to	TO	O
target	VB	O
the	DT	O
3′	CD	O
UTR	NNP	O
region	NN	O
of	IN	O
the	DT	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
RNA	NNP	O
,	,	O
using	VBG	O
published	VBN	O
sequence	NN	O
data	NNS	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
11	CD	O
)	)	O
.	.	O
ISIS	NNP	O
337205	CD	O
is	VBZ	O
a	DT	O
chimeric	JJ	O
oligonucleotide	NN	O
(	(	O
“	JJ	O
gapmer	NN	O
”	NN	O
)	)	O
20	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
,	,	O
composed	VBN	O
of	IN	O
a	DT	O
central	JJ	O
“	NNP	O
gap	NN	O
”	NNP	O
region	NN	O
consisting	VBG	O
of	IN	O
14	CD	O
2′-deoxynucleotides	NNS	O
,	,	O
which	WDT	O
is	VBZ	O
flanked	VBN	O
on	IN	O
both	DT	O
sides	NNS	O
(	(	O
5′	CD	O
and	CC	O
3′	CD	O
directions	NNS	O
)	)	O
by	IN	O
3-nucleotide	JJ	O
“	JJ	O
wings	NNS	O
”	NN	O
.	.	O
The	DT	O
wings	NNS	O
are	VBP	O
composed	VBN	O
of	IN	O
2′-O-methoxyethyl	JJ	O
(	(	O
2′-MOE	JJ	O
)	)	O
nucleotides	NNS	O
.	.	O
The	DT	O
internucleoside	NN	O
(	(	O
backbone	NN	O
)	)	O
linkages	NNS	O
are	VBP	O
phosphorothioate	JJ	O
(	(	O
P═S	NNP	O
)	)	O
throughout	IN	O
the	DT	O
oligonucleotide	NN	O
.	.	O
All	DT	O
cytidine	NN	O
residues	NNS	O
are	VBP	O
5-methylcytidines	JJ	O
.	.	O
Example	JJ	O
32	CD	O
Effects	NNS	O
of	IN	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
on	IN	O
Triglyceride	NNP	O
Synthesis	NNP	O
in	IN	O
Primary	NNP	O
Rodent	NNP	O
Hepatocytes	NNP	O
Diacylglycerol	NNP	O
acyltransferase	VBD	O
2	CD	O
,	,	O
which	WDT	O
is	VBZ	O
abundantly	RB	O
expressed	VBN	O
in	IN	O
the	DT	O
liver	NN	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissues	NNS	O
,	,	O
participates	NNS	O
in	IN	O
triglyceride	JJ	O
synthesis	NN	O
and	CC	O
its	PRP$	O
activity	NN	O
is	VBZ	O
also	RB	O
tightly	RB	O
linked	VBN	O
to	TO	O
the	DT	O
endogenous	JJ	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
pathway	NN	O
.	.	O
Thus	RB	O
,	,	O
it	PRP	O
was	VBD	O
of	IN	O
interest	NN	O
to	TO	O
determine	VB	O
whether	IN	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
would	MD	O
affect	VB	O
triglyceride	JJ	O
synthesis	NN	O
in	IN	O
hepatocytes	NNS	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
rat	NN	O
and	CC	O
mouse	NN	O
hepatocytes	NNS	O
were	VBD	O
isolated	VBN	O
and	CC	O
treated	VBN	O
with	IN	O
ISIS	NNP	O
217357	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
123	CD	O
)	)	O
and	CC	O
ISIS	$	O
217376	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
142	CD	O
)	)	O
,	,	O
respectively	RB	O
.	.	O
ISIS	NNP	O
217357	CD	O
is	VBZ	O
a	DT	O
cross	NN	O
species	NNS	O
oligonucleotide	IN	O
which	WDT	O
exhibits	VBZ	O
100	CD	O
%	NN	O
complementarity	NN	O
to	TO	O
rat	VB	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
.	.	O
Primary	JJ	O
hepatocytes	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
C57BL/6J	NNP	O
mice	NN	O
or	CC	O
Sprague	NNP	O
Dawley	NNP	O
rats	NNS	O
(	(	O
Charles	NNP	O
River	NNP	O
Laboratories	NNPS	O
,	,	O
Wilmington	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
.	.	O
The	DT	O
animals	NNS	O
were	VBD	O
anesthetized	VBN	O
according	VBG	O
to	TO	O
routine	JJ	O
procedures	NNS	O
.	.	O
The	DT	O
livers	NNS	O
were	VBD	O
perfused	VBN	O
via	IN	O
the	DT	O
portal	JJ	O
vein	NN	O
,	,	O
first	RB	O
with	IN	O
Ca2+/Mg2+-free	JJ	O
Hanks	NNP	O
'	POS	O
balanced	VBD	O
salt	JJ	O
solution	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
containing	VBG	O
10	CD	O
mM	JJ	O
Hepes	NNP	O
and	CC	O
0.5	CD	O
mM	NN	O
EGTA	NNP	O
(	(	O
pH	VB	O
7.4	CD	O
)	)	O
for	IN	O
approximately	RB	O
3	CD	O
minutes	NNS	O
and	CC	O
subsequently	RB	O
with	IN	O
digestion	NN	O
buffer	NN	O
(	(	O
William	NNP	O
Medium	NNP	O
E	NNP	O
,	,	O
10	CD	O
mM	NN	O
Hepes	NNP	O
,	,	O
2	CD	O
mM	NN	O
glutamine	NN	O
acid	NN	O
,	,	O
0.63	CD	O
mg/ml	NN	O
collagenase	NN	O
B	NNP	O
from	IN	O
Roche	NNP	O
,	,	O
and	CC	O
0.01	CD	O
mg/ml	NNS	O
gentamycin	NN	O
)	)	O
for	IN	O
approximately	RB	O
5	CD	O
minutes	NNS	O
.	.	O
Perfused	VBN	O
livers	NNS	O
were	VBD	O
removed	VBN	O
from	IN	O
the	DT	O
mice	NN	O
or	CC	O
rats	NNS	O
and	CC	O
dissociated	VBN	O
in	IN	O
ice-cold	JJ	O
wash	NN	O
buffer	NN	O
(	(	O
above	IN	O
digestion	NN	O
buffer	NN	O
with	IN	O
no	DT	O
collagenase	NN	O
but	CC	O
with	IN	O
addition	NN	O
of	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
)	)	O
by	IN	O
agitation	NN	O
.	.	O
Parenchymal	JJ	O
cells	NNS	O
were	VBD	O
separated	VBN	O
from	IN	O
non-parenchymal	JJ	O
cells	NNS	O
by	IN	O
spinning	VBG	O
the	DT	O
harvested	JJ	O
cells	NNS	O
at	IN	O
500	CD	O
rpm	NN	O
for	IN	O
4	CD	O
min	NN	O
in	IN	O
a	DT	O
CR412™	NNP	O
centrifuge	NN	O
(	(	O
Jouan	NNP	O
Inc	NNP	O
,	,	O
Winchester	NNP	O
,	,	O
Va.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
then	RB	O
washed	VBN	O
twice	RB	O
with	IN	O
cold	JJ	O
PBS	NNP	O
.	.	O
The	DT	O
parenchymal	JJ	O
hepatocytes	NNS	O
with	IN	O
>	JJ	O
85	CD	O
%	NN	O
viability	NN	O
,	,	O
as	IN	O
assessed	VBN	O
by	IN	O
staining	VBG	O
with	IN	O
trypan	JJ	O
blue	NN	O
,	,	O
were	VBD	O
seeded	VBN	O
onto	IN	O
60-mm	JJ	O
culture	NN	O
plates	NNS	O
coated	VBD	O
with	IN	O
collagen	NN	O
type	NN	O
I	PRP	O
(	(	O
BD	NNP	O
Biosciences	NNPS	O
)	)	O
at	IN	O
1,000,000	CD	O
cells	NNS	O
per	IN	O
plate	NN	O
in	IN	O
culture	NN	O
medium	NN	O
(	(	O
William	NNP	O
Medium	NNP	O
E	NNP	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
and	CC	O
10	CD	O
nm	JJ	O
insulin	NN	O
)	)	O
and	CC	O
cultured	VBD	O
overnight	VBN	O
at	IN	O
37°	CD	O
C.	NNP	O
and	CC	O
5	CD	O
%	NN	O
CO2	NNP	O
.	.	O
For	IN	O
transfection	NN	O
with	IN	O
antisense	JJ	O
oligonucleotides	NNS	O
,	,	O
the	DT	O
culture	NN	O
medium	NN	O
was	VBD	O
aspirated	VBN	O
and	CC	O
the	DT	O
hepatocytes	NNS	O
were	VBD	O
washed	VBN	O
once	RB	O
with	IN	O
PBS	NNP	O
,	,	O
and	CC	O
subsequently	RB	O
incubated	VBN	O
for	IN	O
4-6	JJ	O
hr	NN	O
with	IN	O
1	CD	O
ml	NNS	O
transfection	NN	O
mixture	NN	O
,	,	O
which	WDT	O
contained	VBD	O
150	CD	O
nM	NN	O
of	IN	O
antisense	JJ	O
oligonucleotide	NN	O
and	CC	O
4.5	CD	O
μg/mL	NN	O
LIPOFECTIN™	NNP	O
reagent	NN	O
(	(	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
in	IN	O
Williams	NNP	O
'	POS	O
Medium	NNP	O
E.	NNP	O
The	DT	O
mixture	NN	O
was	VBD	O
then	RB	O
aspirated	VBN	O
and	CC	O
replaced	VBN	O
with	IN	O
the	DT	O
culture	NN	O
medium	NN	O
for	IN	O
approximately	RB	O
24	CD	O
hours	NNS	O
.	.	O
Triglyceride	NNP	O
synthesis	NN	O
in	IN	O
transfected	JJ	O
hepatocytes	NNS	O
was	VBD	O
determined	VBN	O
by	IN	O
measuring	VBG	O
the	DT	O
incorporation	NN	O
of	IN	O
tritiated	VBN	O
glycerol	NN	O
(	(	O
[	JJ	O
3H	CD	O
]	NNP	O
glycerol	NN	O
)	)	O
into	IN	O
triglycerides	NNS	O
.	.	O
Approximately	RB	O
24	CD	O
hours	NNS	O
following	VBG	O
transfection	NN	O
,	,	O
the	DT	O
culture	NN	O
medium	NN	O
was	VBD	O
replaced	VBN	O
with	IN	O
1	CD	O
ml	NNS	O
of	IN	O
high	JJ	O
glucose	JJ	O
DMEM	NNP	O
medium	NN	O
containing	VBG	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
serum	NN	O
,	,	O
0.5	CD	O
%	NN	O
bovine	NN	O
serum	NN	O
albumin	NN	O
(	(	O
medium	NN	O
and	CC	O
supplements	NNS	O
from	IN	O
Invitrogen	NNP	O
Corporation	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
and	CC	O
10	CD	O
uCi	NN	O
of	IN	O
[	$	O
3H	CD	O
]	NNP	O
glycerol	NN	O
with	IN	O
or	CC	O
without	IN	O
0.5	CD	O
mM	NN	O
oleate	NN	O
.	.	O
As	IN	O
oleate	NN	O
is	VBZ	O
a	DT	O
free	JJ	O
fatty	NN	O
acid	NN	O
,	,	O
and	CC	O
free	JJ	O
fatty	JJ	O
acids	NNS	O
are	VBP	O
incorporated	VBN	O
into	IN	O
triglycerides	NNS	O
during	IN	O
triglyceride	JJ	O
synthesis	NN	O
,	,	O
oleate	NN	O
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
culture	NN	O
medium	NN	O
of	IN	O
some	DT	O
cells	NNS	O
to	TO	O
provide	VB	O
an	DT	O
additional	JJ	O
supply	NN	O
of	IN	O
fatty	JJ	O
acids	NNS	O
and	CC	O
to	TO	O
stimulate	VB	O
triglyceride	JJ	O
synthesis	NN	O
.	.	O
Insulin	NNP	O
,	,	O
present	NN	O
in	IN	O
the	DT	O
culture	NN	O
medium	NN	O
,	,	O
is	VBZ	O
also	RB	O
known	VBN	O
to	TO	O
stimulate	VB	O
triglyceride	JJ	O
synthesis	NN	O
.	.	O
After	IN	O
continued	JJ	O
culture	NN	O
overnight	NN	O
,	,	O
the	DT	O
cells	NNS	O
were	VBD	O
harvested	VBN	O
.	.	O
One	CD	O
small	JJ	O
fraction	NN	O
of	IN	O
the	DT	O
harvested	JJ	O
cells	NNS	O
was	VBD	O
used	VBN	O
for	IN	O
RNA	NNP	O
extraction	NN	O
and	CC	O
gene	NN	O
expression	NN	O
analysis	NN	O
;	:	O
the	DT	O
remaining	VBG	O
fraction	NN	O
was	VBD	O
used	VBN	O
for	IN	O
lipid	JJ	O
extraction	NN	O
with	IN	O
hexane	NN	O
:	:	O
isopropanol	NN	O
(	(	O
3:2	CD	O
in	IN	O
volume	NN	O
)	)	O
mixture	NN	O
.	.	O
The	DT	O
extracted	JJ	O
lipids	NNS	O
were	VBD	O
separated	VBN	O
by	IN	O
thin	JJ	O
layer	NN	O
chromatography	NN	O
by	IN	O
methods	NNS	O
routine	JJ	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
amount	NN	O
of	IN	O
incorporated	JJ	O
[	$	O
3H	CD	O
]	NNP	O
glycerol	NN	O
into	IN	O
triglyceride	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
liquid	JJ	O
scintillation	NN	O
counting	NN	O
.	.	O
Data	NNS	O
are	VBP	O
normalized	VBN	O
to	TO	O
untreated	JJ	O
control	NN	O
cells	NNS	O
and	CC	O
are	VBP	O
presented	VBN	O
as	IN	O
disintegrations	NNS	O
per	IN	O
minute	NN	O
(	(	O
DPM	NNP	O
)	)	O
per	IN	O
mg	NN	O
in	IN	O
the	DT	O
cultured	JJ	O
cell	NN	O
sample	NN	O
.	.	O
Tables	NNS	O
17a	CD	O
and	CC	O
17b	CD	O
show	VBP	O
the	DT	O
effects	NNS	O
of	IN	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglyercol	JJ	O
acyltransferase	NN	O
2	CD	O
in	IN	O
rat	NN	O
primary	JJ	O
hepatocytes	NNS	O
and	CC	O
in	IN	O
mouse	NN	O
primary	JJ	O
hepatocytes	NNS	O
,	,	O
respectively	RB	O
.	.	O
Real-time	JJ	O
PCR	NNP	O
quantitation	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
measure	VB	O
diacylglycerol	VB	O
acyltransferase	JJ	O
2	CD	O
mRNA	NN	O
levels	NNS	O
.	.	O
Mouse	NNP	O
primers	NNS	O
and	CC	O
probe	NN	O
used	VBN	O
were	VBD	O
SEQ	NNP	O
ID	NNP	O
NOs	NNP	O
:	:	O
12	CD	O
,	,	O
13	CD	O
and	CC	O
14	CD	O
.	.	O
For	IN	O
rat	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
probes	NNS	O
and	CC	O
primers	NNS	O
were	VBD	O
designed	VBN	O
to	TO	O
hybridize	VB	O
to	TO	O
a	DT	O
rat	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
sequence	NN	O
,	,	O
using	VBG	O
published	VBN	O
sequence	NN	O
information	NN	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
XM—341887.1	NN	O
,	,	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
412	CD	O
)	)	O
.	.	O
For	IN	O
rat	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
the	DT	O
PCR	NNP	O
primers	NNS	O
were	VBD	O
:	:	O
forward	JJ	O
primer	NN	O
:	:	O
GGAACCGCAAAGGCTTTGTA	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
486	CD	O
)	)	O
reverse	NN	O
primer	NN	O
:	:	O
AATAGGTGGGAACCAGATCAGC	NNP	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
487	CD	O
)	)	O
and	CC	O
the	DT	O
PCR	NNP	O
probe	NN	O
was	VBD	O
:	:	O
FAM-AGCTGGCCCTGCGCCATGG-TAMRA	JJ	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
488	CD	O
)	)	O
where	WRB	O
FAM	NNP	O
is	VBZ	O
the	DT	O
fluorescent	JJ	O
reporter	NN	O
dye	NN	O
and	CC	O
TAMRA	NNP	O
is	VBZ	O
the	DT	O
quencher	NN	O
dye	NN	O
.	.	O
Target	NNP	O
expression	NN	O
was	VBD	O
normalized	VBN	O
to	TO	O
that	DT	O
in	IN	O
cells	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
control	NN	O
oligonucleotide	IN	O
ISIS	NNP	O
141923	CD	O
.	.	O
These	DT	O
data	NNS	O
reveal	NN	O
that	IN	O
the	DT	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
in	IN	O
rat	NN	O
hepatocytes	NNS	O
dramatically	RB	O
reduced	VBD	O
triglyceride	JJ	O
synthesis	NN	O
by	IN	O
5-fold	JJ	O
and	CC	O
3-fold	JJ	O
in	IN	O
the	DT	O
absence	NN	O
and	CC	O
presence	NN	O
of	IN	O
oleate	NN	O
,	,	O
respectively	RB	O
.	.	O
In	IN	O
primary	JJ	O
mouse	NN	O
hepatoctyes	NN	O
,	,	O
triglyceride	JJ	O
synthesis	NN	O
was	VBD	O
reduced	VBN	O
2.5-fold	JJ	O
and	CC	O
5.4-fold	JJ	O
in	IN	O
the	DT	O
absence	NN	O
and	CC	O
presence	NN	O
of	IN	O
oleate	NN	O
,	,	O
respectively	RB	O
,	,	O
following	VBG	O
inhibition	NN	O
of	IN	O
target	NN	O
mRNA	JJ	O
expression	NN	O
.	.	O
These	DT	O
reductions	NNS	O
occurred	VBD	O
regardless	RB	O
of	IN	O
the	DT	O
supply	NN	O
of	IN	O
free	JJ	O
fatty	JJ	O
acid	NN	O
or	CC	O
the	DT	O
concentration	NN	O
of	IN	O
insulin	NN	O
in	IN	O
the	DT	O
medium	NN	O
.	.	O
The	DT	O
expression	NN	O
levels	NNS	O
of	IN	O
lipogenic	JJ	O
genes	NNS	O
in	IN	O
response	NN	O
to	TO	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
were	VBD	O
also	RB	O
measured	VBN	O
.	.	O
Real-time	JJ	O
PCR	NNP	O
was	VBD	O
performed	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
,	,	O
using	VBG	O
primer-probe	JJ	O
sets	NNS	O
designed	VBN	O
using	VBG	O
published	VBN	O
sequence	NN	O
information	NN	O
available	JJ	O
from	IN	O
GenBank®	NNP	O
database	NN	O
and	CC	O
indicated	VBN	O
in	IN	O
Tables	NNP	O
18	CD	O
and	CC	O
19	CD	O
.	.	O
Gene	NNP	O
expression	NN	O
levels	NNS	O
in	IN	O
primary	JJ	O
rat	NN	O
hepatocytes	NNS	O
and	CC	O
primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
were	VBD	O
normalized	VBN	O
to	TO	O
levels	NNS	O
in	IN	O
ISIS	NNP	O
141923-treated	JJ	O
cells	NNS	O
and	CC	O
are	VBP	O
shown	VBN	O
in	IN	O
Tables	NNP	O
18	CD	O
and	CC	O
19	CD	O
,	,	O
respectively	RB	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
18	CD	O
,	,	O
reductions	NNS	O
in	IN	O
the	DT	O
expression	NN	O
of	IN	O
stearoyl-CoA	JJ	O
desaturase	NN	O
1	CD	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
1	CD	O
and	CC	O
acetyl-CoA	JJ	O
carboxylase	NN	O
2	CD	O
were	VBD	O
observed	VBN	O
,	,	O
both	DT	O
in	IN	O
the	DT	O
presence	NN	O
and	CC	O
absence	NN	O
of	IN	O
oleate	NN	O
.	.	O
Reductions	NNS	O
in	IN	O
these	DT	O
genes	NNS	O
were	VBD	O
also	RB	O
observed	VBN	O
in	IN	O
vivo	NN	O
following	VBG	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
,	,	O
as	IN	O
described	VBN	O
herein	NN	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
19	CD	O
,	,	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
oleate	NN	O
,	,	O
a	DT	O
reduction	NN	O
in	IN	O
stearoyl-CoA	JJ	O
desaturase	NN	O
1	CD	O
was	VBD	O
observed	VBN	O
in	IN	O
primary	JJ	O
mouse	NN	O
hepatocytes	NNS	O
treated	VBD	O
with	IN	O
ISIS	NNP	O
217376	CD	O
.	.	O
Reduction	NN	O
in	IN	O
the	DT	O
expression	NN	O
of	IN	O
this	DT	O
gene	NN	O
was	VBD	O
also	RB	O
observed	JJ	O
following	VBG	O
treatment	NN	O
of	IN	O
mice	NN	O
with	IN	O
ISIS	NNP	O
217376	CD	O
.	.	O
Example	RB	O
33	CD	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
in	IN	O
Lean	JJ	O
Rats	NNPS	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
were	VBD	O
investigated	VBN	O
in	IN	O
normal	JJ	O
rats	NNS	O
fed	VBD	O
a	DT	O
lean	JJ	O
diet	NN	O
.	.	O
Male	JJ	O
Sprague-Dawley	NNP	O
rats	NNS	O
,	,	O
at	IN	O
6	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
,	,	O
were	VBD	O
purchased	VBN	O
from	IN	O
Charles	NNP	O
River	NNP	O
Laboratories	NNP	O
(	(	O
Wilmington	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
.	.	O
Rats	NNS	O
were	VBD	O
maintained	VBN	O
on	IN	O
a	DT	O
diet	NN	O
of	IN	O
normal	JJ	O
rodent	NN	O
chow	NN	O
(	(	O
lean	JJ	O
diet	NN	O
)	)	O
and	CC	O
were	VBD	O
placed	VBN	O
into	IN	O
one	CD	O
of	IN	O
three	CD	O
treatment	NN	O
groups	NNS	O
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
.	.	O
One	CD	O
treatment	NN	O
group	NN	O
received	VBD	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
saline	NN	O
,	,	O
twice	RB	O
weekly	RB	O
.	.	O
Two	CD	O
treatment	NN	O
groups	NNS	O
received	VBD	O
twice	RB	O
weekly	RB	O
,	,	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
50	CD	O
mg/kg	NNS	O
oligonucleotide	RB	O
;	:	O
one	CD	O
group	NN	O
received	VBD	O
ISIS	NNP	O
217354	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
51	CD	O
)	)	O
and	CC	O
the	DT	O
other	JJ	O
group	NN	O
received	VBD	O
ISIS	NNP	O
217357	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
123	CD	O
)	)	O
.	.	O
ISIS	NNP	O
217354	CD	O
and	CC	O
ISIS	NNP	O
217357	CD	O
are	VBP	O
cross	JJ	O
species	NNS	O
oligonucleotides	IN	O
which	WDT	O
exhibit	VBP	O
100	CD	O
%	NN	O
complementarity	NN	O
to	TO	O
human	JJ	O
,	,	O
rat	NN	O
and	CC	O
mouse	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
.	.	O
Rats	NNS	O
received	VBD	O
a	DT	O
total	NN	O
of	IN	O
5	CD	O
doses	NNS	O
and	CC	O
were	VBD	O
sacrificed	VBN	O
2	CD	O
days	NNS	O
following	VBG	O
the	DT	O
5th	CD	O
and	CC	O
final	JJ	O
dose	NN	O
of	IN	O
oligonucleotide	NN	O
or	CC	O
saline	NN	O
.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
liver	RB	O
tissue	NN	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
(	(	O
WAT	NNP	O
)	)	O
were	VBD	O
collected	VBN	O
for	IN	O
quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
levels	NNS	O
.	.	O
Real-time	JJ	O
PCR	NNP	O
was	VBD	O
performed	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
The	DT	O
data	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
20	CD	O
,	,	O
normalized	VBN	O
to	TO	O
mRNA	VB	O
expression	NN	O
levels	NNS	O
in	IN	O
saline-treated	JJ	O
mice	NN	O
.	.	O
These	DT	O
data	NNS	O
reveal	VBP	O
that	IN	O
ISIS	NNP	O
217354	CD	O
and	CC	O
ISIS	NNP	O
217357	CD	O
inhibited	VBD	O
the	DT	O
expression	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
expression	NN	O
in	IN	O
liver	NN	O
and	CC	O
white	JJ	O
adipose	JJ	O
tissue	NN	O
from	IN	O
lean	JJ	O
rats	NNS	O
.	.	O
Plasma	NNP	O
cholesterol	NN	O
and	CC	O
triglycerides	NNS	O
were	VBD	O
measured	VBN	O
by	IN	O
chemical	NN	O
analysis	NN	O
as	IN	O
described	JJ	O
herein	NN	O
at	IN	O
the	DT	O
start	NN	O
(	(	O
t=0	JJ	O
weeks	NNS	O
)	)	O
and	CC	O
end	NN	O
(	(	O
t=2	JJ	O
weeks	NNS	O
)	)	O
of	IN	O
treatment	NN	O
.	.	O
Triglyceride	NNP	O
and	CC	O
cholesterol	NN	O
levels	NNS	O
are	VBP	O
shown	VBN	O
as	IN	O
mg/dL	NN	O
in	IN	O
Table	JJ	O
21a	CD	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
21a	CD	O
,	,	O
whereas	NNS	O
cholesterol	NN	O
and	CC	O
triglycerides	NNS	O
in	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
were	VBD	O
similar	JJ	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
treatment	NN	O
,	,	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217354	CD	O
or	CC	O
ISIS	NNP	O
217357	CD	O
resulted	VBD	O
in	IN	O
56	CD	O
%	NN	O
and	CC	O
79	CD	O
%	NN	O
reductions	NNS	O
in	IN	O
plasma	NN	O
cholesterol	NN	O
,	,	O
respectively	RB	O
and	CC	O
in	IN	O
38	CD	O
%	NN	O
and	CC	O
64	CD	O
%	NN	O
reductions	NNS	O
in	IN	O
triglycerides	NNS	O
,	,	O
respectively	RB	O
,	,	O
relative	JJ	O
to	TO	O
levels	NNS	O
observed	VBN	O
in	IN	O
saline-treated	JJ	O
mice	NN	O
.	.	O
Plasma	NNP	O
glucose	NN	O
and	CC	O
insulin	NN	O
were	VBD	O
measured	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
using	VBG	O
a	DT	O
YSI2700	NNP	O
Select™	NNP	O
Biochemistry	NNP	O
Analyzer	NNP	O
and	CC	O
an	DT	O
ELISA	NNP	O
kit	NN	O
,	,	O
respectively	RB	O
,	,	O
at	IN	O
the	DT	O
start	NN	O
(	(	O
t=0	JJ	O
weeks	NNS	O
)	)	O
and	CC	O
end	NN	O
(	(	O
t=2	JJ	O
weeks	NNS	O
)	)	O
of	IN	O
treatment	NN	O
.	.	O
In	IN	O
Table	NNP	O
21b	CD	O
,	,	O
glucose	NN	O
and	CC	O
insulin	NN	O
levels	NNS	O
are	VBP	O
displayed	VBN	O
as	IN	O
mg/dL	NN	O
and	CC	O
ng/mL	NN	O
,	,	O
respectively	RB	O
.	.	O
These	DT	O
data	NNS	O
illustrate	VBP	O
that	IN	O
while	IN	O
insulin	NN	O
levels	NNS	O
in	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
were	VBD	O
similar	JJ	O
at	IN	O
t=0	JJ	O
weeks	NNS	O
,	,	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217354	CD	O
or	CC	O
ISIS	NNP	O
217357	CD	O
decreased	VBD	O
insulin	NN	O
levels	NNS	O
by	IN	O
52	CD	O
%	NN	O
and	CC	O
40	CD	O
%	NN	O
,	,	O
respectively	RB	O
,	,	O
relative	JJ	O
to	TO	O
those	DT	O
in	IN	O
saline-treated	JJ	O
mice	NN	O
.	.	O
Glucose	NNP	O
levels	NNS	O
,	,	O
after	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
,	,	O
were	VBD	O
unchanged	JJ	O
in	IN	O
oligonucleotide-treated	JJ	O
mice	NNS	O
relative	JJ	O
to	TO	O
saline-treated	JJ	O
mice	NN	O
.	.	O
The	DT	O
serum	NN	O
transaminases	VBZ	O
ALT	NNP	O
and	CC	O
AST	NNP	O
were	VBD	O
measured	VBN	O
at	IN	O
the	DT	O
start	NN	O
and	CC	O
end	NN	O
of	IN	O
treatment	NN	O
,	,	O
by	IN	O
routine	JJ	O
analysis	NN	O
using	VBG	O
an	DT	O
Olympus	NNP	O
Clinical	NNP	O
Lab	NNP	O
Automation	NNP	O
System	NNP	O
(	(	O
Olympus	NNP	O
America	NNP	O
Inc.	NNP	O
,	,	O
Melville	NNP	O
,	,	O
N.Y.	NNP	O
)	)	O
.	.	O
Increases	NNS	O
in	IN	O
ALT	NNP	O
or	CC	O
AST	NNP	O
are	VBP	O
indicative	JJ	O
of	IN	O
treatment-induced	JJ	O
toxicity	NN	O
.	.	O
ALT	NNP	O
and	CC	O
AST	NNP	O
levels	NNS	O
are	VBP	O
presented	VBN	O
in	IN	O
Table	JJ	O
22	CD	O
in	IN	O
units	NNS	O
per	IN	O
liter	NN	O
(	(	O
U/L	NNP	O
)	)	O
.	.	O
The	DT	O
data	NN	O
in	IN	O
Table	JJ	O
22	CD	O
demonstrate	NN	O
no	DT	O
toxicities	NNS	O
resulting	VBG	O
from	IN	O
treatment	NN	O
with	IN	O
ISIS	NNP	O
217354	CD	O
and	CC	O
ISIS	NNP	O
217357	CD	O
.	.	O
Body	NN	O
weight	NN	O
was	VBD	O
monitored	VBN	O
throughout	IN	O
the	DT	O
study	NN	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
23	CD	O
,	,	O
increases	NNS	O
in	IN	O
body	NN	O
weights	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
all	DT	O
treatment	NN	O
groups	NNS	O
and	CC	O
thus	RB	O
were	VBD	O
not	RB	O
due	JJ	O
to	TO	O
treatment	NN	O
with	IN	O
oligonucloetides	NNS	O
.	.	O
No	DT	O
changes	NNS	O
were	VBD	O
observed	VBN	O
food	NN	O
intake	NN	O
,	,	O
which	WDT	O
was	VBD	O
also	RB	O
monitored	VBN	O
throughout	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O
These	DT	O
data	NNS	O
reveal	VBP	O
that	IN	O
antisense	NN	O
oligonucleotides	NNS	O
targeted	VBD	O
to	TO	O
rat	VB	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
effectively	RB	O
inhibited	VBN	O
target	NN	O
expression	NN	O
in	IN	O
lean	JJ	O
rats	NNS	O
,	,	O
without	IN	O
causing	VBG	O
toxicity	NN	O
.	.	O
Furthermore	RB	O
,	,	O
insulin	NN	O
,	,	O
cholesterol	NN	O
and	CC	O
triglyceride	NN	O
levels	NNS	O
were	VBD	O
reduced	VBN	O
after	IN	O
2	CD	O
weeks	NNS	O
of	IN	O
treatment	NN	O
.	.	O
Example	RB	O
34	CD	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
in	IN	O
a	DT	O
Rat	NNP	O
Model	NNP	O
of	IN	O
Genetic	NNP	O
Obesity	NNP	O
The	DT	O
Zucker	NNP	O
fatty	NN	O
(	(	O
fa/fa	NN	O
)	)	O
rat	NN	O
is	VBZ	O
an	DT	O
example	NN	O
of	IN	O
a	DT	O
genetic	JJ	O
obesity	NN	O
with	IN	O
an	DT	O
autosomal	JJ	O
recessive	JJ	O
pattern	NN	O
of	IN	O
inheritance	NN	O
.	.	O
The	DT	O
obesity	NN	O
in	IN	O
fa/fa	JJ	O
animals	NNS	O
is	VBZ	O
correlated	VBN	O
with	IN	O
excessive	JJ	O
eating	NN	O
,	,	O
decreased	VBD	O
energy	NN	O
expenditure	NN	O
,	,	O
compromised	VBD	O
thermoregulatory	NN	O
heat	NN	O
production	NN	O
,	,	O
hyperinsulinemia	NN	O
(	(	O
overproduction	NN	O
of	IN	O
insulin	NN	O
)	)	O
,	,	O
and	CC	O
hypercorticosteronemia	NN	O
(	(	O
overproduction	NN	O
of	IN	O
corticosteroids	NNS	O
)	)	O
.	.	O
The	DT	O
fa	NN	O
mutation	NN	O
has	VBZ	O
been	VBN	O
identified	VBN	O
as	IN	O
an	DT	O
amino	NN	O
acid	NN	O
substitution	NN	O
in	IN	O
the	DT	O
extracellular	JJ	O
domain	NN	O
of	IN	O
the	DT	O
receptor	NN	O
for	IN	O
leptin	NN	O
.	.	O
As	IN	O
a	DT	O
consequence	NN	O
,	,	O
the	DT	O
fa/fa	NN	O
animal	NN	O
has	VBZ	O
elevated	VBN	O
plasma	JJ	O
leptin	NN	O
levels	NNS	O
and	CC	O
is	VBZ	O
resistant	JJ	O
to	TO	O
exogenous	JJ	O
leptin	JJ	O
administration	NN	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
antisense	JJ	O
inhibition	NN	O
of	IN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
are	VBP	O
evaluated	VBN	O
in	IN	O
the	DT	O
Zucker	NNP	O
fa/fa	NN	O
rat	NN	O
model	NN	O
of	IN	O
obesity	NN	O
.	.	O
Male	JJ	O
Zucker	NNP	O
fa/fa	NN	O
rats	NNS	O
,	,	O
6	CD	O
weeks	NNS	O
of	IN	O
age	NN	O
,	,	O
are	VBP	O
purchased	VBN	O
from	IN	O
Charles	NNP	O
River	NNP	O
Laboratories	NNP	O
(	(	O
Wilmington	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
.	.	O
Rats	NNS	O
are	VBP	O
maintained	VBN	O
on	IN	O
a	DT	O
normal	JJ	O
rodent	NN	O
diet	NN	O
.	.	O
Animals	NNS	O
are	VBP	O
placed	VBN	O
into	IN	O
treatments	NNS	O
groups	NNS	O
of	IN	O
6	CD	O
animals	NNS	O
each	DT	O
.	.	O
The	DT	O
control	NN	O
group	NN	O
receives	VBZ	O
twice	RB	O
weekly	JJ	O
,	,	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
sterile	JJ	O
phosphate-buffered	JJ	O
saline	NN	O
.	.	O
The	DT	O
oligonucleotide-treated	JJ	O
groups	NNS	O
receive	JJ	O
twice	RB	O
weekly	RB	O
,	,	O
subcutaneous	JJ	O
injections	NNS	O
of	IN	O
an	DT	O
antisense	JJ	O
oligonucleotide	NN	O
targeted	VBD	O
to	TO	O
rat	VB	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
.	.	O
By	IN	O
way	NN	O
of	IN	O
example	NN	O
,	,	O
rats	NNS	O
are	VBP	O
treated	VBN	O
with	IN	O
25	CD	O
,	,	O
37.5	CD	O
or	CC	O
50	CD	O
mg/kg	NN	O
of	IN	O
ISIS	NNP	O
217357	CD	O
(	(	O
SEQ	NNP	O
ID	NNP	O
NO	NNP	O
:	:	O
123	CD	O
)	)	O
.	.	O
Rats	NNS	O
receive	VBP	O
a	DT	O
total	NN	O
of	IN	O
16	CD	O
to	TO	O
20	CD	O
doses	NNS	O
over	IN	O
an	DT	O
8	CD	O
week	NN	O
period	NN	O
.	.	O
The	DT	O
rats	NNS	O
are	VBP	O
sacrificed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
.	.	O
Body	NN	O
weight	NN	O
and	CC	O
food	NN	O
intake	NN	O
are	VBP	O
measured	VBN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
and	CC	O
weekly	JJ	O
thereafter	NN	O
.	.	O
Body	NNP	O
composition	NN	O
is	VBZ	O
measured	VBN	O
approximately	RB	O
3	CD	O
days	NNS	O
prior	RB	O
to	TO	O
the	DT	O
start	NN	O
of	IN	O
the	DT	O
treatment	NN	O
period	NN	O
and	CC	O
during	IN	O
weeks	NNS	O
2	CD	O
,	,	O
4	CD	O
and	CC	O
5	CD	O
of	IN	O
treatment	NN	O
.	.	O
Serum	NNP	O
is	VBZ	O
collected	VBN	O
2	CD	O
days	NNS	O
prior	RB	O
to	TO	O
the	DT	O
first	JJ	O
dose	NN	O
,	,	O
and	CC	O
every	DT	O
two	CD	O
weeks	NNS	O
thereafter	RB	O
.	.	O
The	DT	O
serum	NN	O
samples	NNS	O
,	,	O
analyzed	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
,	,	O
are	VBP	O
subjected	VBN	O
to	TO	O
measurements	NNS	O
of	IN	O
:	:	O
the	DT	O
liver	NN	O
transaminases	VBZ	O
ALT	NNP	O
and	CC	O
AST	NNP	O
,	,	O
using	VBG	O
an	DT	O
Olympus	NNP	O
Clinical	NNP	O
Lab	NNP	O
Automation	NNP	O
System	NNP	O
(	(	O
Olympus	NNP	O
America	NNP	O
Inc.	NNP	O
,	,	O
Melville	NNP	O
,	,	O
N.Y.	NNP	O
)	)	O
;	:	O
triglycerides	NNS	O
and	CC	O
cholesterol	NN	O
,	,	O
using	VBG	O
the	DT	O
Hitachi	NNP	O
7170	CD	O
analyzer	NN	O
instrument	NN	O
(	(	O
Roche	NNP	O
Diagnostics	NNP	O
,	,	O
Indianapolis	NNP	O
,	,	O
Ind	NNP	O
.	.	O
)	)	O
;	:	O
free	JJ	O
fatty	NN	O
acids	NNS	O
,	,	O
using	VBG	O
a	DT	O
NEFA	NNP	O
C	NNP	O
assay	VBP	O
kit	NN	O
(	(	O
part	NN	O
#	#	O
994-75409	CD	O
from	IN	O
Wako	NNP	O
Chemicals	NNP	O
,	,	O
GmbH	NNP	O
,	,	O
Germany	NNP	O
)	)	O
;	:	O
and	CC	O
glucose	VB	O
,	,	O
using	VBG	O
a	DT	O
YSI2700	NNP	O
Select™	NNP	O
Biochemistry	NNP	O
Analyzer	NNP	O
(	(	O
YSI	NNP	O
Inc.	NNP	O
,	,	O
Yellow	NNP	O
Spring	NNP	O
,	,	O
Ohio	NNP	O
)	)	O
.	.	O
Insulin	NN	O
levels	NNS	O
are	VBP	O
measured	VBN	O
using	VBG	O
a	DT	O
rat-specific	JJ	O
ELISA	NNP	O
kit	NN	O
(	(	O
ALPCO	NNP	O
Diagnostics	NNP	O
,	,	O
Windham	NNP	O
,	,	O
N.H.	NNP	O
)	)	O
.	.	O
To	TO	O
assess	VB	O
the	DT	O
effects	NNS	O
of	IN	O
oligonucleotide	JJ	O
treatment	NN	O
on	IN	O
glucose	JJ	O
tolerance	NN	O
,	,	O
an	DT	O
oral	JJ	O
glucose	NN	O
tolerance	NN	O
test	NN	O
is	VBZ	O
administered	VBN	O
during	IN	O
week	NN	O
5	CD	O
and	CC	O
is	VBZ	O
performed	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
At	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
,	,	O
liver	RB	O
tissue	NN	O
and	CC	O
epididymal	JJ	O
fat	JJ	O
tissue	NN	O
are	VBP	O
collected	VBN	O
for	IN	O
RNA	NNP	O
isolation	NN	O
and	CC	O
quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
.	.	O
Diacylglycerol	NNP	O
acyltransferase	NN	O
mRNA	NN	O
levels	NNS	O
in	IN	O
these	DT	O
tissues	NNS	O
are	VBP	O
measured	VBN	O
as	IN	O
described	JJ	O
herein	NN	O
.	.	O
Liver	NNP	O
tissue	NN	O
and	CC	O
epididymal	JJ	O
fat	JJ	O
tissue	NN	O
are	VBP	O
also	RB	O
collected	VBN	O
for	IN	O
routine	JJ	O
histological	JJ	O
analysis	NN	O
.	.	O
The	DT	O
tissues	NNS	O
are	VBP	O
first	JJ	O
fixed	VBN	O
in	IN	O
neutral-buffered	JJ	O
formalin	NN	O
and	CC	O
are	VBP	O
subsequently	RB	O
dehydrated	VBN	O
,	,	O
embedded	VBN	O
in	IN	O
paraffin	NN	O
wax	NN	O
,	,	O
sectioned	VBN	O
and	CC	O
stained	VBN	O
.	.	O
Hematoxylin	NNP	O
and	CC	O
eosin	NN	O
are	VBP	O
used	VBN	O
to	TO	O
stain	VB	O
nuclei	JJ	O
and	CC	O
cytoplasm	NN	O
,	,	O
respectively	RB	O
,	,	O
and	CC	O
oil	NN	O
red	JJ	O
O	NNP	O
is	VBZ	O
used	VBN	O
to	TO	O
visualize	VB	O
lipids	NNS	O
.	.	O
Liver	NNP	O
,	,	O
spleen	NN	O
,	,	O
epididymal	JJ	O
fat	NN	O
and	CC	O
brown	NN	O
adipose	RB	O
fat	JJ	O
tissues	NNS	O
are	VBP	O
weighed	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
study	NN	O
.	.	O
The	DT	O
expression	NN	O
levels	NNS	O
of	IN	O
genes	NNS	O
involved	VBN	O
in	IN	O
lipogenic	JJ	O
and	CC	O
gluconeogenic	JJ	O
pathways	NNS	O
in	IN	O
liver	NN	O
and	CC	O
fat	JJ	O
tissue	NN	O
are	VBP	O
measured	VBN	O
using	VBG	O
quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
genes	NNS	O
measured	VBN	O
are	VBP	O
involved	VBN	O
in	IN	O
triglyceride	JJ	O
synthesis	NN	O
(	(	O
e.g.	NN	O
,	,	O
glycerol	VB	O
kinase	NN	O
)	)	O
,	,	O
de	FW	O
novo	FW	O
fatty	JJ	O
acid	JJ	O
synthesis	NN	O
(	(	O
e.g.	JJ	O
,	,	O
ATP-citrate	JJ	O
lyase	NN	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
1	CD	O
,	,	O
acetyl-CoA	JJ	O
carboxylase	NN	O
2	CD	O
and	CC	O
fatty	JJ	O
acid	JJ	O
synthase	NN	O
)	)	O
fatty	VBZ	O
acid	JJ	O
oxidation	NN	O
(	(	O
e.g.	JJ	O
,	,	O
carnitine	JJ	O
palmitoyltransferase	NN	O
I	PRP	O
)	)	O
,	,	O
fatty	JJ	O
acid	JJ	O
desaturation	NN	O
(	(	O
e.g.	JJ	O
,	,	O
stearoyl-CoA	JJ	O
desaturase	NN	O
1	CD	O
)	)	O
and	CC	O
cholesterol	NN	O
synthesis	NN	O
(	(	O
e.g.	JJ	O
,	,	O
HMG-CoA	NNP	O
reductase	NN	O
)	)	O
.	.	O
Furthermore	RB	O
,	,	O
the	DT	O
expression	NN	O
levels	NNS	O
of	IN	O
genes	NNS	O
that	WDT	O
participate	VBP	O
in	IN	O
glycogen	NN	O
metabolism	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
glycogen	NN	O
phosphorylase	NN	O
,	,	O
are	VBP	O
measured	VBN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
genes	NNS	O
that	WDT	O
participate	VBP	O
in	IN	O
fatty	JJ	O
acid	JJ	O
storage	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
lipoprotein	JJ	O
lipase	NN	O
,	,	O
are	VBP	O
measured	VBN	O
.	.	O
Changes	NNS	O
in	IN	O
the	DT	O
expression	NN	O
of	IN	O
hepatic	JJ	O
transcription	NN	O
factors	NNS	O
,	,	O
such	JJ	O
as	IN	O
sterol	NN	O
regulatory	JJ	O
binding	NN	O
element	NN	O
protein	NN	O
1	CD	O
,	,	O
are	VBP	O
also	RB	O
measured	VBN	O
.	.	O
The	DT	O
expression	NN	O
levels	NNS	O
of	IN	O
genes	NNS	O
related	VBN	O
to	TO	O
gluconeogenesis	NN	O
(	(	O
e.g.	JJ	O
,	,	O
glucose-6-phosphatase	JJ	O
and	CC	O
phosphoenolpyruvate	JJ	O
carboxykinase	NN	O
1	CD	O
)	)	O
,	,	O
glucose	JJ	O
uptake	NN	O
in	IN	O
both	DT	O
liver	NN	O
and	CC	O
fat	NN	O
(	(	O
e.g.	NN	O
,	,	O
glucose	JJ	O
transporter	NN	O
type	NN	O
2	CD	O
and	CC	O
glucose	VB	O
transporter	JJR	O
type	NN	O
4	CD	O
)	)	O
and	CC	O
lipid	JJ	O
homeostasis	NN	O
in	IN	O
fat	NN	O
(	(	O
e.g.	NN	O
,	,	O
hormone	NN	O
sensitive	JJ	O
lipase	NN	O
and	CC	O
lipoprotein	JJ	O
lipase	NN	O
)	)	O
are	VBP	O
also	RB	O
measured	VBN	O
.	.	O
Example	RB	O
35	CD	O
Antisense	NNP	O
Inhibition	NNP	O
of	IN	O
Rat	NNP	O
Diacylglycerol	NNP	O
Acyltransferase	NNP	O
2	CD	O
in	IN	O
Primary	JJ	O
Hepatocytes	NNS	O
:	:	O
Dose	NNP	O
Response	NNP	O
In	IN	O
a	DT	O
further	JJ	O
embodiment	NN	O
,	,	O
oligonucleotides	RB	O
targeted	VBN	O
to	TO	O
rat	VB	O
diacylglycerol	JJ	O
acyltransferase	NN	O
2	CD	O
were	VBD	O
selected	VBN	O
for	IN	O
dose	JJ	O
response	NN	O
studies	NNS	O
in	IN	O
primary	JJ	O
rat	NN	O
hepatocytes	NNS	O
.	.	O
The	DT	O
oligonucleotides	NNS	O
tested	VBN	O
were	VBD	O
ISIS	NNP	O
217320	CD	O
,	,	O
ISIS	NNP	O
217336	CD	O
,	,	O
ISIS	NNP	O
217353	CD	O
,	,	O
ISIS	NNP	O
217354	CD	O
,	,	O
ISIS	NNP	O
217356	CD	O
,	,	O
ISIS	NNP	O
217357	CD	O
and	CC	O
ISIS	NNP	O
217376	CD	O
.	.	O
Primary	JJ	O
rat	NN	O
hepatocytes	NNS	O
were	VBD	O
isolated	VBN	O
from	IN	O
Sprague-Dawley	NNP	O
rats	NNS	O
(	(	O
Charles	NNP	O
River	NNP	O
Laboratories	NNPS	O
,	,	O
Wilmington	NNP	O
,	,	O
Mass	NNP	O
.	.	O
)	)	O
and	CC	O
were	VBD	O
cultured	VBN	O
in	IN	O
Williams	NNP	O
Medium	NNP	O
E	NNP	O
supplemented	VBD	O
with	IN	O
10	CD	O
%	NN	O
fetal	JJ	O
bovine	NN	O
,	,	O
1	CD	O
%	NN	O
penicillin/streptomycin	NN	O
,	,	O
2	CD	O
mM	NN	O
L-glutamine	NNP	O
,	,	O
and	CC	O
0.01	CD	O
M	NNP	O
HEPES	NNP	O
(	(	O
Invitrogen	NNP	O
Life	NNP	O
Technologies	NNPS	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
seeded	VBN	O
into	IN	O
96-well	JJ	O
plates	NNS	O
(	(	O
Falcon-Primaria	NNP	O
#	#	O
3872	CD	O
)	)	O
coated	VBN	O
with	IN	O
0.1	CD	O
mg/ml	NNS	O
collagen	NN	O
at	IN	O
a	DT	O
density	NN	O
of	IN	O
approximately	RB	O
10,000	CD	O
cells/well	NN	O
for	IN	O
use	NN	O
in	IN	O
oligonucleotide	JJ	O
transfection	NN	O
experiments	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
5	CD	O
,	,	O
10	CD	O
,	,	O
25	CD	O
,	,	O
50	CD	O
,	,	O
100	CD	O
and	CC	O
200	CD	O
nM	NN	O
of	IN	O
antisense	JJ	O
oligonucleotide	NN	O
,	,	O
as	IN	O
described	VBN	O
herein	NN	O
.	.	O
Rat	NNP	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
mRNA	NN	O
expression	NN	O
in	IN	O
oligonucleotide-treated	JJ	O
cells	NNS	O
was	VBD	O
measured	VBN	O
using	VBG	O
quantitative	JJ	O
real-time	JJ	O
PCR	NNP	O
.	.	O
The	DT	O
data	NN	O
from	IN	O
the	DT	O
25	CD	O
,	,	O
50	CD	O
,	,	O
100	CD	O
and	CC	O
200	CD	O
nM	JJ	O
treatments	NNS	O
are	VBP	O
averaged	VBN	O
from	IN	O
3	CD	O
experiments	NNS	O
and	CC	O
are	VBP	O
shown	VBN	O
as	IN	O
percent	NN	O
inhibition	NN	O
,	,	O
relative	JJ	O
to	TO	O
untreated	JJ	O
control	NN	O
cells	NNS	O
,	,	O
in	IN	O
Table	JJ	O
24	CD	O
.	.	O
The	DT	O
5	CD	O
and	CC	O
10	CD	O
nM	JJ	O
treatments	NNS	O
did	VBD	O
not	RB	O
inhibit	VB	O
rat	JJ	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
.	.	O
As	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
24	CD	O
,	,	O
the	DT	O
oligonucleotides	NNS	O
tested	VBN	O
in	IN	O
this	DT	O
assay	NN	O
inhibited	VBD	O
rat	NN	O
diacylglycerol	NN	O
acyltransferase	NN	O
2	CD	O
expression	NN	O
in	IN	O
primary	JJ	O
hepatocytes	NNS	O
.	.	O
ISIS	NNP	O
217336	CD	O
,	,	O
ISIS	NNP	O
217353	CD	O
,	,	O
ISIS	NNP	O
217356	CD	O
,	,	O
ISIS	NNP	O
217357	CD	O
and	CC	O
ISIS	NNP	O
217376	CD	O
inhibited	VBD	O
target	NN	O
mRNA	NN	O
expression	NN	O
in	IN	O
a	DT	O
dose-dependent	JJ	O
manner	NN	O
.	.	O
All	DT	O
publications	NNS	O
cited	VBN	O
in	IN	O
this	DT	O
specification	NN	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
herein	NN	O
.	.	O
While	IN	O
the	DT	O
invention	NN	O
has	VBZ	O
been	VBN	O
described	VBN	O
with	IN	O
reference	NN	O
to	TO	O
a	DT	O
particularly	RB	O
preferred	JJ	O
embodiment	NN	O
,	,	O
it	PRP	O
will	MD	O
be	VB	O
appreciated	VBN	O
that	IN	O
modifications	NNS	O
can	MD	O
be	VB	O
made	VBN	O
without	IN	O
departing	VBG	O
from	IN	O
the	DT	O
spirit	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Such	JJ	O
modifications	NNS	O
are	VBP	O
intended	VBN	O
to	TO	O
fall	VB	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
appended	JJ	O
claims	NNS	O
.	.	O
Claims	NNS	O
(	(	O
24	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
4	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
2	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Related	VBN	O
Child	NNP	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=34193960	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
4	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
2	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
After	IN	O
(	(	O
1	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
4	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
6	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
83	CD	O
)	)	O
Citations	NNPS	O
(	(	O
38	CD	O
)	)	O
Family	RB	O
Cites	VBZ	O
Families	NNS	O
(	(	O
211	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
46	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
44	CD	O
)	)	O
Cited	VBN	O
By	IN	O
(	(	O
7	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Year	NNP	O
of	IN	O
fee	JJ	O
payment	NN	O
:	:	O
4	CD	O
Owner	NNP	O
name	NN	O
:	:	O
IONIS	NNP	O
PHARMACEUTICALS	NNP	O
,	,	O
INC.	NNP	O
,	,	O
CALIFORNIA	NNP	O
Free	NNP	O
format	VBD	O
text	NN	O
:	:	O
CHANGE	NN	O
OF	NNP	O
NAME	NNP	O
;	:	O
ASSIGNOR	NNP	O
:	:	O
ISIS	NNP	O
PHARMACEUTICALS	NNP	O
,	,	O
INC.	NNP	O
;	:	O
REEL/FRAME:043029/0538	NNP	O
Effective	NNP	O
date	NN	O
:	:	O
20151218	CD	O
